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Abstract
Autologous chondrocyte implantation in the knee:
systematic review and economic evaluation
Hema Mistry,1 Martin Connock,1 Joshua Pink,1 Deepson Shyangdan,1
Christine Clar,1 Pamela Royle,1 Rachel Court,1 Leela C Biant,2
Andrew Metcalfe3 and Norman Waugh1*
1Warwick Evidence, Division of Health Sciences, University of Warwick,
Coventry, UK
2Department of Trauma and Orthopaedic Surgery, University of Manchester, Manchester, UK
3Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
*Corresponding author norman.waugh@warwick.ac.uk
Background: The surfaces of the bones in the knee are covered with articular cartilage, a rubber-like
substance that is very smooth, allowing frictionless movement in the joint and acting as a shock absorber.
The cells that form the cartilage are called chondrocytes. Natural cartilage is called hyaline cartilage.
Articular cartilage has very little capacity for self-repair, so damage may be permanent. Various methods
have been used to try to repair cartilage. Autologous chondrocyte implantation (ACI) involves laboratory
culture of cartilage-producing cells from the knee and then implanting them into the chondral defect.
Objective: To assess the clinical effectiveness and cost-effectiveness of ACI in chondral defects in the
knee, compared with microfracture (MF).
Data sources: A broad search was done in MEDLINE, EMBASE, The Cochrane Library, NHS Economic
Evaluation Database and Web of Science, for studies published since the last Health Technology
Assessment review.
Review methods: Systematic review of recent reviews, trials, long-term observational studies and
economic evaluations of the use of ACI and MF for repairing symptomatic articular cartilage defects of the
knee. A new economic model was constructed. Submissions from two manufacturers and the ACTIVE
(Autologous Chondrocyte Transplantation/Implantation Versus Existing Treatment) trial group were
reviewed. Survival analysis was based on long-term observational studies.
Results: Four randomised controlled trials (RCTs) published since the last appraisal provided evidence on
the efficacy of ACI. The SUMMIT (Superiority of Matrix-induced autologous chondrocyte implant versus
Microfracture for Treatment of symptomatic articular cartilage defects) trial compared matrix-applied
chondrocyte implantation (MACI®) against MF. The TIG/ACT/01/2000 (TIG/ACT) trial compared ACI with
characterised chondrocytes against MF. The ACTIVE trial compared several forms of ACI against standard
treatments, mainly MF. In the SUMMIT trial, improvements in knee injury and osteoarthritis outcome scores
(KOOSs), and the proportion of responders, were greater in the MACI group than in the MF group. In the
TIG/ACT trial there was improvement in the KOOS at 60 months, but no difference between ACI and MF
overall. Patients with onset of symptoms < 3 years’ duration did better with ACI. Results from ACTIVE have
not yet been published. Survival analysis suggests that long-term results are better with ACI than with MF.
Economic modelling suggested that ACI was cost-effective compared with MF across a range of scenarios.
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Limitations: The main limitation is the lack of RCT data beyond 5 years of follow-up. A second is that
the techniques of ACI are evolving, so long-term data come from trials using forms of ACI that are now
superseded. In the modelling, we therefore assumed that durability of cartilage repair as seen in studies
of older forms of ACI could be applied in modelling of newer forms. A third is that the high list prices of
chondrocytes are reduced by confidential discounting. The main research needs are for longer-term
follow-up and for trials of the next generation of ACI.
Conclusions: The evidence base for ACI has improved since the last appraisal by the National Institute for
Health and Care Excellence. In most analyses, the incremental cost-effectiveness ratios for ACI compared
with MF appear to be within a range usually considered acceptable. Research is needed into long-term
results of new forms of ACI.
Study registration: This study is registered as PROSPERO CRD42014013083.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Damage to the cartilage that covers the ends of the knee bones is common, especially in sportspeople.The ability of cartilage to repair itself is very limited. The damage may lead to later osteoarthritis and a
need for knee replacements.
Attempts to repair the damaged cartilage have mostly used a procedure called microfracture (MF),
involving drilling small holes into the bone under the damaged area. A clot of blood then covers the
damaged area and over time forms scar tissue called fibrocartilage. This relieves symptoms, but
fibrocartilage is not as tough as natural cartilage, and wears out after a few years.
In the procedure called autologous chondrocyte implantation (ACI), a small piece of healthy cartilage is
removed from the knee, and the cartilage-producing cells (chondrocytes) are cultured in the laboratory
until there are many millions of them. They are then used to patch the area of damaged cartilage. The
hope is that the chondrocytes will form natural cartilage, which will last longer than fibrocartilage.
We reviewed trials and other studies that reported that ACI gave better long-term results than MF.
The main limitation was the lack of long-term follow-up data from modern methods of ACI. However,
we thought that data on the cartilage formed using older methods of ACI could be applied to
modern methods.
Our analysis suggested that ACI is cost-effective, taking into account short-term improvements in
symptoms and reduced need for further repairs and, in the long term, knee replacements.
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Scientific summary
Background
The surfaces of the bones in the knee are covered with articular cartilage, a rubber-like substance that is
very smooth, allowing frictionless movement in the joint, and acting as a shock absorber. The cells that
form the cartilage are called chondrocytes. Natural cartilage is called hyaline cartilage.
Various methods have been used to try to repair cartilage defects, usually aiming to replace the damaged
cartilage using bone marrow cells, including stem cells, which then form a tissue called fibrocartilage.
The commonest way of doing this is called microfracture (MF). Small holes are drilled through the bone
underlying the damaged area to allow the marrow cells to fill the defect. However, the fibrocartilage
formed is less durable than natural hyaline cartilage.
Autologous chondrocyte implantation (ACI) aims to replace the damaged cartilage with hyaline cartilage.
A small piece of articular cartilage is taken from the knee, and the chondrocytes are cultured in the
laboratory, until there are millions of cells, which are implanted into the damaged area.
The methods of ACI have evolved. In the first generation of ACI (ACI-P – ‘P’ for periosteum), the cultured
cells were implanted as a liquid suspension, and covered with a cap made from periosteum – the tough
fibrous tissue that covers bones. This required a procedure to harvest the periosteum, which caused
discomfort to the patient afterwards.
In second-generation ACI, the periosteal cover was replaced by a collagen cover (ACI-C for short), but the
cells were still in liquid suspension, and the cover still had to be stitched in place.
One development in ACI has been ‘characterisation’, a process in which the cells thought to have the best
ability to form hyaline cartilage are selected during culture.
In the third generation of ACI, the cells are seeded or loaded into a collagen membrane, which is
implanted into the defect. This is referred to as matrix-applied chondrocyte implantation (MACI).
Decision problem
The scope from the National Institute for Health and Care Excellence (NICE) for this appraisal mentions
three forms of ACI:
1. The ChondroCelect system from TiGenix (Leuven, Belgium), in which characterised cells are capped with
biodegradable collagen: ACI-C.
2. The Matrix ACI system [matrix-applied characterised autologous cultured chondrocyte implant (MACI®)]
now marketed by Vericel (Cambridge, MA, USA).
3. ACI wherein the cells are cultured in hospital or research laboratories, such as the Robert Jones and
Agnes Hunt Hospital in Oswestry, termed ‘traditional ACI’ in the NICE scope.
The main comparator is MF.
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Clinical effectiveness
We reviewed previous systematic reviews of the comparative effectiveness of various forms of ACI and MF.
We then searched for trials [randomised controlled trials (RCTs)] that used the most recent forms of ACI.
The reviews were mostly inconclusive on the choice between ACI and MF, for reasons including poor
quality of primary studies, the heterogeneities of patients recruited, ACI methods used, outcome measures,
variations in previous surgery and short follow-up periods.
Four RCTs have been published since the last appraisal provided evidence on the efficacy of ACI. These are:
Basad E, Ishaque B, Bachmann G, Stürz H, Steinmeyer J. Matrix-induced autologous chondrocyte implantation
versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. Knee Surg
Sports Traumatol Arthrosc 2010;18:519–27. http://dx.doi.org/10.1007/s00167-009-1028-1.
SUMMIT (Superiority of Matrix-induced autologous chondrocyte implant versus Microfracture for Treatment of
symptomatic articular cartilage defects) Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J,
Drogset JO, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year
follow-up of a prospective randomized trial. Am J Sports Med 2014;42:1384–94. http://dx.doi.org/10.1177/
0363546514528093.
The TIG/ACT/01/2000 trial (hereafter TIG/ACT trial) Vanlauwe J, Saris DB, Victor J, Almqvist KF, Bellemans J,
Luyten FP, TIG/ACT/01/2000&EXT Study Group. Five-year outcome of characterized chondrocyte
implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters.
Am J Sports Med 2011;39:2566–74. http://dx.doi.org/10.1177/0363546511422220.
The ACTIVE (Autologous Chondrocyte Transplantation/Implantation Versus Existing Treatment) trial (390 patients)
[Keele University. ACTIVE Trial Web Site. 2011. URL: www.active-trial.org.uk/ (accessed 25 July 2016)].
Two of the trials, Basad et al. with 60 patients and SUMMIT by Saris et al. with 144 patients, compared
MACI with MF. The TIG/ACT trial with 118 patients compared ACI-P with characterised chondrocytes
against MF. The ACTIVE trial compared several forms of ACI against standard treatment, mainly MF.
The primary outcome measures in the Basad trial were Tegner and Lysholm scores. Lysholm scores improved
in both MACI and MF groups from baseline to 12 months, but the improvement was maintained to
24 months only in the MACI group (92 vs. 69; p = 0.005). Tegner scores improved in both groups, but more
so in the MACI group.
In the SUMMIT trial, improvements in knee injury and osteoarthritis outcome knee injury and osteoarthritis
outcome scores (KOOSs) were significantly greater in the MACI group than in the MF group. The
proportion of responders was higher with MACI. Factors that predicted better results with MACI were
male gender, a median age of < 34.5 years, presence of a single lesion due to acute trauma, history of
only one previous surgical procedure, and lesion of size > 4 cm2 located on the femoral condyle. More
patients in the MF group reported adverse events (AEs), most frequently arthralgia.
In the TIG/ACT trial of ChondroCelect, the overall KOOS improved at 60 months with both treatments, with
no statistically significant difference. Patients with onset of symptoms < 3 years’ duration did better with
ACI-P. More patients in the ACI-P group experienced AEs but they were mild to moderate in intensity.
The ACTIVE trial is comparing ACI (including ACI-P, ACI-C and MACI) against standard treatments
(MF, abrasion, drilling, mosaicplasty).
Autologous chondrocyte implantation is less successful in patients who have had previous MF than if it is
done as first repair, because MF damages the subchondral bone.
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Longer-term results: survival analysis
The trials included under the original scope from NICE on second- and third-generation ACI provided
results only up to 3 and 5 years, and, for modelling of cost-effectiveness, longer-term outcome data were
desirable. It was decided that longer-term data from ACI-P could be used, based on an assumption that
data on longer-term outcomes of chondral defect repairs from studies of ACI-P could be extrapolated to
survival of repairs after ACI-C and MACI. ACI-P has been superseded because the new techniques are
simpler and quicker, and because the use of periosteum required harvesting and ensuring a watertight
cap, and could lead to overgrowth hypertrophy requiring reoperation and shaving of the graft, and the
extra discomfort to patients from these procedures. The collagen cap is much easier to use. The third
generation of ACI in which the cells are seeded onto the collagen membrane is quicker still.
It was felt that results after ACI-C and MACI would at least be no worse than after ACI-P.
We searched for studies reporting longer-term results of ACI and MF.
Survival analysis – time to failure in longer-term studies: we included six studies of long-term results of ACI,
the best of which was by Nawaz et al. from Stanmore. (Nawaz SZ, Bentley G, Briggs TW, Carrington RW,
Skinner JA, Gallagher KR, Dhinsa BS. Autologous chondrocyte implantation in the knee: mid-term to long-term
results. J Bone Joint Surg Am 2014;96:824–30.) It was best because of its size (827 patients – greater than
the other studies put together); because it reflected UK practice (albeit from a centre of excellence); because
it provided data from the period 1998–2008, on different generations of ACI; and because it provided very
useful subgroup data.
The findings of the Nawaz study include:
l ACI graft survival was 78% at 5 years and 51% at 10 years for the whole cohort.
l There was no difference between survival rates of ACI-P and ACI-C, and MACI. Most (63%)
received MACI.
l Outcomes were much poorer in patients who had had previous attempts at cartilage repair such as MF,
with an almost fivefold failure rate.
l The presence of osteoarthritis (OA) increased failure rates. Patients with Kellgren–Lawrence grades 2
and 3 had only 25% graft survival to 10 years.
We used the Nawaz results as the main input into survival analysis and cost-effectiveness, but also did a
sensitivity analysis (SA) incorporating five other long-term studies of ACI.
There were few long-term studies of MF. We constructed survival curves based on 5-year data from only
three studies: two trials with 40 and 61 patients and an observational study from routine care in the USA
with 3498 patients having MF.
The ACI groups had lower failure rates than the MF cohorts, except for the ACI group with previous
attempts at repair or with OA. Data were sparse on results of MF in previously treated patients.
In summary:
l More long-term evidence was available for ACI than for MF.
l Study data were generally still too short term. Only one published study allowed an estimate of
observed median time to failure.
l Caveat: immaturity of failure data necessitated parametric modelling beyond observed data so as to predict
lifetime failure. Such extrapolations assume that curves based on the observed data will continue.
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l Most participants in most studies had had previous attempts at repair. Two ACI studies with survival
analyses extending to at least 10 years reported that treatment failure was far more frequent in
patients who had experienced prior intervention(s). This reduced the likelihood of success after ACI and
makes extrapolation of results from older studies to ACI as first procedure rather pessimistic.
l The best fits of long-term failure after ACI were usually characterised by models that, when extrapolated
beyond the observed data, indicated gradually decreasing hazard (probability of failure decreasing with time).
l Conversely, good fits to limited data available for MF were characterised by models that indicated
linearly increasing hazard (probability of failure increasing with time).
Cost-effectiveness
Review of previous economic studies
We reviewed existing economic evaluations of the use of ACI and MF for repairing symptomatic articular
cartilage defects of the knee. A broad search was done in MEDLINE, EMBASE, NHS Economic Evaluation
Database and Web of Science for studies published since the last Health Technology Assessment review in 2005.
We found six relevant articles, all with shortcomings, most notably the lack of long-term clinical follow-up
and good quality-of-life (QoL) data.
Review of submissions received
We reviewed the submissions from Swedish Orphan Biovitrum AB (SoBi, Stockholm, Sweden) on
ChondroCelect, from Aastrom Biosciences (now Vericel, Cambridge, MA, USA) on MACI®, and from
OsCell, including unpublished data from the ACTIVE trial.
Swedish Orphan Biovitrum AB developed a de novo Markov economic model. Their modelling assumed
that MF was the comparator; if the first repair fails then patients can have a second repair, but only with
MF, and the main driver was time to failure of the first repair. They used data from the TIG/ACT trial. Their
key assumptions were that fewer patients who had ACI needed second repairs and that they had a longer
duration of success, thereby postponing the need for knee replacement. Their base-case incremental
cost-effectiveness ratio (ICER) was about £9000 per quality-adjusted life-year (QALY).
Aastrom Biosciences did not provide any cost-effectiveness analysis but did provide a costing forecast. They
explored two scenarios, one with MACI or ACI as first procedure, and the other with MF. Based on data
from the SUMMIT trial, they estimated that there would be cost savings from using MACI due to the lower
need for further repairs.
The Oswestry group provided a cost-effectiveness analysis for the ACTIVE trial. This analysis used EQ-5D-3L
(EuroQol-5 Dimensions, three-level version) data based on up to 8 years of follow-up. It assumed a cost for
cells of £4125, based on production by OsCell. The data showed little difference between ACI and MF for
the first 4 years but, after that, EQ-5D results were better in the ACI group, with a cost per QALY for ACI
compared with MF of around £6000.
Warwick Evidence modelling
We constructed a lifetime Markov model, starting with a cohort of people aged 33 years with symptomatic
articular cartilage defects of the knee treated with ACI or MF. The analysis considered the need for
subsequent events including further repairs and later knee replacements. Most patients (87.5%) did not
need a second repair. We created two scenarios to allow direct comparisons: in scenario 1 all second
repairs were ACI, and in scenario 2 all second repairs were MF. Secondary analyses considered other
options including ACI after prior MF.
For the base-case analysis, we used data mainly from the TIG/ACT trial of ChondroCelect and the SUMMIT
trial of MACI.
SCIENTIFIC SUMMARY
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The results indicated that ACI is more cost-effective than MF as a first repair, and that if a second repair is
needed this should also be ACI. The base-case discounted ICER for ACI compared with MF was just over
£14,000 per QALY for scenario 1, and just under £16,000 per QALY for scenario 2.
Results from SAs were in line with the base-case results.
The key drivers in the base case were the cost of cells for ACI and the relative durations of benefit from
ACI and MF. After the first few years (varying among studies) ACI was more beneficial (more gain in
QALYs) and led to cost savings to the NHS [fewer people in need of a second repair or of a total knee
replacement (TKR), and first TKR postponed reducing the need for second TKR].
Limitations in the economic analyses included uncertainties with long-term progression rates and QoL data.
We then used data from the long-term survival analysis, using the whole Nawaz cohort results for ACI,
and pooling the MF results from three studies. At the request of NICE, we used an implantation cost of
£2396 (assuming an inpatient stay), and we omitted the option for MF failure to be followed by another
MF. So the options were:
l MF followed by ACI if another procedure was considered necessary in the short term. In the long term,
patients would be considered for knee replacement, but most would still be too young for that after
MF failure.
l ACI followed by MF if another attempt at repair was necessary.
l ACI followed by a second ACI if another attempt at repair was necessary.
Microfracture followed if necessary by ACI was the lowest cost option, and we compared other options
with that. ACI followed by MF was dominated by ACI followed if necessary by ACI, because of the poor
long-term results of MF.
The ICER for ACI as primary procedure compared with MF was around £19,000 – a little less in
deterministic analysis, a bit more in probabilistic. A caveat is necessary – the marginal QALY gains were
very small, at 0.0650 in deterministic and 0.0824 in probabilistic.
We carried out a range of SAs. In the base case, we used a cell cost of £16,000 in line with published
prices, but we are aware of discounted prices that vary by time and place. The deterministic ICERs for ACI
as first procedure compared with MF were as follows:
l cost of cells £6000 – ICER £7414
l cost of cells £8000 – ICER £9700
l cost of cells £12,000 – ICER £14,272.
We tested a series of utility assumptions for those whose first repair was not successful but who decided
not to have another. In our first analysis, we assumed that they had had some benefit, and had improved
from a utility of 0.654 before the repair to 0.691 afterwards. NICE asked us to assess the effect of the
following assumptions for utilities:
l Utility set to the same as failure (0.654) – ICER £15,634.
l Utility after failure set to same as success (0.817) – ICER £62,658. This assumption greatly increases utility
gain among those who do not get good results after MF, and reduces the marginal QALY gains from ACI.
l Utility set to midpoint of success and failure (0.746) – ICER £27,123. This also reduces the marginal
QALY gains from ACI as first procedure, because the larger proportion that does not do well after MF
has their utility increased.
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The Nawaz study provides very useful data on subgroups:
l Previous attempts at repair, such as MF – ICER £38,262. ACI is much less successful if the underlying
bone has been damaged.
l Individuals without prior repair attempts – ICER £15,659.
l Kellgren–Lawrence grade 0 – no radiological sign of OA – ICER £15,618.
l Kellgren–Lawrence grade 1 – radiological signs of early OA – ICER £17,104.
l Kellgren–Lawrence grade 2 – ICER £20,096.
l Kellgren–Lawrence grade 3 – ICER £21,207.
In a SA, instead of relying on the Nawaz data alone, we tested the effect of pooling six ACI studies and
found an ICER of £16,708.
Vericel provided details from an unpublished study in which patients with chondral defects were reported
to have a baseline utility of 0.484. Using that baseline and their 3-year utility gain would give an ICER of
£15,648. The baseline utility looks surprisingly low.
Strengths and limitations in evidence
We now have longer follow-up than was available for previous appraisals, and data from several new
trials. The ACTIVE trial has data on some patients to 8 years and will eventually have 10 years of follow-up
for all. The TIG/ACT trial has 5 years of follow-up. However, the two trials of MACI against MF had only
2 years of follow-up. There are few long-term MF studies.
Research needs
Autologous chondrocyte implantation is less successful among people with OA, but ICERs can be in the
range usually considered acceptable. ACI may have a place in early OA with focal damage – research is
needed in this group.
Conclusions
Caveats are necessary. There were more long-term studies of ACI than of MF. Using longer-term data than
were available in the trials, MF comes out much less well. However, there are few long-term studies of MF,
and extrapolation beyond observed data is subject to uncertainties. The evidence base is much stronger
for ACI, but in older studies most patients had had previous attempts at repair. ACI is less successful after
previous attempts at repair. Previous studies may therefore provide a pessimistic assessment. Most, but not
all, studies suggest that ACI is more effective if used soon after the cartilage injury. A key conclusion is
that ACI will give better results if used as first repair procedure.
In summary, the evidence base for ACI has improved since the last appraisal by NICE. In most analyses, the
ICERs for ACI compared with MF appear to be within a range usually considered acceptable.
Study registration
This study is registered as PROSPERO CRD42014013083.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
History
The first appraisal of autologous chondrocyte implantation (ACI) was in 2000, after which the National
Institute for Health and Care Excellence (NICE) issued Technology Appraisal (TA) Guidance 16,1 which
stated that:
1.1 Autologous cartilage transplantation is not currently recommended for routine primary treatment
of articular cartilage defects of the knee joint in the NHS.
1.2 ACT should only be performed as part of a properly structured trial which wherever possible is
randomized and adequately powered.
Reproduced with permission from NICE1
This decision was made because there was then no evidence from randomised controlled trials (RCTs).
The available evidence came from 17 case series of different interventions, and NICE concluded that:
Assessment of the evidence on clinical efficacy is confounded by a number of factors including
variations in patient characteristics, concomitant surgery and use of multiple interventions. With one
exception, all studies reported an improvement in patient status, usually over a follow-up period of less
than 2 years.
These studies are summarised in the report by Jobanputra et al.2 The studies lacked control groups,
without which it is difficult to assess the effectiveness of procedures, relative to natural history or
alternative treatments.
The guidance was reviewed in 2005, supported by a report by Clar et al.3 The guidance issued as TA894
stated that:
Autologous chondrocyte implantation is not recommended for the treatment of articular cartilage
defects of the knee joint except in the context of ongoing or new clinical studies that are designed to
generate robust and relevant outcome data, including the measurement of health-related quality of
life and long-term follow-up.
Reproduced with permission from NICE4
The terminology had changed. The initial term of ‘autologous cartilage transplantation’ had been replaced
by ‘autologous chondrocyte implantation’ (ACI), which is more correct for two reasons. First, the small
group of cells removed is multiplied before being put in, so transplantation is not correct because what
goes back in is not what came out. Second, what is implanted is cells (chondrocytes) rather than cartilage,
which takes time to develop.
The evidence base had improved by 2005, with four RCTs, two comparing ACI with mosaicplasty5,6 and
two comparing it with microfracture (MF).7,8 The duration of follow-up was still short. At 2 years, there
appeared to be little difference between ACI and mosaicplasty or MF. In the absence of long-term data,
it was not possible to produce reliable costs per quality-adjusted life-year (QALY).
This report was written to support the third NICE appraisal of ACI in the knee.9
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Chondral injuries
Articular cartilage covers the ends of the bones and the inner surface of the patella in the knee joint. It
should not be confused with the meniscal cartilages that are cushions of cartilage between the bones –
when people talk of ‘cartilage problems’ in the knee, they often mean the meniscal cartilage.
Normal hyaline cartilage is a rubber-like substance that is normally very smooth, promoting smooth,
frictionless movements of the joints and also acting as a shock absorber. It is formed mainly of a protein
called type II collagen. Under the articular cartilage are the bones of the knee: the femur in the thigh,
the tibia below the knee and the patella or knee-cap.
Cartilage has no blood vessels and has very limited ability to repair itself. Epidemiological studies show a
relationship between knee injury and later development of osteoarthritis (OA). In some people, this will
lead in the long term to a need for a knee replacement with an artificial joint.
Loss of articular cartilage is referred to as a chondral defect, and loss of cartilage and bone as an
osteochondral defect.
Cartilage damage can be caused directly from injury, by various types of arthritis, or spontaneously in a
condition called osteochondritis dissecans (OCD). Cartilage damage may also arise because of knee instability
or abnormal loading, for example secondary to a ligament injury10 or damaged meniscal cartilages.11 Serious
obesity may also affect knee cartilage.12 Conversely, physical activity without injury may be protective.13
In young people the most common cause of hyaline cartilage damage is sporting injuries. Aroen et al.14
reported the causes of injury in patients having knee arthroscopy in Norway over a 6-month period.
Injuries occurred in sport in 55%, in the home in 15%, at work in 12% and in road traffic accidents in
5%. In 13% the cause was unknown.
It should be noted that cartilage defects without any underlying bone involvement may not cause pain –
there are no nerves in cartilage. The source of pain in knees with damaged cartilage is poorly understood
but may come from many sources, including ligaments, the joint capsule and the underlying bone.15 Thus,
results from series of symptomatic patients may not be entirely representative of all people with cartilage
damage. The most common symptom is pain, with others being temporary locking of the knee in one
position, and swelling. Pain and disability from symptomatic cartilage lesions has been shown to be as
significant in magnitude as that from severe arthritis of the knee.16
The International Cartilage Repair Society (ICRS) has a scoring system for grading the severity of
cartilage damage:17
l Grade 1 Soft indentation and/or superficial cracks.
l Grade 2 Small cracks or lesions extending down to under half of cartilage depth.
l Grade 3 Deep cracks or gaps of over 50% of cartilage depth.
l Grade 4 Cracks through the total thickness of cartilage down to the underlying bone.
l Grade 5 Defects of the full thickness of cartilage involving the subchondral bone.
Grading has to be done by arthroscopic examination.
Interventions
Lavage and debridement
In lavage, the arthroscope (a sort of fibreoptic telescope) is inserted into the knee and saline is poured in
through a cannula. This is usually done under general anaesthesia on a day-case basis. The saline washes
out loose debris through the cannula. It is also thought to wash out compounds that cause inflammation.
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Debridement is done under arthroscopic vision, and is the removal of damaged cartilage or bone.
Debridement and lavage are often done together.
The evidence for effectiveness is sparse and mixed. One three-armed RCT – of lavage alone, lavage plus
debridement and a sham arm – reported no difference at 2 years.18 Another by Hubbard19 had methodological
weaknesses, but reported that debridement and lavage was better than lavage alone. The NICE intervention
procedures guidance (IPG230)20 noted uncertainty about the efficacy of the procedure.
Autologous chondrocyte implantation
Cartilage cells are called chondrocytes. In ACI, a small piece of cartilage is removed from the knee, and the
chondrocytes are grown in the laboratory until they number millions. They are then put onto the damaged
area of articular cartilage as a patch. The hope is that this patch will repair the damaged area and form a
new layer of natural articular cartilage, called hyaline cartilage.
Autologous chondrocyte implantation has been used since at least 1987,21 and the procedure has evolved
over time. The Dutch Orthopaedic Association has provided a useful summary of developments.22 In the
first generation of ACI, the cultured chondrocytes were placed in the defect, in liquid form, and then
covered with a cap made from periosteum [autologous chondrocyte implantation–periosteal flap (ACI-P)].
This led to problems with pain in the immediate postoperative period and a need for further procedures to
remove overgrowth in the graft as described in Box 1.
The second generation of ACI used a collagen cap [autologous chondrocyte implantation–collagen cap
(ACI-C)] instead of the periosteal one, but still used cells in a liquid. Gomoll et al.24 compared two cohorts,
one that had a periosteal patch (ACI-P) and one that had a collagen cap (ACI-C). The reoperation rates
were 26% and 5%, respectively. ACI-P is now little used in the UK, but is still used in the USA, where
none of the membranes or scaffolds used in second-generation ACI has yet been approved by the Food
and Drug Administration (FDA) except for in trials.25
BOX 1 Clinical features of ACI-P
The periosteal patch was traditionally harvested via a 3- to 4-cm incision on the subcutaneous border of the
proximal medial tibia. Careful dissection is performed to develop a plane between the periosteum (outer lining of
bone) and overlying fat and fascia (outer lining of muscle). A slightly oversized patch is then harvested with a sharp
surgical blade. This procedure takes approximately 30 minutes to perform and patients suffer from additional pain
and swelling postoperatively. Potential complications include surgical site infection, and haematoma formation at
the harvest site. If an infection does occur they are treated with a 1-week course of oral antibiotics.
The most common complications at site of implantation are graft overgrowth (hypertrophy) and scarring
(arthrofibrosis) following this procedure. Overgrowth typically occurs between 3 and 6 months after the operation,
and results from abrasion of the patch against internal structures in the knee. This can occur in up to 50% of
cases, with a significant proportion requiring further keyhole surgery to debride (‘shave off’) the excess tissue from
the surface of the patch.23 Furthermore, suturing the patch may damage the native surrounding cartilage, as
sutures are passed through normal healthy cartilage to ensure a watertight seal for the chondrocytes.
Contributed by Mr A Sprowson, orthopaedic surgeon.
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In the third generation of ACI, the chondrocyte cells are loaded or embedded, or ‘seeded’, on to a porcine
collagen membrane ACT-C (autologous chondrocyte transplantation seeded collagen membrane) or matrix
[matrix-applied chondrocyte implantation (MACI®)], with a patch cut to fit. These patches can be implanted
by a less-invasive form of surgery, by arthroscopy or mini-arthrotomy, requiring less surgical time than
ACI-C.26 (Arthrotomy = opening of a joint.) ChondroCelect cells (TiGenix, Leuven, Belgium) are now used
in this way, with cells being loaded into the membrane by the surgeon.
The membrane used in MACI is composed of type I/III collagen, with a rough side wherein the
chondrocytes are seeded and a smooth side that faces into the joint cavity.26 The membrane is tough
enough to be cut to shape or stitched in place, though it is more often glued in place.26 The membrane is
biodegradable. The term ‘scaffold’ is often used instead of membrane. However, the membrane needs
careful handling to minimise chondrocyte death during implantation.27
Another development, which can apply to both second- and third-generation ACI, has been that only
selected chondrocytes are used – this is called characterised chondrocyte implantation (CCI). Cells that are
most likely to produce hyaline cartilage with predominantly type II collagen, rather than a less resilient
cartilage called fibrocartilage, which produces mainly type I collagen,28 are identified during CCI using a
panel of biomarkers, including collagen. TiGenix used six biomarkers and Genzyme (Sanofi) also used
additional assays in CCI.29
Table 1 summarises the generations of ACI. (Note: different authors use ‘second generation’ in different
ways.) It is worth noting that graft hypertrophy can occur with second- and third-generation ACI.
Niethammer et al.30 reported graft hypertrophy on magnetic resonance imaging (MRI) in 11 of 44 patients
who had MACI (with Novocart – TETEC AG, B. Braun, Reutlingen, Germany).
Harris et al.31 carried out a systematic review of failures and complications after ACI and reported that
failure rates were higher with first-generation ACI-P than with second-generation ACI-C.
The Medical Services Advisory Committee (MSAC) report concluded that the ideal application of ACI would
be in a full-thickness chondral defect surrounded by healthy cartilage in an otherwise healthy knee.32
Microfracture
The main alternative method of repair is called ‘microfracture’, in which small holes are drilled through the
surface of the bone in the area of damaged cartilage. This allows bleeding from the bone marrow, and the
blood carries stem cells into the area where the damaged cartilage has been debrided. These cells form
scar cartilage called fibrocartilage, composed of type I collagen. This is regarded as being inferior to hyaline
cartilage, being less hardwearing and not expected to last as long.33
MF may be combined with the insertion of a collagen membrane to cover the MF clot, known as
augmented MF.
TABLE 1 The evolution of ACI
Type of ACI Method
First generation ACI-P: Liquid suspension of cultured chondrocyte cells placed in the defect covered with a cap
made from periosteum
Second generation ACI-C: Liquid suspension of cells placed in the defect and covered with a collagen cap
Third generation The cultured cells are seeded on to a membrane or ‘scaffold’ as in MACI (matrix-applied
chondrocyte implantation)
Characterised
chondrocytes
Not all chondrocytes are equally good at producing cartilage. Some are more ‘chondrogenic’
(cartilage producing) than others. The most useful can be selected and are known as ‘characterised’
Fourth generation Newer developments include the implantation not of cells that will form cartilage, but of tissue-
engineered cartilage grown from autologous chondrocytes in collagen gel in the laboratory
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MF can be done arthroscopically (i.e. without opening the knee joint) and could be done at the same time
as washing out a knee joint and stabilising loose tissue (debridement and lavage).
A search of the NICE website found no guidance on MF.
Mosaicplasty
Another method, which is now much less common, is mosaicplasty, sometimes called OATS
(osteochondral autograft transfer system), which involves transplanting small sections of cartilage and
underlying bone from a less-weight-bearing part of the knee into the damaged area. The pieces are in
little cylinder shapes and, once transplanted, have an appearance not unlike a mosaic – hence the name.
Mosaicplasty can be used only for small areas of damage (less than 4 cm2) because the transplanted
sections have to come from elsewhere in the knee, usually the trochlea. (In some countries, allograft
cadaver donor tissue is used, but this does not appear to happen in the UK.)
Mosaicplasty was reviewed by NICE through the Interventional Procedures Programme.34 The guidance is
reproduced in Box 2. It was dated ‘March 2006’ and so may now be out of date.
Mosaicplasty appears to be little used now. In the ACTIVE (Autologous Chondrocyte Transplantation/
Implantation Versus Existing Treatment) trial35 (described in Chapter 4) of ACI versus standard methods,
such as MF and mosaicplasty, few surgeons chose mosaicplasty.
Conservative management
Another option is no surgical treatment. Three case series36–38 reported high levels of return to activities
after cartilage injuries after 14, 9 and 9 years, respectively. Messner and Maletius36 reported a case series
of young athletes (mean age 25 years, range 14–38 years) who had no treatment. Fourteen years later,
most (21 out of 28) had returned to activity and 22 had excellent or good function.36 However despite lack
of symptoms, most showed radiological changes suggestive of early OA.
The British Association for Surgery of the Knee (BASK) UK Consensus recommends that all patients being
considered for ACI should have had physical therapy first, as that may relieve symptoms.39
BOX 2 National Institute for Health and Care Excellence Guidance. Reproduced with permission from NICE34
Guidance
1.1 Current evidence suggests that there are no major safety concerns associated with mosaicplasty for knee
cartilage defects. There is some evidence of short-term efficacy, but data on long-term efficacy are inadequate.
In view of the uncertainties about the efficacy of the procedure, it should not be used without special
arrangements for consent and audit or research.
1.2 Clinicians wishing to undertake mosaicplasty for knee cartilage defects should take the following actions.
l Inform the clinical governance leads in their Trusts.
l Ensure that patients understand the uncertainty about the procedure’s efficacy and the options for
alternative treatments. They should provide them with clear written information. In addition, use of the
Institute’s information for the public is recommended.
l Audit and review clinical outcomes of all patients having mosaicplasty for knee cartilage defects. The
Institute may review the procedure upon publication of further evidence.
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Decision problem
The scope from NICE for this appraisal mentioned three forms of ACI:
l The ChondroCelect ACI system from TiGenix, in which the cultured cells are combined with a
biodegradable collagen I/III patch. This is a form of CCI. ChondroCelect received European marketing
authorisation in October 2009.40 It is marketed by Swedish Orphan Biovitrum (SoBi; Stockholm,
Sweden). Production is being taken over by Pharmacell (Maastricht, The Netherlands).41
l The Matrix ACI system (MACI®* – short for ‘matrix-applied characterised autologous cultured
chondrocyte implant’) from Sanofi (Paris, France). The matrix refers to a collagen membrane with the
chondrocytes. The Sanofi MACI® was approved in Europe in June 2013.42 This product is now being
marketed by Aastrom Biosciences, who have changed their name to Vericel (Cambridge, MA, USA).
l ACI wherein the cells are cultured in hospital or research laboratories, such as the Robert Jones and
Agnes Hunt Hospital (RJAH), Oswestry, termed ‘traditional ACI’ in the NICE scope. This appears to be
the only UK NHS facility that currently cultures cells for use in ACI. Traditional ACI is used under
hospital exemptions from the advanced therapy medicinal products regulations.
(*MACI is used both to refer to third-generation ACI and as a trade name; when referring to the trade
name, we will use MACI®.)
Autologous chondrocyte implantation is much more expensive than MF. The Australian Medical Service
Advisory Committee estimated the cost of ACI to be about 10 times that of MF.32 In the NHS, the
difference appears to be even greater, with list prices for cells alone being around £16,000.
The first decision to be made by NICE is whether or not ACI, in some or all of its forms, is clinically
effective and cost-effective, and should now be used in routine NHS care. Both ChondroCelect and Vericel
MACI® have marketing authorisations, with slightly different indications (Box 3).
It is not clear from the European Medicines Agency (EMA) website whether or not ChondroCelect is
approved for lesions smaller than 1 cm2.
The final scope for this appraisal did not consider sequencing of different technologies for the repair of
cartilage defects, but the place of ACI in the treatment pathway needs to be examined. A second question
is whether or not the much less expensive MF should be tried first, with ACI reserved for MF failures?
Or are the best results with ACI achieved if it is the first treatment for chondral defects?
A third question is how soon cartilage defects should be treated. In a randomised trial of ACI versus MF,
outcomes were better in those treated within 3 years of symptom onset compared with those with
longer duration.43
BOX 3 Licences for ChondroCelect and Verigen MACI®
ChondroCelect has a UK marketing authorisation for the ‘repair of single symptomatic cartilage defects of the
femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults’. The RCT
that supported the marketing authorisation for ChondroCelect included patients with lesions of between
1 and 5 cm2.40
Vericel MACI® has a marketing authorisation for ‘the repair of symptomatic, full-thickness cartilage defects of
the knee (grade III and IV of the Modified Outerbridge Scale) of 3–20 cm2 in skeletally mature adult patients’.42
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Mithöfer et al.28 have also reported better results with ACI sooner after injury, in football players. Harris
et al.44 also concluded that results were better in patients with shorter duration of symptoms and fewer
prior procedures.
Thus, there may be a case for recommending earlier ACI.
Patient group
The patient group, as stated in the final scope from NICE, is ‘adults with a symptomatic cartilage defect
(chondral defect) but without advanced osteoarthritis’. Advanced OA is not defined in the scope. The
chondral defects can be on the femur, tibia or patella. ACI is used in other joints, but such use is outwith
the scope of this appraisal.
No age restriction is given in the scope from NICE, but in past trials, patients had a mean age of 32 years,
range 16–49 years, with about 60% men. In most cases, the cartilage damage was due to injury, usually
from sport.
Following a UK Cartilage Consensus meeting in March 2014, BASK produced a consensus document.39
The points most relevant to this appraisal are summarised in Box 4.
Although the consensus recommends increased use of ACI, it would restrict it to people with symptoms
and higher-grade lesions. As the statement recognises, some people may have symptoms relieved by
physiotherapy. However, physiotherapy cannot repair chondral defects, so this group will still be at risk of
progression to OA.
BOX 4 Consensus statement from BASK
The surgical management of symptomatic articular cartilage defects of the knee:
consensus statement from UK knee surgeons
The statement notes variations in provision of repair of articular cartilage in the knee, and financial constraints
on the more expensive treatment options.
The consensus relates to management of an isolated chondral lesion in a knee that is free of other defects,
or in which these have been corrected. Key points include:
l Surgical treatment should be considered for symptomatic lesions of ICRS grade 3 or 4.
l MF leads to fibrocartilaginous scar tissue that has poorer biomechanical properties than normal hyaline
cartilage, and this repair tissue degenerates. Short-term improvement in symptoms does not persist.
l Mosaicplasty can give good short-term results in small lesions, but longer-term results are poorer. It is not
suitable for larger lesions or patellar defects.
l In small defects, less than 2 cm2, MF, mosaicplasty and ACI may all be considered.
l For lesions > 2 cm2, cell therapy (ACI) is the most effective treatment based on current evidence.
l Outcomes are poorer in smokers, patients with a BMI of > 30 kg/m2, and those with a long duration
of symptoms.
l When ACI is considered appropriate, it should be first-line treatment because results are poorer if it is used
after failure of other procedures.
l Physical therapy may be effective in controlling symptoms and should be provided before surgery
is considered.
BMI, body mass index.
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Chapter 2 Clinical effectiveness
This chapter has three sections. First, we review some recent reviews on ACI and comparators, to givesome general background. In this section, we provide information on most forms of ACI and how they
compare with MF. We do this partly because the evidence on the technologies identified in the NICE scope
is limited, both in terms of number of trials and duration of follow-up. This is a problem with evidence that
is not unusual with non-pharmacological therapies:
l We need long-term follow-up.
l The technologies are evolving.
l By the time we get long-term follow-up from a study, the technology may have been superseded.
This is unlike the situation in drug appraisals where the drug molecule does not usually change over time.
Second, we give an account of two recent trials of MACI.
Third, we present the results from survival analysis based on a review of long-term observation studies of
ACI and MF.
Systematic reviews
Inclusion criteria
Type of studies
We looked first for systematic reviews comparing relative effectiveness of ACI (any generation) and MF.
Type of participants
Adults with symptomatic articular cartilage defects.
Type of interventions
Autologous chondrocyte implantation for chondral defects in the knee only. All forms of ACI
were considered.
Type of comparators
The main interest was MF but no restrictions were applied.
Type of outcomes
The outcomes of interest, as in the NICE scope, were pain and other symptoms, knee function including
long-term function, rates of retreatment, activity levels, such as return to work or sport, avoidance of OA
and knee replacement, adverse effects of treatment and health-related quality of life (QoL).
Searches for systematic reviews
Databases searched for systematic reviews published between 2004 and June 2014 were the Cochrane
Database of Systematic Reviews, MEDLINE and EMBASE. The websites of the EMA, the US FDA and the
Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) database were also
searched for HTAs and other reports.
Detailed search strategies are provided in Appendix 1.
Study selection
Study selection was made independently by two reviewers. Discrepancies were resolved by discussion.
There was no need for discussion with a third reviewer.
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We selected recent reviews that provide comparative effectiveness data for ACI versus another comparator,
but some reviews on other topics such as rehabilitation were also useful.
Data extraction strategy
Data were extracted by one reviewer and checked by a second using a standardised data extraction form.
Discrepancies were resolved by discussion. There was no need for discussion with a third reviewer.
Quality assessment strategy
The quality of the reviews was assessed by one reviewer, and checked by a second reviewer. Any
disagreements were resolved by consensus. There was no need for discussion with a third reviewer.
The following quality criteria were used for assessing systematic reviews:
l inclusion criteria described
l details of literature search given (and adequate)
l study selection described (and adequate)
l data extraction described (and adequate)
l study quality assessment described (and adequate)
l study flow shown
l study characteristics of individual studies described
l quality of individual studies given
l results of individual studies shown
l statistical analysis appropriate.
Overall quality: high (≤ 1 of the criteria are not met)/medium (2–4 of the criteria are not met)/low
(≥ 5 of the criteria are not met).
Methods of analysis/synthesis
Results were summarised narratively and in tables.
Results
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram for
systematic reviews is shown in Appendix 2.
The quality assessment of the reviews is reported in Appendix 3.
Twelve relevant systematic reviews were included. One by Vasiliadis et al.45 was associated with a
Cochrane review46 but the former provides an update with more trials and is used here. The majority of
reviews was rated as ‘at least medium quality’, with three reviews being rated as ‘low quality’,47–49 six
reviews rated as ‘medium quality’ (Bekkers 2009,50 Kon 2009,51 Magnussen 2008,52 Mithöfer 2009,53
Nakamura 2009,54 Negrin 201355) and three reviews rated as ‘high quality’ (Harris 2010,44 Vasiliadis 2010,45
Vavken 201056).
Table 52 in Appendix 4 shows the primary intervention studies included in the reviews. Several reviews
treated separate publications from the same study, or of subgroups of a study, as separate studies. We
therefore checked the original studies and in the table we have grouped all reports from each study
together. The tables describing the characteristics of the reviews also record publications from the
same study.
The 12 reviews included 27 papers from 19 studies. Eleven of the studies were randomised trials (RCTs)
and eight were comparative cohort studies or non-randomised/quasi-randomised trials. None of the
primary studies was included in all of the reviews. Of the included primary studies, one compared
collagen-based ACI with periosteum-based ACI, four compared ACI with MACI, one compared open with
CLINICAL EFFECTIVENESS
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arthroscopic ACI, three compared ACI with mosaicplasty, eight compared ACI with MF, and one each with
bone marrow-derived mesenchymal stem cell therapy and with abrasion.
Characteristics of included reviews
Table 52 in Appendix 4 shows the characteristics of the included reviews. The reviews originated in various
countries worldwide. None of the author teams appears to have had any specific conflicts of interest.
Objectives
Most studies sought to compare the effectiveness of ACI with that of other surgical treatments. Half of
the reviews were very broad in their inclusion of comparators (Bekkers 2009,50 Harris 2010,44 Nakamura
2009,54 Naveen 2012,49 Vasiliadis 2010,45 Vavken 201056), whereas others were more specific, for example
comparing different generations of ACI (Goyal 201347) or focusing on MACI (Kon 200951) and comparing
with MF (Goyal 2013,48 Negrin 201355) or osteochondral autograft transfer (OAT) (Magnussen 200852).
One review focused on the effects of articular cartilage repair on athletic participation (Mithöfer 200953).
Inclusion criteria
Study design
The reviews included various types of study designs. They ranged from studies with very broad inclusion
criteria [any type of primary study (Kon 200951)]; RCT and prospective and retrospective studies with or
without a control group (Mithöfer 200953); RCTs, prospective comparative studies and case series
(Nakamura 200954) to studies including only level I and level II evidence/controlled trials or controlled
prospective observational studies (Goyal 201347 and Goyal 2013,48 Harris 2010,44 Magnussen 2008,52
Negrin 201355) and studies including only RCTs or quasi-RCTs (Bekkers 2009,50 Vasiliadis 2010,45 Vavken
201056). Naveen 201249 stated that they would include only RCTs, but among the actual studies included
were controlled clinical trials (CCTs) and comparative cohort studies. A few specified minimum follow-up
times [6 months (Vavken 201056), 12 months (Harris 2010,44 Magnussen 2008,52 Mithöfer 2009,53 Negrin
201355)] and minimum number of participants (Magnussen 200852).
Participants
Inclusion criteria for participants were not given by all reviews. Some generally referred only to ‘cartilage
defects of the knee’; in others, the criteria were more specific, requiring full-thickness cartilage defects of
the knee (Outerbridge grades III and IV: Harris 2010,44 Magnussen 2008,52 Mithöfer 2009,53 Negrin 2013,55
Vasiliadis 201045) and in some cases also specifying anatomical location (femur, patella, trochlea: Mithöfer
2009,53 Negrin 2013,55 Vasiliadis 201045). An age range was specified only by Vasiliadis et al. 201045
(15–55 years).
Interventions
For most reviews, the index intervention was ACI. In two reviews the focus was on MACI/newer methods
of ACI (Goyal 2013,47 Kon 200951). Magnussen 200852 also includes OAT among the index interventions.
In another review the index intervention was MF (Goyal 201348) and the authors reported outcomes only
for MF, so the review is listed in the tables but will not be considered in the Results section. Comparators
were not always explicitly stated, but included MF only (Goyal 2013,48 Negrin 201355), MF or osteochondral
autograft transplantation (Bekkers 200950), another ACI method (Goyal 201347), any cartilage repair
technique or another generation of ACI or open versus arthroscopic ACI (Harris 201044), any other method
(or placebo) (Magnussen 2008,52 Naveen 2012,49 Vasiliadis 2010,45 Vavken 201056) and any other method
or no comparator (Kon 2009,51 Mithöfer 2009,53 Nakamura 200954).
Outcomes
Often reviews did not explicitly specify outcome measures in their inclusion criteria. Whether specified or
not, the focus was generally on (validated) clinical outcomes. Mithöfer et al. 200953 specifically focused on
outcomes related to athletic activity. Many reviews also included information on the quality of the repair
tissue and on complications.
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Included studies
The reviews included between 3 and 13 comparative studies of individual populations relevant to this
review (i.e. studies not including ACI or without a comparison group were not counted), with data on total
numbers of patients ranging from around 200 to over 1000 participants. Individual study populations
ranged between 19 and 231 participants.
As indicated above, 11 of the 19 comparative studies included were RCTs and eight were comparative
cohort studies or non-randomised/quasi-randomised trials. Follow-up was between 6.5 months and
7.5 years (most reviews included studies with at least a year’s follow-up). Many of the reviews commented
on the quality of the studies, which overall was generally medium to low. Reasons included small sample
sizes, inadequate durations of follow-up, lack of allocation concealment, and not enough information on
method of randomisation, losses to follow-up and blinding of assessment scoring. Harris et al. 201044
reported that in their 13 included studies, quality was better in the later ones, but no studies were
considered good or excellent – seven were scored as fair and six as poor. The origin of the included studies
was generally not reported and only one review mentioned financial conflicts of interest of primary studies
(Harris 201044).
Where reported, the mean age of participants was between 26.4 and 40.4 years, between 47% and 80%
were men, and mean lesion size was between 1.9 and 6.4 cm2. Lesion sites were mainly the femoral
condyles, but sites such as the patella, trochlea and lateral tibia were also included. Both traumatic and
non-traumatic lesions were included. Many of the participants had had previous surgery. Duration of
symptoms before the intervention ranged between 1.5 and 10 years.
Box 5 shows the studies included in the reviews.
Gooding et al.23 compared first-generation ACI-P with second-generation ACI-C, and found them similar
in terms of repair quality, but with ACI-P requiring more subsequent procedures.23 They concluded that
ACI-C should be used and that ACI-P should be discontinued.
One trial by Bartlett et al. compared ACI-C and MACI (Verigen).57 Both gave good results but MACI
appeared slightly better, though most results were not statistically significant. (There were 44 patients in
one group and 47 in the other.) The advantages of MACI were reported to be no need for suturing, a
shorter procedure and a smaller incision. The proportions with good or excellent results were 72% with
MACI and 59% with ACI-C.
Four studies compared ACI (mostly ACI-P) with MACI, one study compared open with arthroscopic ACI,
three studies compared ACI with mosaicplasty, eight studies compared ACI-P with MF, and one study each
with bone marrow-derived mesenchymal stem cell therapy and with abrasion. Clinical outcomes were
measured using a wide range of different instruments. In some studies biopsies were also taken and
histological outcomes reported.
Results and conclusions of reviews
The reviews generally agreed that studies were heterogeneous and had various quality limitations
(as outlined above). The detailed results and the conclusions of the included reviews are provided in
Appendix 6, Tables 54 and 55.
Clinical results
Improvements from clinical baseline scores were found regardless of treatment. One review suggested a
small superiority of ACI (nine studies ACI-P, two ACI-C) compared with MF but not mosaicplasty (Harris
201044), but this review did not comment on the heterogeneity of results. Their forest plot44 comparing MF
and ACI showed three studies (Basad 20048 and Basad 201064 with MACI®; Saris 200869 and Saris 200970
with ChondroCelect; Kon 2009,73 MACI with Hyalograft) with better results with ACI, and one study
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BOX 5 Autologous chondrocyte implantation: primary comparative studies in reviews
Autologous chondrocyte implantation–collagen cap vs. autologous chondrocyte
implantation–periosteal flap
Randomised controlled trial
Gooding 2006.23
Autologous chondrocyte implantation vs. matrix-induced chondrocyte
implantation
Randomised controlled trials
Bartlett 200557 – MACI Verigen vs. ACI-C.
Zeifang 201058 – MACI vs. ACI-P.
Comparative cohort
Erggelet 201059 – MACI (BioSeed-C; BioTissue Technologies, Freiburg, Germany) vs. ACI-P.
Niemeyer 200860 – ACI-P vs. ACI-C vs. MACI (but each done by a different surgeon).
Open vs. arthroscopic autologous chondrocyte implantation
Comparative cohort/controlled clinical trial
Ferruzzi 200861 – MACI, open vs. arthroscopic.
Autologous chondrocyte implantation vs. mosaicplasty
Randomised controlled trial
Bentley 20035 – ACI-P.
Dozin 200562 – ACI-P.
Controlled clinical trial
Horas 200063 – ACI-P (Described as RCT but inadequate randomisation method – alternation).
Horas 20036 – ACI-P.
It is not clear whether the patients in Horas 200063 are included in Horas 2003.6
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Autologous chondrocyte implantation vs. microfracture
Randomised controlled trial
Basad 20048 – This is presumably a preliminary report of the trial and patients reported in the first paper are
expected to be included in the second report, Basad 2010.64
Bachmann 200465 – This trial used MACI.
Crawford 201266 – MACI (Neocart – Histogenics, Waltham, MA, USA).
Knutsen 20047 and Knutsen 200767 – ACI-P.
Lim 2012,68 – ACI-P.
Saris 200869 – RCT ACI-P with CCI.
Saris 2009.70
Vanlauwe 2011.43
Van Assche 200971 (Both Van Assche references involve the same subgroup of patients from the Saris RCT.)
Van Assche 2010.72
Comparative cohort
Kon 200973 – MACI Hyalograft (Anika Therapeutics, Bedford, MA, USA).
Kon 201174 – MACI Hyalograft.
Minas 200975 – Case series on effect of previous MF.
Autologous chondrocyte implantation vs. bone marrow-derived mesenchymal
stem cell
Comparative cohort
Nejadnik 2010.76
Autologous chondrocyte implantation vs. abrasionplasty
Randomised controlled trial
Visna 200477 – MACI fibrin glue.
BOX 5 Autologous chondrocyte implantation: primary comparative studies in reviews (continued)
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(Knutsen 2004 and 20077,67 with ACI-P) reporting better results with MF. It was noted that the Knutsen7,67
results showed an advantage for MF at 2 years but not at 5 years. Harris et al.44 concluded that MF
showed an initial advantage that was then lost over time. They also concluded that there was a trend for
ACI to show better outcomes than MF, but that a lack of long-term data meant that no definite verdict
could be reached. Harris et al.44 also commented on problems in interpretation due to the number of
additional procedures undertaken in some studies, mainly meniscectomy and cruciate ligament repair.
Vakven et al. 201056 compared ACI (five ACI-P, one MACI, one fibrin glue) with mosaicplasty and MF, and
were similarly cautious, mentioning ‘a general trend for higher quality of repair tissue after ACI, suggesting
better long-term results when compared to MF and osteochondral grafts’ especially in higher-quality
studies, but concluded that ‘no clear recommendation can be deducted’.
Various reviews, including Vavken and Samartzis 2010,56 questioned whether or not any small but
significant differences seen in clinical outcomes were of real clinical importance. Significant differences
between different generations of ACI were generally not seen. The delay in reaching maximal functional
improvement (i.e. with respect to return to sports) may be slightly longer with ACI than with other
interventions, but overall long-term durability may be greater with ACI.
Quality of repair tissue
The evidence suggested that ACI (all forms) may have a more durable repair tissue than MF (e.g. more
hyaline-like cartilage).
Complications
Most notably, periosteum-based ACI was associated with a high rate of graft hypertrophy (over 20%)
compared with only 3% with ACI-C (Harris 201044). Failure rates showed a reduction over the ACI
generations: ACI-P 7.7%; ACI-C 1.5%; and 0.83% in all-arthroscopic second-generation ACI. Unplanned
reoperation rates ranged from 27% with ACI-P to 1.4% in second-generation ACI. Harris et al.44 found
too few studies of third-generation ACI to report failure rates.
Modifying factors
Overall, outcomes tended to be better for younger patients [< 30 or < 35 years (age threshold varies
among studies)], more active patients, patients with shorter symptom duration, and patients who had not
had a previous failed surgical intervention. Results also tended to be better for smaller lesions overall,
whereas ACI produced better results than MF in larger lesions (and its effect was largely independent of
lesion size).
Recommendations for practice
Only five reviews made clear practice recommendations. Two of these (Vasiliadis 2010,45 Vavken 201056)
stated that the evidence was insufficient to recommend ACI over any other methods. The other three
reviews agreed that MF was the first-line treatment for smaller lesions (< 1–2 cm2) and that ACI was
indicated for larger lesions (> 2 cm2). The opinion about mosaicplasty was divided, with one review noting
that its usefulness may be limited by donor site morbidity (Harris 201044).
The MSAC report32 also reviewed previous reviews and noted that most had been inconclusive, for reasons
including:
l problems with the quality of the trials and other studies
l heterogeneity of patients recruited and of ACI and MACI techniques used
l variations in ages of recruits and size of defects
l variations in previous surgery
l multiple scoring systems and lack of standard outcomes
l safety data not reported as comprehensively.
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Autologous chondrocyte implantation after previous microfracture
Microfracture is much less expensive than ACI, and is effective in the short term in most cases. It might
therefore be suggested that MF should be tried first, and ACI used if it failed.
However, there is evidence that prior MF makes ACI less effective, because of a higher failure rate. This
may be related to damage to the subchondral bone. Minas et al.75 compared two cohorts of patients who
had ACI-P, one group (111 patients) having had previous marrow stimulation procedures (MF, drilling or
abrasion arthroplasty, all based on repair of the chondral defect by development of fibrocartilage from a
blood clot) and the other (214) not. The groups were similar in age, duration and size of cartilage defect,
duration of follow-up, concomitant procedures such as osteotomy or ligament repair, and size of
repaired areas.
Failure was defined as persistence or recurrence of symptoms, or the need for a repeat procedure or
knee replacement. The failure rate in those who had ACI as first procedure was 8% (17/214), but was
26% (29/111) in those who had had previous marrow procedures, and 20% in those who had had MF
(but numbers small, 5/20).
Minas et al.75 also report a subgroup of 15 patients who had more than one chondral defect (35 defects in
total) about half of which had been treated by marrow stimulation and half not, with all then receiving
ACI. The failure rate was 2 out of 18 in the previously untreated lesions and 16 out of 17 of the previously
treated ones.
If ACI is less effective after prior MF, there are implications for the interpretation of results from some of
the trials. For example, the Stanmore ACI trial78 results were in patients who had had an average of
1.5 previous repair procedures. Only six patients had not had a previous repair procedure, so they could
not compare results in those with/without previous surgery. Similarly, in a case series (Biant 201479) in
patients with long-duration cartilage defects, those who had had previous procedures, such as MF, had
29% (21/72) failure of ACI compared with a 19% (6/32) failure rate in those having primary ACI. Failure
was defined as requiring reoperation, somewhat stricter than in the Minas study.75
One of the largest series of patients having ACI was reported by Nawaz et al. from Stanmore:80
1000 patients had ACI (519 with MACI, the rest ACI-C and some ACI-P) from 1998 to 2008.80 In 827
patients with full follow-up data (mean follow-up 6.2 years), graft survival was 78% at 5 years and 51%
at 10 years. Failure of the graft was 4.7 times as likely in the 34% who had had previous procedures
(MF, mosaicplasty and drilling – numbers of each not given).
Pestka et al.81 reported a case series wherein 28 patients had MACI after previous MF and a matched 28
had MACI as first procedure. Failure was much more common in the previous MF group (7/28) than in the
MACI as first procedure group (1/28).
There are two implications for this review. First, results seen in past trials wherein ACI was being used as a
salvage procedure in patients with long-standing lesions and who had had previous procedures, may
underestimate the benefits of ACI used as first procedure in patients with chondral defects of more recent
origin. Second, a case could be made that ACI should be used as the primary procedure.
Other reviews
Mithöfer et al.82 carried out a systematic review of outcomes of MF, including 28 studies with 3122 patients,
mean follow-up 41 months, with 1524 patients having follow-up of > 5 years. They noted good results in
short-term functioning, but with need for further surgery increasing after 2 years, with rates of up to 31%
by 5 years. Only five studies provided data beyond 5 years, of which one was a RCT and four were case
series. At 6–7 years, most (67–86%) patients had improved knee functioning compared with baseline.
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Several reviews examined factors that might predict success or failure. Behery et al.83 reviewed 12 case
series with 270 knees and found that none of age, gender, duration of symptoms and lesion size
significantly predicted outcomes. They noted successful use of ACI in patients aged over 50 years in three
studies. They concluded that the lack of association with lesion size made ACI preferable to MF in larger
lesions. Another review from the same group84 looked at factors that might influence the choice of repair
method, and concluded that MF was less effective in larger lesions, when larger was defined (in different
studies) as being greater than 2–4 cm2.
Chalmers et al.85 set out to systematically review activity-based outcomes [Tegner score, Lysholm score,
KOOS, International Knee Documentation Committee (IKDC) score and the physical activity component of
the Short Form questionnaire-36 items (SF-36)] after MF, ACI and mosaicplasty. They found only five
studies that reported return to sporting activity. Return was faster after MF than ACI, but, beyond 2 years,
activity scores deteriorated after MF but remained stable after ACI, though there was variation among
sports. They noted the lack of long-term data on effects on later OA.
Mosaicplasty
Early results from the Stanmore trial (Bentley et al.5) showed good or excellent results in 88% after ACI-P
or ACI-C compared with 69% after mosaicplasty, and the results at a minimum of 10 years’ follow-up
showed that repairs failed in 55% (23/42) of the mosaicplasty group and 17% (10/58) in the ACI group.
For ACI, the patients in this trial were a difficult group, having a mean duration of symptoms of 7.2 years
and an average of 1.5 previous procedures (excluding arthroscopy).
The Stanmore trial was omitted from the review by Harris et al. 2010,44 which had only two studies of
mosaicplasty, both favouring ACI, but with very wide confidence limits that overlapped with no difference.
The review by Vasiliadis et al.45 identified three trials of mosaicplasty against ACI, two against ACI-P and
one (Bentley et al.5) with both ACI-P and ACI-C. They reported that one trial (Horas 20036) favoured
mosaicplasty but another (Dozin 200562) found no difference. Vavken and Samartzis, reviewing the same
studies, reported that the Horas trial6 showed no difference in clinical scores.56
Bekkers et al.50 concluded that single-plug mosaicplasty was the best option for small (less than 1- cm2
osteochondral lesions).50
The MSAC concluded that mosaicplasty should probably not be a comparator to MACI on the grounds of
very low use in Australia.32
Trials
Methods
Inclusion criteria
Type of studies
l Randomised controlled trials comparing second- and third-generation ACI and following patients for at
least 2 years.
l Observational studies with at least 50 participants and follow-up of over 3 years were also considered,
for results in routine care, adverse events (AEs) and costs.
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Type of participants
l Adults with a symptomatic cartilage defect (chondral defect) but without advanced OA were included.
The chondral defects can be on the femur, tibia or patella.
l The NICE scope did not report age restriction; however, we included studies comparing interventions of
interest in patients aged 18 years and over.
Type of interventions
l ACI for chondral defects in the knee only. (ACI has also been used in shoulder, elbow, ankle and hip
problems.) The forms of ACI considered were:
¢ The ChondroCelect ACI, referred to by TiGenix as CCI.
¢ The Matrix ACI system (MACI®) from Sanofi.
¢ ‘Traditional ACI’ – the term used by NICE to describe ACI provided in the UK by hospitals that are
using cells produced by non-commercial units, for their own use or for use in trials.
Type of comparators
l Microfracture is the main comparator. Mosaicplasty is now in limited use, for small defects only.
Osteochondral grafts from cadavers can be used but are not to any significant volume in the UK and
were not considered.
Type of outcomes
The outcomes considered, as also mentioned in the NICE scope, were as follows:
l pain
l knee function, including long-term function
l rates of retreatment
l activity levels, such as return to work or sport
l avoidance of OA and knee replacement
l adverse effects of treatment
l health-related QoL.
Table 2 summarises some of the outcomes used in ACI studies.
Howard et al.86 carried out a high-quality systematic review to compare the various patient-reported
outcome measures used in assessing the effects of ACI. They included 42 studies, grading the quality of
studies with the Coleman methodology score. They concluded that the Lysholm and IKDC were the most
responsive to change (i.e. showing larger effect sizes), but that IKDC and KOOS-Sports might reflect
long-term outcomes better. They noted that the Cincinnati knee score also appeared satisfactory but based
on few studies that there were several versions of this score, and many studies were excluded because the
authors failed to state which version was used.
Exclusion criteria
We did not include trials of ACI-P in this section on the grounds that it had been replaced by third-generation
ACI, but it should be noted that most long-term outcomes are from studies of first-generation ACI.
Search strategy
The databases that were searched for primary studies on clinical effectiveness published between 2010
and June 2014 were the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and
the Web of Science.
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The inclusion lists of recent systematic reviews were also checked, and additional searches were done for
ongoing or recently completed studies.
Auto-alerts in MEDLINE and EMBASE were run for the duration of the review to ensure that newly
published studies were identified.
Details of search strategies are given in Appendix 1.
Identification of studies
Two independent reviewers screened titles and abstracts of the results were retrieved against the inclusion
criteria. Those studies meeting the inclusion criteria were retrieved in full and checked for final inclusion by
two reviewers independently. There was no need for discussions with a third reviewer.
Data extraction strategy
The data extraction template used by Harris et al.31 was used and adapted for this review. One reviewer
extracted data, which was checked by a second reviewer.
Quality assessment strategy
The quality of the studies was assessed using the modified Coleman methodology score.31 There are
15 items in total, namely inclusion criteria, power, alpha error, sample size, randomisation, follow-up,
patient analysis, blinding, similarity in treatment, treatment description, group comparability, outcome
assessment, description of rehabilitation protocol, clinical effect measurement and number of patients to
treat. A study could be rated as ‘excellent’ if the total score is between 85 and 100, rated as ‘good’ for
scores between 70 and 84, rated as ‘fair’ with scores between 55 and 69, and, finally, categorised as
‘poor’ for scores of < 55.
The quality of the study was assessed by one reviewer and checked by a second reviewer.
Results
A total of 1672 records were retrieved by the searches. The title and abstracts were screened for inclusion
and exclusion. Based on titles and abstracts, 104 records were considered possible inclusions and full texts
of these were obtained. Out of 104 articles, two RCTs were included as definite inclusions and the
TABLE 2 Outcomes used in cartilage repair studies
Outcome measure Variables included
Lysholm score Range of 0–100 (best), based on patient responses on eight aspects: pain, limping, locking,
stair climbing, need for supports, instability, swelling and squatting
Tegner score A level of activity measure from best 10, with ability to take part in competitive sports at a very
high level, to worst 0, disabled
KOOS Assesses pain, symptoms, ADL, sport and recreational activities, and knee-related QoL, with
scores of 0 (worst) to 100 (best)
Cincinnati knee score Based on symptoms (pain, swelling) and function (walking, climbing stairs, running) with a score
of 0 (worst) to 10 (best). Variants include a sports rating from 0 to 100 points
ICRS score This assesses quality of tissue repair rather than patient-reported outcomes. It could be argued
that the quality of tissue repair might be useful for extrapolating from short-term histological
results to long-term OA and need for knee replacement, but there is far from perfect correlation
between symptoms and the degree of OA
IKDC score Range 0 (worst) to 100 (best), based on function, symptoms, and range of motion. The version
‘IKDC Subjective’ is so-called because it is completed by patients
ADL, activities of daily living.
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remaining 102 articles (which included the 12 systematic reviews included above) were excluded.
The reasons for exclusion of 26 studies retained for final discussion by both reviewers is given in Table 3.
(One of the excluded studies, reported in Saris et al. 200869 and 2009,70 and Vanlauwe et al. 2011,43 is
described in the next chapter.)
MACI® versus microfracture
Two studies (Basad 2010,64 Saris 2014100) compared MACI against MF in patients with a symptomatic
cartilage defect in the knee.
Basad et al. 2010
This RCT compared MACI, a third-generation ACI (then a Genzyme product) against MF in patients with
symptomatic cartilage defects. Patients in the trial came from one centre (the principal author’s clinic in
Germany) between 2000 and 2005.
TABLE 3 Reason for exclusion of studies
First author and year Reason for exclusion
Bartlett 200587 Technique includes bone graft
Bartlett 200557 ACI (first generation) vs. MACI. 1-year FU
Benthien 201188 Not a systematic review – no details of individual studies are given
Bentley 20035 ACI (first generation)
Bentley 201278 ACI (first generation)
Cole 201189 Not a form of ACI that we are including (CAIS)
Crawford 201266 Not a form of ACI that we are including (NeoCart)
Dozin 200562 ACI-P
Ebert 201090 Comparing rehabilitation approaches after MACI
Ebert 201291 Comparing rehabilitation approaches after MACI
Edwards 201392 Comparing rehabilitation approaches after MACI
Harris 201093 Only includes one RCT that is not on ACI
Knutsen 20047 Old RCT of ACI-P
Knutsen 200767 Five-year results from above trial. ACI-P
Lim 201268 ACI-P
Panseri 201294 Osteochondral defects
Rodriguez-Merchant 201295 Short narrative review
Ruano-Ravina 200696 Too old
Saris 2008 and 200969,70 ACI-P
Toonstra 201397 Case series, only 20 patients, no controls
Trinh 201398 About osteotomies, not ACI
United Healthcare 201399 Not based on a systematic review
Van Assche 200971 ACI-P
Van Assche 201072 ACI-P
Ziefang 200958 ACI-P vs. MACI and small numbers
CAIS, cartilage autograft implantation system; FU, follow-up.
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Quality assessment
Using the modified Coleman methodology score, the study scored a total of 45 suggesting that the quality
of the study is poor, though this is partly due to failure to report items, so the study scored 0 points
for those items. The enrolment rate was not reported, losing a maximum of 9 points. The power of the
study (maximum score of 6 points) was not reported and it was not clear whether blinding of outcomes
assessment (maximum score of 6 points) was done. There was no information available on effect size
(maximum 6 points), relative risk (RR) reduction (maximum 6 points) and absolute risk reduction (maximum
6 points). There were some baseline differences between the two groups, so the study scored 6 points out
of a possible 9 points. The study also lost points on the number of patients retained at the end of follow-up
– 86.4% completed the 2-year follow-up period thereby scoring 4 points instead of a maximum 6 points.
Patient characteristics
Basad et al.64 included 60 patients aged ≥ 18 and ≤ 50 years with a single symptomatic chondral lesion of
femur or patella of size between 4 and 10 cm2; 40 received MACI and 20 MF. The mean ages of patients
were 33 years in the MACI group, and 37.5 years in the MF group. The mean body mass index (BMI) of
patients in the MACI was slightly lower than that in the MF group (25.3 kg/m2 vs. 27.3 kg/m2). Previous
surgery, if any, was not reported. Most defects in both groups were condylar (73% in MACI and 80% in
MF), with the remaining lesions being in the patellar–trochlear region (28% in MACI and 20% in MF).
Most patients were male (63% in MACI and 85% in MF). Patients in the MACI group had had symptoms
for 2.2 years and those in the MF group for 2.5 years.
Details of intervention and comparators
Patients in the intervention group received MACI. The published paper states that the original protocol
of the study had three interventions including two MACI groups and one MF group. In the two MACI
groups, two different collagen matrices (supplied from two different manufacturing sites – name not
reported) were used. The two matrices were considered identical in all aspects, so the two MACI groups
were combined in the analysis.
Arthroscopy was done in all patients to assess their eligibility for the study (mainly isolated defect > 4 cm2).
Patients in the MACI group had a sample from healthy cartilage sent for cell culture. Patients allocated to
the MF group received treatment in one procedure. The MACI group returned 4–6 weeks later to have the
chondrocyte-seeded collagen scaffold implanted into the defect, cell side down, facing the subchondral
bone, and sealed with a thin layer of fibrin sealant.
Patients in both groups could also receive treatment for other concomitant lesions of cartilage or meniscus.
All patients underwent a post-surgery rehabilitation programme. Those in the MF group received the
rehabilitation programme recommended by Steadman et al.,101 which included 6 weeks of partial
weight-bearing with 10-kg weight on crutches, continuous passive motion (CPV) and physiotherapy.
After 6 weeks, patients were allowed to gradually progress into full weight-bearing.
The rehabilitation programme in the MACI group was slightly different. All patients had a plaster cast for
2 days after surgery in order to prevent graft delamination. Then, for the next 8 weeks, the programme
included CPV, physiotherapy and partial weight-bearing with 10-kg weight on crutches.
All patients also received low-molecular-weight heparin each day during the partial weight-bearing phase
to prevent deep-vein thrombosis (DVT).
Duration of follow-up
Patients were followed up for 2 years.
Outcomes
The primary outcome measures included the Tegner, Lysholm and ICRS scores. The Tegner score is related
to activity levels of an individual, whereas the Lysholm score is related to pain, stability, gait and clinical
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symptoms. The primary outcomes were measured at 8–12 weeks, 22–26 weeks and 50–54 weeks after
surgery. One week after surgery, MRI scans were done in patients to see if there was delamination and
graft hypertrophy. The efficacy population was defined as patients completing at least 6 months of
follow-up, whereas completers were defined as those completing 2 years of follow-up. The definition of
failure was not given.
Results
In total, 56 patients (39 in MACI and 17 in MF) completed at least 6 months of follow-up, and 48 patients
(33 in MACI and 15 in MF) completed 2 years of follow-up. There was one early failure in the MF group
but time was not reported. Two patients in the MF group (one pregnancy and one who had mosaicplasty)
and one patient in the MACI group dropped out of the study.
There was improvement in the mean Lysholm score in both groups at year 1. The improvement in the
MACI group persisted up to year 2 (52 at baseline, 95 at 12 months, 92 at 24 months), but it declined in
the MF group after 12 months (55 at baseline, 81 at 12 months, 69 at 24 months). The improvement in
Lysholm score from baseline to follow-up was statistically significant in both groups (p < 0.0001).
The improvement in the median Tegner score from baseline was greater in the MACI group than in the MF
group. The Tegner score in the MACI group improved from level 2 to level 4 at 12 months, and remained
at the same level at 24 months. The Tegner score in the MF group improved from level 2 to level 3 at
12 months, which was maintained at 24 months. The improvement from baseline to end of follow-up was
statistically significant in both groups (p < 0.0001) but the improvement was statistically significantly greater
in the MACI group than in the MF group (p = 0.04).
Some patients had issues with irritation during increased weight-bearing, treated with non-steroidal
anti-inflammatory drugs (NSAIDs) and by returning to partial weight-bearing for a week. In the MACI
group, one patient had persistent pain after 12 months and had arthroscopy, at which even and firmly
regenerated cartilage repair was seen. The patient had persistent subchondral oedema. To relieve oedema,
bone grafting was done.
Comments
The Basad group64 has had long experience with ACI, so their results may be better than might be seen in
routine care. Patients were treated with fairly short duration of symptoms, which may improve outcomes
after ACI.
Saris et al. 2014
This trial100 (SUMMIT, Superiority of Matrix-induced autologous chondrocyte implant versus Microfracture
for Treatment of symptomatic articular cartilage defects) was a prospective, open-label, parallel-group,
multicentre (16 European sites) RCT comparing Genzyme MACI (Genzyme, Europe) against MF.
Quality assessment
Using the modified Coleman methodology score, the study scored a total of 72 points, suggesting that
the quality of the study is good. Information on blinding of outcomes assessment was not fully reported.
There was no information on effect size, RR reduction and absolute risk reduction.
Patient characteristics
Patients aged between 18 and 55 years with one or more symptomatic cartilage defects, Outerbridge
grade III or IV focal defects of size ≥ 3 cm2 on medial or lateral femoral condyle and/or trochlea, and with
a moderate to severe KOOS. There were 72 patients in each group. Most patients were male (62% in
MACI, 67% in MF). Patients in the MACI group were slightly older than in the MF group (35 vs. 33 years).
Mean BMIs were similar (26 kg/m2). 90% of patients in the MACI and almost 84% in the MF had
undergone previous knee surgery. The most common prior procedures included diagnostic arthroscopy
(50.3%), marrow stimulation techniques (in MACI group, MF 19%, drilling 11%), debridement of the
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lesion (26.3%) and loose body removal (23.2%). Patients in the MACI group had had knee symptoms for
longer than those in the MF group [mean of 5.8 years (range 0.05–28 years) vs. mean 3.7 years (range
0.1–15.4 years)]. The mean defect size of the lesions was similar across the groups (4.9 cm2 in MACI and
4.7 cm2 in MF). Most defects in both group were on the medial femoral condyle (75% in MACI, 74% in
MF), followed by the lateral femoral condyle (18% in MACI, 21% in MF) and trochlea (7% in MACI,
6% in MF). No tibial defects were reported.
Details of intervention and comparators
All patients underwent arthroscopy at baseline to examine their cartilage lesion and surrounding tissues.
A small biopsy of cartilage (≈ 200 mg) was taken from a non-weight-bearing healthy area of the femoral
condyle in all patients before randomisation, done using an interactive voice response system and
computer-generated randomisation system. Those randomised to MF had it immediately. The technique
recommended by Steadman et al.101 was followed, which included debridement and drilling multiple holes
of centres 3–4 mm apart and 4 mm deep in the subchondral bone. Biopsies from patients receiving MF
were preserved in case they later required MACI treatment. The MACI group had implantation of the cells
4–8 weeks after biopsy, by mini-arthrotomy. The MACI implant was trimmed to the size of the cartilage
defect and implanted securely using a thin layer of fibrin sealant.
After surgery, both groups underwent the same rehabilitation programme, but individualised for patients.
This was a four-phase programme recommended by Steadman et al.101
Duration of follow-up
Patients were followed up for 2 years. At the end of the follow-up, arthroscopy was performed to assess
the condition of the knee.
Outcomes
The primary outcome measures were changes in KOOS for pain and function (sports and recreational
activities subscore) subscales from baseline to year 2. Other outcome measures included histological
evaluation of structural repair biopsy specimens, as measured by the microscopic ICRS-II overall assessment,
and MRI assessment of the degree of defect fill, as measured by the scale of the whole-organ MRI score
(WORMS: 0–25%, 26–50%, 51–75%, 76–100%).
In the study, response was defined as an at least 10-point improvement in KOOS for the pain and function
subscales. Anyone not meeting both criteria was classed as a non-responder.
Failure was defined as any of the following:
l no improvement or worsening of the patient and physician global assessment
l less than 10% improvement in KOOS-pain
l a need for surgical re-intervention.
Those diagnosed as failures by physicians were further assessed by an independent treatment failure
evaluation committee, who decided whether or not those cases were failures.
Results
A total of 144 patients was included in the study, 72 in each group. Ninety-five per cent (137/144) of
patients completed the 2-year follow-up period. None of the patients in the MACI group discontinued
treatment due to lack of efficacy, whereas three patients in the MF group discontinued study because of
lack of efficacy.
The mean change in KOOS-pain from baseline to 2 years was significantly greater in the MACI group than
in the MF group (45.5 vs. 35.5, difference between groups 11.76; p = 0.001). The change in the KOOS-
function from baseline to 2 years was also significantly greater in the MACI group (46 vs. 36.1, difference
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between groups 11.41; p < 0.001). Saris et al.100 reported that the improvement in the KOOS-pain and
pain score in the MACI over MF was observed at 36 weeks and maintained throughout the study period.
The proportion of responders was significantly greater in the MACI group than in the MF group (87.5% vs.
68.1%; p = 0.016) with more non-responders in the MF group (31.9% vs. 12.5%). Subgroup analyses
found that more patients responded after MACI than after MF if patients had the following characteristics:
male with a median age of < 34.5 years, only one lesion, lesions as a result of acute trauma, history of one
previous surgery, symptoms for > 3 years (symptomatic response in those with under 3 years’ duration:
82% with MACI and 69% with MF; over 3 years 92% and 67%) and size of lesions > 4 cm2 and located on
the medial femoral condyle. However, there were no statistically significant differences in response rates
whether patients had or had not had previous cartilage surgery, as shown in Table 4.
In patients with larger lesions, ACI was reported to be more successful: 97% responders for MACI versus
77% for MF.
The improvements in other domains [activities of daily living (ADL), knee-related QoL, other symptoms] of
the KOOS subscales were also statistically significantly greater with the MACI than with the MF. The mean
differences between the two groups were:
l for the domain, ADL (mean change of 43.7 with MACI from baseline to 2 years; 33.2 with MF) at
2 years, estimated mean difference 12.01; p < 0.001
l for knee-related QoL (mean change of 37.4 with MACI from baseline, 30.1 with MF), estimated mean
difference 8.98; p = 0.029
l for other symptoms (mean change of 35.4 with MACI from baseline, 27.8 with MF), estimated mean
difference 11.61; p < 0.001.
At 2 years’ follow-up, the modified Cincinnati knee score was significantly greater with MACI than with
MF (1.05; p = 0.002). The IKDC score also showed favourable results for MACI (mean change from
baseline with MACI 32.8 vs. MF 29.5); however, the difference between the two was not statistically
significant (p = 0.069).
Comparison of treatment failure rates between treatment groups was not conducted because of the small
number of failures: only two patients in the MF and none in the MACI group.
At 2 years’ follow-up, 116 patients (60 in MACI, 56 in MF) underwent second-look arthroscopy and
biopsy. There was good structural tissue repair with both treatments, and the repair was similar to the
surrounding healthy cartilage. The mean ICRS-II overall assessment scores of the two treatments were
similar (63.8 with MACI, 62.3 with MF, difference of 1.52; p = 0.717). The proportion of patients with
overall assessment scores of normal or nearly normal (grade 1/2) was greater in the MACI group than in
the MF group (76% vs. 60%).
At year 1 and year 2, 134 and 139 patients, respectively, underwent MRI evaluation. At year 1, the
improvement was similar, but at year 2, more patients in the MACI group had a defect fill of > 50% of
the defect depth than those in the MF group (83% vs. 77%).
TABLE 4 Response rates after prior cartilage procedures
Prior cartilage surgery MACI (%) MF (%)
No surgery 90 74.2
1 previous repair 87 67.9
> 1 previous repair 84.2 53.9
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More patients in the MF group complained of treatment-related AEs than in the MACI group (83.3% vs.
76.4%), the intensities of which were mild to moderate. The most commonly reported AE was arthralgia
(57.6% overall – 51.4% MACI, 63.9% MF). Other events included back pain (11.1% MACI, 9.7% MF),
joint swelling (9.7% MACI, 5.6% MF), joint effusion (6.9% MACI, 5.6% MF), pyrexia (5.6% MACI, 2.8%
MF), cartilage injury (4.2% MACI, 12.5% MF), procedural pain (4.2% MACI, 5.6% MF) and ligament
sprain (2.8% MACI, 5.6% MF). One patient (1.4%) in each group discontinued treatment due to AEs.
More patients in the MF group had serious adverse events (SAEs) than in the MACI group (26.4% vs.
15.3%) such as treatment failure, cartilage injury and arthralgia.
Similar proportions of patients in the two groups underwent at least one subsequent surgical procedure
(8.3% in MACI and 9.7% in MF). Two patients in the MACI group and none in the MF group underwent
two subsequent surgical procedures. It has been reported that increasing age (not clear at what age)
significantly decreased the likelihood of undergoing further procedures (p = 0.038).
Comments
Two factors will have reduced the chance of improvement: the long duration of symptoms before ACI
(5.8 years) and the high proportion (37%) that had had previous surgery (not counting arthroscopy).
Summary of European Medicines Agency European Public
Assessment Report
The EMA made a positive recommendation on MACI (manufactured by Genzyme Europe but then owned
by Sanofi) on 25 April 2013. MACI has been recommended for the ‘repair of symptomatic, full-thickness
cartilage defects of the knee of 3–20 cm2 in skeletally matured adult patients’.42 The product is available as
an implantation matrix consisting of cultured chondrocyte cells on a membrane (500,000 to 1 million cells
per square centimetre).
The clinical evidence on MACI came from the SUMMIT trial100 (described above), which reported that
MACI was better than MF in treating symptomatic cartilage defects of the knee, with size of the lesions
ranging between 3 and 20 cm2.
The EMA made a positive recommendation on ChondroCelect (TiGenix) on 25 June 2009.40 ChondroCelect
was recommended for the ‘treatment of repair of single symptomatic cartilage defects of the femoral
condyle of the knee (International Cartilage repair Society [ICRS] grade III or IV) in adults.’
The clinical evidence on ChondroCelect came from the TIG/ACT trial (described in detail in Chapter 5 –
Vanlauwe et al. 201143), a phase III, randomised, multicentre trial comparing ChondroCelect with MF in
patients with a single symptomatic cartilage lesion of the femoral condyles of the knee. At the time of
appraisal, results from 12, 18 and 36 months were available, but we now have the 5-year results from
Vanlauwe et al. 2011.43
For discussion and conclusions on clinical effectiveness, see the end of Chapter 5.
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Chapter 3 Survival analysis
Background
Following the second Appraisal Committee meeting, NICE requested additional work and further analyses
from the Assessment Group.
In the assessment report, we focused on the second and third generations of ACI, on the assumption that
the first generation, ACI-P, had been superseded by the later generations, because the new techniques were
simpler and quicker and the use of periosteum was associated with the complexity of harvesting and ensuring a
watertight cap, with overgrowth hypertrophy requiring reoperation and shaving of the graft, and the extra
discomfort to patients from these procedures. The collagen cap is much easier to use but does come at an extra
cost. The third generation of ACI in which the cells are seeded on to the collagen membrane is quicker still.
Because the second (ACI-C) and third (MACI) generations of ACI are fairly recent developments, we lack
long-term data on their success rates. The TIG-ACT trial of ChondroCelect has 5-year follow-up,43 but the
SUMMIT trial100 of MACI has so far published only 2-year results in full, with 36-month results in an abstract.
Therefore, NICE requested a review of all studies that provide long-term outcomes for ACI and MF,
including both RCTs and observational studies, and all generations of ACI. In practice, if we define long
term as more than 5 years, the ACI evidence comes from first-generation ACI; ACI-P.
There is some evidence to support extrapolating long-term outcomes after ACI-P to later generations.
Gooding et al.23 compared first-generation ACI-P with second-generation ACI-C and found them similar in
terms of repair quality. There is no evidence that ACI-P has any advantages over ACI-C or MACI. (There
was once a theory that the periosteal cap might promote chondrocyte function.) So, it seems reasonable
to assume that data on longer-term outcomes of chondral defect repairs from studies of ACI-P can be
extrapolated to survival of repairs after ACI-C and MACI. Niemeyer et al.102 compared ACI-P with ACI-C
with 23 patients receiving each, matched for defect size and site, and age. Lysholm and IKDC scores were
better with ACI-C (Lysholm, 63 versus 76, p = 0.03; IKDC 76 vs. 68, p = 0.023) but failures rates (defined
as need for re-intervention) were the same by 10 years – 4 out of 23 in each group (17%).
Goyal et al.47 carried out a meta-analysis to compare first-generation ACI with later generations, but found only
three relevant studies, one of which was Gooding et al. 2006.23 Niemeyer et al. 2014102 was not included. Goyal
et al.47 concluded that there was only weak evidence that ACI-C was any better than ACI-P because studies
were up to only 2 years’ duration and numbers were small. However, ACI-C was clearly no worse than ACI-P.
Autologous chondrocyte implantation–collagen cap was compared with MACI in one randomised trial
from the Stanmore group. Bartlett et al.57 randomised 91 patients to ACI-C or MACI. Follow-up was for
only 1 year. The MACI group did better in symptoms, but the ACI-C group did better in cartilage quality.
Despite randomisation, the ACI-C group had longer duration of symptoms (119 months vs. 88) and a
higher proportion of previous failed procedures (20% vs. 4%), both of which are associated with poorer
outcomes. However, the surgical team had longer experience of ACI-C than MACI.
In passing, it is worth noting the long duration of symptoms in many of the trials, and that this means that
the results are likely to be worse than if ACI was used much sooner.
We therefore carried out a systematic review of long-term results of MF and ACI, defining long term as
at least 5 years, not restricting study design, and assuming that the survival results of ACI-P could be
extrapolated for modelling purposes to ACI-C.
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Methods
l Inclusions Studies of any type of ACI that uses periosteal or collagen caps, or collagen matrices.
Studies of MF, both traditional and capped [autologous matrix-induced chondrogenesis (AMIC)].
l Exclusions Studies of other forms of ACI, such as those using fibrin glue or synthetic caps or matrices
not using collagen. Trials with fewer than 20 patients per arm. Observational studies with fewer than
40 patients. Studies of < 5 years’ duration (even if a few patients have duration over 5 years). Trials or
case series using drilling or abrasion methods. Studies where over 30% had significant concomitant
surgery, such as tibial osteotomies, patellar realignment, or cruciate ligament repair were excluded.103,104
Minor concomitant surgery, such as partial meniscectomy, was allowed.
Search strategy
Searches, as shown in Appendix 1, were run in Ovid MEDLINE and Ovid EMBASE from 1997 to 15 May 2015.
Thereafter, weekly auto-alerts, in MEDLINE and EMBASE, of these searches, were run until the end of 2015
to check for any new potential inclusions.
The searches retrieved 2907 documents; after removing duplicates and animal studies, 1833 records
remained and the title and abstracts were screened by two authors for inclusions. The full text of
69 articles was checked: 26 articles (21 studies) were included and 43 articles were excluded.
Quality assessment used the National Institutes of Health (NIH) checklist for observational studies.105
Results
A broad search with no restriction on designs (to capture case series) retrieved an initial 1833 studies,
of which 67 were possible inclusions, based on abstracts.
Table 5 shows the included studies. Not all were used in survival analysis. Excluded studies are listed in
Appendix 7. Details of all the studies used are provided in Appendix 8.
Comparing results of different studies is not straightforward, because a number of factors influence the
results, including:
l Previous attempts at repair – these reduce the chance of success. Most of the older studies had
patients who had had unsuccessful previous surgery.
l Size of defect. Large lesions do not do well with MF.
l Site of defect. For example, ACI appears to be less successful in trochlear lesions. Some studies exclude
trochlear lesions (Knutsen 200767).
l Duration of chondral defect.
l Surgical experience and learning curves.
l Length of follow-up and losses to follow-up.
l Age.
l BMI.
l Activity levels after repair. Some studies are in elite sportsmen and women, who may put great
demands on the repair. Some patients may go back to activity too early.
l Concomitant surgery, or lack of it. For example, there was only one concomitant osteotomy in the Moseley
series,115 but some patients had misalignment, which, left uncorrected, increased the failure rate.
l Outcome measures used – reoperation or symptom scores.
l Registry requirements/criteria.
The strong adverse relationship between prior attempts at repair and failure mean that most of the older
studies will give a misleadingly pessimistic picture if applied to ACI carried out in people with recent-onset
SURVIVAL ANALYSIS
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TABLE 5 Included studies
Author Brief description
Quality assessment and
whether or not used in
survival analysis
Asik 2008106 Assessment of a series of 90 patients after MF. Those
having other procedures as well were excluded. Mean
FU; 68 months. No failure data reported. Better results
in those treated sooner (< 12 months) after injury, in
younger (< 35 years) people, defects < 2 cm2 and BMI of
< 25 kg/m2. No data on previous procedures
Good, no
Bentley 201278 Long-term (minimum 10 years, range 10–12 years)
results of the 58 patients in the ACI arm from RCT vs.
mosaicplasty (Bentley et al.5). Loss to FU 9%, censored
at last visit. ACI-P or ACI-C. Long duration of injury
before ACI (mean 7 years, range 1–20 years) and 94%
had had previous surgery such as MF. 175 failure rate –
graft failure or reoperation. Mean defect size 4.6 cm2,
range 1–10 cm2
Good, subsumed into the
Nawaz study80 in survival
analysis, but see Discussion
Beris 2012107 Case series of 42 patients (45 knees) after ACI-P. Mean
defect size 5.3 cm2, range 2–12 cm2. Mean duration
28 months. No data on prior surgery, loss to FU or failures
Poor, no
Bhosale 2009108 Cohort study of first 80 consecutive patients having
ACI-P 1996–2002. ACI-only. 87.5% previous surgery.
Duration of defect not reported. Failures not reported.
Mean defect size 4.1 cm2, IQR 3–6. If success at
15 months, sustained for up to 8 years
Good, no
Biant 201479 Case series 104 patients after ACI-P (19) or ACI-C (85)
in 1998–2001, followed up for at least 10 years.
Duration defect 7.8 years, size 4.8 cm2, range 1–25 cm2.
Loss to FU 4%. Previous surgery in 70% and they had
poorer results. Failures in 26% at mean FU 5.7 years (all
by 8 years), defined as revision of repair or arthroplasty.
Results in non-failures good or excellent in 88%
Good, subsumed under
Nawaz study80 in survival
analysis, but see Discussion
Browne 2005109 Case series. Clinical outcome of ACI at 5 years in 87
subjects. Defect size 4.9 cm2, duration not reported.
Previous failed surgery 70%. In 36%, the ACI was the
first performed by surgeon. Of the 87, 62 (70%)
improved, six no change, 19 were worse
Fair, no
Gomoll 2014110 ACI in the patella only. Case series of 110. 8% failures,
defined as graft failure with pain, requiring revision
surgery
Fair, no
Jungmann 2012111 Cohort study of predictors of failure 2–12 years after
ACI: 26% ACI-P, 57% ACI-C, 17% BioSeed. Failure
defined as need for revision surgery. N = 413. Prior
repairs 70%; with more than one repair, 16%. More
than one prior repair increased risk of failure fourfold.
ACI-P doubled risk of failure vs. ACI-C. No association
of age or BMI with failure but only 85 had a BMI of
> 30 kg/m2. Duration of defect not reported
Fair, used
Knutsen 200767 This RCT of ACI vs. MF showed no difference. N= 80.
5-year FU. 23% failure in both arms, defined as need
for revision. 93% had had prior repairs. Median
duration of defect 3 years. At baseline, people with OA
excluded but by 5 years, 34% had Kellgren–Lawrence
grade 2 or worse in their late thirties. Younger patients
did better (< 30 years)
Fair, used
Krych 2012112 Case series of 48 MF patients from comparative study of
mosaicplasty and MF
Not used in survival analyses
continued
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
TABLE 5 Included studies (continued )
Author Brief description
Quality assessment and
whether or not used in
survival analysis
Layton 2015113,114 Layton et al. report results of MF in a very large
observational study of 3498 patients in the USA. The
data were obtained from an administrative claims
database. The study has not yet been published in full,
but is available as an ISPOR abstract. The authors have
provided a copy of the full poster
Good, yes
Moseley 2010115 Registry-based case series of 72 patients from 35
centres, 24 of which entered only one patient. In 29%,
the ACI was the first procedure done by the surgeon.
Mean defect size 5.2 cm2. 36% had had previous
attempts at repair. Duration of defect not reported.
21% had concomitant surgery but mostly minor with
only one osteotomy. Failure, defined as need for
reoperation, occurred in 17%. At 6–10 years, 69% of
patients had good results
Fair to good, yes
Nawaz 201480
Incorporates Rogers 2010116
with the Briggs series
Also incorporates data from
the ACI arm of the Bentley
2012 trial78 and the patients
in the Biant 2014 study79
Long-term study ACI in 827 patients with mean FU 6.2
years (range 2–12 years) after ACI-P or ACI-C) in 37%
or MACI (63%). 499 had reached 5 years of FU and
366 had reached 8 or more years, making it one of the
most useful studies. Mean defect size 4.1 cm2, range
0.6–20.8 cm2. 34% had had previous cartilage repair
surgery, and they were five times as likely to fail ACI.
Failure was defined as need for further surgery, graft
delamination (MRI or arthroscopic) or symptom scores
close to, or worse than, pre operation. Early OA was
associated with poorer outcomes – HR for failure 2.1 for
Kellgren–Lawrence grade 1; 3.5 for grade 2; and 3.8 for
grade 3. Defect size did not affect failure risk
Good, yes
Niemeyer 2014117 Case series of ACI-P. N= 86 but 16 lost to FU. Duration
of defect ‘several years’, mean size 6.5 cm2. 34% prior
repair attempts. Some concomitant surgery but mainly
partial meniscectomy. 29% had further surgery but not
all related
Good but for 19% dropout
rate
Niemeyer 2014102 Matched-pair comparison of outcomes of ACI-P vs. ACI-C.
23 per group and FU at least 10 years. Same failure rate:
4 (17%) in each group required further surgery including
TKR. ACI-C better on Lysholm and IKDC scores. But small
study
Good, no
Peterson 2010.118 Includes
patients reported in Peterson
2002119 with chondral injury
and 26 of those in Peterson
2003120
Long-term FU of the Gothenburg patients of Brittberg
et al.,21 who had had ACI-P at least 10 years before
(but range given as 9.3–20.7 years) with mean FU
12.8 years; 341 questionnaires sent out and 224 replies
(65%) despite many having moved. Lysholm, KOOS,
etc., plus question about whether or not they would
have again – over 90% would; 74% reported better
or same, 26% worse. No data on failures requiring
reoperation provided. Neither age nor size of lesion
affected outcome. Size 5.3 cm2 mean lesion size, but
some had more than one lesion. So majority had good
result 10–20 years later
Fair, not used
Salzmann 2013121 Reoperative characteristic after MF of knee cartilage
lesions in 454 patients. Retrospective chart review
Mean FU duration:
l Failure subjects 5.0 ± 2.1
l Non-failure subjects 4.4 ± 1.9
Not used in SA
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defects, for which ACI is the first procedure. Nevertheless, some studies in which ACI was a last-resort
salvage procedure reported good results in many patients.
Results of autologous chondrocyte implantation
The most useful study is that from the Stanmore group, by Nawaz et al.,80 because this study is the largest,
is of good quality and reports UK practice, albeit from a centre of excellence. The Nawaz paper80 reports
results in 827 patients, which allows for very useful subgroup analysis. Mean age at baseline was 34 years,
range 14–56 years. Radiographs were taken and assessed for degenerative change according to the
Kellgren–Lawrence grading. The ACI procedures were carried out from 1998 to 2008, and all patients
were assessed in 2010, allowing a Kaplan–Meier (KM) survival curve to be constructed for over 10 years.
Thirty-four per cent (282) of the patients had had previous repair attempts, such as MF, and they had
much poorer graft survival by 10 years: under 25% compared with 75% in those who had had no
previous procedures. The recruitment period spanned the generations from ACI-P to ACI-C and on to
MACI. There was no difference in survival time between ACI-C/ACI-P and MACI.
Patients with Kellgren–Lawrence grades 2 and 3 had only 25% graft survival by 10 years. Those with
grade 1 fared better initially, but by 10 years were catching up on the grades 2 and 3. Those with no
degenerative change did much better, with about 70% graft survival at 10 years.
TABLE 5 Included studies (continued )
Author Brief description
Quality assessment and
whether or not used in
survival analysis
Shive 2015122 (also Frappier
2014123)
This study reports a multicentre RCT of MF with BST-
CarGel® (Piramal Life Sciences, Mumbai, India) vs. MF
alone at 5 years. There was no ACI arm. The trial was
of a form of enhanced MF, with a chitosan framework
to stabilise the blood clot. At 5 years, there was no
difference in clinical outcomes, but the quality of the
cartilage filling was better with CarGel. Whether this
would result in later clinical benefits from a longer-
lasting repair is not yet known. A cost-effectiveness
analysis (Frappier 2014123) making assumptions on
failure and fill, reported that BST-CarGel could be
cost-saving
Fair, not used
Solheim 2014124
(incorporates patients from
Solheim 2010125)
MF treatment of single or multiple articular cartilage
defects of the knee: a 5-year median FU of 110 patients
Not used
Steadman 2003126 FU of cohort of 72 patients after MF for traumatic
chondral defects of the knee. Average FU 11 years,
range 7–17 years. Duration of defect mean 3 years,
range 9 months to 7 years. Mean size 2.8 cm2. Only
two failures, which were excluded from study. Of 71
followed for 7 years, 59 had improved, 11 were the
same and 1 was worse. Unusually low failure rate.
Patients were selected from a larger (302) group by
excluding those with other lesions, degenerative change
and concomitant surgery. Note quite small size of lesion
and inclusion of children
Fair, used
Vanlauwe 201143 5-year results from the TIG-ACT trial of ChondroCelect
vs. MF, dealt with earlier in assessment report
Good, used in SA
FU, follow-up; HR, hazard ratio; IQR, interquartile range; ISPOR, International Society for Pharmacoeconomics and
Outcomes Research; SA, sensitivity analysis; TKR, total knee replacement.
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In summary, results of ACI are poorer in:
l patients who have had previous attempts at repair
l those with early OA as reflected in Kellgren–Lawrence grades 1–3.
Combining these led to very poor results – ACI in a patient with previous repair and Kellgren–Lawrence
grade 3 had little chance of survival at 10 years.
Size of lesion did not affect survival.
Results of microfracture
The long-term evidence on MF was sparse. We note a comment by Salzmann et al.121 that:
The general body of literature concentrating on the clinical outcome following microfracture at the
knee joint is surprisingly light when compared with its clinical popularity.
This applies particularly to studies reporting outcomes beyond 5 years. There are few of these so we
relaxed our exclusion criterion of a minimum of 40 patients in observational studies.
Gobbi et al.,127 in a series of 61 patients followed for 15 years, reported good results at short-term
follow-up, but that deterioration could be expected after 2–5 years. Their failure rate, defined as need for
reoperation, was only 7 patients (11%), but 40% showed osteoarthritic changes.
Gudas et al.128 reported outcomes in the MF arm of a trial against mosaicplasty. In 29 patients, 11 (34%) had
failed (required reoperation) by 10 years. Most failures occurred by 40 months. Defects averaged 2.8 cm2.
Solheim et al.125 followed up 110 patients for 10–14 years after MF, and reported failure, defined as need for
further surgery in 39% and poor results (Lysholm score of 64 or less or needing knee replacement) in 46%.
They commented that although outcomes score improved after MF, normal knee function was usually
not achieved.
Steadman et al.126 reported better results in a series of 72 patients followed for an average of 11 years,
range 7–17 years. Their average defect size was 2.8 cm2 and mean duration of injury was 3 years (range
9 months to 7 years). Two failures were excluded, as were patients having concomitant surgery, or who
had OA, and those over 45 years – so the 72 patients are a subset of 302. At year 7, 59 (80%) had
improved by having less pain. The good results may reflect the good prognostic indicators.
By far the largest MF study has not yet been reported in full, and unfortunately provides follow-up
data only up to 5 years. Layton et al.113 from Quorum Consulting reported results in 3498 patients using
data from an American claims database, published as an abstract from the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) conference113 but with greater detail available in the
poster that is on the Quorum website.114
Not all of the patients reported are relevant to this report, because they included 351 Medicare patients
with average age 73 years. We excluded them. And even the ‘commercial’ group is older – at mean age of
47 years – than most patients being considered for ACI. However, they do provide a good guide to the
success of MF in routine care and have impressive numbers. Layton et al.114 reported failure rates (further
surgery) of 9% within 1 year, 18% at 3 years, and 32% by 5 years. Data on analgesic consumption
suggests that others did not have further surgery, but needed opiate or other analgesia.
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The future of MF has been reviewed by Bert,129 who points out that the landmark studies of MF, such as
that by Steadman et al.,126 did not have control groups of debridement alone. Bert129 cites the 2013 study
by Gudas et al.130 as the only trial in which MF was compared with debridement alone, and which showed
no difference. Unfortunately, the Gudas et al. trial124 was quite small (34 patients per arm), had only
3 years’ follow-up, and would not score well on the Cochrane risk of bias checklist. Bert129 argues that
debridement alone will give as good results as MF, but without damaging the underlying bone, which
would reduce the likelihood of success with later ACI.
Time-to-failure studies
Caveats
When considering survival curves extrapolated beyond the observed data, it should be borne in mind
that the extrapolation assumes that the curve based on the observed data will continue. When using
parametric fits for extrapolation (any fit irrespective of the equation that describes it), the usual option is
to select what is considered to be the best fit to the observed data. Unfortunately, there is no universally
applicable method to determine the best fit and opinions may differ. With some data, most well-fitting
models will produce similar extrapolations; however, with ACI data this has not been the case. Selecting
several plausible models that produce different extrapolations should bracket what can be argued to be
the best estimate of behaviour beyond the observed data.
In most instances it was possible to reconstruct individual patient data (IPD) using published data; in the case
of degenerative change reported by Nawaz 2014,80 the only way to get parametric curve parameters was
using a digitised KM (rather than IPD) with the non-linear regression Stata® (StataCorp LP, College Station, TX,
USA) command specifying candidate parameters. Since in this instance it was not possible to get a meaningful
covariance matrix these particular results could only be used in deterministic cost-effectiveness analysis and
not for probabilistic sensitivity analyses (PSAs). Occasionally with some other parametric models no confidence
interval (CI) could be derived (probably due to lack of numbers for patients and for events) and so uncertainty
was not quantifiable (see Appendix 9); again in these instances for cost effectiveness estimates only
deterministic analysis was possible.
Methods
Published KM graphs were digitised and IPD reconstructed using the Guyot et al. method.131 Where
published graphs had the appearance of KM plots but authors did not specify their method, it was
assumed to be KM. Where plots were presented as scatter graphs rather than stepped lines it was
assumed data points represented the top, rather than bottom or midpoint, of a stepped fall in survival.
Parametric models of time to failure were used to explore failure rate beyond the observed data. In the
absence of patient numbers this was done by least squares non-linear regression. Where patient numbers
allowed use of the Guyot method to reconstruct IPD, the models were implemented in Stata (version 12)
with the ‘streg’ command and or using the ‘stgenreg’ package of Crowther and Lambert 2013.132
Standard models (exponential, Weibull, log-logistic, log-normal, Gompertz and gamma) were explored
together with additional models for increasing hazard through time, either after an initial phase of
decreasing hazard (bathtub model) or with linear increase in hazard (Rayleigh models). CIs (95%) were
estimated with the delta method. The bathtub model was investigated because it has previously been
found useful for modelling failure rates after total hip replacement.133
Linearly increasing hazard models were tried because MF failure rate during 12 years of follow-up of
patients with OA (Bae et al.,134 an excluded study for this report, because patients had OA and were older)
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was found to be best fit with such models. They were therefore judged to be worth investigating. Linear
hazard models were used with one or two parameters in which survival is described as:
A S = exp(−lambda × time2) (1)
B S = exp(−(lambda0 × time + lambda1 × time2) (2)
(lambda0 ≥ zero; when lambda0 is zero, S conforms to equation 1.)
Model fit was judged using information criteria and by visual inspection of cumulative hazard plots135
and KM plots. One study provided Cox multivariate regression analysis of patient subgroups. The hazard
ratios (HRs) from these analyses were used to estimate subgroup failure rates using two methods: (1) A
log-normal model hazard was calculated for the baseline subgroup and multiplied by the appropriate HR for
each of the other subgroups. The time to failure for these subgroups was estimated from exp(–cumulative
hazard). (2) A Weibull or linearly increasing hazard model survival for the subgroups was estimated from:
exp(ln (baseline subgroup survival) × HR).
Log-normal model hazard was calculated from:
Hazard = A/B (3)
where:
A = C × D (4)
C = exp(−0:5 × ((ln(time)−mu)/sigma)2) (5)
D = (time × sigma ×√2 ×√π)
−1
(6)
B = 1−Ф ((ln(time)−mu/sigma)) (7)
where Ф is the standard normal distribution.
Parametric models and KM plots are presented in Appendix 9. The remit for this report was to exclude
studies with less than 5 years of time-to-event data; therefore, except in exceptional circumstances, such
studies were excluded.
Description of time-to-failure data
Seven relevant published studies43,67,80,111,115,117,136 were identified that presented KM plots extending to
at least 5 years. Estimates of IPD reconstructed from such plots are best served (i.e. likely to be more
accurate) when the total number of events, and of patients, are reported; when accompanied by a risk table
indicating the number of participants remaining at risk at multiple time intervals; and when the graphical
display is of sufficient quality to unambiguously identify the times at which events occurred. Extrapolation
of parametric models’ fit to such IPD are more likely to be reliable for more mature data, that is when
follow-up is sufficient that the number of events has reduced the probability of survival at the end of the
plot to a low value. A rough estimate of maturity is whether or not median survival has been reached.
Some of the included studies80,136 aggregated event times to yearly intervals. This may be because precise
times of failure were not recorded. The impact of this on subsequent use of data is difficult to gauge. Risk
tables were rarely presented, and in some studies reporting subgroup analyses the number of patients, as
well as the number of events, for some subgroups was not reported. Median survival was reached in only
one study. One study136 presented KM analyses in scatter plots rather than a more conventional stepped
plot. In this study, it was difficult to be certain whether data points represented the top, bottom or
midpoint of a step in survival. These characteristics are summarised in Table 6.
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The definition of treatment failure varied between studies; failure either consisted exclusively of surgical
re-intervention or a mixture of surgical re-intervention and a poor functional or pain score relative to
pre treatment. Table 7 summarises the treatment failure definitions used in the relevant studies.
TABLE 6 Time-to-event data presented in relevant studies
Item/studya
Knutsen
200767
Minas
2014136
Moseley
2010115
Nawaz
201480
Niemeyer
2014117
Vanlauwe
201143
Patient no. Yes Yesb Yes Yesb Yes Yes
Event no. Yes Yesc Yes Yesc Yes Yes
Risk table No No No Yesd No Yese
Events annualised No Yes No Yes No No
Stepped graph Yes No Yes Yes Yes Yes
Median survival No No No No No No
a Jungmann et al.111 presented KM plots for time to end of follow-up and of time of failure for those who failed, so, as
these did not allow analysis of time to failure, the study was excluded.
b Minas et al.136 reported patient numbers only for the whole cohort, and for previous and no previous intervention
subgroups. Nawaz et al.80 reported patient numbers for whole cohort, for previous and no previous intervention
subgroups, and for site of intervention subgroups, but not for grade of preoperative degenerative change subgroups.
c Minas et al.136 and Nawaz et al.80 event numbers were provided only for the whole cohort.
d A risk table was available only for the whole cohort.
e The risk table for the MF group was anomalous.
TABLE 7 Failure definitions used in relevant studies
Study Definition of failure
Nawaz 201480 (1) Graft delamination proven either by MRI or by arthroscopy; (2) a new surgical intervention,
including arthroplasty, high tibial osteotomy or another revision procedure (graft hypertrophy
was not counted as a failure); (3) a VAS pain score within ≤ 2 points of the preoperative score;
or (4) a Stanmore functional score that was the same or worse than the preoperative score
Minas 2014136 (1) Graft failure with revision using partial knee arthroplasty or TKA; (2) graft failure with
revision cartilage repair; and (3) graft survival but development of new defects elsewhere in
the same knee necessitating additional surgery (progression of disease)
Moseley 2010115 Needed an operation after ACI that necessitated removal of the graft, confirmed a loss of
defect fill or violated the subchondral bone (e.g. abrasion chondroplasty, MF, drilling,
unicompartmental knee replacement, TKR)
Vanlauwe 201143 Re-intervention affecting more than 20% of the index lesion. TTF was the time between the
end of the surgical procedure and ‘the date of failure or re-intervention’
Knutsen 200767 Failure if the patient needed a reoperation because of symptoms due to a lack of healing of
the treated defect. The need for shaving or trimming of a lesion was not defined as a failure
Niemeyer 2014117 Re-intervention surgeries
Jungmann 2012111 Time to event was defined as time to revision surgery
ACTIVE trial protocol
www.active-trial.org.uk35
Cessation of treatment benefit in which: ‘two of the following three conditions below are
satisfied: (a) Overall knee status judged by the assessor as not improved from preoperative
condition (cessation of benefit form), (b) No gain in independently assessed Lysholm knee
score compared with preoperative score, (c) No gain in patient’s self-assessed Lysholm knee
score compared with preoperative score’. Within element (a) re-intervention/additional
procedures could be judged to be treatment failure
TKR, total knee replacement; TTF, time to treatment failure; VAS, visual analogue scale.
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Results of autologous chondrocyte implantation trials
Four small RCTs, each with two arms were identified. Two (Knutsen 2007,67 N = 80 patients; Vanlauwe
2011,43 N = 112 patients) compared ACI with MF. The RCT of Bentley et al. 201278 (N = 100 with about
10 years of follow-up) compared ACI with mosaicplasty – we are interested only in the ACI arm and these
patients were included in the larger study of Nawaz et al.80 and so are not considered further. The RCT of
Gudas et al.128 compared MF with mosaicplasty but did not satisfy inclusion criteria.
Figure 1 summarises the reconstructed time-to-failure KM plots for the Knutsen et al.67 and Vanlauwe
et al.43 RCTs, which extended to 5 and 6 years of follow-up, respectively.
In these small studies the observed data are associated with considerable uncertainty. Extrapolation of
parametric models was associated with large uncertainty beyond the observed data. Figure 2 illustrates this
for Weibull fits extrapolated to 50 years (other models are presented in Appendix 9). The short follow-up
and small size limits their usefulness for modelling failure rates beyond 5 years. Additional (non-RCT)
studies of larger size and longer follow-up were sought.
Results of autologous chondrocyte implantation observational studies
Four single-arm ACI studies with KM plots were included. Niemeyer et al.117 reported event times for 70
German patients with follow-up to 5 years; Minas et al.136 and Moseley et al.115 reported time to failure for
210 and 72 US patients, respectively, with follow-up extending up to or beyond 10 years; and Nawaz
et al.85 reported annualised time to failure for 827 UK patients, with follow-up to about 10 years. ACI
patients from Bentley et al.78 and from Biant et al.79 were included in the study of Nawaz et al.80 and so
survival data from these are not considered separately. For the whole cohort, Nawaz et al.80 reported both
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FIGURE 1 Reconstructed KM plots (95% CI) of time to failure in two RCTs.
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annual event and censoring numbers for each year so that the IPD could be reconstructed without resort
to the Guyot et al.131 algorithm. Jungmann et al.111 presented time to re-intervention for 413 of 500
patients (selected follow-up 2–11.8 years) with analysis truncated at 5 years; this KM was not comparable
with those in other studies and IPD were not reconstructed.
Patient characteristics in the ACI studies are summarised in Table 8. Typically, lesions were full thickness,
with study mean size ranging from 2.7 to 8.4 cm2 in patients with mean age 30–40 years, most of whom
had experienced previous interventions. Symptom duration prior to intervention varied between studies.
Figure 3a shows the reconstructed KM failure plots for the four single-arm and two RCT ACI studies that
provide relevant data to at least 5 years. It should be appreciated that definitions of failure were not
identical between different studies, and the mix of patients who had, or had not, experienced previous
intervention also differed between studies. Because of study size, the uncertainty in the Nawaz et al.80 data
is less than that in the other studies. Up to about 6 years there is reasonable consonance for most studies;
thereafter, the prognosis appears worse for Nawaz et al.80 patients, but this appears partly due to flat
portions of the KM curves for the other studies for which patients at risk have diminished considerably and
uncertainty is at its maximum. These data indicate that the Nawaz et al. study80 is unlikely to flatter failure
rates after ACI, and that to about 6 years of follow-up the Nawaz et al. study80 is reasonably consistent
with other studies; beyond 6 years the KM analyses of the other studies are likely to be less reliable
because of smaller study size. Combination of these different studies would be difficult to justify because
of clinical heterogeneity.
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FIGURE 2 Extrapolated Weibull distributions fit to reconstructed IPD from the RCT studies. Note: there is some
doubt about the reliability of the Vanlauwe et al.43 MF arm because of an anomaly in the published risk table,
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this trial.
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FIGURE 3 (a) Reconstructed KM plots for ACI studies; and (b) best parametric fit (95% CIs) and gamma models for
six ACI arms.
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Figure 3b shows parametric models for these studies extrapolated to 70 years. For clarity Moseley115 is
omitted. A gamma model could not be computed for Minas et al.136 Gamma fits illustrate differences
seen between studies when applying the same single distribution to all; also shown are best fits for each
study. Judged according to information criteria, various parametric models provided best fits: Knutsen67
exponential, Minas136 Gompertz, Moseley115 exponential, Nawaz80 log-logistic, Niemeyer117 exponential and
Vanlauwe43 linear hazard. For Nawaz80 and Vanlauwe43 the best fits differed very little from the gamma
model. The best fit models for Knutsen, Nawaz,80 Niemeyer117 and Vanlauwe43 studies predict that more
than half of ACI interventions fail within about 30 years, whereas the Gompertz model-based Minas
study136 indicates about half or more ACIs remain without failure up to 70 years, and the gamma model
for the Moseley study115 predicts about 25% remain without failure to 70 years.
Potential reasons for differences in KM plots and best fit models between these studies are manifold; they
include uncertainty in the observed data resulting from small numbers of participants and, in some studies,
short-term follow-up, different reliability of IPD reconstructions and differences in study populations,
particularly with regard to experience of previous intervention(s), the degree of degenerative change,
and location and size of lesion.
Post-failure treatments
Biant et al.79 reported the revision surgeries following ACI failure as 44.4% total knee replacement (TKR)
or unicondylar knee replacement or patellofemoral joint replacement or medial and patellofemoral knee
replacement; 25.9% ACI; 18.5% high tibial osteotomy; and 11.1% arthrodesis or chondroplasty. In the
Minas et al. study,136 19 out of 53 patients with failed grafts went on to knee arthroplasty within the
follow-up period, 27 out of 53 patients had revision cartilage repair procedures and 7 out of 53 patients
refused further treatment after failure.
Studies with patient subgroup analyses
Jungmann et al.111 and Bentley et al.78 reported data (but not KM plots) comparing failure rates between
subgroups of patients. Jungmann provided evidence that increased revision was associated with previous
intervention, previous bone marrow stimulation, female gender and ACP-P relative to other ACI types.
Bentley provided 5-year revision rates by subgroup; only older age appeared associated with increased
probability of revision (note that these patients were included in the Nawaz study80).
The Minas and Nawaz studies80,136 both presented KM plots for subgroups of patients, but neither reported
event numbers by subgroup, and patient numbers were available only for some subgroups of patients.
Nawaz et al.80 provided Cox regression HRs for several subgroups of patients. Because of its size, length of
follow-up, the use of multiple surgeons and inclusion of UK patients, the Nawaz study80 was judged to be
the most relevant ACI study for the current decision problem. Therefore, the focus in this section is on the
Nawaz study,80 and the results from the Minas study136 are presented for comparison.
Nawaz et al. 2014 study of UK patients
The most useful study is by Nawaz et al.80 For the whole Nawaz cohort (n = 827)80 a log-logistic distribution
provided the best-fitting parametric model. Figure 4 shows the reconstructed KM plot together with the
log-logistic model extrapolated to 50 years; the model predicts that after about 30 years approximately 90%
of patients would have failed. The partition of failures according to how it was defined (see Table 7) was not
reported (e.g. the proportion of failures receiving previous intervention at the time of failure is unknown).
Patient subgroups examined in the Nawaz study
Nawaz et al.80 presented KM plots for subgroups of patients categorised according to (1) receipt of a
previous intervention; (2) site of intervention; (3) grade of degenerative change; and (4) type of intervention
received (MACI or ACI). The authors used univariate and multivariate Cox regression to investigate if these –
and also age and size of defect – were influential for failure. The most influential patient covariate was
previous intervention (p < 0.001; multivariate HR vs. no previous intervention: 4.72, 95% CI 3.5 – 6.4).
Grade of degenerative change (p < 0.001), site of intervention (p = 0.036 for best vs. worst site), and age at
operation (p < 0.001) were also significantly influential, whereas type of intervention (ACI or MACI) and
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lesion size were not (p = 0.860 and p = 1.00, respectively). The authors did not report on a test of the
proportional hazards assumption. The AG reconstructed the subgroup KM plots and used reconstructed IPD
to investigate good parametric models for the data. Additionally, AG investigated the effect of adjusting
parametric models using the multivariate HRs reported by Nawaz et al.80
Previous and no previous intervention
According to information criteria, log-normal and gamma distributions provided good models for patients
who had previous or no previous intervention (debridement was not included as a previous intervention).
When the HR reported by Nawaz et al.80 (previous vs. no previous intervention) was applied to either
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FIGURE 4 Reconstructed KM plot (a) and extrapolated log-logistic model; and (b) for the Nawaz et al.80 whole cohort.
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
log-normal or Weibull models, the resulting model was very similar to that fit to the previous subgroup IPD
(Figure 5). These results indicate that there was likely to be little difference between the subgroups in the
distribution of other covariates that were influential for failure.
Site of intervention
Nawaz et al.80 published KM plots and multivariate Cox regression HRs comparing time to failure for five
subgroups that differed according to intervention site (medial femoral, n = 421; lateral femoral, n = 109:
patella, n = 200; trochlea, n = 50; multiple sites, n = 47). HRs vs. the lateral femoral condyle group as
baseline reference were medial femoral condyle 1.806 (95% CI 1.036 to 3.149; p = 0.037), patella 1.323
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FIGURE 5 Reconstructed plots for Nawaz et al.80 Previous and no previous intervention subgroups: (a) log-normal
models; and (b) Weibull models. KM plots and extrapolated log-normal (left) and Weibull (right) parametric
models. Dashed lines are 95% CIs.
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(95% CI 0.745 to 2.351; p = 0.339), trochlea 1.409 (95% CI 0.625 to 3.174; p = 0.0408) and multisite
1.678 (95% CI 0.731 to 3.851; p = 0.222). Reconstructed KM plots were similar for all but the lateral
condyle group, which exhibited the least failure. Log-normal distributions provided the best fit parametric
models to reconstructed subgroup IPD. Figure 6 shows reconstructed KM pots and HR-adjusted log-normal
models. Applying the reported HRs diminished the apparent superiority of the lateral femoral condyle
subgroup seen in the KM plots, and indicated that relative to other subgroups the lateral femoral population
may possibly have been favourably free of detrimental covariates for failure (e.g. previous treatment and
high-grade degenerative change). Similar results were obtained with Weibull models.
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FIGURE 6 Reconstructed KM plots and log-normal models for time to failure according to site of intervention,
Nawaz et al.80 (a) KM according to intervention site; and (b) subgroups by intervention site log-normal models
based on HRs. For clarity, KM 95% CIs are shown only for lateral and medial femoral condyle sites and have been
omitted for the model fits.
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Grade of preoperative degenerative change
Nawaz et al.80 published KM plots and multivariate Cox regression HRs comparing time to failure for four
subgroups categorised according to grade of degenerative change (Kellgren–Lawrence). HRs vs. the grade 0
subgroup as baseline reference were grade 1, 1.542 (95% CI 0.930 to 2.557; p = 0.093); grade 2, 1.869
(95% CI 1.381 to 2.529; p < 0.001); and grade 3, 1.985 (95% CI 1.092 to 3.610; p = 0.025). Patient
numbers were not reported and parametric models were fit to digitised KM plots using non-linear regression.
For different subgroup grades, log-normal and linearly increasing hazard models produced acceptable fit to
digitised KM plots in Appendix 9. When the HRs reported by Nawaz et al.80 were applied to either of these
models, the resulting plots for different grades were more similar to each other than was apparent from KM
plots or fits to KM plots (Figure 7). These results may indicate that some of the superiority of the grade 0
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FIGURE 7 Time to failure by grade of OA. (a) Nawaz et al.80 subgroups by grade of degenerative change linearly
increasing hazard models; and (b) Nawaz et al.80 subgroups by grade of degenerative change log-normal models.
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subgroup apparent in the KM plots was possibly due to relative freedom of this group from covariates that
tend to increase the probability of failure.
Minas et al. 2014 study
Minas et al.136 performed several KM analyses for various subgroups of patients. Patient numbers were
reported only for the comparison of previous intervention versus no previous intervention groups. Like in
the Nawaz et al. study,80 worse failure rates were found for patients who had experienced previous
intervention. As was seen for the whole Minas cohort,136 the subgroup failure rates flattened after about
6 years and extended to as far as 17 years with relatively few failure events. Thus failures were much less
frequent in both Minas136 subgroups than in the corresponding Nawaz80 subgroups. No regression analysis
was performed in Minas136 and no HRs were reported. Gamma distributions provided good fits for both
studies’ subgroups. Reconstructed KM plots and gamma models fit to IPD for subgroups from both the
Nawaz80 and Minas136 studies are shown in Figure 8.
Minas et al.136 also provided plots for failure according to subgroups that experienced different types of
previous intervention. Patient numbers were as follows: MF, n = 13; abrasion arthroplasty, n = 30; and
drilling, n = 46. Failure was more frequent after MF than after other forms of marrow stimulation.
Concurrent osteotomy resulted in fewer failures.
Studies of failure after microfracture (Layton 2015, Knutsen 2007, Saris 2009)
Vanlauwe et al.43 (year 3 results in Saris et al.70) and Knutsen et al.67 provided MF failure data to 5 years.
A large US study by Layton et al.114 examined records for 3498 US recipients of MF and reported the
percentages of failures for patients followed to 1, 3 and 5 years. All patients were followed up to 3 years.
The proportion followed to 5 years was not reported. Layton et al. stated ‘Failure rates (TKR, MF or ACI)
increased with increasing years of follow-up: 9% within 1 year, 18% within 3 years, and 32% within
5 years’. In the Knutsen,67 Saris70 and Layton114 studies, failure was defined as re-intervention. Only Layton
et al.114 provided information on the type of re-intervention received, as follows: TKR accounted for most
re-interventions – 56%, 62% and 66% of re-interventions at years 1, 3 and 5, respectively; MF and ACI
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FIGURE 8 Effect of previous interventions on failure rates. (a) Nawaz et al.80 and Minas et al.,136 no previous
intervention populations. Reconstructed KM plots and gamma models; and (b) Nawaz et al.80 and Minas et al.,136
previous intervention populations. Reconstructed KM plots and gamma models. Time to failure for previous
intervention and no previous intervention patient subgroups (Minas136 and Nawaz80) showing reconstructed KM
plots and gamma models of time to failure.
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accounted for nearly all of the remaining re-interventions (very few re-interventions were OATS). The mean
age of patients in the Layton study114 was 47 years [standard deviation (SD) 11.4 years], meaning that many
would be of an age at which TKR would be considered, and there were equal numbers by gender. Table 9
summarises the main characteristics of patients in the MF arms of the Knutsen67 and Saris70 studies.
As all of the patients in the Layton study114 were followed up for 3 years, it was possible to reconstruct
IPD for an annualised KM plot (assuming failure took place at 1 and 3 years, and at 3 years all non-failed
patients were censored). Under the assumption that those followed up for 5 years were representative of
all of those who could have been followed (censoring those without failure at 5 years), the 5-year IPD
were also estimated. The best fit models (Figure 9) for these were provided by Gompertz distributions and
the second best by a gamma model (see Appendix 9).
The linearly increasing hazard model provided the best fit for the MF arm of the Knutsen et al.67 study.
The published 5-year KM plot for the MF arm of the Vanlauwe et al. study43 had anomalous risk table
data and interpretation of the KM plot was problematic. The KM plot for MF has 10 steps and a total of
10 events were reported (one step for each event). Seven steps occur before 36 months: two of these
very close together, at about 20 months, and three after 36 months. This does not tally with the data in
their appendix 1, which depict five MF re-interventions occurring before 36 months and five after 36
months. For the ACI KM plot, two steps occur before 36 months and five steps after 36 months, and this
corresponds to the data provided in appendix 1 of the Vanlauwe et al. study.43 The risk table for the MF
arm is anomalous in that the number at risk is reported as increasing at 36 months. It is unclear what
the correct numbers should be at 24, 36 and 48 months for the MF risk table. Therefore, the Saris et al.70
3-year KM plot for this study was examined. The best fit was again provided by the linearly increasing
hazard model. These and models for the Layton et al. study114 are summarised in Figure 9. The poorer
performance in the Layton et al. study114 may be attributable to older mean age and or real-world
performance of MF relative to that for patients who are carefully selected for a RCT.
TABLE 9 Patient characteristics in the MF arms of the Saris70 and Knutsen67 RCTs
Item Knutsen 200767 Saris 200970
No. 40 61
FU (years) 5 5
Mean (SD) age (years) 31.1 (NR) 33.9 (8.6)
Male (%) NR 67
Mean (SD) defect size (cm2) 4.5 (NR) 2.4 (1.2)
Mean (SD) weight (kg) 82.1 (NR) 80.6 (13.3)
Mean number previous operations 1.4 NR
Previous operation 93% 77%
Median symptom duration, years 3 1.57 [range 0–18]
Site medial femoral 89% NR
Site lateral femoral 11% NR
FU, follow-up; NR, not reported.
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Comparison of failure after autologous chondrocyte implantation and microfracture
A comparison of long-term failure of MF and ACI is problematical in view of the paucity and heterogeneity
of studies. The most reliable comparison may be between the largest UK extended follow-up study (Nawaz
et al.80) and the available MF data (described above), a caveat being that failure definitions differed
between the Nawaz study80 and the three available MF studies. When whole cohorts were compared, ACI
appears to be superior to MF (Figure 10).
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FIGURE 9 Best fit models to observed MF failure in three studies.
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FIGURE 10 Modelled failure profiles following ACI or MF. Best fit models for Nawaz et al.80 whole cohort,
(all) log-log; Nawaz et al.,80 no previous subgroup gamma; Knutsen et al.67 and Saris et al.,70 MF arms linearly
increasing hazard; and Layton et al.,114 Gompertz (for clarity not all 95% CIs are shown).
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No subgroup data was available from the MF studies. Vanlauwe et al.43 did not provide KM plots for
subgroups but reported the failure numbers according to whether or not previous intervention had been
experienced (Table 10). Numbers of patients at risk and numbers of events were small and the time of
events in compared groups was not provided so that firm conclusions are impossible; however, these data
are suggestive of little effect of previous intervention on risk of failure after either ACI or MF. Salzmann
et al.137 followed 454 recipients of MF and compared patient characteristics between those patients who
required re-intervention during follow-up with those who did not require re-intervention. The former
patients, on average, had received more pre-MF interventions (1.9 ± 2.1 previous interventions) than the
latter (1.2 ± 2.1 previous interventions) but the spread in number of pre-interventions was great in both
cases. Unfortunately, no KM time-to-event analyses were reported for the ‘no-previous intervention’ and
‘previous intervention’ subgroups.
In the absence of subgroup KM data for MF, the worst-performing subgroups investigated by Nawaz
et al.80 were compared with the three MF studies. Log-normal models based on the multivariate HRs
reported by Nawaz et al.80 were used for the comparison (Figure 11).
Except for the previous intervention ACI subgroup, the ACI subgroups clearly exhibited less failure than the
MF cohorts. Lack of data does not allow a comparison with previously treated MF patients. It should be
emphasised that uncertainty in these comparisons is substantial, especially with regard to the Knutsen67
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FIGURE 11 Modelled failure in MF studies compared with worst-performing subgroups from Nawaz et al.80 ACI study.
TABLE 10 Failure of ACI and MF according to previous intervention (data from Vanlauwe et al. 201143)
Type of intervention ACI failures/group (risk of failure) MF failures/group (risk of failure)
Previous knee surgery 6/50 (0.120) 8/47 (0.170)
No previous knee surgeries 1/7 (0.143) 2/14 (0.143)
1 previous knee surgery 3/29 (0.103) 4/34 (0.118)
≥ 2 previous knee surgeries 3/21 (0.143) 4/13 (0.308)
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and Saris70 MF arms. Analysis of the MF arm of the RCT of Gudas et al.128 – excluded on the basis of its
small size – showed that the best fit for the reconstructed IPD was a log-normal model, which predicted
poorer survival than the models for MF for the Layton,114 Knutsen67 and Saris70 studies.
Summary of longer-term time-to-event evidence of treatment failure after
autologous chondrocyte implantation and microfracture
l More long-term evidence was available for ACI than for MF.
l Treatment failure definitions differed between studies, with varying, and sometimes unclear, relative
contributions to overall failure from re-intervention and from inadequate pain/function scores.
l Study data were generally still too short term. Only one published study allowed an estimate of
observed median time to failure.
l Most participants in most study populations had experienced intervention(s) prior to enrolment.
When evidence was reported it appears many types of pre-intervention had been tried.
l Two ACI studies with KM analyses extending to at least 10 years reported that treatment failure
was far more frequent in patients who had experienced prior intervention(s); one of these studies
documented greater failure rates after MF than after other marrow stimulation (but patient numbers
were small).
l There was no clear time-to-event evidence that prior intervention influenced failure after MF; other
available evidence was meagre.
l Immaturity of failure data necessitated parametric modelling beyond observed data so as to predict
lifetime failure.
l According to information criteria and visual goodness of fit, the best fits of long-term failure after ACI
were usually characterised by models that, when extrapolated beyond the observed data, indicated
gradually decreasing hazard (probability of failure decreasing with time).
l Conversely, good fits to limited data available for MF were characterised by models that indicated
linearly increasing hazard (probability of failure increasing with time).
l A single large US study of MF in patients with a mean age of 47 years indicated that, in this
population, TKR was the most frequent intervention after failure of MF.
Pooling time-to-failure studies
The second submission from SoBi used parametric models based on pooled data from ACI studies to
derive time to failure for ACI. SoBi did not pool MF studies. A commentary on the SoBi submission follows
in Chapter 4.
The ACI studies pooled by SoBi encompassed studies using different definitions of failure and recruiting
different proportions of previously treated and previously untreated patients. More judicious pooling can
be undertaken, in which there is less heterogeneity among pooled studies. Therefore, as a supplement to
the analysis of single studies described above, the AG have briefly explored pooling of studies for ACI and
for MF.
Autologous chondrocyte implantation studies
In the ACI arms of the studies by Moseley et al.,115 Vanlauwe et al.,43 Knutsen et al.67 and Niemeyer et al.,117
failure was defined as re-intervention and each study included more than 60% of patients who had
experienced previous intervention (range 63–90%). A log-normal model provided the best fit for these
pooled studies (Figure 12).
Microfracture studies
In the three studies providing MF data, failure was defined as re-intervention and two predominantly
recruited patients who had experienced previous interventions. This was not reported by Layton et al.114
When the three studies (Layton,114 Vanlauwe43 and Knutsen67) were pooled the resulting KM plot and best
fit model (Gompertz) were dominated by the large Layton study114 (see Figure 12). Compared with the
pooled ACI studies, failure was more frequent in the MF studies.
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The pooled MF studies were dominated by the Layton study.114 Pooled MF studies, excluding Layton,114
Knutsen67 and Saris,70 again indicated less failure for ACI patients than for MF patients (Figure 13).
When the MF arms of Knutsen67 and Vanlauwe43 (5-year MF data of the TIG/ACT study43) were pooled,
it was difficult to determine the best fit model using information criteria (Table 11). Only the gamma
model of MF failure was superior to ACI (Figure 14). It should be noted that anomalies in the published
Vanlauwe43 MF arm required speculative interpolation of risk table data prior to pooling.
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FIGURE 12 Time to failure after pooling four ACI studies and three MF studies.
Log-normal, ACI Knutsen,67 Niemeyer,117 Moseley,115 Vanlauwe43
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FIGURE 13 Time to failure after pooling four ACI and two MF studies (Knutsen67 and Saris67).
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TABLE 11 Information criteria for models to pooled MF data from Knutsen67 and Vanlauwe43
Model Obs. ll(model) df AIC BIC AIC rank BIC rank
Gamma 101 –58.4314 3 122.8628 130.7081 1 5
Exponential 101 –61.9545 1 125.9089 128.524 5 1
Weibull 101 –60.7536 2 125.5071 130.7374 4 6
Gompertz 101 –61.6625 2 127.325 132.5553 8 8
Log-normal 101 –59.7245 2 123.449 128.6793 2 2
Log-logistic 101 –60.5069 2 125.0139 130.2441 3 4
Linear hazard, one parameter 101 –62.1378 1 126.2756 128.8907 6 3
Bathtub 101 –61.4594 3 128.9189 136.7642 9 9
Linear hazard, two parameter 101 –61.4594 2 126.9189 132.1491 7 7
df, degrees of freedom; Obs., observations.
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FIGURE 14 Time to failure after pooling four ACI and two MF studies (Knutsen67 and Vanlauwe43).
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Chapter 4 Systematic review of existing economic
studies for autologous chondrocyte implantation
Introduction
The objective of this chapter was to conduct a systematic review of existing economic evaluations
(including any model-based economic evaluations) of the use of ACI, MF and mosaicplasty for repairing
symptomatic articular cartilage defects of the knee. We searched the literature since the last HTA review3
for economic evaluations, including any existing models, to help inform our economic modelling.
Methods
The systematic search used MEDLINE Ovid (2004 to 6 July 2014), EMBASE Ovid (2004 to 6 July 2014), NHS
Economic Evaluation Database (NHS EED; issue 2 of 4, April 2014) and the Web of Science Core Collection
(2004 to 6 July 2014). Weekly auto-alerts were set up in Ovid MEDLINE and EMBASE for any new studies
that were added to the database subsequent to July 2014. The search terms included economic and QoL
terms cross-referenced with chondrocyte implantation terms. The search was limited to studies published
since the searches were done for the last HTA review,3 that is from the year 2004. The search was also
limited to studies published in the English language and to humans. Details of the search strategies are
provided in Appendix 10.
Two reviewers independently reviewed titles and abstracts to identify potentially relevant papers. Consensus
was achieved by discussion, but, when consensus was not agreed, a third reviewer reviewed the abstracts to
reach agreement. Abstracts were considered to be relevant to this review if they were a full economic
analysis (including any economic models) on the use of ACI, MF and mosaicplasty for repairing symptomatic
articular cartilage defects of the knee. Abstracts that provide useful information for the economic model
(such as costs, utilities and transition probabilities) were retained but not included in this review.
We obtained the full-text articles of potentially relevant abstracts. The reference lists of retrieved articles
were checked for potentially relevant papers that met the inclusion criteria. A data extraction form was
developed to capture the main characteristics and economic factors. We critically appraised full economic
evaluations against the framework for quality assessment of economic evaluation studies developed by the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) group.138 If the studies contained
an economic model, they were further assessed against a framework for the quality assessment of
decision-analytic modelling adapted from Philips et al.139
Results
The searches identified 272 potentially relevant citations published since 2004. After reviewing the
abstracts, four studies remained, including the HTA review by Clar et al. 20053 (Derrett 2005,140 Gerlier
2010,141 Samuelson 2012142). A further two articles were identified from the clinical effectiveness searches
(MSAC 2010,32 Koerber 2013143). In total, six articles were retained for data extraction. Figure 15 shows
the abstracts identified and number of studies included.
Of the six publications, two have been summarised (see below). The Clar et al. study3 is based on previous
work by some of the authors of this report. The MSAC report published in 201032 compared only the
costs, as MSAC assumed that the clinical effectiveness for the different interventions was identical.
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The HTA review by Clar et al.3 compared ACI with MF and mosaicplasty. and the authors attempted to
calculate reliable costs per QALY. However, they felt that this was not possible because of the absence of
data which were required. For example, QoL data were limited to around 2 years and no long-term studies
(i.e. 20–30 years) were available on the incidence of OA and the need for TKR. The short-term modelling
(QoL improvements at 2 years) found that the gain from ACI vs. MF would have to be between 70% and
100% greater over 2 years for the cost per QALY for ACI compared with MF to be within the £20–30,000
threshold. For the medium-term modelling (using 10-year success rates), the authors found that if the
QoL gains were to be maintained for the next 10 years then for ACI relative to MF the QoL gain would
have to be between only 10% and 20% greater to justify the additional cost of the intervention and be
cost-effective within the £20–30,000 threshold. For the longer-term modelling there may be a need to
offer some (or all) patients TKR, so a 50-year time horizon was considered appropriate. The authors found
that for this scenario mosaicplasty was dominated, and moving from MF to ACI was associated with an
incremental cost-effectiveness ratio (ICER) of between £3500 and £5500 (cells were assumed to cost only
£3200). Overall, the authors concluded that there was insufficient evidence at the moment to say that ACI
was cost-effective compared with MF or mosaicplasty.
The MSAC report32 compared the costs of MACI/ACI with mosaicplasty and MF in patients aged between
15 and 55 years suffering from a focal defect in an otherwise normal knee. In the absence of conclusive
effectiveness data, MSAC assumed that the clinical effectiveness for all the different interventions was
identical, and a cost-minimisation analysis was conducted. Resource use was determined by an Advisory
Panel and the costs of the different procedures were obtained from various sources; for example, the cost
of autologous chondrocyte transplantation was obtained from the prosthesis price list. The authors
assumed that assessment costs and rehabilitation costs were identical, so they were not included in the
Potential abstracts identified 
from electronic searches
MEDLINE, n = 197
EMBASE, n = 165
NHS EED, n = 2
Web of Science, n = 72
Total abstracts
(n = 436)
Potential abstracts 
after removal of duplicates
(n = 272)
Potential full-text 
articles retrieved
(n = 4)
Full-text articles included in 
this systematic review
(n = 6)
Articles identified from the
clinical effectiveness searches
(n = 2)
Abstracts that did not meet 
the inclusion criteria
(n = 268)
FIGURE 15 A PRISMA flow diagram for cost-effectiveness studies.
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comparison. The price year (and time horizon) was not explicitly stated for the different resource use items,
except for the prostheses (August 2010). The cost analysis found that the total costs of MACI/ACI (biopsy
and grafting) procedure were significantly higher per knee than either mosaicplasty and MF (US$14,083 vs.
US$2639 and US$1405, respectively). The main cost difference between the procedures was that MACI/
ACI required the cost of the chondrocyte cell culture and sealant (US$11,780). MSAC felt that the
conclusions that can be drawn from this review were limited by the quantity and the quality of evidence.
The updated MSAC report published in 2012144 concluded that MACI was superior to MF (and mosaicplasty)
with respect to less need for subsequent surgery and also in terms of clinical outcomes; therefore, a costing
analysis was no longer sufficient and a cost-effectiveness/cost–utility analysis was required. A proposed
model structure for the economic evaluation was presented using a decision tree with a Markov process,
along with information on resource use and costs. They stated utility values would be obtained from the
literature. However, no results of the cost-effectiveness analysis were presented.
Study design, intervention and patient populations
The remaining four peer-reviewed journal articles are summarised in Table 12. One study was a cross-sectional
retrospective study (Derrett 2005140) and the other three studies were decision-analytical modelling studies by
Gerlier et al.,141 Samuelson et al.142 and Koerber et al.143 The Derrett study140 was conducted in the UK, and the
other three studies141–143 were based on literature and some trial data from Belgium, Germany and the USA.
Three studies assessed the cost-effectiveness of ACI compared with other interventions: mosaicplasty (Derrett
2005140); MF (Gerlier 2010141); mosaicplasty and MF with different versions of ACI (ACI-C, ACI-P and MACI)
(Koerber 2013143). Samuelson et al.142 compared ACI-C with ACI-P to see whether or not it was more
cost-effective.
The patient populations varied. The retrospective study by Derrett et al.140 was based on 95 patients, of
whom 53 patients received ACI, 20 patients received mosaicplasty and 22 patients were on the waiting list
for ACI. The patients who received ACI were slightly younger than those who had received mosaicplasty
(31.9 years vs. 34.9 years; p = 0.17) and more men received ACI (53% men vs. 47% women) compared
with mosaicplasty (45% men vs. 55% women). The three economic models were based on clinical data
and data from the literature.
Gerlier et al.141 compared adult patients who were less than 50 years of age (a mean age of 35 years at
model entry), with symptomatic cartilage lesions of the femoral condyles, who had not yet developed OA,
and the key efficacy data came from the TIG/ACT trial.43
Samuelson et al.142 compared adult patients with a mean age of 30 years with a focal chondral injury
which satisfied the conditions for an ACI repair.
The model by Koerber et al.143 was said to be based on the model by Gerlier et al.141 In the Koerber
supplementary file it was stated that the study population was patients aged 32 years with symptomatic,
isolated cartilage defects and no contraindication. None of the economic models specified the number of
hypothetical patients used for the modelling.
Time horizon and length of follow-up
The time horizon for any study should be long enough to capture all of the benefits that would accrue from
the different interventions. The follow-up length in the studies varied. The Derrett study140 was based on
follow-up data for 2 years. The economic model by Gerlier et al.141 used two time horizons: a short-term time
horizon of 5 years to take into account knee pain and mobility after the initial intervention (this information
was obtained from a 5-year RCT that compared ACI with ChondroCelect and MF) and a long-term time
horizon of 40 years to take into account the development of OA after 15 years and the need for a TKR
after 20 years. Samuelson et al.142 based their model on a 10-year time horizon that corresponded with the
longest-term evidence that was available in the literature. Koerber et al.143 stated that on the basis of the
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TABLE 12 Characteristics of previous economic studies
Author,
publication
year, country
Aims, study design
and patient group
Economic
evaluation type,
model, perspective,
and currency and
price year Costs and outcomes Results
Derrett 2005140
Country: UK
Aim: To assess costs
and health status
outcomes after ACI
and mosaicplasty
Study design: Cross-
sectional retrospective
study
Patient group and
numbers:
l 53 ACI recipients
l 20 mosaicplasty
recipients
l 22 ACI WL
recipients
Mean age (% male):
l ACI: 31.9 (53%)
l Mosaicplasty:
34.9 (45%)
l ACI WL: n/a
(59%)
Type: Cost–utility
analysis
Model: None
Perspective: Not
stated
Currency and price
year: UK £, 2003–4
prices
Time horizon: 2 years
Discounting: None
Resource use and
costs:
Operations/treatments,
arthroscopies, inpatient
stay, day case and
outpatient visits, MRI
scans, histology and
X-rays
Outcomes:
l Modified
Cincinnati knee
rating system
l Pain Disability
Index
l EQ-5D-3L used to
calculate QALYs
Sensitivity analyses:
One-way
Outcomes – EQ-5D means:
l ACI = 0.64
l Mosaicplasty = 0.47
Costs:
l ACI = £10,600
l Mosaicplasty = £7948
ICER:
l £16,349 cost per QALY
Gerlier 2010141
Country:
Belgium
Aim: To assess the
cost-effectiveness
of ACI with CC
compared with MF
Study design: Decision
tree model
Patient group: Adult
patients < 50 years of
age with symptomatic
cartilage lesions of the
femoral condyles who
had not developed OA
Type: Cost–utility
analysis
Model: Decision tree
Perspective: Global
health-care payer
(public payer
reimbursement plus
possible patient
co-payment)
Currency and price
year: Euros (€), 2008
prices
Time horizon: 5 and
40 years
Discounting:
l Costs: 3%
l Effects: 1.5%
Resource use and
costs: Reimbursed
drugs, medical
procedures including
ACI with CC and MF,
consultations,
hospitalisations and FU
Outcomes:
l KOOS
l SF-36 collected
from a RCT used
to calculate QALYs
Sensitivity analyses:
One-way, two-way and
probabilistic
Outcomes – QALY means:
l CC = 21.08
l MF = 19.79
Costs:
l CC = €29,808
l MF = €9006
ICER:
l €16,229 cost per QALY
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TABLE 12 Characteristics of previous economic studies (continued )
Author,
publication
year, country
Aims, study design
and patient group
Economic
evaluation type,
model, perspective,
and currency and
price year Costs and outcomes Results
Samuelson
2012142
Country: USA
Aim: To assess the
cost-effectiveness of
ACI-C vs. ACI-P
Study design: Decision
tree model
Patient group: Adult
patients (30 years of
age) with a focal
chondral injury that
satisfies the conditions
for ACI repair
Type: Cost–utility
analysis
Model: Decision tree
Perspective: Not
stated
Currency and price
year: US$, price year
not stated
Time horizon:
10 years
Discounting:
l Costs: 3%
l Effects: 3%
Resource use and
costs: Initial
consultation, FU visits,
surgical costs, ACI,
physical therapy,
medical equipment
Outcomes:
l Lysholm knee
score
l Utility values from
literature used to
calculate QALYs
Sensitivity analyses:
Threshold
Outcomes:
l ACI-C = not stated
l ACI-P = not stated
Costs (total):
l ACI-C = $66,940
l ACI-P = $66,752
ICER:
l Not calculated
Koerber
2013143
Country:
Germany
Aim: To assess cost-
effectiveness of
mosaicplasty, ACI-P,
ACI-C, MACI
compared with MF
Study design: Decision
tree model
Patient group: Patients
aged 32 years with
symptomatic, isolated
cartilage defects and
no contraindication
Type: Cost–utility
analysis
Model: Decision tree
Perspective: German
statutory health
insurance
Currency and price
year: Euros (€), price
year not stated
Time horizon:
47 years
Discounting:
l Costs: 3%
l Effects: 3%
Resource use and
costs: Surgical
treatments, inpatient
stays, outpatient visits,
arthroscopy, revisions,
GP visits, imaging,
physiotherapy and
medications
Outcomes:
l Utility values from
literature used to
calculate QALYs
Sensitivity analyses:
Probabilistic
Outcomes – QALY means:
l MF = 19.66
l Mosaicplasty = 19.47
l ACI-P = 19.76
l ACI-C = 19.79
l MACI = 19.80
Costs:
l MF = €13,445
l Mosaicplasty = €17,774
l ACI-P = €19,082
l ACI-C = €18,713
l MACI = €21,204
ICER:
Cost per QALY gained in
relation to MF
l Mosaicplasty is
dominated by MF
l ACI-P = €56,370 per
QALY gained
l ACI-C = €40,523 per
QALY gained
l MACI = €55,421 per
QALY gained
CC, ChondroCelect; FU, follow-up; GP, general practitioner; n/a, not available; WL, waiting list.
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German life expectancy of the patients in the model the time frame was set to 47 years. Although the
authors did not explicitly state the cycle length – from the information provided this can be deduced as
1 year. Neither Gerlier et al.141 nor Samuelson et al.142 reported the cycle length that was used in the model,
and none of the three studies applied a half-cycle correction to the economic models.
Study perspective and outcomes
Study perspective is crucial to the economic evaluation, as it will determine whether the appropriate
resource use and costs have been collected, calculated and reported. Only two studies explicitly stated
the viewpoint for the economic analysis: Gerlier et al.141 conducted the study from the perspective of the
global health-care payer, whereas Koerber et al.143 conducted their study from the viewpoint of the
German statutory health insurance. All four studies conducted a cost–utility analysis for which the final
outcomes were reported as QALYs. In addition, the Derrett study140 used a range of outcome measures to
compare the groups after surgery. The postoperative group consisted of patients who received either ACI
or mosaicplasty who were compared with the ACI waiting list group. Outcome measures included:
l The Cincinnati knee rating scale, which assesses 11 components, including subjective symptoms such
as pain and swelling, and functional activity level such as walking and climbing stairs scores – these
scores were higher in the combined surgery group than the waiting list group.
l The Pain Disability Index, which helps patients measure the degree to which their daily lives are disrupted
by pain – the authors found that patients in the combined surgery group had less pain than the waiting
list group (p = 0.09).
l The generic health-related QoL – EuroQol-5 Dimensions, three-level version (EQ-5D-3L) – measure.
Patients in the combined group had statistically significantly higher EQ-5D scores than the waiting list
group (0.61 vs. 0.41; p = 0.03). The EuroQol-5 Dimensions (EQ-5D) measure was used to calculate
the QALYs.
The Gerlier study141 used data from the SF-36 measure to calculate QALYs (this information was collected
over a period of 60 months after randomisation from a RCT); in addition, they also used the KOOS, which
evaluates five key dimensions: pain, symptoms, ADL, sport and recreation function, and knee-related QoL.
Samuelson obtained utility values from the literature to calculate QALYs, although they did not specifically
state which instrument or what method was used to estimate these utility values that were used in the
model. In addition, some studies used in the model had used the Lysholm knee score (this measure
contains eight domains, with a higher score indicating a better outcome) to estimate the utility values.
Koerber et al.143 obtained from the literature (no information sources were provided) and were based on
the following: utility after treatment pain free (high functionality), utility with low functionality of the knee
(medium functionality) and utility before knee prosthesis with strong pain (low functionality).
Resource use, costs and discounting
Derrett et al.140 provided a comprehensive breakdown of resource use and costs, which were collected for
the economic evaluation. These included secondary-care resource use related to each procedure, which
was collected from patients’ electronic and medical records from the time point of the first preoperative
outpatient appointment to 2 years postoperatively. In addition, they also stated price year for which the
costing was undertaken (year 2003–4). The resource use and costs of the surgical procedures, and the
follow-up costs after initial interventions that were used in the model, have been comprehensively listed by
Gerlier et al.141 This included information detailing the length of stay for each procedure and follow-up
stage and also stated the price year for the economic analysis (year 2008). Both the Samuelson142 and
Koerber143 studies provided resource use and cost information, but not as detailed as the Derrett140 and
Gerlier141 studies. For example, for the different procedures the components were not individually listed
and the price years for which the economic analysis was not explicitly stated – therefore researchers
cannot use these unit costs for their own studies or to conduct a cost comparison with their own or with
other studies.
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All three of the economic models performed discounting using both 3% for costs and outcomes, except
for Gerlier et al.,141 who used 1.5% for outcomes. Derrett et al.140 did not conduct discounting, stating
‘that costs tended to occur in the first year, making discounting unnecessary . . . the exact timing of
postoperative benefit accrual was unknown’. Discounting is important in cost-effectiveness analyses, as it
converts future costs into present values, thereby allowing comparisons between costs and benefits that
occur at different times. This is especially important for different interventions for which costs usually occur
in the current time period, whereas benefits are usually not evident until some point in the future; hence,
discounting should have been undertaken by Derrett et al.140 because the study length was greater than
1 year.
Base-case results and sensitivity analyses
The results and the conclusions offered by each study differed: Derrett et al.140 found that the average cost
was higher for ACI than mosaicplasty (£10,600 vs. £7948 in 2003–4 prices). Outcomes in terms of EQ-5D
were better for the ACI group than with mosaicplasty (0.64 vs. 0.47); this difference was not statistically
significant. Overall, the ICER for providing ACI relative to mosaicplasty was £16,349.
Gerlier et al.141 found that the mean costs of ChondroCelect ACI were higher than MF (€29,808 vs. €9006
in 2008 prices), but the overall mean QALYs were also higher for the ACI group (21.08 vs. 19.79). The
authors found that the probability of ACI being cost-effective was approximately 80% if the payer has a
willingness to pay of €22,000 per QALY. The cost per QALY gained for ACI over MF was €16,229.
Samuelson et al.142 found that the total costs of ACI-C were slightly higher than ACI-P – a difference of
US$188 (US$66,940 vs. US$66,752). However, there was some conflicting evidence when they later
say that ACI-C was less expensive by US$941. The earlier figure we presume relates to the initial cost
difference and the latter figure must be after the model was run for 10 years; however, this was not
explicitly stated. Also, no further information or breakdown was provided by the authors to show how
these costs were obtained or calculated. Individual QALY means were not reported over the 10-year
period, except the authors stated that ACI-C was more effective by 0.07 QALYs. The authors calculated a
cost per QALY for each of the two different ACI interventions by dividing the cost of the intervention by
the QALY to get a cost per QALY; however, this was not an incremental cost. Also, we could not work
backwards to find out what these individual costs and QALYs were for each intervention. From the
information gleaned from the paper, the ICER should have been reported as the cost per QALY gained of
ACI-C relative to ACI-P – US$13,443 (US$941/0.07).
Koerber et al.143 reported mean costs and QALYs for each intervention separately; the costs ranging
from €13,445 (MF) to €21,204 (MACI), and QALYs ranging from 19.47 (mosaicplasty) to 19.80 (MACI).
The cost per QALY gained was worked out for each intervention in relation to MF; the authors found that
mosaicplasty was dominated by MF (MF was cheaper and more effective), whereas the cost per QALY
gained ranged from €40,523 for ACI-C to €56,370 for ACI-P both in relation to MF.
Sensitivity analyses are important in economic analyses, as they deal with uncertainty around key
parameters and assumptions made in the model, and help confirm the robustness of the results. All four
studies conducted some sort of sensitivity analyses (SAs), ranging from the most simplistic one-way SAs
(Derrett140) to the more sophisticated probabilistic analyses (Gerlier 2010,141 Koerber 2013143).
Limitations of the studies
All four articles had some methodological shortcomings. For example, in the Derrett study,140 patients were
not randomly assigned to treatment groups and follow-up was for only 2 years. The perspective of the
economic analysis was not stated, and both costs and benefits were not discounted; only one SA was
carried out, which looked at the lowering the costs of the ACI (where the ICER decreased slightly), and
there were no preoperative utility scores for both groups (therefore utility values from a waiting list group
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were used). Gerlier et al.141 felt that there were not enough data on the probability and time to occurrence
for specific events such as TKR, which meant that a Markov model could not be developed. Another key
limitation was the lack of long-term clinical follow-up data that could be used in the model, but one of the
strengths of the study was the use of the data from the RCT to help populate the model. The limitations in
the Samuelson study142 are most notably the inability to calculate the ICER (cost per QALY gained of ACI-C
relative to ACI-P) accurately; short follow-up (10 years); perspective of the economic analysis was not
stated; lack of trial data and the model relied heavily on assumptions and data from different studies in the
literature; and lack of data on the QoL, that is the authors assumed utility values after both ACI-C and
ACI-P were the same, as were the failure rates. Koerber et al.143 did not explicitly evaluate ACI, but merely
used ACI as an example to explain early evaluation and value-based pricing of regenerative medical
technologies, although they did provide a supplementary file with some of the model inputs.
Quality assessment
The quality of the reporting of the economic analyses by the four articles was assessed using the 27-point
CHEERS checklist.138 Koerber et al.143 did not identify the study as an economic evaluation in the title, nor did
they provide a structured abstract. Only two studies reported the viewpoint of the economic analysis (Gerlier
2010,141 Koerber 2013143). Samuelson et al.142 did not describe all of the comparators fully. The choice of
health outcomes was well reported by all four studies; in terms of analytical methods and study parameters,
these were best reported by Derrett et al.140 and Gerlier et al.141 The article by Gerlier et al.141 was the
most comprehensively completed in terms of economic analysis using the CHEERS checklist: 18 of the 27
statements (66.7%) were a ‘yes’, four statements (14.8%) were partially completed, two statements (7.4%)
were not completed and three statements (11.1%) did not apply. The least comprehensive article in terms of
the economic analysis was the article by Koerber et al.,143 in which their study resulted in ‘yes’ to only 7 out
of the 27 statements (25.9%); eight statements were partially completed (29.6%), five statements were not
completed (18.5%) and three statements did not apply (11.1%).
Using the adapted Phillips et al.139 32-point checklist to critically appraise the economic models, overall the
four articles adequately reported the objective of the model evaluation, the structure of the model, the type
of model for the decision problem, the methods and assumptions to extrapolate short-term results into final
outcomes, and the costs used in the model. The models did not provide clear justification if any feasible
options were excluded. The cycle length was not explicitly stated in any of the studies, the choice of
baseline data was not justified and none of the methods used expert opinion. None of the models applied a
half-cycle correction, or justified that omission. Again, the Gerlier article141 was the most comprehensive
analysis when using the Philips checklist139 to critique the article: 21 out of the 32 statements (65.7%) were
a ‘yes’, five statements (15.6%) were partially completed and six statements (18.8%) were not completed.
The Samuelson article142 was not as comprehensively completed in terms of the economic model: only 8 of
the 32 statements were a ‘yes’ (25.0%), 10 statements (31.3%) were only partially completed and nine
statements were not completed (28.1%).
We also note an Austrian HTA report by Kunzl et al.145 from the Ludwig Boltzmann Gesellschaft HTA unit,
which commented that Austria was one of the few countries that funded ACI. However, the Ludwig
Boltzmann Gesellschaft HTA report concluded that in 2009 there was a lack of evidence that ACI was
more clinically effective than the other options. No cost-effectiveness analysis was performed.
Discussion
The cost-effectiveness search highlighted six studies that had been published since 2004; these studies were
classed as full economic evaluations on the use of ACI, MF and mosaicplasty for repairing symptomatic
articular cartilage defects of the knee. These studies included two technology assessment reports: one from
the UK (Clar et al.3) and one from Australia (MSAC32). In addition, there was one cross-sectional study from
the UK and three economic modelling studies (one each from Belgium, Germany and the USA).
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All the articles had shortcomings. The main limitations are summarised below:
l All models were decision models and no models were Markov-type models. A Markov model is more
appropriate than a decision model because of the nature and progression of the disease and because
articular cartilage defects can evolve over time.
l There was a lack of long-term clinical follow-up data and any studies with trial data were only for short
periods (i.e. 2 years). The model would ideally need two time horizons: a short-term model (i.e. 3 years)
to look at the short-term benefits of ACI and its comparators and a long-term model (i.e. 40 years) to
look at the longer-term benefits of ACI and its comparators and the need for TKR.
l The models did not take into account all of the various health states that a patient with symptomatic
articular cartilage defects of the knee can progress through over time.
l As all the economic models were decision models, transition probabilities were not reported. These
probabilities are important for Markov models, as they show the direction and speed of transitions
between the different health states.
l There was also a lack of good QoL data in each of the studies, and different instruments and methods
that were used in estimating utilities/QALYs were not always reported. Good QoL data is important to
show the benefits that evolve over time from ACI and its comparators.
l Finally, not all resource use, costs and price years were reported. Good resource use and cost data are
important, as technologies are always evolving and accurate costings are needed to make comparisons
with other treatments/interventions.
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Chapter 5 Commentary on submissions by
manufacturers and by the Oswestry group, including
data from the ACTIVE trial
ChondroCelect
The submission on ChondroCelect was prepared by SoBi on behalf of TiGenix. ChondroCelect was
developed by TiGenix, a cell therapy development company based in Belgium (www.tigenix.com). It was
approved by the EMA in 2009, and the commercial launch in Europe was in 2010. The first country to
approve reimbursement was Belgium in 2011, followed by The Netherlands in 2012. ChondroCelect was
licensed to be marketed in Europe by SoBi (Stockholm) in 2014.
The submission starts with a concise and accurate account of cartilage structure and defects, and
treatment options. It then goes on to present evidence of clinical effectiveness from four sources:
l The RCT TIG/ACT/01/2000.43 (TIG is short for TiGenix.)
l A ‘compassionate use’ case series.
l A ‘non-interventional’ study – a registry-based cohort from routine care in Belgium and the Netherlands
where ACI is funded, with 153 patients reaching 6 months or more of follow-up.
l The Belgian reimbursement scheme.
The submission notes the evolution of ACI over time. The TIG/ACT trial43 used the Brittberg technique,
using a periosteal flap (ACI-P). The compassionate case series used the same technique but with a collagen
membrane (ACI-C). The manufacturer notes that current ACI mostly uses a cell-loading technique. The
cells are loaded into the membrane by the surgeon.
As explained earlier, we regard ACI-P as now superseded because it requires more theatre time and has
more subsequent costs (shaving of hypertrophy) but no clinical advantage.57 However, we give details of
the TIG/ACT trial43 below. It was a good-quality trial but results may now be better, with ACI-C. We also
give an account of the compassionate use case series and the other sources.
The product used in both trial and case series had ‘characterised’ chondrocytes.
Trial data: autologous chondrocyte implantation–periosteal flap versus
microfracture: TIG/ACT/01/2000
This trial43 compared ACI-P with CCI against MF in patients with symptomatic cartilage defects of the
femoral condyles. The 5-year results are reported by Vanlauwe et al.43 Other papers from this study include
Saris 200869 and Saris 2009.70 The former provides 12- and 18-month follow-up results and the latter has
36-month follow-up results.
Patient characteristics
Patients were aged between 18 and 50 years, with a single symptomatic cartilage lesion (ICRS grade 3
or 4) of size between 1 and 5 cm2 in the femoral condyles of the knee, who agreed to follow a strict
rehabilitation protocol.
A total of 118 patients were randomised: 57 to the ACI-P CCI group and 61 to the MF group. Six of the ACI
patients were withdrawn because of failed chondrocyte expansion (n = 1) or negative ChondroCelect score
(n = 5). ChondroCelect score helps predict whether or not the cells can grow into stable hyaline cartilage in
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vivo. So only 51 patients were included in the ACI analysis. Details of baseline characteristics of these
patients are from the Saris et al. papers.69,70 The mean ages of patients were similar in both groups (33.9
years). Most patients were male (61% in ACI and 67% in MF). Mean weights were similar (78.3 kg in ACI,
80.6 kg in MF, BMI not reported). Median durations of symptoms were similar (1.97 years in ACI, 1.57 in
MF) and 37% in ACI and 21% in MF had had more than two previous knee procedures. In the ACI group,
five had had previous MF, three had had subchondral drilling, and one had had abrasion arthroplasty.
Only 12% of patients in ACI and 23% in MF groups had no history of previous knee surgery, including
arthroscopy. At baseline arthroscopy, 98% of patients in ACI and 97% in MF had a single cartilage lesion,
mostly grade 4 lesions. Mean sizes of defects after debridement were 2.6 cm2 in ACI and 2.4 cm2 in MF.
Patients in each group were categorised into re-intervention group (RIG) or no re-intervention group (NRIG)
based on whether or not they underwent re-intervention on the index lesion during the study period.
Seven patients in the ACI group and 10 patients in the MF group underwent re-intervention on their index
lesion mainly because of recurring pain. In the ACI group, 5% patients in the NRIG group and none in the
RIG group had BMI of > 30 kg/m2.
Details of intervention and comparators
Details of intervention and comparators were given in the Saris et al. papers.69,70 All patients underwent
baseline arthroscopy to assess eligibility to participate in the study. Patients in the MF group were treated
following a technique recommended by Steadman et al.101 and those allocated to the ACI group were
treated following the method recommended by Brittberg et al.21 Patients who were allocated to ACI group
had cells implanted about 27 days after initial arthroscopy, secured beneath a periosteal flap.
Patients from both groups underwent an identical rehabilitation programme. In the first 2 weeks after
surgery, patients were not allowed to bear any weight on their operated knee. After this, they were
allowed to bear weight of up to 10–15 kg in the third week, and in the fourth to sixth weeks the weight
was increased up to 15–30 kg. Then, the weight was increased progressively, as long as patients could
tolerate it. For the first 8 weeks, all patients wore an unloader brace.
Duration of follow-up
Patients were followed up for 60 months.
Outcomes
At 12 months, cartilage biopsies were collected via arthroscopy from the middle of the repaired tissue for
histopathological analysis. The primary outcome measure was change in overall KOOS from baseline at
36 months and 60 months. Other outcomes included AEs, changes from baseline in different KOOS
domains, and analysis of overall KOOS after adjusting for the baseline covariates age, associated lesions
and lesion location. Exploratory analysis was undertaken according to the time since onset of symptoms
(< 3 years or ≥ 3 years) and age (< 35 years vs. ≥ 35 years).
Treatment failure was defined as ‘a reintervention affecting more than 20% of the index lesion’. Time to
treatment failure (TTF) was defined as ‘the time between the end of the surgical procedure and the date of
failure or reintervention’. All treated patients were included in the efficacy and safety population.
Results
Knee injury and OA outcome results were available from 43 patients in the ACI group and 45 patients in
the MF group at both 36 and 60 months (Table 13). (To recap, an increase in KOOS indicates improvement.
A score of 100 indicates no symptoms, a score of 0 is worst possible.)
At 60 months’ follow-up, the overall KOOS and its subdomains improved in both treatment groups (see
Table 13). The difference between the two groups was not statistically significant (7.10 95% CI –0.52 to
14.73; p = 0.068). In both treatment groups, the improvement in mean KOOS started as early as 6 months
and was maintained up to 60 months’ follow-up (Table 14).
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In the subgroup analysis according to the duration of onset of symptoms, the mean improvement in KOOS
was greater in the ACI group than MF in patients with onset of symptoms of < 3 years’ duration [25.96
(standard error, SE 3.45) vs. 15.28 (SE 3.17); difference 10.69, 95% CI 1.30 to 20.07; p = 0.026]. There
was no significant different in the mean KOOS between the groups in patients with onset of symptoms of
> 3 years’ duration [ACI 13.09 (SE 4.78) vs. MF 17.02 (SE 4.50); p = 0.554].
However, the groups differed in more than duration. Several factors that tend to lead to poorer outcomes
were more common in the > 3 years group, including a higher proportion of previous lesions, fewer with
acute onsets, and abnormal fellow knees.
Subgroup analysis by age found no statistical difference between the treatment groups [younger age
patients: < 35 years ACI 22.4 (SE 3.70) vs. MF 16.59 (SE 3.55); p = 0.262; patient aged 35 years and more:
ACI 19.61 (SE 4.51) vs. MF 15.16 (SE 4.01); p = 0.465].
Seven patients (13.7%) in the CCI group and 10 patients (16.4%) in the MF group had to undergo
revision surgery on the index lesion. Most of the failures in the MF group occurred in the first 3 years,
whereas those in the ACI group occurred in the fourth year or later.
The number of failures was lower in male patients than in female patients (ACI 6/19 females vs. 1/32
males, RR 4.21, 95% CI 1.03 to 17.57; MF 7/20 females vs. 3/41 males, RR 4.78 95%, CI 1.49 to 15.62).
TABLE 13 Mean change in overall KOOS and subscalesa from baseline at 60 months
Score
60 months (total group)
ACI (SE) MF (SE) Difference (95% CI; p-value)
Overall KOOS 21.17 (2.88) 14.07 (2.54) 7.10 (–0.52 to 14.73; 0.068)
ADL 16.42 (2.97) 11.35 (2.62) 5.07 (–2.79 to 12.94; 0.203)
Pain 19.04 (3.17) 13.27 (2.74) 5.77 (–2.55 to 14.09; 0.172)
Symptoms/stiffness 17.70 (2.82) 10.90 (2.52) 6.81 (–0.70 to 14.32; 0.075)
QoL 32.12 (4.30) 21.23 (3.87) 10.89 (–0.59 to 22.38; 0.062)
Function, sports and recreational activities 32.50 (5.88) 22.98 (5.69) 9.52 (–6.87 to 25.90; 0.250)
SE, standard error.
a All subscales range from 0 to 100.
TABLE 14 Mean change in overall KOOS from baseline
Time point ACI MF
Baseline 56.30 59.53
Change from baseline
6 months 14.27 13.18
12 months 16.96 13.54
18 months 18.45 15.5
24 months 19.38 13.09
30 months 20.71 15.16
36 months 21.35 14.72
60 months 21.17 14.07
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Radiographic results of 49 patients taken at baseline and at 60 months were available. The Kellgren–Lawrence
grading of severity of knee OA showed no difference between the treatment groups at 60 months.
More patients in the ACI group experienced at least one related AE than those in the MF group (82% vs.
62%) during the 5 years. The AEs were mild to moderate in intensity. The most common AE reported was
arthralgia (75% ACI vs. 62% MF in first 3 years; 36–60 months, ACI 14% vs. 4% MF). Other AEs included
joint swelling (22% in ACI and 7% in the MF group in first 3 years; from 36–60 months, 0% in CCI and
2% in MF group), joint effusion (12% in ACI vs. 2% in MF between 36 and 60 months). None of the
effusions was categorised as severe.
There were three AEs classed as serious in the ACI group and considered related to treatment: one DVT,
one arthralgia and one tendinitis.
At the end of the follow-up, most of the AEs had disappeared, but there were 3 out of 37 cases and 1 out
of 40 cases of effusion in the ACI and MF groups, respectively.
Commentary
Better results were seen with ACI in patients with shorter duration (< 3 years) of chondral defects.
Case series
The baseline characteristics of patients in the case series were more varied in some ways than in the RCT,
as shown in Table 15.
TABLE 15 Comparison of baseline characteristics trial and case series patients
Characteristic RCT Case series
Age (years), mean (range) 34 (18–50) 34 (range not given)
Male (%) 64 57
Duration of injury, years Median 1.57, range 0–18
Site Femoral condyles Medial condyle 43%
Patella 19%
Lateral condyle 15%
Trochlea 9%
Condyle unspecified 7%
Previous procedures 88% in ACI group, with 37% having had 2 or
more, ‘in particular marrow stimulation’
NR
BMI of > 30 kg/m2 10% NR
Mean BMI (kg/m2) NR 25
Mean weight (kg) 81 NR
Inclusions Symptomatic single lesion of femoral condyles,
between 1 and 5 cm2 in size
No predefined entry criteria.
Exclusions Significant knee abnormalities, patellar lesions, OA,
previous mosaicplasty, MF in previous year
Active infection at biopsy site,
significant OA, drug allergies
Size of lesion (cm2) 1–5 3.5 (0.2–20)
NR, not reported.
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The outcomes in the compassionate case series were the Clinical Global Impression measures of
improvement (CGI-I) and efficacy (CGI-E). CGI-I measures change from baseline (no change, improvement,
worsening). CGI-E has four points: very good, moderate, slight and no change or worse. Results were
divided into short-term follow-up (under 18 months, mean 9 months, which is too short for best outcome)
and longer term (> 18 months, mean 27 months) but figures in each group are not given.
Note that these scales are reported by the surgeon, not the patient. The CGI-I results were reported as
showing good outcomes (much improved or very much improved) in 68%, with serious worsening in only
2%. The CGI-E results showed 38% with very good results, 36% with moderate improvement, 12% with
slight improvement and 11% unchanged or worse. (From submission table 10, p. 30 – results total 97%
not 100%.)
The submission reports that no differences were seen by duration of follow-up (< 18 months vs. > 18 months),
site of lesion (patella vs. condyles) or size of lesion (small vs. large, not defined). Patients with single lesions did
better than those with multiple ones, but only significantly so in CGI-I results (improved 86% vs. 77%). Results
in multiple lesions were good.
The most common AE was knee pain (24%) and 54% had no AEs. As expected with the ACI-C method,
few patients (2%) developed cartilage hypertrophy.
Registry cohort
Details from this cohort are sparse and only about half of the cohort (153 out of 308) had 6 months or
more of follow-up. The mean age of 32 years (range 15–50 years) is similar to the RCT and case series.
The only benefit reported is an increase in KOOS, at up to 36 months, but numbers at each follow-up
period are not given. There were six treatment failures, and two DVTs among a total of 17 SAEs (but no
denominator given). Treatment failure was defined as the need for a re-intervention for more than 20% of
the treated area, associated with symptoms. The summary states that no new AEs were reported in the
registry cohort.
Belgian reimbursement scheme
Little information is reported from this source. Two procedures failed within 12 months and another two
procedures failed between 12 and 24 months, in 254 patients. Only 51 patients had reached 3 years of
follow-up.
The data show an increase in numbers treated, from 51 in the first year (May 2011 to April 2012), 93 in
the second and 110 in the third, possibly suggesting levelling off in numbers. The population of Belgium is
11.2 million, so the third year rate is about 10 per million per year. The equivalent numbers per year in
England would be 540, and in Wales 30.
The ChondroCelect submission argues, with some justification (see Chapter 2 of this report), that ACI is
more successful as a primary procedure in patients who have had previous MF. The Minas et al. study75
is cited in support of the assertion.
Cost-effectiveness
The health-related QoL was measured in the TIG/ACT trial43 using the SF-36 administered at 18, 24, 30, 36,
48 and 60 months post procedure. At 36 months, SF-36 scores were slightly better for ACI.
Introduction and model structure
The economic analysis by SoBi used a de novo Markov model to assess the cost-effectiveness of ACI in
relation to MF from a NHS and Personal Social Services (PSS) perspective. Both costs and outcomes were
discounted at a rate of 3.5% per annum in line with NICE guidelines. Only the written assessment was
provided to the Assessment Group. The model used is simpler than the Warwick model, but is regarded as
fit for purpose.
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Microfracture was considered to be the only relevant comparator for ACI, and other comparators such as
mosaicplasty were not considered for this analysis – this is a reasonable assumption. The SoBi submission
states that mosaicplasty is little used and ‘not recommended by NICE’. The last assertion is not quite
correct. The NICE Interventional Procedures Guidance (2006),34 which is concerned only with safety and
efficacy (not cost-effectiveness), states that there were no major safety concerns and mentions ‘some
evidence of short-term efficacy but data on long-term efficacy inadequate’.
Evidence of benefit came from a RCT with only 1 year of follow-up, in which ACI was better, and from
case series with 2 or 3 years’ follow-up. NICE recommended that mosaicplasty should be used only with
‘special arrangements for consent and audit or research’. So it is correct to say that NICE has not
recommended mosaicplasty in routine care.
The SoBi model is similar to the Warwick Assessment Group model, whereby patients enter the model
at the time that they receive the procedure (ACI or MF). However, there are differences between the
Warwick model and the SoBi submission: the cycle length used in the submission model is 1 month,
whereas the Warwick model used a cycle length of 1 year. The average age of patients receiving a
procedure in the SoBi model is 33 years and the model has time horizon of 75 years: on this basis the
model assumes that patients can live up to an average age of 108 years (however, they did state that by
this point > 99.9% of patients will have died). The model is separated by gender, but we know that there
is no difference in the success or failure of the two different procedures if lesions are comparable.146
The model structure is logical and similar to the Warwick model, as it allows both temporary and
permanent successes. If either MF or ACI fail, the patient has debridement to remove the damaged tissue
and can go on to receive another repair, but this second repair is MF only. Otherwise the patient may
choose not to have a repair and is offered conservative pain relief treatment only. If this second repair (MF)
fails, the patient will receive debridement and pain relief only.
Patients who receive best supportive care (BSC) may deteriorate and are assessed for a TKR. The SoBi
model assumes that a patient can receive up to a maximum of only three TKRs. The modelling uses TTF as
the outcome that drives the ICERs, using 5-year data from the TIG/ACI RCT and the case series. Delaying
treatment failure leads to postponement of TKR costs. If the second TKR fails then the patient receives just
analgesics. The following is unclear from the SoBi model:
l The average age that a patient will require a TKR.
l As evidence has shown, some patients may receive more than two TKRs.
l Also, the first knee replacement can either be partial or a TKR. As described later, this affects the costs
of the second replacement.
Finally, the model assumes that patients can die at any stage from all-cause mortality, and there is a low
risk of mortality from undergoing a TKR or a TKR revision.
Model inputs
Efficacy of first treatment
The SoBi model uses TTF as a proxy measure of treatment efficacy (i.e. when a new procedure for the
same defect was required). This information on TTF (i.e. transition probability for moving from primary
treatment success to treatment failure) was obtained from KM plots as reported in the Vanlauwe et al.43
article. This article43 reported that ACI was better than MF, and that patients in the ACI group waited
longer before needing a further procedure because of the longer benefits. This is a reasonable assumption
for the model.
Four different scenarios were used for the TTF after the observed data: scenarios 1–3 assumed no ACI
benefit after the observed data, or after 10 or 20 years, at which point then the benefit of MF is applied to
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the patient cohort; scenario 4 used the line of best fit for the entire model duration. For all scenarios, ACI
was better than MF. These scenarios seem plausible.
Another four different scenarios were also used for treatment failure using observational ACI data (to take
into account a normal clinical setting rather than a trial setting). The observed failure rates for ACI were
0.79%, 1.39% and 0.00% in years 1, 2 and 3, respectively. A weighted average failure was calculated as
0.89% and this was applied. Scenarios 1–3 assumed no ACI benefit after the observed data, or after 10 or
20 years, and in scenario 4 it was assumed that the average ACI benefit was maintained.
Subsequent treatment
The SoBi model in the base-case analysis assumed, based on clinical advice, that, when ACI fails, 90% of
the patients will receive MF, and, that, when MF fails, only 5% of patients receive another MF. As the
manufacturers said, this latter value is too low (these values are set to 50% in the SA). The submission did
not say why patients who receive a first MF are less likely to receive second MF than patients who receive
an ACI first.
Two papers from the TIG/ACT trial43 reported failure rates for subsequent MF: Vanlauwe et al.43 reported
MF failure rate of 16.4% at 5 years (converted monthly rate 0.30%) and Saris et al.70 reported MF failure
rate as 11.5% at 3 years (converted monthly rate 0.34%). The latter value was used in the SA. The
submission assumed that, based on clinical advice, a second MF following a first MF would be half as
effective, that is twice the failure rate.
Two studies that reported failure rates for debridement were used for BSC following initial and subsequent
treatment failure in the analysis: Forster et al.147 reported a failure rate of 20.0% at 1 year (converted
monthly rate was 1.84%) and Bernard et al.148 reported a failure rate of 18.0% at 5 years (converted
monthly rate was 0.33%). The latter value was used in the SA. Failure of BSC leads to knee replacement.
For TKR, based on expert clinical advice, the SoBi model assumed that 95% of the cohort would be
suitable for a TKR and that a TKR is expected to last for 10–20 years (a midpoint of 15 years was used in
the base-case model and was converted into a monthly transition probability). For those patients who need
a TKR revision, the model assumed that there was a slightly higher failure rate than for the first TKR, and
the first TKR will only last for 10 years – these are plausible assumptions for this patient group.
Mortality
Swedish Orphan Biovitrum AB used Office for National Statistics (ONS) data for all-cause mortality (split by
age and gender) and, for the base-case, TKR mortality data was based on a figure reported on the NHS
Choices website149 (1.6%). A paper by Mahomed et al.150 was used for TKR mortality (0.7% for initial TKR
and 1.1% for a revision TKR) in a SA. The SoBi model assumed that the mortality rate for TKR revision
would be 2.5% (i.e. based on Mahomed et al.,150 a 57.1% increased risk). This is a reasonable assumption,
as this is a longer operation, patients are older and rehabilitation might be slower.
Costs
The costs for the different procedures, rehabilitation, TKR, TKR revisions and pain relief were obtained from
UK sources, literature and the HTA report by Clar et al.3 The cost of procedures included the costs of surgery,
inpatient stays and physiotherapy follow-up. The submission stated that cost of TKR could not be identified
from the NHS reference costs so they used information from the previous HTA report3 (whereas the Warwick
model uses a NHS reference cost151 for TKR). The costs that have been inflated from the previous HTA report
by Clar et al.3 are underestimated, as the wrong base-case year was used: the submission model should have
used the year 2003–4 prices instead of 2005–6 prices. The inflation multiplier will have been 1.286 instead
of 1.200. For example, the cost of MF as an inpatient procedure should be £3020 instead of £2818.
The submission reports that ‘All costs are updated to 2014 using the latest Hospital & Community Health
Services (HCHS) index’ – when, in fact, the prices are uplifted to year 2012–13. We have not amended any
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of the costs below, as this would mean that the total costs and ICER value would be different. However, we
believe that the magnitude and direction of the costs differences will not change substantially.
The cost of ACI included the cost of the product including two-way courier and cell culture (£16,000) plus
the cost of arthroscopy and cell harvest (procedure 1: £722.45) and arthrotomy conducted in an outpatient
setting (procedure 2: £109.65). However, the cost for implantation of the cells is an underestimate, as the
procedure would be done as a day case, not an outpatient visit. The total cost of ACI was £16,832.10.
Adjustment of the cost of the second procedure gives a total cost of ACI of £16,832 + £722 = £17,554.
The SoBi model also included the cost of a TKR assessment, which included a general practitioner (GP)
assessment and cost of an outpatient appointment (£146.65) whether the patient went on to receive a TKR
or not. The costs for TKR and TKR revision (£6500.85 and £12,093.24, respectively) look correct.
The SoBi model also included the cost of rehabilitation after ACI, MF and TKR in line with the Warwick
model. However, the cost used by SoBi is lower than the cost used in the Warwick model (£42.47 vs.
£256.00). In addition, the submission model also included the cost of pain relief medication – which
consisted of paracetamol (this cost was not included, as the patients would have purchased this over the
counter) and NSAIDs. SoBi estimated a weighted average cost for NSAID per month as £9.79. This cost is
negligible and has not been included as a cost in the Warwick model.
The SoBi model also included a cost for patients who were classed as ‘unresolved patients’. This cost was
estimated at £384.43 per year, which included the cost of GP visits, treatment visits, medications, outpatient
visits, physiotherapist, prescribed aids (not specified but presumably walking aids), and complementary (not
specified) and other therapies. This total cost was based on patients with lower limb OA, but for some
patients this cost may be an overestimate, as some of these patients may just have pain relief medication
and choose to put up with the pain.
The different cost values were varied in the SA.
Health-related quality of life
The SoBi submission states that there is lack of utility data in patients with a knee cartilage defect. Utility
scores were based upon analysis of the SF-36 questionnaires, which were collected up to 60 months post
surgery, as reported in Gerlier et al.141 in table II. These are plausible utility values. The model also accounted
for the decreasing utility over time by using age-related UK population EQ-5D weights as reported by Kind
et al.152 The model assumed that after successful ACI and MF, patients would have the same benefits, and
the utility value used after surgery was 0.8170. The model does not specifically state how long this benefit
lasts but we assume it is 5 years in line with the Gerlier et al.141 paper. This does not take into account that
after MF the utility value will stay at this value for a few years but is likely to decline later, eventually to the
presurgery value, as these patients are most likely to require another repair. Values were varied in the SA.
Adverse events
Adverse events were not included, as SoBi stated that there were no key differences between the two
treatment arms.
Model results
The total cost of ACI was £22,586. The total cost of MF was £13,547. Total QALYs gained for ACI
compared with MF were 1.29. The ICER for ACI compared with MF was £7077 per QALY. The main cost
drivers were the cost of the cells and the fact that fewer people needed further repair or TKR with ACI
than with MF. The model also assumed that further QALYs are gained by ACI patients when they received
a subsequent MF (4.15 more QALYs when looking at QALY results disaggregated by health state) than MF
patients when they received a subsequent MF (as these patients will fail more quickly).
The SoBi SAs found that the ICERs for the different efficacy scenarios and the subsequent treatment
efficacy scenarios, as listed earlier, were consistent with the base-case analysis, that is, although ACI was
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more expensive it was also more effective. For the subsequent treatment scenario in the base-case analysis,
the use of subsequent MF after ACI was 90%, but only 5% had a second MF after the first MF (i.e. only a
small proportion of patients would receive a second MF). In the SA this value was changed so that 50%
would have a second MF after both ACI and MF. The resulting ICER was nearly £25,000. This is due to
more people having MF and the QALY gain being lower (0.46 vs. 1.29).
The ICER was also sensitive to the model time horizon. For example, if a 5-year time horizon was used,
the resulting ICER was approximately £290,000. This was due to the majority of costs of ACI being incurred
in the first few years, and the benefits from ACI not being seen until later, in other words fewer people
moving to an unresolved state and fewer people in need of a TKR. The model became cost-effective only
when it was run for 20 years (ICER approximately £22,000). The ICER was robust to other scenarios that
were tested, such as different utility values, TKR mortality and discounting. The probabilistic SA results
were similar to the deterministic, with ACI probably the most cost-effective around the £6000–7000 range
(i.e. a 98.8% chance of being cost-effective).
Overall, the model assumptions and results look plausible.
Aastrom Biosciences submission
Aastrom have now changed their name to Vericel Corporation.
The submission from Aastrom was based mainly on the SUMMIT trial,100 including the extension study up
to 3 years (it will, in time, produce 5-year data). The SUMMIT trial100 was described in detail in Chapter 2.
Data from the Basad study8 were also presented.
The Aastrom submission states that an indirect comparison of MACI and ACI was performed, using MF as
the common comparator, but this is illustrated by two separate forest plots: one showing the SUMMIT100
results for MACI versus MF and the other showing the Saris et al. results70 for ACI versus MF. Some RRs for
SUMMIT100 versus Saris et al.70 are then presented, but the underlying methods and calculations are not
provided. However, results were similar and CIs overlapped with 1. So no claim for clinical effectiveness
superiority of MACI over ACI is made.
Data on ACI versus mosaicplasty are presented and used to argue, reasonably, that MACI is superior
to mosaicplasty.
Aastrom argues that the main comparator is MF, particularly as the lesion sizes considered in the
submission (3–20 cm2) are too large for mosaicplasty.
Cost-effectiveness
The submission by Aastrom Biosciences did not provide any cost-effectiveness analyses because of the
recent purchase of the MACI product by Vericel from Sanofi. Cost-effectiveness evidence was presented in
the MSAC submission32 and the manufacturers aimed to adapt this. However, this was not possible
because of time constraints, so only a budget impact/costing forecast model was provided.
The budget impact model estimated by Aastrom indicated that 9549 patients in England and Wales were
eligible for cartilage repair in 2013. Of these 9549 patients, as indicated by the NICE scope, 500 will be
eligible for MACI or an ACI in year 5. The manufacturers assumed that there would be an equal split
of the use of MACI and ACI. The rest of the eligible patients would receive MF, though the reasons for not
offering ACI are not explained. Based on data from three studies (Minas 2009,75 Nawaz 2014,80 Vijayan
2014153) the manufacturers reasonably assumed that reoperations after MF do not have the same success
rate as primary MACIs or ACIs.
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List prices were used for the costs for ACI (£18,300) and MACI (£16,226 excluding VAT). The cost of MF
was £2464, which was obtained from the NHS reference costs.151 Cost of theatre, surgery for implantation
of MACI/ACI was assumed to be the same as the cost of MF, though our clinical opinion is that MF usually
requires an inpatient stay (because of pain), whereas ACI is usually a day case procedure. The Aastrom
assumption may therefore slightly disadvantage MACI. The submission states that patients have one
procedure. It is not clear whether this means that they would have only one MACI or it is an error by not
accounting for both arthroscopy and harvesting, and later implantation. The manufacturers assumed that
the cost of MACI/ACI reoperation would be £16,226. The cost of initial MF with MACI/ACI as second
repair at an average cost of £17,623 also seems appropriate. This extra differential cost approximates to
3.5 extra rehabilitation visits. The cost of rehabilitation was £376, which was obtained from the Unit Costs
of Health and Social Care (Curtis 2013154). This cost was based on the use of a community-based therapist,
with 6–8 rehabilitation sessions, each lasting 30 minutes. Alternative rehabilitation costs could have been
obtained from the NHS reference costs.151 The budget impact model did not take into account any
outpatient visits and any inpatient stays for MACI/ACI.
Three-year probabilities for MACI reoperation and MF reoperation were obtained from the SUMMIT trial
data100 and these were converted to annual probabilities: 0.005 and 0.014, respectively. The annual
probability for MACI was also assumed for the ACI reoperation, which seems a reasonable assumption.
The Saris et al. 200970 data provided alternative 3-year probabilities for reoperation – these were converted
to annual probabilities: 0.010 for ACI/MACI reoperation and 0.040 for MF reoperation. The manufacturers
assumed that if MACI/ACI failed then a reoperation would be either MACI/ACI; however, if MF failed then
a reoperation would be MACI/ACI.
The budget impact model explored two scenarios: one scenario with MACI/ACI as first-line treatment and
the other scenario without MACI/ACI (with MF only). Using failure rates based on the SUMMIT data100
there were total cost savings from using MACI/ACI, ranging from approximately £5.9M in year 1 to £8.3M
in year 5 – this was due to the lower reoperation rate and the expectation that 500 procedures (of the
approximate 10,000 procedures) were either MACI/ACI. The Aastrom submission also included a budget
impact model using the higher failure rates from Saris et al. 2009.70 There were further total cost savings,
although lower than the cost savings when the SUMMIT trial100 failure rates were used – using MACI/ACI
the cost savings ranged from approximately £5.8M in year 1 to £7.8M in year 5 – these lower cost savings
were due to the need for more reoperations after MF. In conclusion, the cost calculations provided by
Aastrom seem reasonable and plausible.
Submission by OsCell
The Oswestry submission included interim data from the ACTIVE trial,35 which had about 5 years to run.
The ACTIVE trial
The ACTIVE trial35 is a Medical Research Council-funded multicentre RCT of ACI against standard
treatment, which could include debridement, abrasion, drilling, MF, mosaicplasty or bone graft (according
to surgeon’s discretion) in 390 patients (195 in each group) with symptomatic chondral defect(s) on the
medial or lateral femoral condyle, trochlea or patella, who had failed previous treatment and who were
also considered suitable for ACI/MACI.
The protocol is available online from the ACTIVE trial35 website (www.active-trial.org.uk/).
Details of the results were made available to NICE for the ACI appraisal as academic in confidence.
Only some of the results are reproduced here, with permission from the ACTIVE trial35 group.
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Patients were recruited from 29 centres. The RJAH in Oswestry recruited 87 patients (22%). Six centres
recruited between 20 and 29 patients, six centres recruited between 10 and 19 patients, and 16 centres
recruited fewer than 10 patients.
Quality assessment
Using the modified Coleman methodology score, the study scored a total of 73, suggesting that the
quality is good.
The cells used came from two sources. In the Oswestry centre, the locally produced cells were used, but in
all other centres commercially produced cells were used. So ACTIVE35 is a trial of ‘traditional ACI’ only in
the Oswestry centre.
The first primary outcome was to have been time to cessation of benefit, but this proved difficult to
measure, and the second primary outcome, Lysholm assessor outcome score, was used. (The submission
uses the phrase ‘independently assessed’.) Other outcome measures included patient-assessed Lysholm
score, Cincinatti knee score, IKDC score and EQ-5D.
As part of secondary outcomes, patients were asked to state their rating of operation at all follow-up
points with responses ranging from extremely pleased to much worse (Table 16).
The Oswestry group report that ACI-C with Chondro-Gide™ (Geistlich, Wolhusen, Switzerland) is better
than ACI-P, as the former leads to repair of the defect with better-quality tissue. The evidence for this
comes from a study (McCarthy and Roberts155) comparing the two in 88 Oswestry patients: 55 treated with
ACI-P and 33 patients treated with ACI-C.
Cost-effectiveness
The cost-effectiveness analysis by Oswestry was based on the ACTIVE trial35 data, but using cell costs
only from Oswestry. The cells used in other ACTIVE35 sites came mainly from Genzyme. The submission
provided the costs of ACI and the different comparators. The benefits were in terms of QALYs, which were
estimated from the EQ-5D-3L.
The total costs and incremental costs with and without the market forces factor (MFF) provided in the
submission have been summarised in Table 17 (MFF estimates the unavoidable cost differences of providing
health care.) With Payment by Results (PbR), the MFF directly funds providers for the relative level of
unavoidable costs they face. Each NHS Trust receives an individual MFF value used to establish the level of
unavoidable costs they face relative to each other.
Accounting for unavoidable costs ensures a level basis across the country to provide equal amounts of
health care per pound. So, in terms of PbR income, this would equal the activity multiplied by its tariff price,
and this is then multiplied by the MFF value. All costs are in 2014–15 prices in UK pounds sterling (£).
TABLE 16 Patients’ responses
Time point (years)
Proportion (%) pleased or extremely pleased
ACI Controls
1 60 50
2 58 47
3 57 45
4 52 47
5 59 43
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The second stage for ACI includes the cost of the cells. Production of cells in Oswestry costs £4125 per
patient, but this does not include overheads and set-up costs. The submission stated that the incremental
cost of ACI over TKR was £3746 and the incremental cost of ACI over MF, osteotomy or mosaicplasty
was £7094.
Autologous chondrocyte implantation costs included operations, hospital stays, the cells and any further
implants. The TKR cost is in line with NHS reference costs (2012–13), which is £5676 (NHS reference costs
2012–13151). The costs included only the direct costs of the procedures. No information in the submission
was provided on any further outpatient or rehabilitation visits. The submission also stated that further data
have been collected using patient diaries on patient and societal costs, such as any out-of-pocket expenses
and time off work, but were not available in time for this submission.
In the ACTIVE trial,35 QALYs were estimated using the EQ-5D-3L version, weighted using the UK utility
values. The control group consisted of patients who received MF, MF plus collagen membrane, and
mosaicplasty. The ACI group had 192 observations at baseline, with a mean EQ-5D index score of 0.506,
and by 8 years this score had increased to 0.676 (n = 29). The control group had 187 observations at
baseline with a mean EQ-5D index score of 0.532 (slightly higher than the ACI group) and by 8 years this
score was 0.647 (n = 29); this score was slightly lower than the corresponding score for the ACI group at
8 years. One year postoperatively, the EQ-5D index score had risen to 0.636 in the ACI group and 0.675 in
the control group. The submission stated ‘these mean 1-year levels are largely maintained up to seven
years post-surgery, after which the mean score for the control group seems to drop slightly’. Too few
patients had reached the later years for a reliable analysis. Cumulative QALYs were also presented, which
represented the total increase in health utility. These cumulative QALYs increased at a similar constant rate
for both the ACI and control groups up to 6 years. The submission concluded that ‘at the 8-year time
point, the ACI group has experienced – on average – an incremental gain of 1.19 QALYs more than the
control group’ – this figure relates to cumulative QALYs and not mean QALYs.
Numbers of patients and EQ-5D for later years are reproduced in Table 18.
The submission concluded that the trial found that the ACI group gained more QALYs than the control
group (incremental gain = 1.19 QALYs) at the 8-year time point, which resulted in a crude estimate of an
incremental cost per QALY gain of £5961 for ACI over the control group.
In the base case, both groups were treated as homogeneous, but because of differences in the treatments
for the control group and cell sources for the ACI group, further analyses tested for heterogeneity in
TABLE 17 Costs of ACI and its comparators by Oswestry
Procedure Costs (2014–15 prices, £) Costs (£) including MFF
Incremental costs (£) of ACI over
the comparator (including MFF)
Intervention – ACI
First stage 2398 – –
Second stage 6876 – –
Total cost of ACI 9274 9565 –
Comparators
TKR 5642 5819 7094
MF 2396 2471 3746
Osteotomy 2396 2471 3746
Mosaicplasty 2396 2471 3746
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each group. For the control groups (MF, MF plus collagen membrane and mosaicplasty), the data from the
ACTIVE trial35 suggested little difference in the EQ-5D scores. For the ACI group, as the cells came from
different sources, the submission included a regression analysis to see whether or not cell origin might
affect their benefit. The regression analysis provided a negative value from which the authors concluded
that ‘ACI patients treated outside Oswestry are unlikely to have more benefit from ACI’.
The absolute values for EQ-5D from the ACTIVE data35 often show little difference, as shown in Table 18,
but changes from baseline EQ-5D show a more consistent advantage for ACI, as shown in Table 19.
Discussion: clinical effectiveness
The four main trials8,35,43,100 described in this review all show some superiority of various forms of ACI over
MF, but in different timescales and to different degrees. The Basad8 and SUMMIT100 trials show clear
differences in favour of MACI by 2 years in Lysholm and KOOS, respectively. The SUMMIT trial100 found no
significant difference in EQ-5D visual analogue scale (VAS) changes – both groups improved by 17 at
2 years. The TIG/ACT trial43 shows superiority overall by 3 years. The ACTIVE trial35 (in which ACI was a
mixture of ACI-P, ACI-C and MACI) showed no benefit in most outcome measures at 5 years, but some
separation in EQ-5D after that. With the exception of EQ-5D, results are available only to 5 years in an
interim analysis provided for the NICE appraisal. The ACTIVE trial35 will continue to 10-year follow-up.
Previous repairs
As reported earlier, in case series previous MF appears to reduce the success of ACI. The trials reviewed
above do not contribute much evidence on this. Basad did not give details of previous surgery. In TIG/
ACT43 only a few (8/57) of the ACI group had had previous MF. In the SUMMIT trial,100 32% of the MACI
TABLE 19 Increases in EQ-5D from baseline
Time point, years Standard care ACI
1 0.143 0.130
2 0.135 0.163
3 0.141 0.168
4 0.142 0.141
5 0.086 0.171
6 0.143 0.175
7 0.173 0.229
8 0.115 0.170
TABLE 18 The EQ-5D scores in the ACTIVE trial35
Time point, years
Standard arm ACI arm
No. of patients Mean EQ-5D No. of patients Mean EQ-5D
5 87 0.618 102 0.677
6 75 0.675 80 0.707
7 53 0.705 59 0.735
8 27 0.647 29 0.676
9 5 0.486 2 0.761
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group had had previous repair attempts with MF, but this appeared to have little effect on response rates
(no prior repairs, 90% response; more than one, 84%). In the ACTIVE trial,35 almost half had a previous
repair procedure, but results are not given separately for them.
Several factors need to be considered in interpreting the evidence. First, we are somewhat reliant on
subgroup analysis. Second, those who have had previous surgery may be older than those going straight
to ACI, and chondrocyte viability declines with age. Third, some of the older trials had few patients who
had not had prior surgery. Last, and most important, the evidence does not suggest that ACI is not
worthwhile after prior MF, but only that it is not as successful. Hence there is no reason not to try ACI.
Duration of symptoms
In the SUMMIT trial,100 response rates were similar at 2 years: 82% for those with symptoms for less than
3 years, 92% in those with longer durations. Basad did not report results by prior duration but his MACI
patients had a mean duration of symptoms of only 2.2 years. The ACTIVE trial35 did not report durations.
The main evidence comes from the TIG/ACT43 5-year data for which only those with duration of symptoms
under 3 years showed a significant difference between ACI and MF. Improvements in KOOS at 5 years
were 26 for the ACI group versus 15 for the MF group (p = 0.026). For the subgroup with over 3 years’
duration, KOOS improvements were 13 for ACI and 17 for MF (not significant). This might suggest that
ACI is of less value, relative to MF, in patients with longer duration.
Previous studies have shown improvements with ACI after long duration of symptoms. In the trial by
Bentley et al.,78 most patients receiving ACI had excellent Cincinnati scores results despite a mean duration
of symptoms of 7.2 years. In the trial of ACI-C versus MACI by Bartlett et al.,57 59% of the ACI-C group
and 72% of the MACI group had good or excellent Cincinnati scores despite duration of symptoms of
approximately 10 and 7 years, respectively. In another study from Stanmore by Biant et al.,79 of a cohort of
104 ACI patients followed for at least 10 years, 66% had excellent or good Cincinnati scores despite an
average duration of symptoms before ACI of 7.8 years.
ACI-C or MACI?
In a very large cohort of 827 patients with mean duration of follow-up 6.2 years, Nawaz et al.80 reported
better results with MACI than ACI-P or ACI-C, though this was probably due to different durations, as the
ACI groups came from an earlier period and so had more time for knee status to decline. The RCT of
ACI-C versus MACI by Bartlett et al.57 found no difference at 1 year.
In practice, ACI has evolved and most use is now expected to be MACI, with characterised chondrocytes.
Predicting success
Nawaz et al.80 noted that the chance of success was reduced by previous attempts at repair and the presence
of any osteoarthritic change in the knee. They summarised the results from their very large cohort study thus:
Our study suggests that the ‘ideal’ candidate for autologous chondrocyte implantation is a younger
individual with a single lesion on the trochlea or the lateral femoral condyle, with no previous
procedures or evidence of degenerative changes.
At 12 years after ACI, their ideal patients had a repair survival of almost 80% compared with 50% in the
whole group. Graft survival was < 25% in those who had had a previous repair (including MF and
mosaicplasty) and > 75% in those who had not.
Survival of repairs
The 2-year differences between MF and ACI or MACI arise mainly because symptom scores reach a
plateau sooner after MF than after ACI. Saris et al.70 reported (from graph) that a KOOS plateau was
reached with MF by 12–18 months, whereas improvements continued after ChondroCelect ACI-P.
The SUMMIT100 investigators showed a plateau before 12 months with MF but not until 18 months
with MACI.
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In the TIG/ACT trial,43 Saris et al.70 reported (from graph, so approximate) that about 7% of MF repairs had
failed by 20 months and 11.5% by 36 months (but based on only seven failures in the MF group). The
longer-term results reported by Vanlauwe et al.43 showed the plateau in the KOOS in the MF group from
12 to 60 months, whereas the ChondroCelect group with duration of symptoms < 3 years at surgery,
reached a plateau at 36 months. The CC group with duration of symptoms of > 3 years showed no
difference in KOOS from MF with an early plateau and lines almost overlapping.
Basad et al.64 reported that the Lysholm score in the MF group improved from 55 at baseline to 81 at
12 months, but then declined to 69 at 24 months. The MACI group had a baseline score of 55, improving
to 95 at 12 months, maintained at 92 at 24 months.
Bhosale et al.,108 from Oswestry, report results at an average of 5 years (range about 3–9 years) among
80 patients, all but four having had ACI-P. The median baseline Lysholm score was 54, which improved to
a median of 78 at 12 months post operation. Of the 80 patients, 65 improved and scores at 15 months
were maintained for up to 9 years. They also reported that higher age, female gender and larger defect
size were associated with greater benefit, but none of these associations was statistically significant.
They concluded that a good result at 15 months is durable.
Commentary on SoBi submission October 2015: survival analysis
SoBi pooled reconstructed IPD for five ACI studies that provided data beyond 5 years. The studies varied
in failure definition and proportion of patients previously treated. Parametric models were fitted and
according to information criteria, the best fit was from a Gompertz model followed by a gamma model.
These studies encompassed 507 patients, and included one study with 62 participants, which was not
included by the Assessment Group. This study was by Filardo et al.,156 who were using the Hyalograft
scaffold, which was a bioengineered non-collagen product that was not covered by the NICE scope.
Hyalograft was withdrawn from the market in January 2013. SoBi excluded the largest relevant study
(Nawaz 201480) with 827 patients, which we think is the most relevant study because it was undertaken
with UK patients; had a mix of ACI generations and patients; and provided subgroup analyses. Also
excluded were arms of studies with data to 5 years. When the six ACI studies (which we identified, with
5 years’ or more follow-up) are pooled the best fits are provided by a gamma model (Table 20).
Figure 16 shows the KM plot and best fit gamma model (95% CI) to 70 years post intervention for the
pooled six ACI studies (Knutsen 2007,67 Vanlauwe 2011,43 Nawaz 2014,80 Niemeyer 2014,117 Minas 2014,136
Moseley 2010115), together with the SoBi best- and worst-scenario models based on five ACI studies.
TABLE 20 Information criteria for six studies with ACI arms examined in the Assessment Group report
Model Obs. ll(model) df AIC BIC
Gamma 1270 –975.825 3 1957.649 1973.09
Exponential 1270 –1013.96 1 2029.922 2035.069
Weibull 1270 –1006.09 2 2016.178 2026.472
Gompertz 1270 –1013.86 2 2031.712 2042.005
Log-normal 1270 –982.15 2 1968.301 1978.594
Log-logistic 1270 –993.514 2 1991.028 2001.321
df, degrees of freedom.
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Alternative models for the six pooled studies are shown in Figure 17. It may be a moot question whether
pooling the five ACI studies of SoBi or all of the studies that we identified is preferable, but omission of
the largest UK study by SoBi does not seem appropriate.
For the purposes of base-case economic modelling, SoBi used the Gompertz fits to five pooled studies
to develop a model of failure of ACI for times beyond the 71 months of observed data (KM) from the
Vanlauwe TIG/ACT study43 (Figure 18). The TIG/ACT study43 included only 51 patients in ACI arm and it
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FIGURE 16 Pooled ACI studies compared with SoBi curves. The gamma model for six studies generates poorer
survival than the Gompertz model generated by SoBi for five pooled studies.
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might be suggested that using the pooled data for all the ACI arms would be more appropriate. The resulting
hybrid curve generated by SoBi incorporates data for 51 patients to 71 months and an extrapolation based
on a Gompertz curve that excluded these 51 patients. The resulting hybrid may be considered to probably
flatter ACI, in that the major Nawaz study80 has been excluded.
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FIGURE 18 SoBi hybrid curve for ACI failure. (TIG/ACT43 KM to 70 months then a Gompertz model for five pooled ACI
studies.) Also shown is the SoBi MF failure model based on an exponential fit to the MF arm of the TIG/ACT study.
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FIGURE 17 Alternative models for six pooled ACI studies (n= 1270).
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SoBi have not pooled MF studies. For the comparator MF arm, the new submission appears to have used
an exponential survival curve based on the MF arm of the TIG/ACT study43 as in a previous submission;
however, this is unclear.
The Assessment Group found an anomaly in the published risk table for the MF arm of the TIG/ACT study.43
A speculative correction to the risk table allowed reconstruction of IPD that yielded the exponential model
shown in Figure 19a. This plot is closely similar to that proposed by SoBi. Alternative candidate models
(Figure 19b) produce variously different models of failure. The small number of patients and apparent
anomaly in published data render these curves problematical.
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Based on their pooled studies, the SoBi analysis concludes that survival of ACI was 70% after 15 years.
Applying their long-term survival data in the modelling reduces the ICER from about £26,000 to £21,000,
and adding a confidential Patient Access Scheme reduces further.
The weakness in the SoBi analysis is the lack of similar survival analysis for MF, but that is partly because
there are fewer long-term studies of MF than of ACI.
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Chapter 6 The cost-effectiveness of autologous
chondrocyte implantation
Introduction
The first aim of this analysis is to determine whether or not ACI is cost-effective compared with the current
standard treatment of MF as primary treatment for patients with symptomatic articular cartilage defects of
the knee. We use ACI as a generic term to cover all of the relevant forms of ACI.
After the first procedure, patients may have a number of outcomes:
l Permanent success, more likely with ACI than MF.
l Temporary success followed by a second attempt at repair, or at a longer interval, knee replacement.
l Failure followed by another repair.
l Failure, but the patient may decide against another repair and treat symptoms with analgesics, perhaps
because they got some relief from the first repair. He/she would probably develop OA, and might have
a knee replacement in later life, ideally not until over 55 years old.
Second repairs could be ACI or MF.
A simplified diagram of the repair options is shown in Figure 20. The simplifications are twofold.
First, ‘success’ may not be permanent, especially in the case of MF. Second, this figure does not show
longer-term sequelae, such as OA and need for knee replacement. This is shown in the detailed model
diagram below (see Figure 21). We distinguish repairs, ACI and MF, from replacements such as partial or
total knee arthroplasties (PKR and TKR).
Scenario 1 (top) shows that all second repairs are ACI and scenario 2 (bottom) shows that all second
repairs are MF. This is to allow a direct comparison between ACI and MF as first procedure. In practice,
if a second repair is needed, the choice may vary according to what the first repair was – we deal with
other possible sequences later.
This chapter describes the structure of the model, the parameters used within the model (transition
probabilities, resource use, costs and utilities), the assumptions made, the different scenarios that have
been evaluated, the base-case results and the SAs undertaken.
Model structure
A Markov (state-transition) model was developed in Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA). A Markov model was considered to be the most appropriate, as we wanted to determine
whether ACI would postpone or avoid knee replacement in the longer term. The economic model reflects
the different clinical pathways for patients with symptomatic articular cartilage defects of the knee.
We have used information from the systematic review of cost-effectiveness studies for ACI, most notably
Clar et al.3 and Gerlier et al.,141 and this has been supplemented by information from expert clinical
opinion in order to develop the clinical pathways.
In practice, some patients who would be considered for ACI should that be approved will have had a
previous procedure, most often MF, but this is covered in the set of sequences below. For those who do
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need a second repair, we considered both ACI and MF in the sequences within the model. We have
assumed that patients will have a maximum of two repairs and combinations could be as follows:
1. ACI(ACI) Patients receive ACI as a primary repair and if they require a second repair then this will also
be an ACI.
2. MF(MF) Patients receive MF as a primary repair and if they require a second repair then this will also
be MF.
3. ACI(MF) Patients receive ACI as a primary repair and if they require a second repair then this will
be MF.
4. MF(ACI) Patients receive MF as a primary repair and if they require a second repair then this will be
an ACI.
Clinical pathways
Figure 21 shows the detailed clinical pathway for people receiving treatment for symptomatic articular
cartilage defects of the knee.
Defect
ACI
Success
(a)
Failure
ACI No further
repair
Success Failure
ACI No further
repair
MF
Defect
ACI
Success
(b)
Failure
MF No further
repair
Success Failure
MF No further
repair
MF
FIGURE 20 Patient pathways for ACI or MF: scenario 1 (above), scenario 2 (below).
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Knee repairs
The starting point for the model is the primary repair, which could be either ACI or MF. After the primary
repairs, patients can then either move to the ‘successful primary repair’ health state or to the ‘failure of
primary repair’ health state. Success can be permanent: the first repair works and they do not require a
second repair. So they can stay in the ‘successful primary repair’ health state until they die. Or success can
be temporary (the patient has no symptoms for years but after a while the repair fails), so the patient then
moves to the ‘failure of primary repair’ health state. They can then have a second repair or they can
choose not to have another repair (no further repair health state) and rely on analgesics to relieve
Primary repair
Successful 
primary repair
Failure of
primary repair
Second repair
No further
repair
Successful 
second repair
Failure of
second repair
Successful first
knee replacement
Failure of first
knee replacement
First knee
replacement
Further knee
replacement
No further knee
replacement
Successful further 
knee replacement
Failure of further 
knee replacement
FIGURE 21 Clinical pathways for patients with articular cartilage defects of the knee joint.
l All health states lead to the ‘dead’ health state.
l The little loop arrow in the top left-hand corner means that this can be temporary or permanent success.
l The dashed line indicates that at 55 years of age, the patient can have a knee replacement (total or partial).
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symptoms, that is, the patient chooses to accept the pain and treat it rather than have another attempt at
repair, though later he/she may have a knee replacement.
The second repair could be either ACI or MF. Based on clinical opinion, we have assumed that patients will
have a maximum of two repairs. Once the patient has had a second repair he/she can then either move to
the ‘successful second repair’ health state or to the ‘failure of second repair’ health state. The successful
second repair can be permanent (similar to the successful primary repair) and patients stay in this health
state until they die. Or it could be a temporary success, so then the patient later moves to the ‘failure of
second repair’ health state. We are assuming that patients whose second repair fails do not have another
repair and they move to the ‘no further repair’ health state.
Patients who move to the ‘no further repair’ health state after failure of repair can choose not to have
another repair procedure and accept the pain, taking analgesics as required (that is, they can stay in this
health state), until they reach the knee replacement age range, when their options are knee replacement
or continued symptomatic treatment. Those who choose not to have a further repair may have had partial
relief from symptoms, so we rate their utility as better than the baseline one.
Knee replacements
We assume for simplicity that patients over the age of 55 years cannot have an ACI or MF, but have only a
knee replacement or symptomatic care. This is line with the MSAC report, which indicated that MACI/ACI
was not indicated for patients older than 55 years.32 The first knee replacement can be either a partial
(unicompartmental) knee replacement (PKR) or TKR. According to statistics from the National Joint Registry,
the average ages of patients having a PKR and TKR are 64 and 70 years of age, respectively.157 However,
we know that patients being considered for ACI are a lot younger than the general population (average
age early thirties), so that if the repair fails, they are more likely to have a knee replacement at an earlier
age. In line with expert clinical advice, we are assuming that patients can have one or more knee
replacements. The first may succeed for life; if not, they can have another replacement or choose not to
have another replacement. The first knee replacement could be either a PKR or a TKR, but we have
assumed that all subsequent replacements will be TKRs.
A patient can move to ‘first knee replacement’ from either a temporarily ‘successful primary repair’ health
state, a temporarily ‘successful second repair’ health state or from the ‘no further repair’ health state when
they reach the knee replacement age range. The first knee replacement can be a success, so the patient
moves to the ‘successful first knee replacement’ health state or the replacement can fail over time, so they
move to the ‘failure of first knee replacement’ health state. The first knee replacement can be a permanent
success until the patient dies or a temporary success because the knee replacement fails over time, so he/
she moves to the ‘failure of first knee replacement’ health state, from which patients can choose to have
another knee replacement or to have no further knee replacement (so move to the ‘no further knee
replacement’ health state).
The second knee replacement can be a permanent success (until death) or it could be a temporary success,
and patients move to the ‘failure of further knee replacement’ health state, from which they can choose to
have no further knee replacement (but use symptomatic treatment) and or to have another (third) knee
replacement. Based on clinical opinion, we have assumed that patients can have more than two knee
replacements. Patients who move to the ‘no further knee replacement’ health state choose not to have
another knee replacement and stay in this health state until they die.
Deaths
Patients can move to death from any of the repair and replacement health states due to all-cause
mortality, or because of the rare mortality associated with PKR or TKR (such as DVT and pulmonary
embolism). The latter becomes more relevant in later stages because replacing previous knee replacements
requires more extensive procedures.
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Markov model structure
The Markov model structure is shown in Figure 22. In line with the clinical pathway shown in Figure 21,
the model shows the different health states and events that can take place. The different events health
states for the model are shown by the ovals. The model shows all of the transitions that can happen
between the different health states by the direction of the arrows. The little loop arrows in the left-hand
corner of the ovals (recurring arrow) means that a patient can stay in that health state for more than one
cycle, and perhaps indefinitely (until they die). The dashed line indicates that at 55 years of age, the
patient can choose to have a knee replacement (total or partial). Transition probabilities, that is, the rate of
progression from one health state to another (or for staying in the same health state), were identified from
the literature.
Base-case analysis
Many people with cartilage injury are young and involved in sports, and this is where most of the injuries
occur. We have not differentiated by gender, as evidence shows that there is no difference in the success
or failure of the two different procedures (ACI and MF) if lesions are comparable.146 For the base-case
analysis, we have adopted a lifetime horizon (i.e. patients can live to 100 years), with a cycle length for the
model set at 1 year, and transitions between each health state occurring at the end of each cycle. A cycle
length of 1 year is reasonable, given the time that it takes patients to recover from surgery. A hypothetical
cohort of a 1000 patients with symptomatic articular cartilage defects of the knee with a starting age of
33 years is followed from their first repair. The analysis is conducted from the perspective of the NHS and
PSS. All costs are in UK pounds sterling in 2012–13 prices. Health outcomes were measured in QALYs.
Results are expressed as incremental cost per QALY gained. An annual discount rate of 3.5% is applied to
both costs and outcomes.
Model inputs
Transition probabilities
For the base-case analysis, annual transition probabilities were based on data derived from the literature
and in consultation with clinical experts. For the primary and second repairs for both ACI and MF, these
transition probabilities were based on success rates for ACI compared with MF, and these probabilities
came from two main studies: Saris et al. 200970 and 2014.100
Figure 23 shows a flow chart with the proportion of people achieving success or failure with each repair.
Saris et al.70 reported a success rate of 83.0% over a 3-year period for ACI, and, of the remaining 17% of
people, 3.9% would require reoperation of the same lesion (either ACI or MF as a second repair). We
therefore assumed that 13.1% of people would have no further repair following the first repair. After ACI
as a first repair, for those patients who required a second repair, and if this repair was another ACI, we
assumed the same success rate for this second repair as the first repair. If this second repair was MF,
we used information from Vanlauwe et al.,43 who reported that for 16.4% of people MF after a first
ACI failed at 5 years. We assumed that the rest of the people had successful MF procedures following
an ACI.
Saris et al.70 also reported a success rate of 62.0% over a 3-year period for MF and, of the remaining 38%
of people, 11.5% would require reoperation of the same lesion (either ACI or MF as a second repair).
We therefore assumed that 26.5% of people would have no further repair following the first repair.
After MF as a first repair, for those patients who required a second repair and if this repair was MF, we
assumed the same success rate for this second repair as the first repair. If this second repair was an ACI,
this information was obtained from Biant et al.,79 who reported that for 30.9% of people an ACI after a
first MF failed at 10 years. We assumed that the rest of the people had a successful ACI procedure
following MF.
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The timing of knee replacement after one of the repair health states was based on data from the RCT of ACI
and MF by Knutsen et al.67 Transition probabilities for success and failure for patients who needed knee
replacements or knee replacement revisions were derived from two studies: Gerlier et al.141 and Dong and
Buxton.158 Appendix 11 details the literature used and the assumptions made for deriving these probabilities,
and Tables 57–59 show the transition probabilities that have been used in the base-case analysis.
Utilities
There are very few studies reporting health-state utility values for patients with symptomatic articular
cartilage defects of the knee. The main studies reporting utility values have been summarised in Chapter 4
(Clar 2005,3 Derrett 2005,140 Gerlier 2010141). In the previous HTA report, the preoperative QoL value was
taken to be 0.80 and for those who had successful knee repair there was a utility gain of 0.10 (utility score
for successful knee repair was 0.90); for those where the knee repair failed the utility value remained at
the preoperative value (utility score for knee repair failure was 0.80) (Clar 20053). Derrett et al.140 used the
EQ-5D-3L to elicit utility scores, and the ACI waiting list group had a pre-surgery utility score of 0.41. After
surgery, the EQ-5D-3L mean score for the ACI group was 0.64 and for mosaicplasty was 0.47, a utility
gain of 0.23 and 0.06, respectively.
For our model we have used utility values for knee repairs from the Gerlier et al. study,141 comparing ACI
with MF using data from the TIG/ACT43 ChondroCelect trial. They used a short-term model with a time
horizon of 5 years to take into account knee pain and mobility after the initial intervention (QoL information
was obtained from a 5-year RCT using the SF-36) and also a long-term model with a time horizon of
40 years to take into account the development of OA after 15 years and the need for a TKR after 20 years.
We used two other studies to supplement utility values for knee replacement. The first study is by Dong and
Buxton,158 who developed a Markov model to compare the cost-effectiveness of TKR using computer-
assisted surgery with that of TKR using a conventional manual method in the absence of formal clinical trial
evidence. The second study is by Jansson and Granath,159 who analysed EQ-5D data before and after
knee arthroplasty.
Defect
ACI
Success
(83.0%)
Failure
(17.0%)
Second procedure
(ACI or MF)
(3.9%)
No further
repair
(13.1%)
Success
(62.0%)
Failure
(38.0%)
Second procedure
(MF or ACI)
(11.5%)
No further
repair
(26.5%)
MF
FIGURE 23 Proportion of patients achieving success/failure with ACI or MF at 36 months.
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Table 21 shows the base-case mean utility values used in the model. For the repairs these values were all
obtained from the paper by Gerlier et al.,141 who used the SF-36 and the KOOS measures to estimate
utility scores. The mean utility value for patients before they have a primary repair (before ACI or MF) was
0.654: this utility value was based on the initial value before the intervention. For those patients who had
an ACI as a first repair and moved to the ‘successful primary repair’ health state, we assumed that the
patients’ mean utility value after surgery for the first year would be 0.760 (this value was based on year 1
post intervention, regardless of the outcome, and takes into account the long rehabilitation period and
abstinence from active pursuits), and, if they remain in this health state in subsequent years, their utility
value would remain constant at 0.817. This latter value was based on patients who had clinical success for
TABLE 21 Base-case mean utility values used in the economic model
Repairs/replacements
First repair
SourceACI MF
Repairs
Before primary repair 0.654 Gerlier 2010141
Successful primary First year 0.760 0.760 Gerlier 2010141
Second year 0.817 0.817
Third year 0.817 0.817
Fourth year 0.817 0.817
Five years plus 0.817 0.654
Before second repair 0.654
Choose not to have a second repair 0.691a
Second repair
ACI MF ACI MF
Successful second First year 0.760 0.760 0.760 0.760 Gerlier 2010141
Second year 0.817 0.817 0.817 0.817
Third year 0.817 0.817 0.817 0.817
Fourth year 0.817 0.817 0.789 0.817
Five years plus 0.817 0.654 0.789 0.654
No further repair 0.691
Replacements
Before first knee replacement (TKR) 0.615 Dong and Buxton 2006,158
Jansson and Granath 2011159
Before first knee replacement (PKR) 0.615 Dong and Buxton 2006,158
Jansson and Granath 2011159
Successful first knee replacement – TKR 0.780 Dong and Buxton 2006158
Successful first knee replacement – PKR 0.780 Dong and Buxton 2006158
Before further TKR 0.557 Gerlier 2010141
Successful further TKR 0.780 Dong and Buxton 2006158
No further TKR 0.691 Gerlier 2010141
a Some patients decide not to have another repair attempt after unsuccessful first repair. We have assumed that they had
some benefit and do not go back to their baseline utility.
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5 years after the intervention. For those patients who had MF as a first repair and moved to the ‘successful
primary repair’ health state, we assumed that the patients’ mean utility value after surgery for the first year
would be 0.760 (this value was based on year 1 post intervention, regardless of the outcome). For years 2–4
after MF this mean utility value would increase to 0.817. This reflects the quite long rehabilitation required
in the first year after the procedures, and the time taken for the cartilage to be replaced. For years 5 and
onwards for patients who stay in this same health state, we have assumed that utility would fall to the same
as that pre-surgery (mean utility value is 0.654) because the benefit of MF declines after 5 years and patients
may choose to have another procedure.
For those patients who require a second repair, the mean utility value was 0.654: this value was based on
the utility value before the intervention.141 For those requiring a second repair there are four possible
sequences: ACI(ACI), ACI(MF), MF(ACI) and MF(MF).
Utilities for patients having a second successful ACI after the first ACI were assumed to be the same as for
those who had a successful ACI as a first repair. Utilities for patients having a successful MF after an initial
ACI that failed were assumed to be the same as for those who had a successful MF as a first repair and
moved to the ‘successful primary repair’ health state.
Patients who have a successful ACI after an initial MF move to the ‘successful second repair’ health state.
However, as noted previously, ACI is less effective in patients who have had prior MF, so for years 4 and 5
we have used the average of two utility values from Gerlier et al.,141 based on year 1 post intervention
(utility value = 0.760) and clinical success after 5 years following the intervention (utility value = 0.817), so
the mean utility value for ACI after MF was 0.789. Utilities for patients having a successful second MF after
a failed initial MF and who moved to the ‘successful second repair’ health state were assumed to be the
same as those who had a successful MF as a first repair.
For patients who moved to the ‘no further repair’ health state, the mean utility value was 0.691: this value
was based on patients who had not had a successful result 5 years after surgery (Gerlier 2010141), but we
have assumed that those who choose to have no further repair may have had some benefit from the first
repair, and so do not go back as far as the original baseline utility.
Mean utility values are the same for knee replacements after ACI or MF. Before the first knee replacement
procedure, patients who received a TKR and PKR are assumed to have the same utility value, 0.615. This
value was based on an average of two utility values: (1) the EQ-5D index score at baseline preoperatively
for knee arthroplasty (value = 0.51)159 and (2) an estimated value for TKR operation for knee problem
(value = 0.72).158 For patients who move to the ‘successful first knee replacement’ health state (TKR or PKR),
a utility value of 0.780 was also obtained from Dong and Buxton.158 This utility value was estimated from the
generic Knee Society Score scale and was applied to the Markov health state for normal health after primary
TKR. We have also assumed that if patients move to the successful ‘further total knee replacement’ health
state then they will have the same utility value as if it was a first TKR. For those patients for whom TKR has
failed and need a further TKR, the utility value was 0.557 based on the failed TKR/revision health state from
Gerlier et al.141 Finally, for those patients who move to the ‘no further replacement health state’ this value
(mean = 0.691) was also from Gerlier et al.141 and was based on patients who had no clinical success 5 years
after surgery (in line with patients who move to the ‘no further repair’ health state).
Resource use and costs
Costs for the different procedures (ACI, MF, PKR/TKR, TKR revisions) and for outpatient visits and
rehabilitation are shown in Table 22. We have used national reference costs where possible (NHS reference
costs 2013151) supplemented by the previous HTA report on ACI 3. All unit costs are presented in pounds
sterling (£) in 2012–13 prices.
The cost of the ACI (ChondroCelect and MACI) includes the costs associated with cell development,
including the ACI kit, staff time and transporting the cells to and from the laboratory. ACI involves two
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procedures: the arthroscopic cell harvest and the re-implantation during arthrotomy. We assumed both
would be done as day cases. Based on clinical experience, we have also included the costs of six outpatient
visits and three rehabilitation visits in the first year (Table 23).
The cost of MF procedure (including an inpatient stay) was obtained from Clar et al.3 and the cost has been
updated to 2012–13 prices using the Hospital and Community Health Services (HCHS) index.154 The inpatient
stay is required because, unlike after ACI, the patients can have considerable pain after MF because of the
drilling into bone. Over the course of the year, the patient would also have three outpatient visits and three
rehabilitation visits, and these costs have been added for this health state (based on clinical experience).
The cost for a first knee replacement was obtained from the NHS reference costs151 and we have assumed
that it could be either a TKR or a PKR. After a TKR, a subsequent TKR is almost double the cost, because
it is technically more difficult. After a PKR, a second knee replacement would be a TKR, and we have
assumed that this would cost £5676. If the patient required any more subsequent knee replacements (all
of which would be TKRs) then these would cost £12,959. Based on consultation with clinical experts, in
the first year after knee replacement, we have included the cost of two outpatient visits (see Table 23).
Unit costs were obtained from the NHS reference costs.151
TABLE 22 Base-case mean costs (UK pounds sterling) used in the economic model
Procedure Information Unit cost (£) Source
ChondroCelect and
MACI
Product including courier services and
development of cell culture
16,000 UK price for ChondroCelect
Procedure 1 – arthroscopy and cell harvest 710a Clar 20053
Procedure 2 – arthrotomy (day case) 1030a
Total cost 17,740
MF Procedure (inpatient) 3020a Clar 20053
First TKR (PKR or TKR) HRG code: HB21C – major knee procedures for
non-trauma, category 2, without complications
5676 NHS reference costs151
Further TKR Second TKR 12,959a Clar 20053
Outpatient visit HRG code: WF01A – non-admitted face-to-face
consultant led outpatient attendance
102 NHS reference costs151
Rehabilitation HRG code: REHABL2 – rehabilitation for joint
replacement
256
HCHS, Hospital and Community Health Services; HRG, Healthcare Resource Group.
a Cost inflated to 2012–13 prices using the HCHS index.154
TABLE 23 Base-case resource use for economic model
Components (over a year)
Procedure
SourceACI MF TKR
Inpatient days 0 1a 4.5a Expert clinical opinion
Outpatient visits 6 3 2
Rehabilitation visits 3 3 0
a The cost of inpatient stay has been included in the cost for the different procedures.
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We have assumed that there will be no further costs after year 1 once patients enter the successful health
states (‘successful primary repair’, ‘successful second repair’, ‘successful first knee replacement’ and
‘successful further knee replacement’), as patients incur costs such as outpatient or rehabilitation visits
during the first year of either a knee repair or a knee replacement. In addition, for the ‘no further repair’
health state or the ‘no further knee replacement’ health state, we have not added any costs for the
analgesics based on advice from our clinical experts, as these costs are negligible and these patients are
not followed up routinely, and it is up to the GP to refer the patient back to the hospital for a knee repair
or a knee replacement.
Complications
Adverse events have not been included, as there were no important differences between the two
treatment arms.
Mortality
Age-specific mortality rates used in the economic model were based on the UK general population lifetime
tables from the ONS.160 Using the ONS data, the average probabilities of death for men and women were
combined. As the cohort ages, mortality rates generally increase throughout the time horizon in the model.
In the model, patients from any health state can move to the ‘dead’ health state. Patients undergoing a
knee replacement are subject to a mortality risk during surgery. To reflect this higher mortality, rates were
obtained from a study by Mahomed et al.150 For those patients undergoing a TKR and a TKR revision, the
mortality rates were reported as 0.7% and 1.1%, respectively.
Measuring cost-effectiveness
The base-case analysis assessed the cost-effectiveness of ACI compared with MF. We calculated for a
cohort of patients the expected quality-adjusted survival based on their likelihood of surviving each cycle,
their expected health-state utility value, and their expected costs. We have adopted a lifetime horizon from
a starting age of 33 years. The analysis is conducted from the perspective of the UK NHS and PSS. Costs
are expressed in 2012–13 UK pounds sterling. The main outcome of interest was the QALY. The different
sequences of procedures were ranked in order of increasing cost. We eliminated any categories for which
another category was cheaper and more effective (simple dominance). If the ICER for a given category
was higher than that of the next more effective alternative then this category was eliminated (extended
dominance). For the remaining options, we reported the ICERs, measured as cost per QALY gained.
Discount rates of 3.5% were applied to both future costs and benefits, as costs and benefits accrued in
the future are valued at less than those accrued today.
Sensitivity analysis assesses the uncertainty in parameter inputs used in the Markov model and to check
whether or not the results obtained are robust. We present both deterministic and probabilistic results.
For the deterministic analysis, we identified the key factors driving the cost-effectiveness. For the PSA, to
reflect the amount and pattern of the variation, the analysis attributes probability distributions randomly
around specified parameters with simulations, which are repeated to generate ICERs. The PSA was
undertaken using 1000 simulations. We used the gamma distribution for costs and the beta distribution
for utility values and transition probabilities.161 As the values for costs, utilities and transition probabilities
used in the model were means or weighted averages, an assumption was made for the SE in order to
calculate the alpha and beta values, which are required for the PSA. For example, we have assumed the SE
to be 0.1 of the mean value.162,163 These bootstrapped simulations obtained from the PSA were used to
construct cost-effectiveness acceptability curves (CEACs) to illustrate the effect of sampling uncertainty in
which individual model parameters were sampled from the appropriate probability distribution. CEACs
were presented to indicate the probability of a procedure being cost-effective using a willingness-to-pay
threshold from £0 to £60,000.
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Scenario and sensitivity analyses
Several scenario and sensitivity analyses were conducted by altering base-case inputs to the model.
l SA1 In the base-case analysis, the cost of cells for ChondroCelect and MACI procedures was £16,000.
We are aware that confidential discounts are provided to the NHS by manufacturers. So in the SA we
have varied this figure by reducing the costs by 25%, 50% and 75%, so that the costs of cells are
£12,000, £8000 and £4000, respectively. Note that the cost of cell production in the OsCell laboratory
in Oswestry is £4125 per patient.
l SA2 In the base-case analysis, a lifetime horizon was chosen, with the starting age of 33 years for the
cohort. In the SA we have varied the time horizon (10, 20, 30, 40 and 50 years) to see how this affects
the ICER.
l SA3 In the base-case analysis, according to clinical advice we costed MF as an inpatient procedure
(£3020). However, we know that sometimes this procedure is done as a day case. In the SA we have
assumed that MF is done as a day case procedure and the associated cost is £1034.
l SA4 In the base-case analysis, the success rates for MF were based on existing evidence. However,
there are new types of MF procedures and these could have better success rates. We have no evidence
for this, but in a ‘what if’ SA we have checked what would happen to ICERs if the success rates for MF
could increase by 20% and 40%. The effect are to increase duration of benefit after MF. In addition,
we assumed that the utility benefit for MF lasted longer as well: for the 20% increase in year 5, and
the 40% increase in years 5 and 6, we applied a utility value of 0.817, as opposed to 0.654.
l SA5 In the base-case analysis the starting age for the cohort was 33 years. In the SA the starting age is
changed to 45 years (patients are nearer to the knee replacement age) to see how this affects
the ICER.
l SA6 In the base-case analysis we used utility values from the paper by Gerlier et al.,141 who compared
ACI with MF. In this SA we have used utility values that are from the ACTIVE trial35 (Oswestry submission).
Results
We present here the cost-effectiveness deterministic and probabilistic results for ACI compared with MF.
Base-case cost-effectiveness results
One thousand patients entered the model, with a starting age of 33 years. For the primary repair these
patients can receive either an ACI or MF, and if these patients require a second repair it could either be an ACI
or MF. Many will not require a second repair, but the cost-effectiveness of the primary repair depends partly
on the costs of subsequent interventions required or avoided, so we need to consider the sequence options.
Table 24 shows the base-case deterministic and probabilistic cost-effectiveness results for the lifetime
horizon for the two different scenarios. For scenario 1, if patients required a second repair this would be
an ACI and for scenario 2 if patients required a second repair this would be MF. After MF, 11.9% of
patients required a second procedure, and after ACI 3.9% of patients required a second repair. Looking
at the discounted deterministic results, for scenario 1, ACI costs £14,314 more than MF, but generated
0.9944 more QALYs than MF. The cost per QALY gained for ACI compared with MF was £14,395. For
scenario 2, ACI, again, was more costly (incremental cost = £14,877), but generated more QALYs (0.9537)
and the resulting cost per QALY gained was £15,598. For both scenarios, ACI as a first repair was more
cost-effective than MF as a first repair. These results were of similar magnitudes and directions for both the
undiscounted deterministic results and the probabilistic results.
One of the key cost drivers was the cost of the cells for the ACI procedure, but, over the lifetime horizon,
there are QALYs gained from using ACI, and there are cost savings to the NHS later due to fewer people
needing a second repair, fewer people in need of a TKR, and fewer people moving to the no further
repair/replacement health states (in which the utility is lower).
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Figure 24 presents the CEACs for the base-case results for scenarios 1 and 2, respectively. For scenario 1,
if the decision-maker was willing to pay £14,000, the probability that both ACI and MF were cost-effective
was approximately 50%; however, if the decision-maker was willing to pay £20,000, ACI was probably
59% more likely to be cost-effective than MF (see Figure 24a). These results were similar for scenario 2:
if the decision-maker was willing to pay £20,000, the probability that ACI was more cost-effective than MF
was 56% (see Figure 24b).
Table 25 shows the base-case deterministic and probabilistic cost-effectiveness results for the lifetime
horizon, ranked by the least costly sequence (option). For the discounted deterministic results MF(MF) was
the least costly option and had the fewest QALYs, whereas ACI(ACI) was the most expensive option but
generated more QALYs. The option MF(ACI) was extendedly dominated by a linear combination of MF(MF)
and ACI(MF) and therefore this option was eliminated from the comparison. The ICER ACI(MF) and MF(MF)
was just under £15,000; doing ACI first is more cost-effective. The ICER between the two initial ACI
options: ACI(ACI) vs. ACI(MF) was just under £16,000; even if the first ACI fails, there is good enough
chance of a second ACI succeeding to make the ICER for a repeat ACI quite reasonable. So initial ACI
appears more cost-effective than initial MF and for those who need a second repair after the first ACI, this
should be another ACI. These results were of similar magnitudes and directions for the probabilistic results
and also for the undiscounted deterministic results.
TABLE 24 Base-case deterministic and probabilistic cost-effectiveness results (by scenario)
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: undiscounted
Scenario 1
MF(ACI) 8028 34.1648 – – –
ACI(ACI) 22,252 35.7922 14,524 1.6273 8925
Scenario 2
MF(MF) 6234 34.1259 – – –
ACI(MF) 21,155 35.6504 14,921 1.5245 9788
Deterministic: discounted
Scenario 1
MF(ACI) 6607 17.0284 – – –
ACI(ACI) 20,921 18.0228 14,314 0.9944 14,395
Scenario 2
MF(MF) 5015 17.0033 – – –
ACI(MF) 19,892 17.9570 14,877 0.9537 15,598
Probabilistic: discounted
Scenario 1
MF(ACI) 6624 16.9878 – – –
ACI(ACI) 20,838 18.0343 14,214 1.0466 13,581
Scenario 2
MF(MF) 5030 16.9654 – – –
ACI(MF) 19,809 17.9490 14,779 0.9836 15,026
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FIGURE 24 Cost-effectiveness acceptability curve: base case results: (a) scenario 1; and (b) scenario 2.
TABLE 25 Base-case deterministic and probabilistic cost-effectiveness results
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: undiscounted
MF(MF) 6234 34.1259 – – – –
MF(ACI) 8028 34.1648 MF(ACI) vs. MF(MF) 1795 0.0389 Extendedly dominated
ACI(MF) 21,155 35.6504 ACI(MF) vs. MF(MF) 14,921 1.5245 9,788
ACI(ACI) 22,252 35.7922 ACI(ACI) vs. ACI(MF) 1,397 0.1418 9,856
Deterministic: discounted
MF(MF) 5015 17.0033 – – – –
MF(ACI) 6607 17.0284 MF(ACI) vs. MF(MF) 1592 0.0251a Extendedly dominated
ACI(MF) 19,892 17.9570 ACI(MF) vs. MF(MF) 14,877 0.9537 15,598
ACI(ACI) 20,921 18.0228 ACI(ACI) vs. ACI(MF) 1,029 0.0658 15,648
Probabilistic: discounted
MF(MF) 5030 16.9654 – – – –
MF(ACI) 6624 16.9878 MF(ACI) vs. MF(MF) 1595 0.0223a Extendedly dominated
ACI(MF) 19,809 17.9490 ACI(MF) vs. MF(MF) 14,779 0.9836 15,026
ACI(ACI) 20,838 18.0343 ACI(ACI) vs. ACI(MF) 1,029 0.0853 12,059
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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Figure 25 presents the CEAC for the base-case results for all sequences. The graph shows that for amounts
below £14,000 then MF(MF) appears cost-effective compared with the other three options. At a willingness
to pay of £16,000, there is not much difference between the four options. However, if the decision-maker
is willing to pay £18,000 or more for a QALY then ACI as a first procedure [either ACI(ACI) or ACI(MF)] is
probably more cost-effective than MF [either MF(ACI) or MF(MF)] as a first procedure.
Scenario and sensitivity analysis cost-effectiveness results
This section highlights the results from the different SAs that were undertaken.
Sensitivity analysis 1: cell cost reduction
In the base-case analysis, the cost of cells for ChondroCelect and MACI procedures was taken to be
£16,000. We know that there are confidential discounts provided to the NHS by manufacturers. In this SA
we have varied this figure by reducing the cell costs by 25% (£12,000), 50% (£8000) and 75% (£4000).
The last figure may seem very low, but it is similar to the cost provided in the Oswestry submission for cells
produced in a NHS facility.
Table 26 shows the results when the cost of cells is reduced. When there was a reduction in cell costs, even
though ACI was more costly than MF, there were more QALYs gained with ACI than MF. For a 25% cell
cost reduction, the deterministic cost per QALY gain ratio for ACI compared with MF was £10,523 for
scenario 1 and £11,404 for scenario 2. The cost per QALY gain ratio for a 50% cell cost reduction for ACI
compared with MF was £6651 (scenario 1) and £7210 (scenario 2), and the resulting figures for a
75% reduction were £2779 (scenario 1) and £3016 (scenario 2). With the reduction in cell costs,
the cost-effectiveness of ACI improved relative to MF. Hence, the cost of cells was a key driver for the
cost-effectiveness. These results were of similar magnitudes and directions for the probabilistic results.
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FIGURE 25 Cost-effectiveness acceptability curve: base-case results – all sequences.
TABLE 26 Sensitivity cost-effectiveness results (by scenario): cell cost reduction
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 25% reduction
Scenario 1
MF(ACI) 6183 17.0284 – – –
ACI(ACI) 16,647 18.0228 10,464 0.9944 10,523
continued
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TABLE 26 Sensitivity cost-effectiveness results (by scenario): cell cost reduction (continued )
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Scenario 2
MF(MF) 5015 17.0033 – – –
ACI(MF) 15,892 17.9570 10,877 0.9537 11,404
Probabilistic: 25% reduction
Scenario 1
MF(ACI) 6183 17.0305 – – –
ACI(ACI) 16,637 18.0497 10,454 1.0192 10,258
Scenario 2
MF(MF) 5009 17.0086 – – –
ACI(MF) 15,880 17.9502 10,871 0.9416 11,545
Deterministic: 50% reduction
Scenario 1
MF(ACI) 5760 17.0284 – – –
ACI(ACI) 12,373 18.0228 6614 0.9944 6651
Scenario 2
MF(MF) 5015 17.0033 – – –
ACI(MF) 11,892 17.9570 6877 0.9537 7210
Probabilistic: 50% reduction
Scenario 1
MF(ACI) 5770 17.0250 – – –
ACI(ACI) 12,362 18.0100 6592 0.9850 6693
Scenario 2
MF(MF) 5020 16.9907 – – –
ACI(MF) 11,876 17.9123 6856 0.9216 7439
Deterministic: 75% reduction
Scenario 1
MF(ACI) 5336 17.0284 – – –
ACI(ACI) 8100 18.0228 2763 0.9944 2779
Scenario 2
MF(MF) 5015 17.0033 – – –
ACI(MF) 7892 17.9570 2877 0.9537 3016
Probabilistic: 75% reduction
Scenario 1
MF(ACI) 5346 16.9755 – – –
ACI(ACI) 8083 18.0442 2737 1.0687 2561
Scenario 2
MF(MF) 5023 16.9546 – – –
ACI(MF) 7878 17.9253 2854 0.9707 2940
THE COST-EFFECTIVENESS OF AUTOLOGOUS CHONDROCYTE IMPLANTATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Figure 26a–f presents the CEACs for the SA for cell cost reductions for scenarios 1 and 2. For a 25% cell
cost reduction: scenario 1, if the decision-maker was willing to pay £20,000, the probability that ACI was
more cost-effective than MF was 65% (see Figure 26a); scenario 2, the probability that ACI was more
cost-effective than MF was 58% (see Figure 26b). For a 50% cell cost reduction: scenario 1, if the
decision-maker was willing to pay £20,000, the probability that ACI was more cost-effective than MF was
67% (see Figure 26c); scenario 2, the probability that ACI was more cost-effective than MF was 64% (see
Figure 26d). For a 75% cell cost reduction: for scenario 1, if the decision-maker was willing to pay £20,000,
there was a 71% probability that ACI was more cost-effective than MF (see Figure 26e); scenario 2, there
was a 70% probability that ACI was more cost-effective than MF (see Figure 26f). The graphs indicate that
reductions in cell costs improve the cost-effectiveness of ACI compared with MF.
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FIGURE 26 Cost-effectiveness acceptability curves: cost reductions: (a) 25% cell cost reduction – scenario 1;
(b) 25% cell cost reduction – scenario 2; (c) 50% cell cost reduction – scenario 1; (d) 50% cell cost reduction –
scenario 2; (e) 75% cell cost reduction – scenario 1; and (f) 75% cell cost reduction – scenario 2. (continued )
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Table 27 shows the deterministic and probabilistic cost-effectiveness results for the lifetime horizon for
cell cost reduction, and results were ranked by least costly option. When the cost of cells was reduced
by 25%, 50% and 75%, these results were in line with the base-case cost-effectiveness results. That is,
for the discounted deterministic results MF(MF) was the least costly option and had the fewest QALYs,
whereas ACI(ACI) was the most expensive option, but generated more QALYs. Again, the option MF(ACI)
was extendedly dominated by a linear combination of MF(MF) and ACI(MF) and therefore this option was
eliminated from the comparison. The deterministic ICER between ACI(MF) and MF(MF) was just over
£11,000; and the ICER between the two ACI options: ACI(ACI) vs. ACI(MF) was just under £11,500 when
there was a 25% reduction in costs. These ICER figures are £7200 and £7300, respectively, when there was
a 50% reduction in costs, and the corresponding figures are £3000 and £3200, respectively, when there
was a 75% reduction in costs. For all cell cost reduction scenarios, both the deterministic and probabilistic
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FIGURE 26 Cost-effectiveness acceptability curves: cost reductions: (a) 25% cell cost reduction – scenario 1;
(b) 25% cell cost reduction – scenario 2; (c) 50% cell cost reduction – scenario 1; (d) 50% cell cost reduction –
scenario 2; (e) 75% cell cost reduction – scenario 1; and (f) 75% cell cost reduction – scenario 2.
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results indicate that ACI as a first procedure was more cost-effective than MF as a first procedure, and from
these results, again, we see that the cost of cells is a key driver of the cost-effectiveness estimates.
Figure 27a–c presents the CEACs for the SA results for the cell cost reduction. The graphs clearly show
that if the decision-maker is willing to pay £20,000 then the probability that ACI(ACI) is more cost-effective
than the other three comparisons is 32% for a 50% reduction in the costs of cells (although there is not
TABLE 27 Sensitivity cost-effectiveness results: cell cost reduction
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 25% reduction
MF(MF) 5015 17.0033 – – – –
MF(ACI) 6183 17.0284 MF(ACI) vs. MF(MF) 1168 0.0251a Extendedly dominated
ACI(MF) 15,892 17.9570 ACI(MF) vs. MF(MF) 10,877 0.9537 11,404
ACI(ACI) 16,647 18.0228 ACI(ACI) vs. ACI(MF) 755 0.0658a 11,483
Probabilistic: 25% reduction
MF(MF) 5009 17.0086 – – – –
MF(ACI) 6183 17.0305 MF(ACI) vs. MF(MF) 1174 0.0219a Extendedly dominated
ACI(MF) 15,880 17.9502 ACI(MF) vs. MF(MF) 10,871 0.9416 11,545
ACI(ACI) 16,637 18.0497 ACI(ACI) vs. ACI(MF) 758 0.0994a 7618
Deterministic: 50% reduction
MF(MF) 5015 17.0033 – – – –
MF(ACI) 5760 17.0284 MF(ACI) vs. MF(MF) 744 0.0251a Extendedly dominated
ACI(MF) 11,892 17.9570 ACI(MF) vs. MF(MF) 6877 0.9537 7210
ACI(ACI) 12,373 18.0228 ACI(ACI) vs. ACI(MF) 481 0.0658a 7319
Probabilistic: 50% reduction
MF(MF) 5020 16.9907 – – – –
MF(ACI) 5770 17.0250 MF(ACI) vs. MF(MF) 750 0.0343a Extendedly dominated
ACI(MF) 11,876 17.9123 ACI(MF) vs. MF(MF) 6856 0.9216 7439
ACI(ACI) 12,362 18.0100 ACI(ACI) vs. ACI(MF) 486 0.0977a 4979
Deterministic: 75% reduction
MF(MF) 5015 17.0033 – – – –
MF(ACI) 5336 17.0284 MF(ACI) vs. MF(MF) 321 0.0251a Extendedly dominated
ACI(MF) 7892 17.9570 ACI(MF) vs. MF(MF) 2877 0.9537 3016
ACI(ACI) 8100 18.0228 ACI(ACI) vs. ACI(MF) 207 0.0658a 3155
Probabilistic: 75% reduction
MF(MF) 5023 16.9546 – – – –
MF(ACI) 5346 16.9755 MF(ACI) vs. MF(MF) 322 0.0209a Extendedly dominated
ACI(MF) 7878 17.9253 ACI(MF) vs. MF(MF) 2854 0.9707 2940
ACI(ACI) 8083 18.0442 ACI(ACI) vs. ACI(MF) 205 0.1189a 1725
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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much difference if MF was the second repair after the ACI) and 38% for a 75% reduction in the costs
of cells. Whereas, if the decision-maker pays £30,000 for a 25% reduction in the cost of cells then the
probability that ACI(ACI) is more cost-effective than the other three comparisons is 34%. This suggests
that ACI as first procedure is more cost-effective than MF as first procedure.
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FIGURE 27 Cost-effectiveness acceptability curves: cell cost reduction: (a) 25% cell cost reduction; (b) 50% cell cost
reduction; and (c) 75% cell cost reduction.
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Sensitivity analysis 2: changing the time horizon
In the base-case analysis, a lifetime horizon was chosen with the starting age 33 years for the cohort. In
this SA we have varied the time horizon (10, 20, 30, 40 and 50 years) to see how this affects the ICER.
Table 28 shows the sensitivity cost-effectiveness results for the different time horizons. For all of the time
horizons, even though ACI was more costly than MF, there were more QALYs gained with ACI than MF.
For the 10-year time horizon, the deterministic cost per QALY gain for ACI compared with MF was
TABLE 28 Sensitivity cost-effectiveness results (by scenario): changing the time horizon
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 10-year time horizon
Scenario 1
MF(ACI) 5983 7.3030 – – –
ACI(ACI) 20,082 7.8454 14,098 0.5424 25,992
Scenario 2
MF(MF) 4498 7.2906 – – –
ACI(MF) 19,329 7.8321 14,831 0.5415 27,388
Probabilistic: 10-year time horizon
Scenario 1
MF(ACI) 5989 7.2950 – – –
ACI(ACI) 20,075 7.8501 14,086 0.5550 25,379
Scenario 2
MF(MF) 4505 7.2845 – – –
ACI(MF) 19,326 7.8270 14,821 0.5425 27,320
Deterministic: 20-year time horizon
Scenario 1
MF(ACI) 6104 11.2812 – – –
ACI(ACI) 20,340 12.1040 14,286 0.8228 17,301
Scenario 2
MF(MF) 4524 11.2587 – – –
ACI(MF) 19,384 12.0654 14,860 0.8067 18,421
Probabilistic: 20-year time horizon
Scenario 1
MF(ACI) 6098 11.2630 – – –
ACI(ACI) 20,359 12.1136 14,261 0.8506 16,766
Scenario 2
MF(MF) 4526 11.2362 – – –
ACI(MF) 19,414 12.0625 14,888 0.8263 18,019
Deterministic: 30-year time horizon
Scenario 1
MF(ACI) 6329 13.9997 – – –
ACI(ACI) 20,614 14.9318 14,285 0.9321 15,326
continued
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TABLE 28 Sensitivity cost-effectiveness results (by scenario): changing the time horizon (continued )
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Scenario 2
MF(MF) 4739 13.9750 – – –
ACI(MF) 19,609 14.8774 14,871 0.9024 16,480
Probabilistic: 30-year time horizon
Scenario 1
MF(ACI) 6326 14.0117 – – –
ACI(ACI) 20,642 14.9494 14,316 0.9377 15,267
Scenario 2
MF(MF) 4728 13.9748 – – –
ACI(MF) 19,628 14.8754 14,900 0.9006 16,545
Deterministic: 40-year time horizon
Scenario 1
MF(ACI) 6492 15.7604 – – –
ACI(ACI) 20,798 16.7368 14,306 0.9764 14,652
Scenario 2
MF(MF) 4901 15.7354 – – –
ACI(MF) 19,775 16.6747 14,875 0.9393 15,836
Probabilistic: 40-year time horizon
Scenario 1
MF(ACI) 6494 15.7558 – – –
ACI(ACI) 20,763 16.7219 14,269 0.9662 14,768
Scenario 2
MF(MF) 4900 15.7279 – – –
ACI(MF) 19,376 16.6504 14,837 0.9225 16,083
Deterministic: 50-year time horizon
Scenario 1
MF(ACI) 6579 16.7164 – – –
ACI(ACI) 20,891 17.7078 14,313 0.9914 14,437
Scenario 2
MF(MF) 4987 16.6913 – – –
ACI(MF) 19,864 17.6427 14,876 0.9514 15,636
Probabilistic: 50-year time horizon
Scenario 1
MF(ACI) 6557 16.7119 – – –
ACI(ACI) 20,841 17.6964 14,284 0.9845 14,509
Scenario 2
MF(MF) 4974 16.6777 – – –
ACI(MF) 19,820 17.6182 14,845 0.9405 15,785
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£25,992 for scenario 1 and £27,388 for scenario 2. The cost per QALY gained for the two scenarios
ranged from £17,000 to £18,000 for the 20-year time horizon; £15,000 to £16,000 for the 30- and
40-year time horizons; and £14–16,000 for the 50-year time horizon. For both scenarios, ACI as a first
repair was more-cost-effective than MF as a first repair, the longer the time horizon. These results were of
similar magnitudes and directions for the probabilistic results.
Figure 28a–j presents the CEACs for the SA for the different time horizons for scenarios 1 and 2. For the
10-year time horizon, scenario 1: if the decision-maker was willing to pay £20,000 then the probability
that MF was more cost-effective than ACI was 62% (see Figure 28a); for scenario 2, MF was 64% more
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
(a)
0 10 20 30
Willingness to pay (£000)
40 50 60
ACI(ACI)
MF(ACI)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0 10 20 30
Willingness to pay (£000)
40 50 60
(b)
ACI(MF)
MF(MF)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0 10 20 30
Willingness to pay (£000)
40 50 60
(c)
ACI(ACI)
MF(ACI)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
FIGURE 28 Cost-effectiveness acceptability curves: different time horizons: (a) 10-year time horizon – scenario 1;
(b) 10-year time horizon – scenario 2; (c) 20-year time horizon – scenario 1; (d) 20-year time horizon – scenario 2;
(e) 30-year time horizon – scenario 1; (f) 30-year time horizon – scenario 2; (g) 40-year time horizon – scenario 1;
(h) 40-year time horizon – scenario 2; (i) 50-year time horizon – scenario 1; and (j) 50-year time horizon –
scenario 2. (continued )
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FIGURE 28 Cost-effectiveness acceptability curves: different time horizons: (a) 10-year time horizon – scenario 1;
(b) 10-year time horizon – scenario 2; (c) 20-year time horizon – scenario 1; (d) 20-year time horizon – scenario 2;
(e) 30-year time horizon – scenario 1; (f) 30-year time horizon – scenario 2; (g) 40-year time horizon – scenario 1;
(h) 40-year time horizon – scenario 2; (i) 50-year time horizon – scenario 1; and (j) 50-year time horizon –
scenario 2. (continued )
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likely to be cost-effective than ACI (see Figure 28b). ACI became more cost-effective than MF when the
decision-maker was willing to pay approximately £26,000 for scenario 1 and £28,000 for scenario 2.
For all other time horizons, the probability that ACI was more cost-effective than MF was approximately
55% for both scenarios when the decision-maker was willing to pay £20,000. The results highlighted that,
for the longer time horizons, ACI as a first repair was more cost-effective than MF as a first repair.
Table 29 shows the deterministic and probabilistic cost-effectiveness results for the different time horizons
and results were ranked by the least costly option. Again, the option MF(ACI) was extendedly dominated
by a linear combination of MF(MF) and ACI(MF) and therefore this option was eliminated from the
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FIGURE 28 Cost-effectiveness acceptability curves: different time horizons: (a) 10-year time horizon – scenario 1;
(b) 10-year time horizon – scenario 2; (c) 20-year time horizon – scenario 1; (d) 20-year time horizon – scenario 2;
(e) 30-year time horizon – scenario 1; (f) 30-year time horizon – scenario 2; (g) 40-year time horizon – scenario 1;
(h) 40-year time horizon – scenario 2; (i) 50-year time horizon – scenario 1; and (j) 50-year time horizon –
scenario 2.
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TABLE 29 Sensitivity cost-effectiveness results: changing the time horizon
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 10-year time horizon
MF(MF) 4498 7.2906 – – – –
MF(ACI) 5983 7.3030 MF(ACI) vs. MF(MF) 1485 0.0124a Extendedly dominated
ACI(MF) 19,329 7.8321 ACI(MF) vs. MF(MF) 14,831 0.5415 27,388
ACI(ACI) 20,082 7.8454 ACI(ACI) vs. ACI(MF) 753 0.0132a 56,816
Probabilistic: 10-year time horizon
MF(MF) 4505 7.2845 – – – –
MF(ACI) 5989 7.2950 MF(ACI) vs. MF(MF) 1484 0.0105a Extendedly dominated
ACI(MF) 19,326 7.8270 ACI(MF) vs. MF(MF) 14,821 0.5425 27,320
ACI(ACI) 20,075 7.8501 ACI(ACI) vs. ACI(MF) 749 0.0231a 32,448
Deterministic: 20-year time horizon
MF(MF) 4524 11.2587 – – – –
MF(ACI) 6104 11.2812 MF(ACI) vs. MF(MF) 1580 0.0225a Extendedly dominated
ACI(MF) 19,384 12.0654 ACI(MF) vs. MF(MF) 14,860 0.8067 18,421
ACI(ACI) 20,340 12.1040 ACI(ACI) vs. ACI(MF) 955 0.0386a 24,742
Probabilistic: 20-year time horizon
MF(MF) 4526 11.2362 – – – –
MF(ACI) 6098 11.2630 MF(ACI) vs. MF(MF) 1572 0.0268a Extendedly dominated
ACI(MF) 19,414 12.0625 ACI(MF) vs. MF(MF) 14,888 0.8263 18,019
ACI(ACI) 20,359 12.1136 ACI(ACI) vs. ACI(MF) 944 0.0511a 18,486
Deterministic: 30-year time horizon
MF(MF) 4739 13.9750 – – – –
MF(ACI) 6329 13.9997 MF(ACI) vs. MF(MF) 1590 0.0247a Extendedly dominated
ACI(MF) 19,609 14.8774 ACI(MF) vs. MF(MF) 14,871 0.9024 16,480
ACI(ACI) 20,614 14.9318 ACI(ACI) vs. ACI(MF) 1005 0.0544a 18,472
Probabilistic: 30-year time horizon
MF(MF) 4728 13.9748 – – – –
MF(ACI) 6326 14.0117 MF(ACI) vs. MF(MF) 1598 0.0369a Extendedly dominated
ACI(MF) 19,628 14.8754 ACI(MF) vs. MF(MF) 14,900 0.9006 16,545
ACI(ACI) 20,642 14.9494 ACI(ACI) vs. ACI(MF) 1014 0.0740a 13,705
Deterministic: 40-year time horizon
MF(MF) 4901 15.7354 – – – –
MF(ACI) 6492 15.7604 MF(ACI) vs. MF(MF) 1591 0.0250a Extendedly dominated
ACI(MF) 19,775 16.6747 ACI(MF) vs. MF(MF) 14,875 0.9393 15,836
ACI(ACI) 20,798 16.7368 ACI(ACI) vs. ACI(MF) 1022 0.0621a 16,466
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comparison. When comparing ACI(MF) with MF(MF) the deterministic ICER for a 10-year time horizon was
over £27,000. For the same time period the deterministic ICER for the two initial ACI options: ACI(ACI) vs.
ACI(MF) was approximately double this at £57,000. For the two initial ACI options, the deterministic
ICER falls to just under £25,000 for a 20-year time horizon, and for the 30-year time horizon the ICER is
just under £19,000. For both the 40- and 50-year time horizons (for the two initial ACI options), the
deterministic ICER is very similar to the base-case ICER. The clear reason why the shorter time horizons are
not cost-effective is due to the costs of ACI occurring at the start of the model and the benefits appearing
much later, especially in terms of the reduced need for TKRs and fewer people going to the ‘no further
repair’ or ‘no further knee replacement’ health states (where the utility is lower).
Figure 29a–e presents the CEACs for the SA results for the different time horizons. The graphs suggest
that for the 10-year time horizon, MF(MF) is the most cost-effective option if the decision-maker is willing
to pay £30,000 per QALY. At over £36,000 per QALY, the most cost-effective option is ACI as a first repair
– if a second repair is needed then this could either be ACI or MF. For the 20-year time horizon, MF(MF)
appears to be the most cost-effective option if the decision-maker is willing to pay £22,000 per QALY. At
over £26,000 per QALY, the most cost-effective option is ACI(ACI) – ACI as a first repair, and, if a second
repair is needed, this should also be ACI. As the time horizon increases ACI(ACI) – ACI as a first repair,
and, if a second repair is needed, this should also be an ACI – is probably more cost-effective than the
other three sequences. So, for example, if the decision-maker is willing to pay £24,000 per QALY then
the probability that ACI(ACI) is more cost-effective for both the 30- and 40-year time horizons is 28%,
and the probability that ACI(ACI) is more cost-effective for the 50-year time horizon is 29%.
Sensitivity analysis 3: microfracture done as a day case procedure
In the base-case analysis, according to clinical advice we have used a cost for MF as an inpatient procedure
(£3020); however, we know that sometimes this procedure is done as day case. In the SA we have
assumed that MF is done as a day case procedure at a cost of £1034. Table 30 shows the sensitivity
TABLE 29 Sensitivity cost-effectiveness results: changing the time horizon (continued )
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Probabilistic: 40-year time horizon
MF(MF) 4900 15.7279 – – – –
MF(ACI) 6494 15.7558 MF(ACI) vs. MF(MF) 1594 0.0276a Extendedly dominated
ACI(MF) 19,736 16.6504 ACI(MF) vs. MF(MF) 14,837 0.9225 16,083
ACI(ACI) 20,763 16.7219 ACI(ACI) vs. ACI(MF) 1026 0.0716a 14,336
Deterministic: 50-year time horizon
MF(MF) 4987 16.6913 – – – –
MF(ACI) 6579 16.7164 MF(ACI) vs. MF(MF) 1592 0.0251a Extendedly dominated
ACI(MF) 19,864 17.6427 ACI(MF) vs. MF(MF) 14,876 0.9514 15,636
ACI(ACI) 20,891 17.7078 ACI(ACI) vs. ACI(MF) 1028 0.0651a 15,793
Probabilistic: 50-year time horizon
MF(MF) 4974 16.6777 – – – –
MF(ACI) 6557 16.7119 MF(ACI) vs. MF(MF) 1583 0.0341a Extendedly dominated
ACI(MF) 19,820 17.6182 ACI(MF) vs. MF(MF) 14,845 0.9405 15,785
ACI(ACI) 20,841 17.6964 ACI(ACI) vs. ACI(MF) 1022 0.0782a 13,073
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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FIGURE 29 Cost-effectiveness acceptability curve: changing the time horizon. (a) 10-year time horizon; (b) 20-year
time horizon; (c) 30-year time horizon; (d) 40-year time horizon; and (e) 50-year time horizon. (continued )
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FIGURE 29 Cost-effectiveness acceptability curve: changing the time horizon. (a) 10-year time horizon; (b) 20-year
time horizon; (c) 30-year time horizon; (d) 40-year time horizon; and (e) 50-year time horizon.
TABLE 30 Sensitivity cost-effectiveness results (by scenario): MF procedure as a day case surgery and not as
an inpatient
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic
Scenario 1
MF(ACI) 4621 17.0284 – – –
ACI(ACI) 20,921 18.0228 16,300 0.9944 16,391
Scenario 2
MF(MF) 2819 17.0033 – – –
ACI(MF) 19,756 17.9570 16,937 0.9537 17,758
Probabilistic
Scenario 1
MF(ACI) 4620 17.0412 – – –
ACI(ACI) 20,951 17.9975 16,332 0.9563 17,078
Scenario 2
MF(MF) 2811 17.0137 – – –
ACI(MF) 19,788 17.9065 16,977 0.8928 19,017
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cost-effectiveness results for MF as a day case procedure. The costs for MF have fallen, but the QALY gain
does not change. Hence, ACI as a first repair is still the most cost-effective procedure compared with MF
as a first repair, with ICERs of just over £16,000 (scenario 1) and just under £18,000 (scenario 2).
Figure 30a and b presents the CEACs for MF as a day case procedure for scenarios 1 and 2, respectively.
If the decision-maker was willing to pay £20,000, for scenario 1 the probability that ACI was more
cost-effective than MF was 55% (see Figure 30a), and for scenario 2 the probability that ACI was
more cost-effective than MF was 52% (see Figure 30b).
Table 31 presents the deterministic and probabilistic cost-effectiveness results. Compared with the
base-case analysis, even though the costs for MF have fallen, there is no change in the QALYs.
The ICERs between the different options were in line with the base-case results and initial ACI appears
more cost-effective than initial MF, and, for those who need a second repair after the first ACI, this should
be another ACI.
Figure 31 presents the CEAC and the graph highlights that if the decision-maker is not willing to pay more
than £22,000 then MF(MF) is the most cost-effective option. If willing to pay more than £24,000, then
ACI(MF) is the most cost-effective option – that is, the first repair should be ACI and if a second repair is
needed this should be MF because of the lower costs (even though having an ACI as a second repair
generates more QALYs).
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FIGURE 30 Cost-effectiveness acceptability curves: MF as a day case. (a) MF as a day case – scenario 1; and (b) MF as
a day case – scenario 2.
THE COST-EFFECTIVENESS OF AUTOLOGOUS CHONDROCYTE IMPLANTATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
Sensitivity analysis 4: improving the success rates of microfracture
In this SA we have conducted a ‘what if’ scenario, for which we have assumed that the duration of success
for MF increases (1) by 20% and (2) by 40%. Table 32 shows the sensitivity cost-effectiveness results by
scenario for the increase in the duration of success for MF. ACI was still more costly than MF and there
were more QALYs gained with ACI than MF; even though there was a slight fall in the incremental QALYs
gained compared with the base-case results, this was not enough to change the ICERs. For both scenarios,
ACI as a first repair was more cost-effective than MF as a first repair. These results were of similar
magnitudes and directions for the probabilistic results.
Figure 32a–d presents the CEACs for the SA for the increase in the duration of success for MF for scenarios 1
and 2. For a 20% increase in the duration of success for MF: scenario 1, if the decision-maker was willing to
pay £20,000, the probability that ACI was more cost-effective than MF was 58% (see Figure 32a); scenario 2,
TABLE 31 Sensitivity cost-effectiveness results: MF procedure as a day case surgery and not as an inpatient
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic
MF(MF) 2819 17.0033 – – – –
MF(ACI) 4621 17.0284 MF(ACI) vs. MF(MF) 1802 0.0251a Extendedly dominated
ACI(MF) 19,756 17.9570 ACI(MF) vs. MF(MF) 16,937 0.9537 17,758
ACI(ACI) 20,921 18.0228 ACI(ACI) vs. ACI(MF) 1165 0.0658a 17,715
Probabilistic
MF(MF) 2811 17.0137 – – – –
MF(ACI) 4620 17.0412 MF(ACI) vs. MF(MF) 1809 0.0275a Extendedly dominated
ACI(MF) 19,788 17.9065 ACI(MF) vs. MF(MF) 16,977 0.8928 19,017
ACI(ACI) 20,951 17.9975 ACI(ACI) vs. ACI(MF) 1163 0.0910a 12,777
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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FIGURE 31 Cost-effectiveness acceptability curve: MF as a day case procedure.
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the probability that ACI was more cost-effective than MF was 56% (see Figure 32b). For a 40% increase in
the duration of success for MF these probability figures were 57% (see Figure 32c) and 55% (see Figure 32d),
respectively.
Table 33 presents the deterministic and probabilistic cost-effectiveness results. The costs of MF have fallen
slightly and also the QALYs for MF have increased. ACI(ACI) has an ICER of just under £18,000 (for a 20%
increase in the duration of success rate for MF) and over £21,000 (for a 40% increase in the duration of
success rate for MF).
TABLE 32 Sensitivity cost-effectiveness results (by scenario): improving the success rates of MF
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 20% increase in success rates
Scenario 1
MF(ACI) 6392 17.0756 – – –
ACI(ACI) 20,921 18.0228 14,529 0.9472 15,338
Scenario 2
MF(MF) 4969 17.0607 – – –
ACI(MF) 19,892 17.9639 14,923 0.9033 16,521
Probabilistic: 20% increase in success rates
Scenario 1
MF(ACI) 6387 17.0546 – – –
ACI(ACI) 20,895 18.0271 14,509 0.9725 14,919
Scenario 2
MF(MF) 4954 17.0403 – – –
ACI(MF) 19,856 17.9429 14,901 0.9027 16,508
Deterministic: 40% increase in success rates
Scenario 1
MF(ACI) 5698 17.0787 – – –
ACI(ACI) 20,921 18.0228 15,223 0.9441 16,125
Scenario 2
MF(MF) 4820 17.0758 – – –
ACI(MF) 19,892 17.9741 15,072 0.8983 16,778
Probabilistic: 40% increase in success rates
Scenario 1
MF(ACI) 5682 17.0535 – – –
ACI(ACI) 20,975 18.0331 15,292 0.9796 15,611
Scenario 2
MF(MF) 4803 17.0520 – – –
ACI(MF) 19,939 17.9887 15,136 0.9367 16,159
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FIGURE 32 Cost-effectiveness acceptability curves: increase in MF success rate: (a) 20% increase in MF success rate –
scenario 1; (b) 20% increase in MF success rate – scenario 2; (c) 40% increase in MF success rate – scenario 1; and
(d) 40% increase in MF success rate – scenario 2.
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Figure 33a and b presents the CEACs for the SA results for the ‘what if’ scenario if the duration of success
of MF was to increase by 20% and 40%, respectively. For a 20% increase in the MF success rate, the
graph suggests that if the decision-maker is willing to pay only £20,000 then there is not much difference
in the four options; however, if the decision-maker is willing to pay £22,000 or more then ACI as a first
repair is more cost-effective than MF as a first repair. For a 40% increase in the MF success rate, the graph
indicates that if the decision-maker is willing to pay £20,000 then ACI as a first repair [ACI(ACI) or ACI(MF)]
is more cost-effective than MF (approximately 32–33% probability that it is more cost-effective).
Sensitivity analysis 5: starting age of cohort is 45 years
In the base-case analysis the starting age for the cohort was 33 years. In this SA the starting age is
changed to 45 years (patients are nearer to the knee replacement age) to see how this affects the ICER.
Table 34 presents the deterministic and probabilistic cost-effectiveness results by scenario. Even though the
model is starting at a later age (45 years), the results are very similar to the base case, with ACI as a first
repair being cost-effective compared with MF as a first repair.
Figure 34a and b presents the CEACs for the SA with a starting age of 45 years for the cohort for
scenarios 1 and 2. For scenarios 1 and 2, if the decision-maker was willing to pay £20,000, the probability
that ACI was cost-effective relative to MF was 64%.
TABLE 33 Sensitivity cost-effectiveness results: improving the success rates of MF
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic: 20% increase in success rates
MF(MF) 4969 17.0607 – – – –
MF(ACI) 6392 17.0756 MF(ACI) vs. MF(MF) 1423 0.0149a Extendedly dominated
ACI(MF) 19,892 17.9639 ACI(MF) vs. MF(MF) 14,923 0.9033 16,521
ACI(ACI) 20,921 18.0228 ACI(ACI) vs. ACI(MF) 1029 0.0589a 17,480
Probabilistic: 20% increase in success rates
MF(MF) 4954 17.0403 – – – –
MF(ACI) 6387 17.0546 MF(ACI) vs. MF(MF) 1433 0.0144a Extendedly dominated
ACI(MF) 19,856 17.9429 ACI(MF) vs. MF(MF) 14,901 0.9027 16,508
ACI(ACI) 20,895 18.0271 ACI(ACI) vs. ACI(MF) 1040 0.0842a 12,356
Deterministic: 40% increase in success rates
MF(MF) 4820 17.0758 – – – –
MF(ACI) 5698 17.0787 MF(ACI) vs. MF(MF) 878 0.0029a Extendedly dominated
ACI(MF) 19,892 17.9741 ACI(MF) vs. MF(MF) 15,072 0.8983 16,778
ACI(ACI) 20,921 18.0228 ACI(ACI) vs. ACI(MF) 1029 0.0487a 21,130
Probabilistic: 40% increase in success rates
MF(MF) 4803 17.0520 – – – –
MF(ACI) 5682 17.0535 MF(ACI) vs. MF(MF) 880 0.0015a Extendedly dominated
ACI(MF) 19,939 17.9887 ACI(MF) vs. MF(MF) 15,136 0.9367 16,159
ACI(ACI) 20,975 18.0331 ACI(ACI) vs. ACI(MF) 1036 0.0443a 23,356
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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TABLE 34 Sensitivity cost-effectiveness results (by scenario): starting age for cohort is 45 years
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic
Scenario 1
MF(ACI) 6422 15.0445 – – –
ACI(ACI) 16,784 16.0327 10,362 0.9882 10,486
Scenario 2
MF(MF) 5267 15.0187 – – –
ACI(MF) 16,116 15.9766 10,849 0.9579 11,326
Probabilistic
Scenario 1
MF(ACI) 6441 15.0833 – – –
ACI(ACI) 16,724 16.0377 10,283 0.9544 10,755
Scenario 2
MF(MF) 5281 14.9900 – – –
ACI(MF) 16,053 15.9562 10,772 0.9962 11,149
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FIGURE 33 Cost-effectiveness acceptability curves: increase in MF success rate. (a) Increase in MF success rate by
20%; and (b) increase in MF success rate by 40%. Note that MF only becomes cost-effective if the duration of
benefit is much longer.
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Table 35 shows the deterministic and probabilistic cost-effectiveness results with a starting age of 45 years
for the cohort and results were ranked by the least costly option. Results were similar to the base-case
results and ACI(ACI) remained the most cost-effective procedure.
Figure 35 presents the CEAC for a starting age of 45 years for the cohort. If the decision-maker is willing
to pay £20,000 per QALY then either ACI(ACI) or ACI(MF) are the most cost-effective options.
Discussion
For the base-case analysis, a hypothetical cohort of 1000 patients with cartilage knee defects with a starting
age of 33 years was followed over a lifetime horizon. The cycle length for the model was set to 1 year.
The analysis was conducted from the perspective of the NHS and PSS. Data for the transition probabilities,
mortality rates and utilities were obtained from the literature. Health outcomes were measured in QALYs.
The majority of unit costs were obtained from the NHS reference costs151 database and all costs are in
pounds sterling in 2012–13 prices. Results were compared in two different ways for ACI and MF:
l First, we used two scenarios: scenario 1 with all second repairs ACI and scenario 2 with all second
repairs MF.
l Second, all four options were ranked in order of increasing costs; any options (sequences) that were
more expensive and less effective were excluded (simple dominance); and if the ICER for a given
category was higher than that of the next more effective alternative then this category was eliminated
(extended dominance).
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FIGURE 34 Cost-effectiveness acceptability curves: starting age is 45 years: (a) scenario 1; and (b) scenario 2.
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Results are expressed as incremental cost per QALY gained. An annual discount rate of 3.5% was applied
to both costs and QALYs. We ran the model deterministically and probabilistically with 1000 iterations. We
undertook various SAs. These bootstrapped iterations were used to construct the CEACs. The CEACs were
presented using a willingness-to-pay threshold from £0 to £60,000.
Methods and summary of findings
For the base-case analysis, for the discounted deterministic results MF was the less costly option but had
fewer QALYs, whereas ACI was the more expensive option but generated more QALYs.
For scenario 1, the cost per QALY gained for ACI compared with MF was £14,395, and for scenario 2 the
cost per QALY gained £15,598. These results were confirmed by the CEACs: so if the decision-maker is
willing to pay £20,000 for a QALY, ACI is 56–59% more likely to be cost-effective than MF. For both
scenarios, ACI as a first repair appeared more cost-effective than MF as a first repair.
When looking at the different sequences (options), the initial ACI appears more cost-effective than initial
MF, and, for those who need a second repair after the first ACI, this should also be another ACI.
TABLE 35 Sensitivity cost-effectiveness results: starting age for cohort is 45 years
Procedure
Total mean
costs (£)
Total mean
QALYs Comparison
Incremental
costs (£)
Incremental
QALYs
ICER (£) (cost per
QALY gained)
Deterministic
MF(MF) 5267 15.0187 – – – –
MF(ACI) 6422 15.0445 MF(ACI) vs. MF(MF) 1155 0.0258a Extendedly dominated
ACI(MF) 16,116 15.9766 ACI(MF) vs. MF(MF) 10,849 0.9579 11,326
ACI(ACI) 16,784 16.0327 ACI(ACI) vs. ACI(MF) 667 0.0561a 11,898
Probabilistic
MF(MF) 5281 14.9900 – – – –
MF(ACI) 6441 15.0833 MF(ACI) vs. MF(MF) 1160 0.0933a Extendedly dominated
ACI(MF) 16,053 15.9562 ACI(MF) vs. MF(MF) 10,772 0.9662 11,149
ACI(ACI) 16,724 16.0377 ACI(ACI) vs. ACI(MF) 671 0.0815a 8241
a As the incremental QALYs are near zero, the ICER can fluctuate widely.
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FIGURE 35 Cost-effectiveness acceptability curve: starting age of cohort is 45 years.
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
The option MF(ACI) was extendedly dominated by a linear combination of MF(MF) and ACI(MF) and
therefore this option was eliminated from the comparison. For the different sequences, the CEAC for the
base-case results confirmed these results and showed that if the decision-maker is willing to pay £18,000
or more for a QALY than ACI as a first procedure is more cost-effective than MF as a first procedure.
We found that the key cost driver was the cost of the cells for the ACI procedure, but, over the time
horizon, ACI is more beneficial (more gain in QALYs) and cost saving to the NHS (fewer people in need of
a second repair or of a TKR).
A number of SAs were undertaken to determine the cost-effectiveness of various options and the majority
of results were in line with the base-case analysis. However, we found that the model was sensitive to
the cost of cells – we know that these are not the true costs as the NHS receives confidential discounts
from the manufacturers. This means that with the cell cost reduction ACI(ACI) is likely to be even more
cost-effective than the base-case cost per QALY ratio that was presented. We also found that the model
was sensitive to the time horizon: with a shorter time horizon – 10 years – the cost per QALY for the two
initial ACI options rose to around £26,000 because of the costs of the ACI procedure occurring at the start
and the benefits of ACI not being realised until much later, such as the reduced need for TKRs. When the
time horizon was longer, the model results were in line with the base-case results. The SAs conducted
using Oswestry data found ACI not to be cost-effective compared with MF and mainly due to the lower
utility value in the fourth year for ACI compared with MF. However, for reasons explained in Chapter 5,
there are several confounding factors that influence these utility values.
Strengths and limitations
If the first repair fails, the Markov model considers patients having a maximum of two knee repairs
(any combination of MF and ACI) if they choose to.
However, the model does have a number of limitations. First, the length of follow-up we found in the trials
published in the literature was too short and hence, there are no long-term data on the success and failure
rates (including long-term benefits and AEs) for each of these procedures and what the average age is for
these patients when a TKR/PKR is required. Hence, we relied heavily on two papers70,100 to obtain transition
probabilities for our economic model. In addition, because of the paucity of data from clinical studies,
transition probabilities were not available for each transition in the model; hence we made a number of
assumptions for our model, which were checked for plausibility with our clinical advisors. However, results
from the long-term ACTIVE trial35 (comparing ACI/MACI with standard treatments) and the TOPKAT trial
(comparing TKR with PKR)164 will provide useful information with which to populate our economic model,
although results will not be available until 2017 and 2019, respectively.
Second, because of the short follow-up, we also found that there were no long-term data on utility values
that were associated with each of these procedures. We have had to rely heavily on the literature and on a
few studies in particular, such as Gerlier et al.141 Also, we found no studies that mapped any of the clinical
measures – such as Lysholm score or the KOOS – to either the EQ-5D or SF-6D to generate utility values,
which would have been helpful in our model.
Third, we relied on clinical experience for information on the average resources used (e.g. outpatient and
rehabilitation visits) for these patients.
Fourth, we did not take into account any costs for the analgesics, based on advice from our clinical
experts, as these costs are negligible and would not have altered the base-case cost per QALY. Also, not all
of the costs obtained were from the NHS reference costs. We used the previous HTA report by Clar et al.,3
who obtained costs from Aberdeen and Southampton hospitals to populate their economic model.
Although these costs were inflated to 2012–13 prices using the HCHS index,154 to get a more accurate
picture of these costs it would have been better to have carried out ‘bottom-up costing’.
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Fifth, the model has not taken into account any private patient costs, such as time off work and loss of
pay (productivity): this population, of those who have either an ACI or MF, is a young cohort and it will
primarily have an effect on their own costs. In line with this, it would have been interesting to know how
long it would take this population cohort to return to normal activities after each of these procedures
(return to work or sports).
Finally, we did not include any AEs, as there were no key differences between the two treatment arms.
Additional analyses based on survival analysis
Next, we report the results of the additional economic analyses undertaken, incorporating new parameter
values, in particular the survival curves for failure rates reported in Chapter 3. We have used data from the
long-term studies in a new base-case analysis, using the whole Nawaz cohort80 results for ACI, and pooling
the MF results from the three studies. At the request of NICE, we have used an implantation cost of £2396
and also omitted the option for MF failure followed by another MF. Unless specified, the model structure
and parameter values remain the same as those in the initial report.
The different sequences of procedures were ranked in order of increasing cost. We eliminated any
categories for which another category was cheaper and more effective (simple dominance). If the ICER for
a given category is higher than that of the next more effective alternative this category was eliminated
(extended dominance). For the remaining options, we reported the ICERs, measured as cost per
QALY gained.
When QALY differences are small, the probabilistic ICERs will fluctuate quite a lot. The deterministic ICERs
are more reliable.
New base case
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396, as requested by NICE. This includes an inpatient stay. ACI can be done on
a day case basis, though it should be noted that, because it is often provided as a specialist ‘regional’
service, overnight stays may be unavoidable because of distance. The clinical authors of this report vary
between one-night stays for all and some being done as day case. The operation is often open, and
such exposure is much more painful than the arthroscopic surgery used for harvesting the initial tissue).
However, mini-arthrotomy may be used.
l MF is nearly always a day case procedure.
Table 36 presents the results from the new base-case analysis. The discounted deterministic results show
that MF(ACI) was the least costly option and had the fewest QALYs; although ACI(ACI) generated the
most QALYs, it was also the most expensive option. The option of ACI(MF) was extendedly dominated
by a linear combination of MF(ACI) and ACI(ACI), and therefore this option was eliminated from the
comparison. The ICER comparing ACI(ACI) with MF(ACI) was just under £19,000; doing ACI first is more
cost-effective. The discounted probabilistic results were very similar. Figure 36 shows the cost-effectiveness
analysis for the two remaining options. The graph shows that, for amounts below £20,000, MF(ACI) is the
most cost-effective option; at a willingness to pay of £20,000 there is not much difference between the
two options, and, at a willingness to pay above £20,000, ACI(ACI) is probably more cost-effective.
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Sensitivity analyses on prices
Note that in analysis of price changes, the QALY gain does not change in the deterministic arms, as
expected. However, when the model is run probabilistically all of the input variables change because of the
different distributions, hence both the costs and QALYs will change.
Cells at £6000
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £6000.
Table 37 shows the results when the price of cells is reduced to £6000. The deterministic discounted
results highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER
comparing ACI(ACI) with MF(ACI) was just under £7500. Figure 37 shows that at a willingness to pay of
£8000 there is not much difference between the two remaining options.
TABLE 36 Base-case deterministic and probabilistic cost-effectiveness results
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,661 35.5596 14,926 1.2711 Extended dominated MF(ACI)
ACI(ACI) 24,134 35.6999 1473 0.1403 11,619 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,400 17.9304 15,152 0.7954 Extended dominated MF(ACI)
ACI(ACI) 22,461 17.9953 1062 0.0650 18,844 MF(ACI)
Probabilistic: discounted
MF(ACI) 6261 17.1523 – – – –
ACI(MF) 21,410 17.9048 15,210 0.7525 Extended dominated MF(ACI)
ACI(ACI) 22,532 17.9872 1061 0.0824 19,487 MF(ACI)
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FIGURE 36 Cost-effectiveness acceptability curve: base case.
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Cells at cost £8000
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £8000.
Table 38 shows the results when the price of cells is reduced to £8000. The deterministic discounted
results highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER
comparing ACI(ACI) with MF(ACI) was just under £10,000. Figure 38 shows that at a willingness to pay of
£10,000 there is not much difference between the two remaining options.
TABLE 37 Deterministic and probabilistic cost-effectiveness results: £6000 price
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 6771 34.2885 – – – –
ACI(MF) 12,661 35.5596 5,890 1.2711 Extended dominated MF(ACI)
ACI(ACI) 13,244 35.6999 583 0.1403 4586 MF(ACI)
Deterministic: discounted
MF(ACI) 5441 17.1350 – – – –
ACI(MF) 11,400 17.9304 5,959 0.7954 Extended dominated MF(ACI)
ACI(ACI) 11,820 17.9953 420 0.0650 7414 MF(ACI)
Probabilistic: discounted
MF(ACI) 5452 17.1340 – – – –
ACI(MF) 11,486 17.9110 6,034 0.7770 7766 MF(ACI)
ACI(ACI) 11,909 17.9474 423 0.0364 11,622 ACI(MF)
0 10 20 30
Willingness to pay (£000)
40 50 60
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
ACI(ACI)
MF(ACI)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
FIGURE 37 Cost-effectiveness acceptability curve: £6000.
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Cells at cost of £12,000
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £12,000.
Table 39 shows the results when the price of cells is reduced to £12,000. The deterministic discounted
results highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER
comparing ACI(ACI) with MF(ACI) was just under £14,500. Figure 39 shows that at a willingness to pay of
£16,000 there is not much difference between the two remaining options.
Sensitivity analyses: post-repair utility
In our first assessment report, we assumed that patients who decided not to have a further repair had had
some benefit, and had improved from a utility of 0.654 before the repair to 0.691 afterwards. NICE asked
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FIGURE 38 Cost-effectiveness acceptability curve: £8000.
TABLE 38 Deterministic and probabilistic cost-effectiveness results: £8000 price
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 6964 34.2885 – – – –
ACI(MF) 14,661 35.5596 7697 1.2711 Extended dominated MF(ACI)
ACI(ACI) 15,422 35.6999 761 0.1403 5993 MF(ACI)
Deterministic: discounted
MF(ACI) 5602 17.1350 – – – –
ACI(MF) 13,400 17.9304 7797 0.7954 Extended dominated MF(ACI)
ACI(ACI) 13,948 17.9953 549 0.0650 9700 MF(ACI)
Probabilistic: discounted
MF(ACI) 5608 17.1630 – – – –
ACI(MF) 13,430 17.9500 7822 0.7871 9938 MF(ACI)
ACI(ACI) 13,983 18.0242 553 0.0742 7454 ACI(MF)
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us to assess the effect of several assumptions for utilities in those in whom repair is unsuccessful, but who
choose not to have another operation.
Utility for choose no second repair set to same as failure
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Utility for those who choose no second repair: 0.654.
Table 40 shows the results when the utility value for those who choose no second repair is 0.654. The
deterministic discounted results highlighted that the option of ACI(MF) was extendedly dominated and
therefore the ICER comparing ACI(ACI) with MF(ACI) was just over £15,500 (results are similar to the new
base-case results). Figure 40 shows that at a willingness to pay of £16,000 there is not much difference
between the two remaining options.
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FIGURE 39 Cost-effectiveness acceptability curve: £12,000.
TABLE 39 Deterministic and probabilistic cost-effectiveness results: £12,000 price
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7350 34.2885 – – – –
ACI(MF) 18,661 35.5596 11,312 1.2711 Extended dominated MF(ACI)
ACI(ACI) 19,778 35.6999 1117 0.1403 8806 MF(ACI)
Deterministic: discounted
MF(ACI) 5925 17.1350 – – – –
ACI(MF) 17,400 17.9304 11,475 0.7954 Extended dominated MF(ACI)
ACI(ACI) 18,205 17.9953 805 0.0650 14,272 MF(ACI)
Probabilistic: discounted
MF(ACI) 5918 17.1425 – – – –
ACI(MF) 17,320 17.9539 11,402 0.8114 Extended dominated MF(ACI)
ACI(ACI) 18,131 17.9899 811 0.0360 14,412 MF(ACI)
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Utility for choose no second repair set to same as success
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
l Utility for those who choose no second repair: 0.817. Note that this assumption greatly increases utility
gain among those who do not get good results after MF, and reduces the marginal QALY gains from ACI.
Table 41 shows the results when the utility value for those who choose no second repair is 0.817. Here we
are assuming that there are increases in utility gain among those who do not get good results after MF,
and therefore this reduces the marginal QALY gains from ACI. The deterministic discounted results
highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER comparing
ACI(ACI) with MF(ACI) was just over £62,000. Hence, the option ACI(ACI) is no longer considered to be
cost-effective. Figure 41 shows that, at a willingness to pay of £20,000, MF(ACI) is 70% more likely to
be cost-effective than ACI(ACI).
TABLE 40 Deterministic and probabilistic cost-effectiveness results: utility= 0.654
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 32.8665 – – – –
ACI(MF) 22,661 34.4351 14,926 1.5686 Extended dominated MF(ACI)
ACI(ACI) 24,134 34.6021 1473 0.1670 9449 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 16.5058 – – – –
ACI(MF) 21,400 17.4667 15,152 0.9609 Extended dominated MF(ACI)
ACI(ACI) 22,461 17.5428 1062 0.0762 15,634 MF(ACI)
Probabilistic: discounted
MF(ACI) 6247 16.4820 – – – –
ACI(MF) 21,446 17.4583 15,198 0.9763 Extended dominated MF(ACI)
ACI(ACI) 22,2522 17.5499 1077 0.0916 15,241 MF(ACI)
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FIGURE 40 Cost-effectiveness acceptability curve: utility = 0.654.
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Utility for choose no second repair set to mid-point of success and failure
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Utility for those who choose no second repair: 0.746. This also reduces the marginal QALY gains from ACI
as first procedure because the larger proportion who do not do well after MF have their utility increased.
Table 42 shows the results when the utility value for those who choose no second repair is 0.746. The
deterministic discounted results highlighted that the option of ACI(MF) was extendedly dominated and
therefore the ICER comparing ACI(ACI) with MF(ACI) was just over £27,000. Figure 42 shows that at
a willingness to pay of £26,000 there is not much difference between the two remaining options.
TABLE 41 Deterministic and probabilistic cost-effectiveness results: utility= 0.817
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 39.1309 – – – –
ACI(MF) 22,661 39.3889 14,926 0.2580 Extended dominated MF(ACI)
ACI(ACI) 24,134 39.4383 1473 0.0494 53,352 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 19.2776 – – – –
ACI(MF) 21,400 19.5096 15,152 0.2320 Extended dominated MF(ACI)
ACI(ACI) 22,461 19.5363 1062 0.0267 62,658 MF(ACI)
Probabilistic: discounted
MF(ACI) 6250 19.2966 – – – –
ACI(MF) 21,438 19.5140 15,188 0.2290 Extended dominated MF(ACI)
ACI(ACI) 22,512 19.5484 1074 0.0384 64,581 MF(ACI)
ACI(ACI)
MF(ACI)
0.0
0.1
0.2
0.3
0.4
0.5
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0.6
0.7
0.8
0.9
1.0
0 10 20 30
Willingness to pay (£000)
40 50 60
FIGURE 41 Cost-effectiveness acceptability curve: utility = 0.817.
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Subgroup analyses
Individuals with prior repair attempts
l Data used for ACI failure rates: Nawaz et al.80 previous intervention.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 43 shows the results for those individuals with prior repair attempts. The deterministic discounted
results highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER
comparing ACI(ACI) with MF(ACI) was just over £38,000. Figure 43 shows that, at a willingness to pay of
£30,000 or less, MF(ACI) is the more cost-effective option.
TABLE 42 Deterministic and probabilistic cost-effectiveness results: utility= 0.746
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 36.4022 – – – –
ACI(MF) 22,661 37.2311 14,926 0.8289 Extended dominated MF(ACI)
ACI(ACI) 24,134 37.3317 1473 0.1006 17,643 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 18.0702 – – – –
ACI(MF) 21,400 18.6197 15,152 0.5495 Extended dominated MF(ACI)
ACI(ACI) 22,461 18.6680 1062 0.0483 27,123 MF(ACI)
Probabilistic: discounted
MF(ACI) 6248 18.0400 – – – –
ACI(MF) 21,419 18.6257 15,171 0.5857 Extended dominated MF(ACI)
ACI(ACI) 22,496 18.6684 1077 0.0427 25,857 MF(ACI)
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FIGURE 42 Cost-effectiveness acceptability curve: utility = 0.746.
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Individuals without prior repair attempts
l Data used for ACI failure rates: Nawaz et al.80 no previous intervention.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970)
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 44 shows the results for those individuals without any prior repair attempts. The deterministic
discounted results showed that the ICER comparing ACI(ACI) with ACI(MF) was just over £15,500.
Figure 44 shows that at a willingness to pay of £12,000 there is not much difference between the two
remaining options.
TABLE 43 Deterministic and probabilistic cost-effectiveness results: previous intervention
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,718 34.7835 14,983 0.4950 Extended dominated MF(ACI)
ACI(ACI) 24,314 34.9315 1595 0.1480 25,780 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,462 17.4918 15,214 0.3569 Extended dominated MF(ACI)
ACI(ACI) 22,746 17.5661 1284 0.0743 38,262 MF(ACI)
Probabilistic: discounted
MF(ACI) 6236 17.1315 – – – –
ACI(MF) 21,503 17.4889 15,267 0.3575 Extended dominated MF(ACI)
ACI(ACI) 22,798 17.5522 1295 0.0632 39,370 MF(ACI)
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FIGURE 43 Cost-effectiveness acceptability curve (previous interventions).
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TABLE 44 Deterministic and probabilistic cost-effectiveness results: no previous intervention
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 21,956 37.4216 14,220 3.1332 4539 MF(ACI)
ACI(ACI) 22,826 37.5038 870 0.0822 10,586 ACI(MF)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,101 18.7446 14,853 1.6097 9227 MF(ACI)
ACI(ACI) 21,644 18.7793 543 0.0347 15,659 ACI(MF)
Probabilistic: discounted
MF(ACI) 6268 17.1506 – – – –
ACI(MF) 21,114 18.6100 14,846 1.4594 10,172 MF(ACI)
ACI(ACI) 21,930 18.6211 816 0.0310 26,324 ACI(MF)
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FIGURE 44 Cost-effectiveness acceptability curve: no previous interventions.
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Individuals with Kellgren–Lawrence grade 0
l Data used for ACI failure rates: Nawaz et al.80 Kellgren–Lawrence grade 0.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 45 shows the results for those individuals with Kellgren–Lawrence grade 0. The deterministic
discounted results highlighted that the ICER comparing ACI(ACI) with ACI(MF) was just over £15,500.
Individuals with Kellgren–Lawrence grade 1
l Data used for ACI failure rates: Nawaz et al.80 Kellgren–Lawrence grade 1.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 46 shows the results for those individuals with Kellgren–Lawrence grade 1. The deterministic
discounted results highlighted that the option of ACI(MF) was extendedly dominated and therefore the
ICER comparing ACI(ACI) with MF(ACI) was just over £17,000.
Individuals with Kellgren–Lawrence grade 2
l Data used for ACI failure rates: Nawaz et al.80 Kellgren–Lawrence grade 2.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 47 shows the results for those individuals with Kellgren–Lawrence grade 2. The deterministic
discounted results highlighted that the option of ACI(MF) was extendedly dominated and therefore the
ICER comparing ACI(ACI) with MF(ACI) was just over £20,000.
TABLE 45 Deterministic cost-effectiveness results: Kellgren–Lawrence grade 0
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,489 36.4611 14,753 2.1726 6791 MF(ACI)
ACI(ACI) 23,727 36.5794 1238 0.1183 10,470 ACI(MF)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,294 18.3745 15,046 1.2395 12,138 MF(ACI)
ACI(ACI) 22,079 18.4247 785 0.0503 15,618 ACI(MF)
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Individuals with Kellgren–Lawrence grade 3
l Data used for ACI failure rates: Nawaz et al.80 Kellgren–Lawrence grade 3.
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
Table 48 shows the results for those individuals with Kellgren–Lawrence grade 3. The deterministic
discounted results highlighted that the option of ACI(MF) was extendedly dominated and therefore the
ICER comparing ACI(ACI) with MF(ACI) was just over £21,000.
Pooled autologous chondrocyte implantation curve (six studies)
l Data used for ACI failure rates: pooled data (Knutsen 2007,67 Minas 2014,136 Moseley 2010,115
Nawaz,165 Niemeyer 2014,117 Vanlauwe 201143).
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970).
l Cost of harvesting: £870.
l Cost of implantation: £2396.
l Cost of cells: £16,000.
TABLE 47 Deterministic cost-effectiveness results: Kellgren–Lawrence grade 2
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,718 35.4402 14,983 1.1517 Extended dominated MF(ACI)
ACI(ACI) 24,233 35.5842 1514 0.1440 12,732 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,423 17.8779 15,175 0.7430 Extended dominated MF(ACI)
ACI(ACI) 22,520 17.9447 1097 0.0667 20,096 MF(ACI)
TABLE 46 Deterministic cost-effectiveness results: Kellgren–Lawrence grade 1
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,679 35.7135 14,943 1.4250 10,486 MF(ACI)
ACI(ACI) 24,129 35.8516 1450 0.1381 10,499 ACI(MF)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,395 18.0173 15,147 0.8824 Extended dominated MF(ACI)
ACI(ACI) 22,408 18.0798 1013 0.0624 17,104 MF(ACI)
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Table 49 shows the results for the pooled six ACI data sets. The deterministic discounted results showed
that the ICER comparing ACI(ACI) with MF(ACI) was just under £12,000. Figure 45 shows that, at a
willingness to pay of £12,000 or less, MF(ACI) is the more cost-effective option.
TABLE 49 Deterministic and probabilistic cost-effectiveness results: six ACI data sets
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,140 36.7771 14,405 2.4886 5788 MF(ACI)
ACI(ACI) 23,195 37.8748 1055 0.0978 10,794 ACI(MF)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,192 18.4290 14,944 1.2940 11,549 MF(ACI)
ACI(ACI) 21,933 18.4734 741 0.0444 16,708 ACI(MF)
Probabilistic: discounted
MF(ACI) 6271 17.1731 – – – –
ACI(MF) 21,235 18.4253 14,964 1.2522 11,950 MF(ACI)
ACI(ACI) 21,991 18.4948 757 0.0695 10,882 ACI(MF)
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FIGURE 45 Cost-effectiveness acceptability curve: six ACI data sets.
TABLE 48 Deterministic cost-effectiveness results: Kellgren–Lawrence grade 3
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs ICER vs. MF(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 34.2885 – – – –
ACI(MF) 22,726 35.3609 14,990 1.0724 Extended dominated MF(ACI)
ACI(ACI) 24,258 35.5063 1532 0.1455 13,566 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 17.1350 – – – –
ACI(MF) 21,430 17.8358 15,183 0.7008 Extended dominated MF(ACI)
ACI(ACI) 22,552 17.9038 1122 0.0680 21,207 MF(ACI)
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Using utility data from Vericel
l Data used for ACI failure rates: Nawaz et al.80 (whole cohort)
l Data used for MF failure rates: pooled data (Layton 2015,114 Knutsen 2007,67 Saris 200970)
Tables 50 and 51 shows the results when using utility data for Vericel. The deterministic discounted results
highlighted that the option of ACI(MF) was extendedly dominated and therefore the ICER comparing
ACI(ACI) with MF(ACI) was just over £15,500. Figure 46 shows that at a willingness to pay of £16,000
there is not much difference between the two remaining options.
TABLE 50 Utility data from Vericel
Time point MACI MF
Baseline
n 141
Mean utility value (SD) 0.484 (0.296)
Response at week 52
n 71 68
Mean utility value (SD) 0.7848 (0.2113) 0.7472 (0.2270)
Response at week 104
n 70 70
Mean utility value (SD) 0.8051 (0.1899) 0.7188 (0.2969)
Response at week 156
n 65 59
Mean utility value (SD) 0.8131 (0.2105) 0.7769 (0.2553)
TABLE 51 Deterministic and probabilistic cost-effectiveness results
Procedure
Total mean
costs (£)
Total mean
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER vs. MF
(ACI) Comparator
Deterministic: undiscounted
MF(ACI) 7736 33.8297 – – – –
ACI(MF) 22,661 35.2364 14,926 1.4067 Extended
dominated
MF(ACI)
ACI(ACI) 24,134 35.3784 1473 0.1420 10,588 MF(ACI)
Deterministic: discounted
MF(ACI) 6248 16.6956 – – – –
ACI(MF) 21,400 17.6627 15,152 0.9671 Extended
dominated
MF(ACI)
ACI(ACI) 22,461 17.7317 1061 0.0690 15,648 MF(ACI)
Probabilistic: discounted
MF(ACI) 6283 16.7221 – – – –
ACI(MF) 21,381 17.6499 15,098 0.9277 Extended
dominated
MF(ACI)
ACI(ACI) 22,456 17.7528 1075 0.1029 15,692 MF(ACI)
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Summary of long-study modelling
l In many scenarios, ACI(MF) is extended dominated, meaning that the relevant choice is between
ACI(ACI) and MF(ACI), and the use of MF as a post-ACI treatment is not a relevant alternative.
l The exceptions to this tend to be in scenarios in which ACI is particularly effective (e.g. no previous
repair, Kellgren–Lawrence grade of 0), for which there is less additional benefit to be gained from a
more effective second procedure.
l Decreases in ACI treatment costs, unsurprisingly, lead to reductions in the ICERs for ACI.
l Higher utilities in the ‘no further treatment’ state make ACI less cost-effective, as there is less benefit
gained from successful procedures, and, likewise, lower utilities in the ‘no further treatment’ state
make ACI more cost-effective.
l Including evidence from a wider range of studies makes ACI appear more cost-effective than using
data from Nawaz et al.80 alone.
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FIGURE 46 Cost-effectiveness acceptability curve.
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Chapter 7 Discussion
S tatement of principal findings:
l ACI has evolved since the last review by NICE in 2005, and now chondrocytes are seeded into
membranes or scaffolds, rather than a liquid suspension of cells being secured under a periosteal or
collagen cap.
l Selection of the chondrocytes that are most likely to produce good quality repairs (‘characterisation’) is
now used, though there are no published trials proving benefit.
l ACI is an effective way of treating defects in articular cartilage, giving good results in over 80% of
patients. If results are good at 2 years, benefit is generally sustained for up to 10 years. A very large UK
cohort showed graft survivals of 78% at 5 years, and 51% at 10 years.
l The main comparator, MF, is effective in a smaller proportion and appears to be less durable.
l Our economic modelling found that ACI appeared to be cost-effective compared with MF, with a key
driver being duration of benefit and likely avoidance or postponement of a second repair or of knee
replacement. MF was less costly, but provided fewer QALYs.
l Total costs were influenced by the proportion needing a second repair, and by the method used for
second repairs. If all second repairs were by ACI, the cost per QALY gained for initial ACI compared
with initial MF was £8925. If all second repairs were by MF, the cost per QALY gained was £9788.
These results were confirmed by the CEACs: so if the decision-maker is willing to pay £20,000 for a
QALY, ACI is 56–59% more likely to be cost-effective than MF. For both scenarios, ACI as a first repair
was more cost-effective than MF as a first repair.
l There is a shortage of long-term studies, particularly of MF. As requested by NICE, we carried out
survival analysis making the best of what data there were. Caveats are required.
l We included six studies of long-term results of ACI, the best of which was by Nawaz et al.,80 from
Stanmore. It was best because of size (827 – all of the other studies put together provided 371); it
reflected UK practice (albeit from a centre of excellence); it provided data from the period 1998–2008,
on different generations of ASCI; and it provided very useful subgroup data.
l Using the older data, MF comes out less well, with progressive failure over time.
l As noted in the previous report, ACI is less successful in people who had had prior repair attempts,
such as MF.
l The new base-case analysis used MF followed, if necessary, by ACI, as the lowest cost option, with
other options being compared with that. The ICER for ACI as a primary procedure compared with MF
was around £19,000. The range of economics analyses produced ICERs that might be considered
acceptable by NICE.
Strengths and weaknesses of evidence
l At the last appraisal, there were no long-term data from trials. The evidence base has also evolved with
data on longer-term follow-up both from trials and cohort studies. However, the longest-term data
come from older generations of ACI, and recruits to such studies had often had several prior attempts
at repair, which appear to reduce the effectiveness of ACI.
l Because of short follow-up of the MACI trials, there is a lack of long-term utility data.
l The TIG/ACT trial43 of ChondroCelect used ACI-P, which has now been superseded by ACI-C or MACI.
ChondroCelect cells are now used in a MACI procedure wherein the cells are loaded on to a
membrane by the surgeon.
l There is a general problem when long-term results are needed but the technology continues to evolve.
Data on long-term results come mainly from first-generation ACI.
l Utilities vary considerably among studies. For example, baseline utility before repair ranges from 0.41
(Derrett2005140) to 0.532 or 0.504 (ACTIVE,35 MF and ACI groups, respectively) to 0.654 (Gerlier 2010141).
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l When considering survival curves extrapolated beyond the observed data, it should be borne in mind
that the extrapolation assumes that the curve based on the observed data will continue. However, this
may not always be the case. For example, if ACI failures occurred mainly in the early observed years,
longer-term observations would show a levelling off. However, this may apply only after successful ACI.
Bhosale et al.,108 from Oswestry, in a series of 80 patients, reported that success at 15 months was
sustained, but average follow-up was for only 5 years. The Nawaz study80 suggests that when ACI is
most successful, the survival curve shows some levelling off by about 7 years, whereas in those in
whom it fails, the curve shows a linear decline.
l The lack of data on the benefits of MF compared with debridement alone is a problem. (And it is
worth remembering that in a previous assessment report, we noted a lack of evidence for debridement
and lavage over non-operative approaches.3)
l We relied heavily on the Nawaz study.80 We confirmed with the lead author that the patients in the
ACI arm of the Bentley trial,78 and the cohort in the long-term outcome study by Biant et al.,79 were
included. Before obtaining that information, we had included the Bentley78 and Biant79 studies on
pooled survival analysis. Curiously, removing them worsened the ACI results, despite them having, in
some ways, patients with poorer prognostic factors. For example, the proportions having previous
repair attempts were 34% in Nawaz, 94% in Bentley and 73% in Biant. The patients in the Bentley78
and Biant79 studies were from the earliest days (1998–2001) and were ‘salvage’ cases after means of
1.7 and 1.3 previous procedures, respectively.
l The reason for the better results in the Minas series136 than in the Nawaz study80 is not clear. The
Minas136 patients all had MACI. The definitions of failure may explain some of the difference, with
failure in Minas136 very surgically defined, such that some failures in the Nawaz study might not have
been classed as failure by Minas et al.136
l Another variable that may cause differences in outcomes could be differences in comparator treatments,
such as drilling and MF. After MF, microscopic cracks form around the holes. These do not occur when
bone is drilled. So MF may do more damage to the subchondral bone.
l As noted, there are rather more long-term studies of ACI than of MF. Why are there so few of MF?
Could it be that long-term results are poor and that people with data do not publish it? Should the
questions in this appraisal have included: Should MF be done at all, irrespective of whether ACI
is available?
l The evidence base has many deficiencies. One is that older studies tended to recruit patients who had
had previous attempts at repair, and these may give a misleadingly pessimistic picture of how ACI
would perform if used as first procedure.
Other issues
Asymptomatic lesions
The BASK UK39 Consensus recommends that patients should have conservative treatment with physical
therapy before being considered for cartilage repair. Many will become asymptomatic and will no longer
qualify for ACI according to the NICE scope. However, their cartilage defect will not recover spontaneously,
and they are likely to develop OA in later years. Should they be considered for ACI?
The Dutch Orthopaedic Association recommends treatment of asymptomatic ICRS grade 5 lesions.22
Osteoarthritis
The NICE scope excludes people with ‘advanced osteoarthritis’. OA can be defined as generalised
degenerative change affecting both sides of an articulation. ACI is used for isolated cartilage defects. There
can be isolated defects on both surfaces (‘kissing lesions’), which could be considered for ACI if the rest of
the joint is in good order. Patients with only early OA (less than grade 2 which has definite osteophytes
and possible joint space narrowing) could have been included in some trials. However, no details for such
a subgroup are given in the results. In the TIG/ACT trial,43 patients with advanced OA (as defined by
radiographic atlas OA grade 2–3) were excluded.
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A systematic review of cartilage repair in early OA by de Windt et al.166 found evidence of benefit in those
having various forms of ACI, ranging from ACI-P to MACI. Early OA was defined in different ways in the
nine case series, and de Windt et al.166 described the studies as being of ‘generally low methodological
quality’. Nevertheless, they reported that outcomes to 9 years were good, and suggested that ACI in early
OA might be used to postpone TKR, but recommended a RCT.
There may, therefore, be a place for ACI in early OA, even if only to postpone TKR until patients are older,
and some of the ICERs reported earlier are within the acceptable range. However, the evidence base is
much weaker than for purely chondral lesions.
However, if ACI were to be restricted based on radiological signs of OA, there are some problems to be
considered. One of the difficulties in comparing the results of studies involving patients with OA is the
definition of the disease and the assessment of its severity. The European League Against Rheumatism
(EULAR) definition of OA emphasises the importance of pain and functional loss alongside physical
changes in the joint, but this definition is hard to objectively apply in research terms, and symptoms are
significantly influenced by environmental and psychosocial factors.167–170
There is a variable relationship between symptoms and structural changes in OA and it is recognised
that plain radiographs, MRI and arthroscopic findings do not universally correlate with pain or
physical function.171–173
The most common method for assessing structural changes in knee OA is plain radiography, graded using
the Kellgren–Lawrence classification.174 Care has to be taken in interpreting plain radiographic findings, as
Kellgren–Lawrence grades have moderate, but not strong, correlations with other measures of structural
change, such as MRI measures of OA or operative findings.175–180
The Kellgren–Lawrence classification is a widely accepted tool in OA research and good reliability has been
quoted in series in which the assessors were experienced in its use.173,178 However, it is based on a
subjective assessment of structural changes and different authors often apply different criteria to define
the boundaries between the grades, making comparisons across studies difficult.181
The boundary between Kellgren–Lawrence grades 2 and 3 is often difficult to define, as the interpretation
of ‘possible’ and ‘definite’ joint space narrowing can be very subjective.182 However, this is not so
important when considering suitability for ACI, as the Nawaz study80 showed that there was little
difference in outcomes. The distinction between lower Kellgren–Lawrence grades is also difficult and is
dependent on the interpretation of small osteophytes, which can variably give a score of 0, 1 or 2,
depending on the exact definitions used and the radiological technique.181
The diagnosis of OA is often made based on the combination of symptoms and a Kellgren–Lawrence
grade of ‘2 or more’, despite evidence that Kellgren–Lawrence grade of 1 (‘doubtful osteophytes’) has a
high chance of progressing to ‘2 or more’ with time.183,184
The studies in this review have varied in terms of their reporting of the radiological assessment, and
definitions were not always clearly defined in the reports, which may explain some of the variance in
findings between studies. For example, relatively little detail is given in the Minas paper185 on the
radiological assessment and the Kellgren–Lawrence paper is not referenced, whereas the radiological
grading is reported in detail by Nawaz et al.80 A relatively high proportion of cases with Kellgren–Lawrence
grade 2 or above were reported by Knutsen,67 which may explain the poor results for ACI in this series in
comparison to others.
Defining OA is problematic. A big cartilage lesion with pain and some joint space loss could variably be
defined as no, mild or moderate OA.
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Age threshold for knee replacement
In our modelling we have assumed that TKR would not be performed for people with OA until age 55 years
or later. We used that age restriction because knee replacements do not last for ever, and replacing a
replacement is more difficult, more expensive and less successful than the first replacement, and may not
last as long.
With increasing longevity, it may no longer be the case that a knee replacement in someone over 60 years
is likely to last them all of their days. Perhaps especially in women who live longer. However, a TKR in a
younger person with OA is very likely to need replacement. (This may not apply to people having knee
replacement because of inflammatory arthritis because their activity, and hence the stresses put upon the
prosthesis, will often be limited by problems with other joints.)
In the National Joint Registry 2015 report,157 figure 3.16 shows that the probability of a first revision after
TKR is higher in people who have replacements at younger ages. Those who have TKR under the age of
55 years have a 12% probability of it being replaced by 11 years, which is more than double the risk after
first TKR at older ages.
It is therefore a major decision to carry out TKR in people with OA under the age of 60 years, and very few
are done. It should be noted that TKR is rarely an absolute necessity. The aim is to reduce pain, and that
can be done in other ways, such as with analgesics or reducing activity.
It should also be borne in mind that TKR does not fully restore knee function. The TKR does not move like
a normal knee, and younger, active patients may find function on stairs and slopes disappointing.
Autologous chondrocyte implantation can restore normal function in younger patients. In patients who
are older but too young for TKR, but who do not have generalised wear and tear, ACI may help bridge
the gap to TKR, even if the results are not as good as in younger patients with only an isolated
chondral defect.
Body mass index
Jaiswal et al.186 from Stanmore reported a lack of benefit from ACI or MACI in patients with BMI score of
over 30 kg/m2, though this was based on small numbers in the high BMI group. Their data came from the
trial of MACI versus ACI. In 53 patients with BMI scores of under 25 kg/m2, 82% of patients had a good or
excellent result. In the overweight group (BMI 25–30 kg/m2) 49% (22 of 45) had a good or excellent result,
whereas only one of 18 patients with BMI over 30 kg/m2 had a good result.
Mithöfer et al.82 also reported worse outcomes in those with BMI score of over 30 kg/m2. Behery et al.83
reported no correlation but had data on only eight patients.
Data on the effect of high BMI on outcomes of cartilage repair is sparse. Jaiswal et al.186 reported that their
literature review found few previous studies. In most studies, mean BMI scores were well below 30 kg/m2,
perhaps because cartilage injuries occur largely in people active in sports. Jaiswal used the term ‘obese’ but
some sportsmen with high BMI scores may be lean but very muscular.
Similar findings have been reported for MF by Asik et al.,106 with better results in those with BMI score of
less than 25 kg/m2.
Research needs
Recommendations for research made in the systematic reviews.
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Some of the recommendations made in the reviews are now out of date and are not included here. Other
recommendations include:
l High-quality clinical trials are needed, fulfilling the following criteria:
¢ Multicentre, adequate sample size with long-term follow-up (preferably 5–10 years).
¢ Patients in trials should be stratified based on BMI, defect location, post-debridement defect size
and previous cartilage repair.
¢ Transparent patient enrolment with clearly stated inclusion and exclusion criteria.
¢ Proper independently performed randomisation techniques.
¢ No concurrent surgical interventions (anterior cruciate ligament reconstruction, realignment
osteotomy, meniscal surgery, etc.), consistent surgical technique.
¢ Use of validated, responsive and reliable patient-orientated outcome measures; clear reporting of
data with a statement of both clinical relevance and significance; and use of independent assessors.
¢ Further information is needed on the relationship between clinical, histological and radiological
outcomes, and the most appropriate measure of functional outcomes that relates to a generic
measure of health-related QoL.
l Cohort studies of long-term effects (≥ 10 years) are needed.
l Research is needed to explain lack of return to sports by some patients.
l Prospective long-term studies are needed to determine if articular cartilage repair in athletes can
influence the high incidence of OA associated with high-impact sports.
l More studies should be done on the maturation process of finally formed repair tissue and on
appropriate rehabilitation programmes for the different techniques.
Fourth-generation autologous chondrocyte implantation
There are several lines of investigation.
Mesenchymal cells
It has been suggested that mesenchymal stem cells from bone marrow can be used as an alternative
to ACI and that their reproduction is less affected by age. (For reviews see Nakamura et al.187 and
Perera et al.188)
A review of scaffold-based repair by Filardo et al.189 mentions another option, using mesenchymal stem
cells and a degradable scaffold, covered with fibrin.190
The ASCOT trial191 will compare repairs with chondrocytes and bone marrow mesenchymal stem cells, and
with the combination of both.
INSTRUCT
This appears to be a one-stage procedure mixing chondrocytes and bone marrow cells, without cell
culture. Cells from a biopsy of cartilage are mixed with bone marrow cells then seeded into a porous
scaffold, which is then implanted into the defect. Evidence comes from a poster by Hendriks et al.192 So
far, only 37 patients had reached 12-month follow-up, of whom 72% had hyaline cartilage on biopsy.
Cartilage implantation
The development here is that instead of implanting cultured chondrocytes into the defect, the autologous
chondrocytes are used to grow new cartilage in the laboratory, which is then implanted.193
Gel-type autologous chondrocyte implantation
Gel-type ACI appears to be a new variant without using membrane or periosteum, but using cells held in
place with fibrin. Choi et al.194 report a case series with 98 patients. There do not appear to have been
RCTs against standard ACI.
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Single-stage procedures
Cole et al.89 report a RCT with 29 patients, comparing MF (nine patients) with a cartilage autograft
implantation system (CAIS) in which chondrocytes are not sent for culture. Instead, hyaline cartilage is
harvested in similar amount as for traditional ACI, but then minced and attached to a biodegradable
scaffold with fibrin glue, in a single operation. Results at 24 months showed some advantages for the
CAIS group, with IKDC score 83 for CAIS and 60 for MF, and KOOS also better.
Other cells
Mizuno et al.195 report that ear cartilage cells can be used, at least in dogs.
New forms of microfracture
Filardo et al.189 report five case series of autologous matrix-induced chondrogenesis, which combines MF
with a collagen matrix to stabilise the blood clot. Long-term results are not yet available.
Siclari et al.196 used a combination of MF and a cell-free hyaluronan cap that had been immersed in
autologous plasma in 52 patients. At 2 years, KOOS results showed good improvement. Biopsies were
taken from four patients and showed hyaline or hyaline-like repair tissue.
Metal or plastic patches for knees
These were excluded by NICE as comparators, but sound sufficiently promising to be used in trials. They
may not be suitable for younger patients but might be an option for the 40–60 years subgroup, perhaps in
order to postpone knee replacement.
The HemiCAP® (Arthrosurface, Franklin, MA, USA)197 is used for resurfacing localised damage in femoral
condyles, and is described by the manufacturer as a ‘contoured articular resurfacing implant’, and as
‘bridging the gap between biological therapies and TKR’. The evidence base seems to consist of a few case
series with no RCTs:
l Patello Femoral HemiCAP®198
l UniCAP®199
l HemiCAP® Classic.200
The BioPoly™ RS Knee System201 (Schwartz Biomedical, Fort Wayne, IN, USA) is CE marked for sale in the
European Union. It is a hyaluronic and polythene implant for repairing the joint surface.
The Episealer (Episurf AB, Stockholm, Sweden)202 comes in two forms, for femoral condyle and trochlea,
and is described as a small metallic button with implants tailored for each patient.
These products are said to allow rapid return to activities, unlike the long rehabilitation that is required
after ACI. A recent study203 reported that after ACI or MF followed by a long period of rehabilitation, 33%
and 26% of sportspeople did not regain full quadriceps power after MF and ACI, respectively. Another
study204 reported good results after ACI-P, with 26 of 33 patients having good or excellent results at
10 years, but also noted that patients did not return to full pre-injury activity levels. This may be partly due
to the long lay-off during the rehabilitation process. However, those who return to previous activity too
early have poorer outcomes than those who wait at least 12 months.205
Conclusion
The evidence base for ACI has improved since the last appraisal by NICE. In most analyses, the ICERs for
ACI compared with MF appear to be within a range usually considered acceptable.
The evidence base for ACI is much better than for MF.
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Appendix 1 Search strategies for systematic
review and primary studies
Searches for systematic reviews and assessment reports
Cochrane Database of Systematic Reviews: Issue 6 of 12, June 2014
(autologous chondrocyte* near/3 (implant* or transplant*))
Ovid MEDLINE® 1946 to 17 June 2014
1. exp Chondrocytes/tr [Transplantation]
2. exp Cartilage, Articular/tr [Transplantation]
3. exp Transplantation, Autologous/
4. (MACI or MACT or chondrocelect or ACI).tw.
5. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
6. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
7. (cartilage* adj2 (transplant* or implant*)).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (systematic review or meta-analysis).tw.
10. meta-analysis.pt.
11. “cochrane database of systematic reviews”.jn.
12. 9 or 10 or 11
13. 8 and 12
14. limit 13 to yr=“2004 -Current”
15. knee*.af.
16. 14 and 15
EMBASE 1980 to 17 June 2014
1. exp *chondrocyte implantation/
2. (MACI or MACT or chondrocelect or ACI).tw.
3. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
4. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
5. (cartilage* adj2 (transplant* or implant*)).tw.
6. 1 or 2 or 3 or 4 or 5
7. knee*.af.
8. 6 and 7
9. limit 8 to yr=“2004 -Current”
10. systematic review or meta-analysis).tw.
11. 9 and 10
Health Technology Assessment and other assessment reports
Searched the website of the CRD HTA database at www.crd.york.ac.uk/CRDWeb/HomePage.asp and EMA,
the US FDA.
Searches for primary studies for clinical effectiveness
Cochrane Central Register of Controlled Trials, Issue 6 of 12, June 2014
(autologous chondrocyte* near/3 (implant* or transplant*))
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Ovid MEDLINE 1946 to 17 June 2014
1. exp Chondrocytes/tr [Transplantation]
2. exp Cartilage, Articular/tr [Transplantation]
3. exp Transplantation, Autologous/
4. MACI or MACT or chondrocelect or ACI).tw.
5. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
6. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
7. (cartilage* adj2 (transplant* or implant*)).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. Knee/ or knee*.mp.
10. 8 and 9
11. limit 10 to yr=“2010 -Current”
12. Animals/
13. Humans/
14. 12 not 13
15. 11 not 14
EMBASE 1947 to 17 June 2014
1. exp *chondrocyte implantation/
2. MACI or MACT or chondrocelect or ACI).tw.
3. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
4. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
5. (cartilage* adj2 (transplant* or implant*)).tw.
6. 1 or 2 or 3 or 4 or 5
7. exp knee/
8. knee*.tw.
9. 7 or 8
10. 6 and 9
11. limit 10 to yr=“2010-Current”
12. (rat or rats or pig or pigs or porcine or mice or murine or mouse or sheep or rabbit* or canine
or dog*).ti.
13. 11 not 12
Web of Science Core Collection 2010 to June 2014
TITLE: ((“autologous chondrocyte” or “autologous cartilage”) ... More TITLE: ((“autologous chondrocyte”
or “autologous cartilage”) and (implant* or transplant*)) AND TOPIC: (knee*)
TITLE: (MACI or MACT or ACI or condrocelect or “characteri* chondrocyte*”) AND TOPIC: (knee*)
Additional searches for other literature
Societies with meetings abstracts available online
l ISAKOS International Society of Arthroscopy Knee Surgery & Orthopaedic Sports Medicine Biennial
Congress 2013: www.isakos.com/
l AAOS American Academy of Orthopaedic Surgeons Annual Meeting: www.aaos.org/Annual
l ORS Orthopaedic Research Society from 1999 to 2014: www.ors.org/abstract-search/
l AOSSM American Orthopaedic Society for Sports Medicine 2013 Annual Meeting: www.sportsmed.org/
l BASK British Association for Surgery of the Knee 2013 abstracts: http://professional.baskonline.com/
content/BASKCurrent.aspx
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Searches for guidelines
l NHS Evidence: www.evidence.nhs.uk/
l British Orthopaedic Association: www.boa.ac.uk/
l BASK: www.baskonline.com/
Ongoing or recently completed studies searched on 3 October 2014
1. ClinicalTrials.gov: http://clinicaltrials.gov/
2. World Health Organization (WHO) Clinical Trials Registry Platform Search Portal: http://apps.who.int/
trialsearch/Default.aspx
3. Current Controlled Trials: www.controlled-trials.com/
4. UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk/default.aspx
5. EU Clinical Trials Register website: www.clinicaltrialsregister.eu/
6. UK Clinical Research Network Study Portfolio: http://public.ukcrn.org.uk/search/
7. European Clinical Trials Database (EudraCT): https://eudract.ema.europa.eu/
Additional searches
In addition, the inclusion lists of recent systematic reviews were checked.
Auto-alerts in MEDLINE and EMBASE were run for the duration of the review to ensure that newly
published studies were identified.
Search strategy for long-term studies
The search strategy below was run in Ovid MEDLINE 1846 to May week 2 2005 and Ovid MEDLINE®
In-Process & Other Non-Indexed Citations 15 May.
1. *Cartilage Diseases/su [Surgery]
2. *Arthroplasty, Subchondral/
3. *Cartilage, Articular/su [Surgery]
4. Chondrocytes/tr [Transplantation]
5. microfracture.tw.
6. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
7. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
8. (cartilage* adj2 (transplant* or implant*)).tw.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. knee.tw.
11. *Knee Injuries/su [Surgery]
12. 10 or 11
13. 9 and 12
14. limit 13 to yr=“1997 -Current”
15. limit 14 to english language
The strategy below was run in Ovid EMBASE 1974 to 15 May 2015:
1. exp microfracture/
2. exp chondrocyte implantation/
3. *Cartilage Diseases/su [Surgery]
4. *Arthroplasty, Subchondral/
5. *Cartilage, Articular/su [Surgery]
6. microfracture.tw.
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7. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
8. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
9. (cartilage* adj2 (transplant* or implant*)).tw.
10. knee.tw.
11. *Knee Injuries/su [Surgery]
12. 10 or 11
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
14. 12 and 13
15. limit 14 to (english language and yr=“1997 -Current”)
Records identified through
database searching
(n = 2907)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1833)
Records screened
(n = 1833)
Full-text articles
assessed for eligibility
(n = 69)
Records excluded
(n = 1764)
Full-text articles
excluded, with reasons
(n = 43)
Included in final analysis 
(n = 21 studies in 26 articles)
FIGURE 47 Flow diagram for long-term studies.
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Appendix 2 Flow diagram systematic review
Records identified 
(total before deduplication)
from database searching
(n = 109)
Records screened
(after duplicates removed)
(n = 73)
Records assessed for eligibility
on the basis of full text
(n = 37)
Records excluded on
basis of title and abstract
(n = 36)
Full-text articles excluded 
because they did not
provide comparative
effectiveness data for
ACI vs. another comparator
(n = 25)
Full-text articles included in 
qualitative synthesis
(n = 12)
FIGURE 48 A PRISMA study flow diagram for searches for systematic reviews.
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Appendix 3 Quality assessment of reviews
Methodology and quality
Most reviews were rated as being of at least medium quality, with three reviews being rated as of low
quality (Goyal 201347 and Goyal 2013,48 Naveen 201249), six reviews rated as medium quality (Bekkers
2009,50 Kon 2009,51 Magnussen 2008,52 Mithöfer 2009,53 Nakamura 2009,54 Negrin 201355) and three
reviews rated as high quality (Harris 2010,44 Vasiliadis 2010,45 Vavken 201056).
Ten of the 12 studies had an adequate description of inclusion criteria. Goyal 201347 and Goyal 201348
had no adequate description of participants and outcome measures. Only Harris et al. 201044 was rated as
having a fully adequate search strategy. Search limitations included ‘only PubMed/MEDLINE used’ (Goyal
201347 and Goyal 2013,48 Nakamura 200954); ‘English studies only included’ (Goyal 201347 and Goyal
2013,48 Kon 2009,51 Magnussen 2008,52 Mithöfer 2009,53 Nakamura 200954); ‘limited search terms (limited
description or only few terms used)’ (Goyal 201347 and Goyal 2013,48 Nakamura 2009,54 Naveen 2012,49
Negrin 2013,55 Vavken 201056); and ‘no additional searches mentioned’ (Bekkers 2009,50 Goyal 201347 and
Goyal 2013,48 Nakamura 2009,54 Naveen 2012,49 Negrin 201355).
Study selection was adequately described by only four reviews (Harris 2010,44 Nakamura 2009,54 Negrin
2013,55 Vasiliadis 201045); where described, selection was done by independent reviewers. Study flow
was adequately shown (or described) by seven reviews (Goyal 201347 and Goyal 2013,48 Harris 2010,44
Magnussen 2008,52 Naveen 2012,49 Negrin 2013,55 Vavken 201056). Quality assessment was adequately
described by eight reviews (Bekkers 2009,50 Harris 2010,44 Kon 2009,51 Mithöfer 2009,53 Nakamura 2009,54
Negrin 2013,55 Vasiliadis 2010,45 Vavken 201056); quality assessment tools included the Cochrane risk of
bias tool (Bekkers 2009,50 Negrin 2013,55 Vasiliadis 201045), the Coleman methodology score (modified in
some cases) (Bekkers 2009,50 Harris 2010,44 Kon 2009,51 Magnussen 2008,52 Mithöfer 200953), the Delphi
list (Harris 201044), the rating system of the Journal of Bone and Joint Surgery plus Cochrane criteria
(Nakamura 200954), a quality scale for observational studies by Deeks (Negrin 201355) and an unnamed list
of quality items (Vavken 201056). One review used quality as a basis for further selection (Bekkers 200950).
Items for data extraction were listed by eight reviews (Bekkers 2009,50 Harris 2010,44 Kon 2009,51
Magnussen 2008,52 Mithöfer 2009,53 Naveen 2012,49 Vasiliadis 2010,45 Vavken 201056) and data extraction
was done in duplicate by independent reviewers in five reviews (Kon 2009,51 Nakamura 2009,54 Negrin
2013,55 Vasiliadis 2010,45 Vavken 201056). Most reviews did not include a meta-analysis and data were
summarised in text and tables. A meta-analysis was included in the review by Negrin 201355 and the
Cochrane review by Vasiliadis et al. 2010.45 Some reviews looked for patient characteristics that were
related to treatment outcome.
All of the studies described the characteristics of included studies at least to some extent – but a number
of reviews did not give details of the quality of individual studies (Goyal 201347 and Goyal 2013,48 Kon
2009,51 Negrin 201355). All reviews showed the results of individual studies – but this was sometimes
limited and numerical data were not always reported.
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Appendix 4 Studies included in reviews
Table 52 shows publications belonging together and referring to the same study population.
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Appendix 5 Characteristics of systematic reviews
TABLE 53 Characteristics and quality of systematic reviews
Review
Inclusion criteria and
methodology Included studies Quality
Bekkers 200950
Focus: to identify
parameters for valid
treatment selection in
the repair of articular
cartilage lesions of the
knee
Funding: not reported,
but stated that the
authors have no
conflicts of interest
INCLUSION CRITERIA
Study design: prospective
randomised and quasi-
randomised trials
Participants: focal cartilage
lesions of the knee
Intervention: comparison of
at least two of ACI, MF or
osteochondral autologous
transplantation
Outcomes: not specified
METHODOLOGY
Search strategy:
Databases: PubMed, EMBASE,
The Cochrane Library,
CENTRAL
Date of search: 25 August
2009; keywords indicated
Limitations: PubMed limited by
title and abstract, articles in
English, German, French or
Dutch
Additional searches: none
Study selection: based on
titles and abstracts, but not
stated how many reviewers
were involved
Quality assessment: done by
two independent reviewers,
based on Cochrane risk of bias
tool and Coleman methodology
score; quality used as a basis for
further selection
Data extraction: items
extracted listed
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: looked for
indicators of treatment
selection/patient profile
No. of included trials: Four
(three studies including ACI;
only these are considered here)
No. of participants: 298
TRIALS
Design: RCTs
Follow-up: 19 months to
5 years
Quality: only level of evidence
1b included; one of three studies
had some selection, detection
and reporting bias; Coleman
score 74–94
Origin: NR
Funding: NR
PARTICIPANTS
Age: 30.9–33.9 years
Sex: 57–80% men
Defect size: mean 2.4–5.1 cm2
Duration of symptoms: NR
Other:
Femoral condyles, n= 2
n= 1; 53% medial femur,
25% patella, 18% lateral femur,
3% trochlea, 1% lateral tibia
INTERVENTIONS
l ACI, n= 2
l CCI, n= 1
l Mosaicplasty, n = 1
l MF, n= 2
OUTCOMES
Clinical outcomes (modified
Cincinnati, KOOS, Lysholm,
VAS, Tegner), SF-36, ICRS
macroscopic grading, histology
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
partly, no additional
searches
Study selection
described/adequate: no
Data extraction
described/adequate: yes
Study quality
assessment described/
adequate: yes
Study flow shown:
partly, in the text
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: yes
OVERALL QUALITY:
medium
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Goyal 201347
Focus: to examine the
level I and level II
evidence for newer
generations of ACI vs.
first-generation ACI,
and to establish if the
newer generations
have overcome the
limitations of first-
generation ACI
Funding: not reported,
but stated that the
authors have no
conflicts of interest
INCLUSION CRITERIA
Study design: phase I or II
RCTs, systematic reviews/
meta-analyses, prospective
cohort studies
Participants: no criteria
specified
Intervention: comparison of
newer methods of ACI
(suspended cultured
chondrocytes with covering of
collagen membrane; procedures
delivering ACI using cell carriers
or cell-seeded scaffolds)
Outcomes: no criteria specified
METHODOLOGY
Search strategy:
Databases: PubMed
Date of search: November
2012; keywords listed
(partially), including restriction
by study type
Limitations: past 10 years,
English language
Additional searches: not
specified
Study selection: methods not
stated; flow chart shown
Quality assessment: no
quality assessment reported
Data extraction: methods not
stated
Meta-analysis: no
Data analysis: text
Subgroup/SAs: none;
comparisons described
individually
No. of included trials: Seven
(four studies comparing
interventions; one study
comparing younger and older
patients; two studies of
rehabilitation); only first four
studies considered here
No. of participants:
comparative intervention studies,
180 [only reported for 3 of 4
studies, range 21–91 per study
(n = 3)]
TRIALS
Design: comparative
intervention studies: 3 RCTs,
1 cost-effectiveness study
Follow-up: 1–2 years
Quality: not reported; two trials
referred to as level I evidence,
and two trials as level II evidence
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean age 29.3–33.7 years
(reported by three RCTs)
Defect size: mean 4.1–6 cm2
(reported by three RCTs)
No further details reported
INTERVENTIONS
l Periosteum-based ACI vs.
collagen-based ACI, n = 2
l Periosteum-based ACI vs.
MACI, n= 1
l Collagen-based ACI vs.
MACI, n= 1
OUTCOMES
Clinical and activity scores, cost-
effectiveness, QoL, MRI results
Inclusion criteria
described/adequate:
partially described;
inadequate
Literature search
described/adequate:
partially described;
inadequate
Study selection
described/adequate:
not described; inadequate
Data extraction
described/adequate:
not described; inadequate
Study quality
assessment described/
adequate: not described;
inadequate
Study flow shown: yes
Study characteristics of
individual studies
described: yes, but
limited
Quality of individual
studies given: no
Results of individual
studies shown: yes, but
limited
Statistical analysis
appropriate: n/a
OVERALL QUALITY: low
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Goyal 201348
Focus: to examine the
level I and level II
evidence for MF
techniques for cartilage
repair
Funding: not reported,
but stated that the
authors have no
conflicts of interest
INCLUSION CRITERIA
Study design: phase I or II
RCTs, systematic reviews/meta-
analyses, prospective cohort
studies
Participants: no criteria
specified
Intervention: MF/marrow
stimulation techniques
Outcomes: no criteria specified
METHODOLOGY
Search strategy:
Databases: PubMed
Date of search: November
2012; keywords listed
(partially), including restriction
by study type
Limitations: past 10 years,
English language
Additional searches: not
specified
Study selection: methods not
stated; flow chart shown
Quality assessment: no
quality assessment reported
Data extraction: methods not
stated
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: none;
comparisons described
individually
No. of included trials: 15 (11
studies comparing with ACI, only
these are considered here –
counts separate papers as
separate studies, probably just
six separate study populations)
No. of participants: Six
separate ACI study populations:
449 (range–118 per study)
TRIALS
Design: study types not clearly
reported (n= 4 RCTs, n= 2
comparative cohort)
Follow-up: 1.5–7.5 years
Quality: not reported; 5/11
studies referred to as level I
evidence and 5/11 as level II
evidence
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean age 26.5–37.5 years
(one study reported only on
range 18–45 years)
Sex: unclear, reported only for
MF group, more men than
women
Defect size: mean 1.9–2.8 cm2
(two studies reported only
ranges 2–10 cm2 and 4–10 cm2)
Duration of symptoms: 1.6–3
years (reported by three studies)
INTERVENTIONS
ACI (n = 6)
l Characterised
chondrocytes, n= 2
l MACI, n= 1
l Scaffold-based ACI, n= 2
l Periosteum-based ACI, n= 1
All vs. MF
OUTCOMES
Clinical and activity scores,
histology
Inclusion criteria
described/adequate:
partially described;
inadequate
Literature search
described/adequate:
partially described;
inadequate
Study selection
described/adequate:
not described; inadequate
Data extraction
described/adequate:
not described; inadequate
Study quality
assessment described/
adequate: not described;
inadequate
Study flow shown: yes
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: no
Results of individual
studies shown: yes
Statistical analysis
appropriate: n/a
OVERALL QUALITY: low
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Harris 201044
Focus: effect of ACI vs.
other cartilage
procedures on clinical
outcomes, MRI,
arthroscopic
assessment and
durability; effect of
different generations
of ACI and of patient-
and defect-specific
parameters
Funding: no specific
funding
INCLUSION CRITERIA
Study design: level I and II
evidence (RCTs with > 80% FU;
RCTs with < 80% FU,
prospective cohort studies);
minimum duration of FU
12 months
Participants: participants with
Outerbridge/ICRS grade 3 or 4
focal cartilage defects of the
knee
Intervention: (1) comparison
of any generation ACI with any
cartilage repair or restoration
technique; (2) comparison of
any generation ACI with a
different generation of ACI;
(3) evaluation of both
arthroscopic and open
arthrotomy ACI
Outcomes: validated clinical
outcome measures
METHODOLOGY
Search strategy:
Databases: MEDLINE,
EMBASE, CINAHL, PubMed,
SPORTDiscus, The Cochrane
Library Systematic Reviews
Date of search: latest search
February 2010; keywords listed
Limitations: no relevant
limitations
Additional searches:
bibliographies of reviewed
papers
Study selection: independent
search and selection by four
reviewers, agreement by
discussion or in case of persistent
disagreement by the senior
author
Quality assessment: yes,
Delphi list and modification of
the Coleman methodology
score
No. of included trials: 13
(but really just 10 distinct trial
populations)
No. of participants: 917
(700 distinct participants)
TRIALS
Design:
Level I, n= 6
Level II evidence, n= 7 (n= 7
RCTs, n= 3 CCT/comparative
cohort)
Follow-up: 1–5 years
Quality: mean Coleman
methodology score 54/100
(range 36–64); (n= 7 fair, n= 6
poor)
Origin: NR
Funding: four studies declared a
financial conflict of interest
PARTICIPANTS
Age: mean age 28.7–34.2 years
Sex: NR
Defect size: mean 1.9–6.2 cm2
Duration of symptoms:
1.75–8.6 years
Other: full thickness (100%)
and isolated single defects
(80–100%); median 88.5%
(0–100%) had had previous
surgery (reported by 10 studies)
INTERVENTIONS
l ACI (497 distinct), n= 604
l MF (161 distinct), n= 271
l Osteochondral autograft,
n= 42
l ACI:
l Open ACI second-
generation (MACI), n= 4
l Open periosteum cover CCI
(ChondroCelect), n= 2
l Open periosteum cover
ACI, n = 7
l Arthroscopic ACI second
generation (Hyalograft C),
n= 2
l n= 2 open collagen
membrane ACI
Inclusion criteria
described/adequate: yes
Literature search
described/adequate: yes
Study selection
described/adequate: yes
Data extraction
described/adequate:
partly; inadequate
Study quality
assessment described/
adequate: yes
Study flow shown: yes
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: yes
OVERALL QUALITY:
high
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Data extraction: details of
extracted outcomes reported,
but no details of methodology
Meta-analysis: no
Data analysis: tables and text;
effect sizes calculated
Subgroup/SAs: data
presented by comparator
OUTCOMES
Clinical outcomes (Lysholm,
Tegner, KOOS, ICRS, IKDC,
modified Cincinnati), SF-36,
histology/histomorphology
Kon 200951
Focus: to summarise all
studies related to the
clinical application of
MACI
Funding: not reported;
stated that the authors
have no potential
conflict of interest
INCLUSION CRITERIA
Study design: any
Participants: articular cartilage
repair of the knee
Intervention: second-
generation ACI, MACI
Outcomes: ‘clinical
information’
METHODOLOGY
Search strategy:
Databases: MEDLINE,
MEDLINE preprints, EMBASE,
CINAHL, Life Science Citations,
British National Library of
Health, CENTRAL
Date of search: 1 January 1995
to 1 July 2008; keywords
indicated
Limitations: English language
Additional searches:
bibliographies of relevant
studies and reviews
Study selection: studies
selected by three independent
reviewers
Quality assessment: modified
Coleman methodology score
Data extraction: data
extracted by three independent
reviewers; items extracted listed
No. of included trials: 18
No. of participants: 731
(range 8–141)
TRIALS
Design:
l n= 2 RCTs
l n= 3 prospective
comparative (but 1 of these
is a RCT)
l n= 11 prospective cohort
studies or case series
l n= 2 retrospective case
series
Follow-up: range 6.5 months to
5 years, median 2 years
Quality: mean modified
Coleman methodological score
(of 100) 53.1 (SD 1.5 (range
33–82)
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean age
26.4–37.6 years
Sex: NR
Defect size: mean
2.4–6.1 cm2
Duration of symptoms: NR
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes, but English only
Study selection
described/adequate: yes
Data extraction
described/adequate: yes
Study quality
assessment described/
adequate: yes
Study flow shown: no
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: no
Results of individual
studies shown:
individual results plotted,
but studies not specified
Statistical analysis
appropriate: unclear,
results of comparative
studies not reported
OVERALL QUALITY:
medium
continued
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: none
Other:
l Traumatic lesions,
n = 334 cases
l Degenerative, n = 236
l OCD, n = 105
l Other, n= 56; 58% on
medial femoral condyle,
17% lateral femoral condyle,
12% patella, 7% trochlea,
4% tibial plateau, 2%
multiple areas; 63% had
had previous surgery, 41%
had additional surgery
INTERVENTIONS
Only reported for ACI:
l Hyalograft C (Anika
Therapeutics, MA,
USA), n= 9a
l BioSeed-C (BioTissue
Technologies, Freiburg,
Germany), n= 1
l Atelocollagen (Reprocell
Europe, Glasgow, UK), n= 1
l BioCart II (Prochon Biotech,
Woburn, MA, USA), n= 1
l MACI, n= 4
l Cartipatch (TBF Tissue
Engineering, Bron,
France), n= 1
l Chondrograft (Primecell,
Prague, Czech Republic),
n= 1
OUTCOMES
Clinical outcomes (IKDC
subjective, IKDC objective,
Lysholm, Cincinnati; Tegner,
ICRS subjective and functional,
Stanmore, Meyers, VAS scales,
KOOS), SF-36, EQ-5D
Magnussen 200852
Focus: to determine
whether ACI or OAT
results in better clinical
outcomes compared
with each other or with
traditional abrasive
treatment of isolated
articular cartilage
defects, and assess
effects of lesion size on
outcome
INCLUSION CRITERIA
Study design: level I and
level II studies – prospective
comparative studies; minimum
30 participants, minimum FU
1 year
Participants: articular cartilage
defects of the knee, full-
thickness lesions (Outerbridge
grade III or IV)
No. of included trials: 6
(5 involving ACI, 1 trial of OAT
vs. MF not considered here)
No. of participants: 361
(studies involving ACI, range
40–100)
TRIALS
Design:
l RCTs, n= 4
l CCT, n = 1
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes, but English only
Study selection
described/adequate: no
Data extraction
described/adequate:
partially
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Funding: authors have
received funding from
Vanderbilt Sports
Medicine research fund,
the National Institute
of Arthritis and
Musculoskeletal Skin
Diseases, and the Pfizer
Scholars Award in
Epidemiology
Intervention: operative
treatment with ACI or OAT
compared with another
method
Outcomes: any clinical
outcome measures
METHODOLOGY
Search strategy:
Databases: MEDLINE,
CENTRAL, EMBASE, CINAHL
Date of search: 1 January 1966
to 1 January 2007; keywords
listed, restricted by study type
Limitations: English language
Additional searches:
bibliographies of included trials
Study selection: methods not
stated
Quality assessment: modified
Coleman methodology score
Data extraction: predesigned
form used and data extracted
listed; no further methodology
described
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: none
Follow-up: 1–2 years
Quality: quality scores for each
study not detailed; all included
studies were subject to some
degree of bias, including
selection bias, transfer bias,
detection bias
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean 30.8–33.5 years
Sex: NR
Defect size: mean 3.72–6.1 cm2
Duration of symptoms:
36–102.7 months (reported by
three trials)
Other: 43–100% traumatic
lesions; 45–89% medial
femoral condyle, 10–18% lateral
femoral condyle, 0–32% patella,
0–13% trochlea, 0–8% tibial
plateau; one trial reported
co-interventions; time to full
weightbearing 1 day to
12 weeks
INTERVENTIONS
Every trial examined a
different comparison:
l C-ACI vs. MACI
l P-ACI vs. MF
l MACI vs. abrasion
l P-ACI or C-ACI vs.
open OAT
l P-ACI vs. open OAT
OUTCOMES
Clinical scoring systems (ICRS,
VAS, Stanmore, Lysholm, IKDC,
Tegner, Meyers, modified
Cincinnati), arthroscopy,
histology
Study quality
assessment described/
adequate: partially
Study flow shown: yes,
described in the text
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: not
overall, but quality criteria
described in the text
Results of individual
studies shown: yes
Statistical analysis
appropriate: n/a
OVERALL QUALITY:
medium
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Mithöfer 200953
Focus: to assess the
effects of articular
cartilage repair on
athletic participation
Funding: NR
INCLUSION CRITERIA
Study design: RCTs,
prospective and retrospective
studies with or without a
control group with FU data
of ≥ 2 years; studies with
macroscopic or histological
data from second-look
arthroscopy > 12 months after
surgery; FU > 80%
Participants: athletes with
articular cartilage lesions (ICRS
grade 3 or 4 chondral or
osteochondral defects of the
knee (femoral condyle, tibia
and patellofemoral); ≥ 20
participants
Intervention: articular
cartilage repair
Outcomes: sports activity-
related functional outcome
scores, ability to return to
sports after surgery, ability to
continue participation in
athletic activity over time
METHODOLOGY
Search strategy:
Databases: MEDLINE,
MEDLINE preprints, EMBASE,
CINAHL, Life Science Citations,
British National Library of
Health (including CENTRAL)
Date of search: 1966 to 31 May
2009; keywords indicated
Limitations: English language
Additional searches:
bibliographies of relevant
studies and reviews; meeting
abstracts
Study selection: NR
Quality assessment: modified
Coleman methodology scores
Data extraction: items
extracted listed, no details of
methodology
Meta-analysis: no
No. of included trials: 20
(seven including ACI, with six
distinct populations – only these
are considered here)
No. of participants: 535
distinct participants
TRIALS
Design:
l RCT, n = 1
l Comparative cohort, n = 1
l Cohort without comparison
group, n= 2
l Case series, n= 2
Follow-up: 3–5 years
Quality: Coleman methodology
score 65–100
l Level 1 evidence, n= 1
l Level 2 evidence, n= 3
l Level 4 evidence, n= 2
Origin: NR
Funding: NR
PARTICIPANTS
Age: overall 29 (SE 6) years; ACI
28 (SE 4) years
Sex: NR
Defect size: overall, 3.6 (SE
0.4) cm2; ACI, 5.1 (SE 0.8) cm2
Duration of symptoms: overall
21 (SE 3 months; ACI 23 (SE 3)
months
Other: ACI: lesion type: single
only 57%, single and multiple
43%; traumatic only 86%,
traumatic and degenerative 14;
lesion location: femorotibial only
29%, femorotibial and
patellofemoral 71%
INTERVENTIONS
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes, but English only
Study selection
described/adequate: no
Data extraction
described/adequate:
partly; inadequate
Study quality
assessment described/
adequate: yes
Study flow shown:
partly in the text
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: yes
OVERALL QUALITY:
medium
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Data analysis: text, tables,
correlations
Subgroup/SAs: analysis by
comparison
Of 20 studies:
l ACI, n = 7
l MF, n= 12
l OAT, n = 5
l Allograft, n= 1
OUTCOMES
Functional outcomes (KOOS,
Tegner), return to sports
Nakamura 200954
Focus: to determine
the effectiveness of
cell-based therapy for
articular cartilage
defects of the knee
Funding: ISAKOS
Scientific Committee
(presumably)
INCLUSION CRITERIA
Study design: RCTs,
prospective comparative
studies, systematic reviews,
case series
Participants: symptomatic
chondral lesions of the knee
Intervention: cell-based
therapies
Outcomes: no criteria specified
METHODOLOGY
Search strategy:
Databases: MEDLINE
Date of search: 1994 to
January 2009; keywords not
indicated
Limitations: English language
Additional searches: none
Study selection: independent
selection by three reviewers,
differences resolved by
discussion
Quality assessment: quality
assessment according to the
rating system of the Journal
of Bone and Joint Surgery,
supplemented by criteria of The
Cochrane Collaboration and
Schulz 1995;206 data evaluated
by reviewers independently,
differences resolved by
discussion
Data extraction: data
evaluated by reviewers
independently, differences
resolved by discussion
No. of included trials: 12
(n= 10 comparing interventions,
n= 2 regarding activity levels/
rehabilitation), plus three
systematic reviews – only 10
studies comparing interventions
considered here (n= 9 with
distinct populations)
No. of participants: 754 in
intervention studies reported
(really 674 distinct participants)
TRIALS
Design:
l RCTs, n= 9
l CCT, n = 1
Follow-up: 1–5 years
Quality:
l RCTs classified as
level I evidence, n= 2
l RCTs, n= 6
l CCT as level II evidence,
n= 1
Quality limitations included lack
of allocation concealment, not
enough information on losses to
FU and blinding
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean 28.7–33.5 years
Sex: NR
Defect size: mean 1.9–6 cm2
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
partly; inadequate
Study selection
described/adequate: yes
Data extraction
described/adequate:
partly; inadequate
Study quality
assessment described/
adequate: yes
Study flow shown: no
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: n/a
OVERALL QUALITY:
medium
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Meta-analysis: no
Data analysis: text and
tables
Subgroup/SAs: data
presented by comparator
Duration of symptoms: NR
Other: 36–100% traumatic
lesions; 24–89% medial femoral
condyle, 8.5–23% lateral femoral
condyle, 0–61% patella,
0–15.2% trochlea, 0–10%
lateral tibial condyle/tibial plateau
INTERVENTIONS
ACI:
l P-ACI, n = 5
l C-ACI, n = 3
l Characterised ACI, n= 1
l Hyalograft C, n= 1
l MACI, n= 2
l OAT, n= 3
l MF, n= 3
l Abrasion, n = 1
OUTCOMES
Clinical outcomes (modified
Cincinnati, Stanmore, ICRS,
IKDC, KOOS, Lysholm, Meyers,
Tegner, VAS), SF-36; histology
Naveen 201249
Focus: to determine
the effectiveness of
ACI when compared
with other treatment
modalities
Funding: no specific
funding
INCLUSION CRITERIA
Study design: RCTs
Participants: no criteria
specified
Intervention: ACI vs. other
treatment modalities (MF,
mosaicplasty, abrasionplasty,
BMSC, MACI) for cartilage
repair in the knee
Outcomes: clinical outcomes
and evaluation scores;
histological outcomes
METHODOLOGY
Search strategy:
Databases: PubMed, Scopus,
NICE, CCTR
Date of search: up to June
2010; only two keywords
searched
Limitations: none
Additional searches: none
No. of included trials: 17
(but only 13 separate trial
populations)
No. of participants: 1644
(range 21–321 per study)
(number as stated by authors,
only 1339 distinct participants)
TRIALS
Design: not specified (n= 7
RCTs, n= 6 CCT/comparative
cohort)
Follow-up: 12 months to
5 years
Quality:
l Classified as level I
evidence, n= 4
l Level II, n= 8
l Level III, n= 1
l Level IV, n= 2
l No classification, n= 2
Origin: NR
Funding: NR
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
partly; inadequate
Study selection
described/adequate: no
Data extraction
described/adequate: no
Study quality
assessment described/
adequate: no
Study flow shown: yes
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: limited
Results of individual
studies shown: yes
Statistical analysis
appropriate: n/a
OVERALL QUALITY: low
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Study selection: as per
inclusion criteria, methods not
stated (but obviously actual
inclusion was different from
inclusion criteria)
Quality assessment: limited,
for histological assessments,
reported blinding of assessors,
attrition and level of evidence
Data extraction: limited; brief
note on items extracted but
not methodology
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: ACI vs.
different comparators
PARTICIPANTS
Age: NR
Sex: 57–76% male (reported by
14 studies)
Defect size: mean 1.9–6.4 cm2
INTERVENTIONS
ACI vs.:
l Mosaicplasty, n = 4
l MF, n= 8
l MACI, n= 3
l BMSC, n= 1
l Abrasionplasty, n= 1
OUTCOMES
Clinical scores (subjective
outcome, Lysholm, Tegner,
Cincinnati, Stanmore, Meyers,
IHC, ICRS, IKDC, Hop test,
KOOS, Gillquist), QoL (SF-36),
histology/MRI
Negrin 201355
Focus: to test the
hypothesis that ACI
has a better treatment
effect than MF, and
increasing superiority
over the years (under
similar patient- and
defect-specific
conditions)
Funding: not reported;
the authors state that
they have no conflict
of interest
INCLUSION CRITERIA
Study design: CCT or
controlled prospective
observational study, FU
≥ 1 year
Participants: patients with
full-thickness cartilage defects
(Outerbridge grades III and IV)
on the medial or lateral femoral
condyle, the trochlea, or the
patella due to acute or
repetitive trauma,
osteonecrosis, or OCD
Intervention: MF (without
implantation of a scaffold or
injection of substitutes) vs. any
type of ACI
Outcomes: clinical scores
(functional capacity)
METHODOLOGY
Search strategy:
No. of included trials: 6
No. of participants: 399
TRIALS
Design:
l RCTs, n= 4
l Comparative cohort, n= 2
Follow-up: 1–5 (7.5?) years
Quality: NR
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean 25.1–40.4 years
Sex: NR
Defect size: mean 2.0–4.8 cm2
Duration of symptoms: NR
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes; inadequate
Study selection
described/adequate: yes
Data extraction
described/adequate: yes
Study quality
assessment described/
adequate: yes
Study flow shown: yes
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: no
Results of individual
studies shown: yes
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
Databases: MEDLINE,
EMBASE; CINAHL, CENTRAL
Date of search: up to 31 March
2013; only one search term
Limitations: none
Additional searches: none
Study selection: studies
selected by two independent
reviewers using standardised
forms; discrepancies resolved
by consensus
Quality assessment: for RCTs,
Cochrane risk of bias tool; for
observational studies criteria
proposed by Deeks et al.
2003,207 assessment by two
independent reviewers,
discrepancies resolved by
consensus
Data extraction: items
extracted are listed
Meta-analysis: yes
Data analysis: SMD (random-
effects model), heterogeneity,
funnel plot; text and tables
Subgroup/SAs: duration of
FU; generation of ACI
No other characteristics
systematically reported
INTERVENTIONS
l First-generation ACI, n= 1
l Second-generation
ACI, n= 4
l Third-generation ACI, n = 1
All vs. MF
OUTCOMES
Clinical outcome (Lysholm, IKDC,
KOOS), treatment failure,
histology
Statistical analysis
appropriate: no; meta-
analyses show substantial
heterogeneity, which was
not explored
OVERALL QUALITY:
medium
Vasiliadis 201045
Focus: to assess the
effectiveness and
safety of ACI
compared with other
treatment options
(conservative or
surgical) for patients
who require knee
repair of clinically
significant symptomatic
defects of the knee
joint
Funding: NR
Note: refers to a 2010
Cochrane review,
which is slightly less
inclusive [three of the
trials included here
were excluded in the
Cochrane review (two
trials were comparisons
INCLUSION CRITERIA
Study design: RCTs or quasi-
randomised trials
Participants: 15–55 years with
symptomatic cartilage defects
of the femur or patella (in
joints free from rheumatoid
arthritis, OA)
Intervention: ACI vs. any
other intervention
Outcomes: clinical efficacy and
complications
METHODOLOGY
Search strategy:
Databases: Cochrane Bone,
Joint and Muscle Trauma
Group specialised register,
CENTRAL, MEDLINE, EMBASE,
No. of included trials: 9
No. of participants: 626
(19–118 per study)
TRIALS
Design:
l RCTs, n= 8
l Quasi-RCT, n= 1
Follow-up: 10 months to
5 years
Quality: overall, average to
low quality:
l < 75% adequate
sequence generation
l < 50% adequate
allocation concealment
l < 75% incomplete outcome
data addressed
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes, but no additional
searches mentioned
Study selection
described/adequate: yes
Data extraction
described/adequate: yes
Study quality
assessment described/
adequate: yes
Study flow shown: no
Study characteristics of
individual studies
described: yes
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184
TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
of different forms of
ACI, one trial was
excluded because of
the heterogeneous
patient population)]
SPORTDiscus, WHO
International Clinical Trials
Registry Platform, CCT
Date of search: December
2009; reference for search
strategy given
Limitations: none
Additional searches: none
Study selection:
independently by two
reviewers, differences resolved
by discussion
Quality assessment:
Cochrane risk of bias tool,
similarity at baseline; quality
assessed by two reviewers
independently, differences
resolved by discussion
Data extraction: items
extracted reported; authors
contacted for missing
information; data extracted by
two reviewers independently,
differences resolved by
discussion
Meta-analysis: no/limited for
Cochrane review
Data analysis: text and tables
Subgroup/SAs: none
Origin: NR
Funding: NR
PARTICIPANTS
Age: mean 29.7–35.4 years
Sex: 47–68% male
Defect size: mean 1.9–6.1 cm2
Duration of symptoms:
1.5–10 years
Other: location (reported by
n= 7): medial femoral condyle
24–89%, lateral femoral condyle
5–25%, trochlea 0–21%, patella
0–61%, tibial plateau 0–10%,
multiple 0–13%; Aetiology
(n= 5): trauma 36 to 92%, OCD
8–28%, chondromalacia patellae
0–46%, failed previous surgery
0–20%, uncertain 3–31%
INTERVENTIONS
l ACI, n = 1
l C-ACI, n= 3
l P-ACI, n= 5
l CCI, n = 1
l MACI, n= 1
l MF, n= 2
l Mosaicplasty, n= 3
l Abrasion, n= 1
OUTCOMES
Clinical outcomes (Lysholm,
Tegner, KOOS, modified
Cincinnati, VAS, Mayers, ICRS,
Stanmore), SF-36, biopsy, IKDC,
complications
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: yes
OVERALL QUALITY:
high
Vavken 201056
Focus: effectiveness of
ACI compared with
other treatments with
respect to clinical
outcome and quality of
repair tissue
Funding: none; authors
state that they have no
conflict of interest
INCLUSION CRITERIA
Study design: controlled trials,
minimum FU 6 months
Participants: cartilage defects
of the knee
Intervention: ACI (any type)
vs. another cartilage repair
procedure or placebo
Outcomes: clinical outcome,
quality of repair tissue
No. of included trials: 10 (but
really only seven independent
trials)
No. of participants: 441 (range
19–118 per study)
TRIALS
Design:
l RCTs, n= 6
l Quasi-RCT, n= 1
Inclusion criteria
described/adequate: yes
Literature search
described/adequate:
yes, although limited
search terms
Study selection
described/adequate:
partly
Data extraction
described/adequate: yes
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TABLE 53 Characteristics and quality of systematic reviews (continued )
Review
Inclusion criteria and
methodology Included studies Quality
METHODOLOGY
Search strategy:
Databases: PubMed; EMBASE,
CENTRAL, CINAHL, BioMed
Date of search: December
2009; search strategy shown
Limitations: none
Additional searches:
bibliographies of relevant
papers
Study selection: records
compared against inclusion
criteria, but no further
methodology reported
Quality assessment: level of
evidence determined, quality
criteria listed, independent
assessment by two reviewers
Data extraction: items
extracted listed; independent
extraction by two reviewers
Meta-analysis: no
Data analysis: text and tables
Subgroup/SAs: results
reported by comparator
Follow-up: 1–5 years
Quality:
l Level I evidence, n= 3
l Level II evidence, n= 4;
attrition 0–28%, deficits
with respect to sample size,
randomisation procedure,
blinding of outcome
assessment
Origin: NR
Funding: NR
PARTICIPANTS
Age: NR
Sex: 57–68% male
Defect size: mean 1.9–5.1 cm2
Duration of symptoms: NR
Other: NR
INTERVENTIONS
ACI vs.:
l Osteochondral graft
transfer, n = 3
l MF, n= 3
l Abrasion, n = 1
OUTCOMES
Clinical outcome (subjective,
Lysholm, Tegner, Meyer,
modified Cincinnati, Stanmore,
IKDC, KOOS), SF-36, histology,
safety
Study quality
assessment described/
adequate: yes
Study flow shown: yes
Study characteristics of
individual studies
described: yes
Quality of individual
studies given: yes
Results of individual
studies shown: yes
Statistical analysis
appropriate: n/a
OVERALL QUALITY:
high
BMSC, bone marrow-derived mesenchymal stem cell; C-ACI, collagen-based ACI; CCT, Current Controlled Trials;
CCTR, Cochrane controlled trials reports; CINAHL, Cumulative Index to Nursing and Allied Health Literature; FU, follow-up;
ISAKOS; International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine; n/a, not available; NR, not
reported; P-ACI, periosteum-based ACI; SMD, standardised mean difference; WHO, World Health Organization.
a An application for to the EMA for approval of Hyalograft in Europe was withdrawn. URL www.ema.europa.eu/ema/
index.jsp?curl=pages/medicines/human/medicines/002657/wapp/Initial_authorisation/human_wapp_000161.jsp&
mid=WC0b01ac058001d128 (accessed 7 December 2016).
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
186
Appendix 6 Results and conclusions of
systematic reviews
TABLE 54 Results and conclusions of systematic reviews
Review Outcome No. of studies Result of meta-analysis/review Comments
General ACI vs. other
Mithöfer
200953
Clinical
outcome
1 RCT, 5 non-RCTs
with ACI, 20 studies
overall
Good and excellent results in 82 (SE 7)%
[vs. 79 (SE 5)% for all methods]
Increase in Tegner activity score was seen
in 84 SE6% of patients overall, the highest
average Tegner scores were found for ACI;
decreasing Tegner scores were seen in six
studies after initial increase: five after MF
and one after OAT, no decrease seen with
ACI (36–60 months)
Return to sports 1 RCT, 5 non-RCTs
with ACI, 20 studies
overall
Return to sports, 33–96% with ACI [mean
67 (SE 17)% vs. 73 (SE 7)% for all
methods]
Time to return to sports, 18 (SE 4) months
after ACI (range 12–36 months) vs. 8 (SE 1)
months after MF, 7 (SE 2) months after
osteochondral autograft
Return to sports at the pre-injury level, 71
SE12% with ACI (vs. 68 SE4% overall)
Continued sports participation at the
pre-injury level [average FU 50 (SE 7)
months], 96 (SE 4)% with ACI vs. 52
(SE 6)% with MF and 52 (SE 1)% with
osteochondral autograft transplantation
Subgroups 1 RCT, 5 non-RCTs
with ACI, 20 studies
overall
Better results with younger age
(< 25–30 years)
Better results with shorter time between
diagnosis and surgical treatment
(< 12 months)
Lesion size < 2 cm2 associated with
significantly higher return to sports (but no
effect of lesion size with ACI)
In patients treated with ACI: lower average
number of previous surgeries in those who
returned to sports; return to sports
significantly better and time to return
significantly shorter in competitive than
recreational athletes
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Vasiliadis
201045
Subgroups 4 RCTs 1 RCT (1 year): no significant difference by
anatomical site, but none of the patellar
lesions had a good arthroscopic result
1 RCT (1 year): patients with previous
surgical procedures had worse clinical
outcomes, but correlation not statistically
significant; longer duration of symptoms
before surgery (C-ACI or MACI)
significantly correlated to worse clinical
outcomes; patients < 35 years had
significantly better clinical outcomes
1 RCT: onset of symptoms < 2 years before
surgery associated with larger improvement
in KOOS (MF and CCI, < 3 years in the
latter group)
1 RCT (2 years): patients < 30 and more
active patients had better results; patients
with smaller lesions (< 4 cm2) had better
results in the MF group only (result
independent of lesion size with P-ACI)
C-ACI vs. P-ACI
Goyal 201347 General
effectiveness
1 RCT No statistical difference in results after
2 years
Outcomes not
specified; actual
values not
reported for any
of the outcomes
Retreatment 1 RCT, 1 cost-
effectiveness
Significant number of patients in P-ACI
group required periosteal shaving; high risk
of patch hypertrophy
Cost-
effectiveness
1 cost-effectiveness Both methods cost-effective but C-ACI
slightly more so because of risk of
hypertrophy with P-ACI
Harris 201044 Clinical
outcome
1 RCT No significant difference in modified
Cincinnati (2 years) and ICRS AKS (1 and
2 years) scores
Histology 1 RCT No significant difference in macroscopic
and histological examination at 1 and
2 years, but 36% in the P-ACI group vs.
0% in the C-ACI group needed
arthroscopic knee surgery because of
hypertrophy at 1 year
Nakamura
200954
Clinical
outcome
1 RCT No significant difference in modified
Cincinnati and ICRS AKS scores (2 years)
Histology 1 RCT Significant number of patients in P-ACI
group required shaving of hypertrophied
graft
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Vasiliadis
201056
Clinical
outcome
1 RCT No significant difference in modified
Cincinnati score at 2 years (good and
excellent results in 66.7% with C-ACI and
74.3% with P-ACI)
Histology 1 RCT 81% good to excellent results with P-ACI
and 79% with C-ACI according to ICRS
evaluation system (1 year; p= NS), but
biopsies better for C-ACI (statistical
significance unclear)
Complications 1 RCT 12/31 (1 year) and 1/9 (2 years) graft
hypertrophies with P-ACI, 1/35 (2 years)
with C-ACI
General MACI and second-generation ACI
Kon 200951 Clinical
outcome
18 studies (incl.
2 RCTs, 3 additional
comparative studies)
Mean subjective preoperative IKDC score
ranged from 37.0 to 41.1 and improved to
70.2–80.2 at 5 years (results at earlier time
points 73.6–80.6)
Mean preoperative Lysholm score ranged
from 46.3 to 57.5 and improved to 80.8 at
3 years (results at earlier time points
69.7–96.7)
Complications 8 studies l n = 7 graft hypertrophy (4 for MACI,
2 for Hyalograft C, 1 for BioSeed)
l n = 4 joint stiffness (3 for MACI and
1 for Hyalograft C)
l n = 1 graft detachment for MACI
l n = 1 synovitis for Hyalograft C
One study reported n = 3 hypertrophy,
n= 3 graft detachments and n = 1 partial
ossification with atelocollagen scaffold
(only product used in conjunction with a
periosteal flap; impossible to determine
if the complication was related to the
periosteal flap)
ACI vs. MACI
Naveen
201249
Clinical
outcome
1 RCT, 2
comparative cohort
For 1 RCT and 1 comparative cohort, no
significant difference in clinical outcomes
(2 years); 1 comparative cohort had
significantly better clinical outcomes for
MACI, higher complication rate with ACI
(4.5 years)
Actual values not
reported for any
of the outcomes
C-ACI vs. MACI
Goyal 201347 Knee function/
clinical scores
1 RCT Improvements in all clinical scores with
both techniques after 1 year
Actual values not
reported for any
of the outcomes
Arthroscopic/
histological
assessment
1 RCT No significant difference after 1 year
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Magnussen
200852
Clinical
outcome
1 RCT No significant difference between groups
in modified Cincinnati, VAS and Stanmore
scores (1 year)
Arthroscopic/
histological
assessment
1 RCT ICRS CRA (CRA, 12= normal cartilage);
CRA 8–12, no significant difference (C-ACI
79.2%, MACI 66.6%) (1 year)
Per cent with hyaline-like or mixed hyaline/
fibrocartilage, no significant difference
(C-ACI 42.9%, MACI 36.4%) (1 year)
Subgroups 1 RCT Patients < 35 years had better clinical
outcome (p = 0.03)
Complications 1 RCT C-ACI: 6.8% arthofibrosis, 9.1% tissue
hypertrophy
MACI: 6.4% arthofibrosis, 6.4% tissue
hypertrophy, 2.1% superficial wound
infection
Nakamura
200954
Clinical
outcome
1 RCT No significant difference between groups
in modified Cincinnati, VAS, ICRS AKS and
Stanmore scores (2 years)
Vasiliadis
201045
Clinical
outcome
1 RCT No significant difference in modified
Cincinnati score (outcome good or
excellent in 59.1% after C-ACI, in 72.3%
after MACI, 12 months); no significant
difference in VAS or Stanmore score
Histology 1 RCT 79.2% good to excellent results with
C-ACI and 66.6% with MACI according to
ICRS evaluation system (1 year; p = NS),
with hyaline- or mixed hyaline-like repair
tissue in 42.9% with C-ACI and 36.4%
with MACI
P-ACI vs. MACI
Goyal 201347 Knee function 1 RCT At 2 years, no significant difference
between groups in IKDC scores and Tegner
activity scores between groups; Lysholm
and Gillquist scores (function) favoured
P-ACI group
Actual values not
reported for most
of the outcomes
QoL 1 RCT At 2 years, no significant difference
between groups in SF-36 scores
MRI cartilage
repair tissue
score
1 RCT At 1 and 2 years, no significant difference
Harris 201044 Clinical
outcome
2 RCTs No significant difference in clinical scores
after 1 year (IKDC, Lysholm, Tegner, ICRS,
modified Cincinnati)
Open vs. arthroscopic ACI
Harris 201044 Clinical
outcome
1 comparative
cohort
IKDC (objective) results significantly better
for arthroscopic group at 1 year [effect size
0.58 (SE 0.21)] but no significant difference
at 5 years
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
ACI vs. mosaicplasty/OAT
Bekkers
200950
Clinical
outcome
1 RCT No significant difference in modified
Cincinnati good–excellent score (> 55) at
19 months (ACI 88%, mosaicplasty 69%)
Significant difference in modified Cincinnati
good–excellent score (> 55) at 12 months
for medial femur (ACI 88%, mosaicplasty
73%, p= 0.032) but not lateral femur or
patella
Macroscopic/
histological
outcome
1 RCT ICRS macroscopic grading significantly
better with ACI at 12 months
(excellent–good ACI 82%, mosaicplasty
34%; p< 0.01)
Only biopsies from ACI group (n= 7
predominantly hyaline, n= 7 mixed hyaline
and fibrocartilage, n= 5 predominantly
fibrocartilage)
Harris 201044 Clinical
outcome
1 RCT, 1 CCT 1 RCT: no significant difference in Lysholm
score after 1 year
1 CCT: Lysholm score significantly better
after 1 year for mosaicplasty but no
significant difference at 2 years
Magnussen
200852
Clinical
outcome
1 RCT, 1 CCT 1 RCT: no significant difference in modified
Cincinnati > 55 (ACI 88%, OAT 69%;
p= 0.27) (1 year)
1 CCT: significantly better Lysholm scores
with OAT [P-ACI 67 (SD 8), OAT 74 (SD 6);
p< 0.05]; no significant difference in
Tegner or Meyers scores (2 years)
Arthroscopic/
histological
assessment
1 RCT, 1 CCT 1 RCT: per cent with CRA 8–12 significantly
better with ACI (ACI 82%, OAT 34%;
p< 0.01); 74% of ACI patients with hyaline-
or mixed hyaline/fibrocartilage-like (not
reported for OAT) (1 year)
1 CCT: OAT patients with hyaline cartilage
not integrated into surrounding cartilage;
P-ACI specimens with mainly fibrocartilage,
focalised areas or hyaline-like cartilage
(2 years)
Subgroups 1 RCT, 1 CCT 1 RCT: significantly more with modified
Cincinnati score > 55 with ACI of patients
with femoral condyle lesions only (ACI
88%, OAT 74%; p= 0.03) (1 year)
Complications 1 RCT, 1 CCT 1 RCT: 7 poor results, all in OAT group
(1 year)
Arthofibrosis ACI 0–15%, OAT 7.1–15%
(up to 2 years)
OAT group only: Superficial wound
infection 2.4–5%, DVT 2.4%,
postoperative haemarthrosis (10%)
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Nakamura
200954
Clinical
outcome
2 RCTs, 1 CCT 1 RCT: modified Cincinnati score
significantly better for ACI than OAT in the
medial femoral condyle (19 months)
1 RCT: no significant difference in Lysholm
scores, IKDC (36 months); 1 CCT
significantly better Lysholm scores with
OAT (2 years)
Naveen
201249
Clinical
outcome
2 RCTs, 1 CCT 1 CCT: no difference in clinical scores,
improvement with ACI lagged behind
improvement with mosaicplasty (2 years)
1 RCT: 88% good and excellent after
ACT, 69% after mosaicplasty (p < 0.05,
19 months)
1 RCT: complete recovery in 68% after
ACI, 88% after mosaicplasty (but
difference presumably non-significant as
treatments are considered equivalent,
36 months)
Actual values not
reported for any
of the outcomes
Histological
outcome
1 RCT, 1 CCT 1 CCT: fibrocartilaginous defect filling with
ACI, no visible changes in tissue after
mosaicplasty (24 months)
1 RCT: 82% good or excellent after ACI,
34% after mosaicplasty (19 months)
Vasiliadis
201045
Clinical
outcome
2 RCTs, 1 CCT 1 CCT: significantly better recovery
(Lysholm) with mosaicplasty than P-ACI
(up to 2 years; p= 0.012), no significant
difference in Tegner or Meyers score
1 RCT: no significant difference in Lysholm
score (10 months)
1 RCT: no significant overall difference
between P-ACI/C-ACI and mosaicplasty,
but ACI significantly better for medial
femoral condyle lesions at 12 months
(88% good or excellent results vs. 74% for
mosaicplasty; p = 0.032)
(Cochrane
review)
Satisfactory
outcome
2 RCTs, 1 CCT Meta-analysis showed no significant
difference (risk ratio 1.02, 95% CI 0.81 to
1.28; p= NS), significant heterogeneity
Histology 2 RCTs 1 RCT: 82% good or excellent after ACI,
34% after mosaicplasty (12 months;
p< 0.01) – fibrous tissue between grafts
in four mosaicplasty patients, plugs
disintegrated in three patients; in one ACI
patient, with mixed hyaline–fibrohyaline
repair tissue, ongoing maturation of repair
tissue to hyaline-like tissue was seen
2 years postoperatively
1 RCT: only short-term results –
fibrocartilage in central and superficial
layers and hyaline cartilage only in deep-
layer areas 6 months after ACI’ good
quality of cartilage of transplanted plugs
(but > 50% of biopsies taken at 3 months)
Complications 1 CCT No significant differences in complication rates
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Vavken
201056
Clinical
outcome
2 RCTs, 1 CCT 1 RCT: no significant difference
1 RCT: complete recovery in 68% after
ACI, 88% after mosaicplasty
1 RCT: 88% good and excellent after ACT,
69% after mosaicplasty (p< 0.05,
19 months)
Histology 2 RCTs 1 RCT: fibrocartilaginous filling after ACI,
no visible changes in tissue after OAT
(2 years)
1 RCT: 82% good or excellent after ACI,
34% after mosaicplasty (19 months)
Complications 1 RCT, 1 CCT 1 RCT: four failed treatments with OAT
1 CCT: gaps between plugs and adjacent
tissue in all second look arthroscopies
ACI vs. MF
Bekkers
200950
Clinical
outcome
2 RCTs 1 RCT: CCI vs. MF no significant difference
in KOOS at 18 months
1 RCT: ACI vs. MF no significant difference
in Lysholm, VAS or Tegner scores at
5 years; SF-36 physical functioning
significantly better with MF at 2 years
(p= 0.01), no significant difference at
5 years
Macroscopic/
histological
outcome
2 RCTs 1 RCT: significantly higher
histomorphometric score with CCI than
with MF (p= 0.003), as well as significantly
higher histology assessment score
(p= 0.012)
1 RCT: no significant difference in ICRS
macroscopic grading between ACI and MF
at 2 years; histology (n= 67): hyaline ACI
19%, MF 11%; hyaline/fibrocartilage ACI
31%, MF 17%; fibrocartilage ACI 34%,
MF 57%; no tissue ACI 16%, MF 15%
Subgroups 1 RCT Better clinical outcomes for both groups for
age < 30 years (p= 0.007 at 2 years and
p= 0.013 at 5 years)
Lesions < 4 cm2 showed better clinical
results in the MF group (p< 0.003)
Goyal 201348 Clinical
outcome
7 comparative Numerical data only reported for MF, no
results reported for comparison with ACI
Harris 201044 Clinical
outcome
6 RCTs, 1 CCT Participants in 3/7 studies had significantly
better clinical scores after 1–5 years with
ACI than with MF (effect sizes for Lysholm,
Tegner, ICRS, KOOS 0.66–1.52); no
significant difference for the rest of the
studies (KOOS, Lysholm, SF-36 physical
component); 1 RCT had significantly better
results on the SF-36 physical component at
2 years for MF (effect size –0.65 for ACI)
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Histological
outcome
1 RCT 1 RCT had a significant difference in
histomorphology and histology score in
favour of ACI at 1 year
Durability 2 RCTs, 1 CCT Clinical results for MF tended to plateau or
deteriorate at longer FUs, whereas results
for ACI tended to improve (three studies);
at 5 years, sports activity remained stable in
the ACI group but declined in the MF
group (1 CCT)
Magnussen
200852
Clinical
outcome
1 RCT At 2 years, no significant difference in
Lysholm or VAS scores (2 years)
SF-36 physical component significantly
better with MF (46 (SD 2 vs. P-ACI 42
(SD 2; p= 0.01)
Arthroscopic/
histological
assessment
1 RCT At 2 years, no significant difference in CRA
No significant difference in percentage
with hyaline- or mixed hyaline/
fibrocartilage-like (MF 29%, P-ACI 50%;
p= 0.08)
Subgroups 1 RCT At 2 years, patients < 30 years (p = 0.007)
and patients with Tegner scores > 4
(p= 0.0005) had better SF-36 scores in
both groups; higher SF-36 scores in MF
group associated with lesions < 4 cm2
(p= 0.003)
Complications 1 RCT P-ACI: 25% tissue hypertrophy
MF: 7.5% tissue hypertrophy, 2.5%
arthofibrosis
Mithöfer
200953
Clinical
outcome
1 RCT Higher increases in KOOS (sports and
recreation) with ACI than MF
Histology 1 RCT Significantly better histological assessment
(p< 0.05) and histomorphometric scores,
including higher proteoglycan content,
higher type II collagen content, and more
normal chondrocyte morphology (p< 0.01)
after characterised ACI compared with MF
at 12–18 months
Nakamura
200954
Clinical
outcome
2 RCTs, 1 CCT 1 RCT: no significant difference in Lysholm,
Tegner, VAS scores; SF-36 physical
component significantly better with MF
(2 years); no significant difference in any of
the scores at 5 years
1 RCT: no significant difference in KOOS
(18 months)
1 CCT: significantly better IKDC scores with
ACI at 5 years
Histology 2 RCTs No significant difference in 1 RCT (2 years),
better result for ACI in 1 RCT (18 months)
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Naveen
201249
Clinical
outcome
3 RCTs,
2 comparative
cohort
No significant difference in clinical scores
in 1 RCT and 1 comparative cohort
(2–5 years), ACI better in 1 RCT and
1 comparative cohort (12 months to
5 years), 1 RCT no significant difference at
18 months, but ACI significantly better at
36 months
Actual values not
reported for any
of the outcomes
Histological
outcome
2 RCTs No significant difference in 1 RCT (2 years),
better result for ACI in 1 RCT (18 months)
QoL (SF-36) 2 RCTs No significant difference in 1 RCT (5 years),
better result for MF in 1 RCT (2 years)
Negrin
201355
Clinical
outcome
4 RCTs At 1 year, SMD 1.05 (95% CI –1.35 to
3.45); p= NS; heterogeneity, p< 0.0001
4 RCTs,
1 comparative
cohort
At 2 years, SMD 0.38 (95% CI –0.13 to
0.90); p= NS; heterogeneity, p= 0.0008
2 RCTs,
1 comparative
cohort
At 5 years, SMD 0.28 (95% CI –0.23 to
0.79); p= NS; heterogeneity, p= 0.0143
Subgroups:
second and
third generation
ACI
3 RCTs At 1 year, SMD 2.22 (95% CI 1.01 to
3.42); p< 0.05; heterogeneity p= 0.0003
3 RCTs,
1 comparative
cohort
At 2 years, SMD 0.56 (95% CI 0.30 to
0.82), p< 0.05; heterogeneity, p= NS
1 RCT,
1 comparative
cohort
At 5 years, SMD 0.51 (95% CI 0.21 to
0.80), p< 0.05; heterogeneity, p= NS
Treatment
failure
4 RCTs,
2 comparative
cohort
Overall, 21 treatment failures with MF vs.
16 with ACI
Histology 2 RCTs 1 RCT: no significant difference between
ACI and MF, but ACI biopsy specimens
tended to have a more hyaline-like
appearance 2 years postoperatively
1 RCT: clear morphological superiority of
cartilaginous tissue after ACI; MF resulted
in significantly lower histological scores for
type II collagen and matrix proteoglycan
content
Vasiliadis
201045
Clinical
outcome
3 RCTs 1 RCT: no significant difference between
P-ACI and MF (5 years) in Lysholm or
Tegner scores or VAS; SF-36 significantly
better with MF at 2 years but no significant
difference at 5 years
1 RCT: MACI more improvement in Lysholm
and Tegner scores than MF but unclear if
the difference was significant (12 months)
1 RCT: no significant difference in modified
KOOS at 18 months; CCI slightly better at
36 months (p= 0.05), slower recovery with
CCI, but no significant difference in
function at 2 years
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Histology 2 RCTs 1 RCT (12 months): significantly better
histomorphogenic score (p= 0.003) and
better mean histology score (p= 0.012)
with CCI than MF – obvious cartilaginous
restoration after chondrocyte implantation,
repair scar tissue after MF
1 RCT: 71.4% poor-quality repair tissue
with MF vs. 50% with P-ACI (2 years), but
no statistically significant difference; no
association between histological quality
and clinical outcomes at 2 and 5 years, but
the worse the image at 2 years, the bigger
the risk of failure up to 5 years (p = 0.02)
Complications 2 RCTs 1 RCT (2 years): 25% debridement due to
graft hypertrophy with P-ACI, 10% with
MF, 23% in each group had a failure (one
in each group a total arthroplasty)
1 RCT (3 years): similar complication rates
with CCI and MF – 2/57 failures with CCI
and 7/61 with MF
Vavken
201056
Clinical
outcome
3 RCTs 1 RCT (12 months): significantly better
results with ACI than MF; 1 RCT no
significant difference in clinical scores
(2 and 5 years), 1 RCT no significant
difference at 18 months but ACI
significantly better at 36 months; 1 RCT
SF-36 significantly better with MF than ACI
at 2 years but not at 5 years
Histology 2 RCTs 1 RCT: no significant difference (2 years),
1 RCT: better results for ACI at 18 months
Complications 2 RCTs 1 RCT: nine failures in each group; 25%
debridement with ACI and 10% with MF
(after 5 years)
1 RCT: 25% cartilage hypertrophy with
ACI, 13% with MF, 67% and 59% AEs
with ACI and MF (9% and 13% serious)
ACI vs. BMSC
Naveen
201249
Clinical
outcome
1 comparative
cohort
Significantly better clinical outcomes for
BMSC than ACI (2 years)
Actual values not
reported for any
of the outcomes
Histological
outcome
1 comparative
cohort
Comparison not possible: histological
results presented only for BMSC, not ACI
ACI vs. abrasionplasty
Naveen
201249
Clinical
outcome
1 RCT Significantly better clinical outcomes for
ACI (12 months)
Actual values not
reported for any
of the outcomes
Magnussen
200852
Clinical
outcome
1 RCT At 1 year, significantly better clinical scores
in MACI than abrasion group [Lysholm
MACI 86 (SD 9), abrasion 74 (SD 11)
(p= 0.001); IKDC MACI 76 (SD 13),
abrasion 68 (SD 10) (p< 0.05); Tegner
MACI 5.9 (SD 0.8), abrasion 4.2 (SD 11)
(p< 0.01)]
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TABLE 54 Results and conclusions of systematic reviews (continued )
Review Outcome No. of studies Result of meta-analysis/review Comments
Histological
outcome
1 RCT At 1 year, histology on four samples
(presumably MACI): evidence of hyaline-
like cartilage; fibroblast-like cells in two
Complications 1 RCT 24% reactive synovitis in MACI group
Nakamura
200953
Clinical
outcome
1 RCT At 1 year, significantly better Lysholm and
IKDC scores with MACI than abrasion
Vasiliadis
201044
Clinical
outcome –
Lysholm scores
1 RCT ACI significantly better than abrasion at
1 year (p < 0.001 for improvement in
Lysholm scores, 72% with ACI vs. 40%
with abrasion good or excellent results;
p< 0.01 for difference in Tegner score),
IKDC subjective score also significantly
better for ACI
Vavken
201056
Clinical
outcome
1 RCT Significantly better clinical outcomes for
ACI (12 months)
AKS, arthroscopic knee surgery; BMSC, bone marrow-derived mesenchymal stem cell; C-ACI, collagen-based ACI;
CRA, Cartilage Repair Assessment; FU, follow-up; NS, not significant.
TABLE 55 Systematic review conclusions
Study Conclusions Recommendations Comments
Bekkers
200950
Clinical outcomes: all trials
showed an improvement from
clinical baseline scores, regardless
of treatment; lesion size, activity
level and patient age are factors
that should be considered in
selecting treatment of articular
cartilage lesions of the knee
Practice: small chondral and
osteochondral lesions (< 1 cm2)
should preferably be treated by
MF or single-plug OAT; for larger
lesions (> 4 cm2) MF has been
associated with limited
effectiveness; for larger lesions,
OAT and ACI are both good
treatment options
Research: patients in trials should
be stratified based on BMI, defect
location, and post-debridement
defect size; outcomes should be
reported after at least 2 years of
FU using biopsy, MRI and
validated clinical outcome tools,
including assessment of activity
level
Goyal 201347 General: C-ACI is marginally
more effective than P-ACI, with
evidence limited to a FU period of
2 years; MACI gives comparable
results to P-ACI or C-ACI
(evidence from studies with a
short duration of FU, with a small
sample size and medium-sized
defects in a younger age group)
Practice: NR
Research: multicentre RCTs with
adequate sample size needed of
second-and third-generation ACI
vs. first-generation ACI; cohort
studies of long-term effects
(10 years) needed
Goyal 201348 Only refers to MF Publications including the
same study populations
counted as separate studies
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TABLE 55 Systematic review conclusions (continued )
Study Conclusions Recommendations Comments
Harris 201044 General: studies were very
heterogeneous and had important
quality limitations
Practice: ACI may be the best
option for large defects in young,
active patients with a short
duration of symptoms and no
previous cartilage surgery; MF is
indicated for smaller defects in
young, active patients;
osteochondral autograft may
provide a more rapid
improvement in terms of clinical
outcome, but is limited by donor
site morbidity
Publications including the
same study populations
counted as separate studies
Clinical outcomes: intermediate-
term clinical outcomes after ACI
tended to be better than after
MF; difference compared with
osteochondral autograft unclear;
no significant differences in
clinical outcomes between first-
and second-generation ACI
Histology: ACI may provide a
more durable repair tissue than
MF
Research: higher-quality studies
needed, with the following
characteristics: proper and
transparent patient enrolment
with clearly stated inclusion and
exclusion criteria; proper
independently performed
randomisation techniques; no
concurrent surgical interventions
(anterior cruciate ligament
reconstruction, realignment
osteotomy, meniscal surgery, etc.);
consistent surgical technique;
longer clinical FU with an
independent observer; use of
validated, responsive and reliable
outcome measures; clear
reporting of data with a
statement of both clinical
relevance and significance
Modifying factors: outcomes
tended to be better for younger
patients (< 30/35 years), more
active patients, patients with
shorter symptom duration and
patients who had not had a
previous failed surgical
intervention; possibly better
results for smaller lesions and
better effects of ACI than other
techniques for larger lesions
Complications: graft hypertrophy
highest with ACI-P (22%), lower
with other methods (4–7%);
reported ‘failure’ rates slightly
lower with ACI (2.8%) than with
MF (3.7%) or mosaicplasty (7.1%)
Kon 200951 Clinical outcomes: matrix-
assisted second-generation ACI is
a promising technique for the
treatment of isolated chondral
defects; good clinical results were
reported by all products, but FUs
were short and quality levels of
studies were low
Practice: NR
Research: high-quality, long-term
RCTs are needed
Magnussen
200852
General: FU relatively short,
heterogeneous outcome measures
Practice: MF is ideal first-line
treatment for small stage III or IV
articular cartilage defects; more
complex surgery needed for larger
lesions (larger than 2–4 cm2)
Clinical outcomes: all trials
revealed short-term improvement
in all clinical scores with every
treatment method evaluated (ACI,
MACI, OAT, MF, abrasion)
Research: large multicentre trial
needed comparing ACI, MACI,
OAT, MF, simple debridement and
a non-operative control; trial
should use validated patient-
orientated clinical outcome
measures, e.g. the KOOS, the
WOMAC®, SF-36 score, or the
IKDC score, with FU at 5 and
10 years
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TABLE 55 Systematic review conclusions (continued )
Study Conclusions Recommendations Comments
Mithöfer
200953
Return to sports: return to
sports was possible in 73%
overall, with highest return rates
after osteochondral autograft
transplantation; time to return to
sports was between 7 and 18
months (longest with ACI); initial
return to sports at the pre-injury
level was possible in 68% and did
not significantly vary between
surgical techniques; continued
sports participation at the pre-
injury level was possible in 65%,
with the best durability after ACI;
several factors affected the ability
to return to sport after ACI:
athlete’s age (better at younger
age), preoperative duration of
symptoms (better with shorter
duration)
Practice: NR
Research: systematic research is
needed to explain lack of return
to sports and unsustained sports
participation in some patients;
prospective long-term studies are
needed to determine if articular
cartilage repair in athletes can
influence the high incidence of
OA associated with high impact
sports
Nakamura
200954
General: studies were of limited
quality; there is insufficient
evidence from the included
studies to say whether or not cell-
based therapy is superior to other
treatment strategies in articular
cartilage lesions of the knee
Practice: NR Publications including the
same study populations
were counted as separate
studies
Research: high-quality RCTs with
long-term FU are needed
Naveen
201249
Clinical outcomes: there is
heterogeneity and inconsistency
between studies; it is unclear to
what extent any differences
between treatments in clinical
outcomes are clinically important
Practice: NR Stated that non-RCTs were
excluded, but not all of the
included trials were RCTs;
publications including the
same study populations
counted as separate studies
Histology: ACI is associated with
superior structural regeneration of
cartilage tissue compared with
other methods (but reported by
only 6/17 studies)
Research: studies of long-term
effects needed
Negrin 201355 Clinical outcomes: the meta-
analyses (of all forms of ACI vs.
MF or only second-and third-
generation ACI) did not reveal any
clinically relevant superiority of
ACI over MF – results converged
over time; decision-making must
take patient objectives, physical
demands and patient- and defect-
specific factors into consideration
(e.g. MF has worse outcomes with
defect sizes > 4 cm2)
Practice: NR
Research: large, well-designed,
long term multicentre studies
needed
continued
DOI: 10.3310/hta21060 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mistry et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
TABLE 55 Systematic review conclusions (continued )
Study Conclusions Recommendations Comments
Vasiliadis
201045
General: studies are of poor
quality, heterogeneity regarding
techniques followed and
populations studied
Practice: there is insufficient
evidence to conclude whether
or not autologous cartilage
implantation is superior to other
treatment strategies for treating
full-thickness articular cartilage
defects in the knee
Clinical outcomes: body of
evidence does not suggest
superiority of ACI over other
techniques; complication rates
were comparable between
interventions except from an
increased rate of graft
hypertrophies after P-ACI; ACI
is an effective treatment for
full-thickness chondral defects
of the knee, providing an
improvement of clinical outcomes
Research: there is a need for
more high-quality RCTs and
uniformity of their reported
outcomes; more studies should be
done on maturation process of
finally formed repair tissue and
appropriate rehabilitation
programmes for the different
techniques; more information and
research is needed to compare
chondrocyte techniques with
conservative treatment, such as
intensive physiotherapy; further
information is needed on the
relationship between clinical,
histological and radiological
outcomes, and the most
appropriate measure of functional
outcomes that relate to a generic
measure of health-related QoL
Vavken
201056
General: rather low overall
quality of studies, including high
attrition rates and small sample
sizes
Practice: no clear
recommendation regarding ACI
vs. other treatments possible
Clinical outcomes: some
evidence for better clinical
outcomes with ACI compared
with OAT and equivalent
outcomes with MF in studies with
higher validity; higher-quality
repair tissue with ACI compared
with other procedures; unclear if
statistical significance corresponds
to real clinical significance
Research: evolution of techniques
needs to be taken into account;
further high-quality studies
needed
FU, follow-up; NR, not reported; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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Appendix 7 Excluded studies: survival analysis
Author ID/year Reason
Adachi 2014193 The procedure described seems to be about implantation of cartilage-like tissue rather than
chondrocytes
Bert 2015129 Editorial and opinion piece with no primary data
Bae 2013134 All had Kellgren–Lawrence score of 3. EMA MACI SPC excluded such patients
Patients had OA and mean age 62.1 years so would not be considered for ACI
Behery 201484 Systematic review. Used only for checking completeness of our search retrieval. Six studies with
50 patients in case series
Brix 2012208 The 8 years’ details are too sparse to be of much use. It is only an abstract and we have other much
better ACI data
Briggs 2013
(abstract)209
Mean FU only 4 years. No data on subgroup with longer FU
Ebert 2013210 Has patients from Ebert 2011211
Ebert 2011211 Case series
Matrix-applied autologous chondrocyte implantation (MACI)
Excluded because almost half had concomitant procedures. No FU beyond 5 years
Ebert 2013212 Includes too many patients having concomitant procedures
Filardo 2012213 Second-generation ACI Hyalograft C
Filardo 2013189 Hyaluronan-based scaffold Hyaff 11 (Fidia Advanced Biopolymers Laboratories, Padua, Italy)
Filardo 2014214 Hyalograft: HYAFF 11 (Fidia Advanced Biopolymers Laboratories)
Filardo 2014215 Hyalograft C (Fidia Advanced Biopolymers Laboratories)
Gobbi 2014127 Excluded because large proportion had concomitant surgery such as meniscectomy, cruciate ligament
repairs
Gooding 200623 Only 2 years’ FU
Gudas 2012128 Mosaic-type osteochondral autologous transplantation (OAT) and MF, but only 30 patients in each
arm
Health Quality
Ontario216
Not about MF or ACI
Kon 200973 Second-generation ACI Hyalograft C
Kon 2011217 Biocompatible and biodegradable hyaluronan-based scaffold (Hyalograft C)
Kon 201174 Arthroscopic Hyalograft C technique
Kon 2011218 Second-generation ACI (Hyalograft C)
Kon 2009219 Systematic review
Kreuz 2006220 FU too short
McNickle 2009221 FU too short
Minas 2012222 FU only 12 months
Mithöfer 200982 Systematic review: mentions only five studies with FU > 5 years
Mithöfer 201228 Review: mentions only five studies with FU > 5 years
Nawaz 2011223 Only an abstract
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Author ID/year Reason
Ebert 2011
(abstract)211
Case series abstract only; n= 41 patients (44 knees; 53 grafts)
Negrin 201355 FU 2–5 years
Negrin 2012104 Most studies in meta-analysis had FU only 2 years. Some had 5 years but we have the individual trials
Niemeyer 2010224 FU too short
Noyes 2013225 Review. Checked for studies
Oussedik 2015226 Systematic review. We have all the individual trials that are eligible
Rosenberger
2008227
Mean FU < 5 years and quite a lot had other procedures, such as osteotomy, so pure ACI < 40 patients
Salzmann 2013121 Minimum postoperative FU of 2 years
FU time: 4.2± 1.8 years
Sciarretta 2013228 19 patients
Polyvinyl alcohol hydrogel implant (Cartiva Synthetic Cartilage Implant, Cartiva, Alpharetta, GA, USA)
Scillia 2015229 Not ACI or MF. Debridement
Ulstein 2014230 MF technique (MF) vs. osteochondral autologous transplantation (OAT mosaicplasty)
MF n = 11
OAT mosaicplasty n = 14
Upmeier 2007231 FU costs
Patients had to have been diagnosed with knee cartilage defects and, according to their operation
record, treated between 1997 and 2001 with any of the following techniques: ACI, osteochondral
allografts or autografts, MF or subchondral drilling, chondroplasty/laser chondroplasty, abrasion
arthroplasty, debridement/cartilage shaving (without further information)
Wylie 2015232 Systematic review
Zak 2012233 Two-step procedure, a biopsy sample was arthroscopically harvested to culture the cells and to seed
them on a matrix [MACI (Genzyme, Cambridge, MA, USA), 15 patients; Hyalograft C (Fidia Advanced
Biomaterials, Abano Terme, Italy), 44 patients; CaReS (Arthro Kinetics Biotechnology GmbH, Krems,
Austria), 11 patients]
FU, follow-up; SPC, Summary of Product Characteristics.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
202
Appendix 8 Included long-term studies: data
extraction and quality assessment
Asik 2008
Asik 2008106 Data
Title The Microfracture Technique for the Treatment of Full-Thickness Articular Cartilage
Lesions of the Knee: Midterm Results
Type of study Cohort study (pre–post)
Eligibility criteria reported
Quality of study NIH Good
No. of patients 90
Population 34.5 years (range 20–58 years)
47.8% male
Reason for injury not reported
Intervention MF
Duration of injury? NR
Previous attempts at repair? NR
Size of defect in cm2; depth or
severity if given
Mean not reported
Reports n with < 2 cm and ≥ 2 cm (see subgroup results)
Duration of FU 1.5, 3, 6, 12 months and last visit
Mean 68 months (range 24–108 months)
Survival curve provided? No
Results
Lysholm score, mean (SD) [range] Preop.: 52.4 (6.2) [38–70]
Last FU: 84.6 (7.8) [68–100]
Change: 30.4 (4.2)
p < 0.0001
Tegner activity scale scores, mean
(SD) [range]
Preop.: 2.6 (1.5) [2–5]
Last FU: 5.2 (1.3) [4–9]
Change 2.6 (0.8)
p < 0.0001
Oxford knee questionnaire, mean
(SD) [range]
Preop.: 23.1 (4.8) [12–30]
Last FU: 44.8 (5.7) [24–48]
Change: 21.7 (3.8)
p < 0.0001
Subgroup data given?
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Asik 2008106 Data
Lysholm score, mean (SD) Age:
l < 35 years, n= 42, 36.2 (5.8)
l ≥ 35 years, n= 48, 24.3 (6.1)
l p< 0.001
Size of defect:
l < 2 cm2, n= 68, 37.4 (5.9)
l ≥ 2 cm2, n= 22, 26.9 (4.7)
l p< 0.001
Location of defect:
l weight-bearing surface n= 42, 26.8 (5.3)
l non-weight-bearing surface, n= 48, 37.3 (6.4)
l p< 0.001
BMI:
l < 25 kg/m2, n = 52, 38.2 (5.4)
l ≥ 25 kg/m2, n = 38, 26.2 (4.8)
l p< 0.001
Tegner activity scale scores, mean
(SD)
Age:
l < 35 years, n= 42, 2.6 (0.8)
l ≥ 35 years, n= 48, 2.1 (0.4)
l p< 0.001
Size of defect:
l < 2 cm2, n= 68, 2.8 (0.6)
l ≥ 2 cm2, n= 22, 2.0 (0.4)
l p< 0.001
Location of defect:
l weight-bearing surface n= 42, 2.2 (0.5)
l non-weight-bearing surface, n= 48, 2.6 (0.6)
l p< 0.001
BMI:
l < 25 kg/m2, n = 52, 2.8 (0.4)
l ≥ 25 kg/m2, n = 38, 2.0 (0.3)
l p< 0.001
Oxford Knee Questionnaire, mean
(SD)
Age:
l < 35 years, n= 42, 21.7 (3.4)
l ≥ 35 years, n= 48, 16.5 (2.8)
l p< 0.001
Size of defect:
l < 2 cm2, n= 68, 22.2 (3.6)
l ≥ 2 cm2, n= 22, 15.8 (2.8)
l p< 0.001
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Asik 2008106 Data
Location of defect:
l weight-bearing surface n= 42, 16.2 (2.7)
l non-weight-bearing surface, n= 48, 23.2 (2.4)
l p< 0.001
BMI:
l < 25 kg/m2, n= 52, 22.8 (2.1)
l ≥ 25 kg/m2, n= 38, 16.3 (2.4)
l p< 0.001
Losses to FU: percentage and
reasons if given
Excluded:
28 lost to regular FU
30 who had undergone a secondary surgical intervention after the index operation
(16 ACL ruptures, 13 meniscus ruptures and 1 posterior cruciate ligament rupture)
98 because an ACL rupture, meniscal lesion, patellofemoral problems, plica lesion,
other location of defect, or more than one location of defect was observed at
index operation
Any costs given? No
Survival curve No
ACL, anterior cruciate ligament; FU, follow-up; NR, not reported; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? CD
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
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Bentley 2012
Bentley 201278 Data
Title Minimum 10-year Results of a Prospective Randomised Study of
Autologous Chondrocyte Implantation vs. Mosaicplasty for
Symptomatic Articular Cartilage Lesions of the Knee
Type of study Long-term results of Bentley 20035 RCT of MF vs. mosaicplasty,
so only MF arm used here
Quality of study Uncertain risk of bias (Cochrane risk of bias tool)
No. of patients ACI: 58
Mosaicplasty: 42 (data not extracted)
Population Total group mean 31.3 years (range 16–49 years)
ACI: 30.9 years (16–49 years)
58% male
Reason for injury?
ACI: trauma 24 (41%); OCD 14 (24%); chondromalacia patellae
12 (21%); other/unknown: 8 (14%)
Intervention ACI-P or ACI-C
Duration of injury? Mean 7.2 years (range 9 months to 20 years)
Previous attempts at repair?
(Do not count debridement and lavage – only previous
MF, abrasion, drilling, ACI)
94 (94%) had previous surgery (no details by study arm)
No. of previous repairs: mean 1.5 (range 0–4)
Included MF, abrasion, debridement, drilling, and carbon-fibre
matrix support prostheses
Size of defect in cm2
Depth or severity if given
ACI 44.1 cm2 (range 10–105 cm2)
Duration of FU Minimum 10 years (range 10–12 years)
Survival curve provided? Yes
Results
Failure ACI 10/58 (17%)
Defined as a clinically poor result, with arthroscopic evidence of
failure of the graft, or revision surgery to the defect of any kind
Modified Cincinnati rating system
Graded as:
l excellent (> 80 points), good (55–79)
l fair (30–54)
l poor (< 30)
ACI: n= 48 (10 failures excluded)
l excellent 28
l good 7
l fair 6
l poor 2
‘Excellent’ or ‘good’ seen as significant improvement, ‘fair’ as
marginally better or unchanged, ‘poor’ as worse
Stanmore/Bentley functional rating system
Function and pain measure, 5-point scale of pain
related to function (0= no pain with any activity,
4= pain at rest and severe pain with activity)
ACI:
l 0: 7
l 1: 23
l 2: 3
l 3: 6
l 4: 4
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Bentley 201278 Data
Subgroup data
KM estimates (SE) of per cent failure rates at 5 years
according to preoperative factors
Age (years), p = 0.028:
l < 26 (n= 16) 0 (–)
l 26–35 (n= 25) 8 (5)
l > 35 (n= 17) 12 (8)
Gender, p = 0.87:
l male (n= 33) 6 (4)
l female (n= 25) 8 (5)
Cause, p= 0.31:
l chondromalacia patellae (n= 11) 19 (12)
l OCD (n= 11) 0 (0)
l trauma (n= 29) 7 (5)
l other/unknown (n = 7) 0 (–)
Site, p= 0.81:
l lateral femoral condyle (n = 11) 9 (9)
l medial femoral condyle (n= 24) 8 (6)
l patella (n= 20) 5 (5)
l other/unknown (n = 3) 0 (–)
Losses to FU: percentage and reasons if given ACI 5 (8.6%)
Patients who were lost to FU were included until last review and
then withdrawn from the study
Any costs given? No
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes
Risk table attached? No
Total events reported? No
HRs, p-value and/or 95% CI, and whether adjusted or
not
No
FU, follow-up.
Cochrane risk of bias
Bias
Author
judgement Support for judgement
Random sequence generation (selection bias) Low risk Computer generated
Allocation concealment (selection bias) Unclear risk Sequential envelopes, unclear if opaque
Blinding of participants and personnel
(performance bias)
Unclear risk No details
Blinding of outcome assessment (detection bias) Unclear risk No details
Incomplete outcome data (attrition bias) Unclear risk Some missing data for subjective outcomes for
one study arm (not relevant to the review though)
Selective reporting (reporting bias) Unclear risk No information to judge
Other bias Low risk
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Beris 2012
Beris 2012107 Data
Title Treatment of Full-thickness Chondral Defects of the Knee with Autologous
Chondrocyte Implantation: A Functional Evaluation with Long-term Follow-up
Type of study Case series
Quality of study NIH Fair
No. of patients 42 (45 knees)
Population Mean age 28.9 years (range 12–47 years)
69% male
Reason for injury?
l Trauma (38/45 knees)
l OCD (7/45 knees)
Intervention ACI-P
Duration of injury? 28 months
Previous attempts at repair? NR
Size of defect
Depth or severity if given
Mean 5.33 cm2 (range 1.8–12 cm2)
All had isolated moderate to large full-thickness (Outerbridge grade III
or IV) chondral defects
Duration of FU Mean 96 months (range 62–144 months)
Evaluation at 6, 12, 24, 48 months and annually thereafter
Survival curve provided? No
Results
Lysholm score, median Preop.: 56.0
Last FU: 89.0
p< 0.05
IKDC Preop.: 45
Last FU: 69
p< 0.05
Tegner activity score Preop.: 5.5
Last FU: 6.5
p< 0.05
ICRS Preop.: 3.8
Last FU: 2.8
p< 0.05
Stanmore functional rating score Preop.: 3.06
Last FU: 0.94
Pain VAS Preop.: 7.33
Last FU: 2
p< 0.05
Does not appear to be a validated scale
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Beris 2012107 Data
Subgroup data given? None
Losses to FU: percentage and reasons if given NA
Any costs given? None
Survival curve? No
FU, follow-up; NA, not applicable; NR, not reported; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
CD
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
Selective reporting of study results
Reports median for Lysholm score, mean or median not stated for other outcomes. No measure of variance.
Bhosale 2009
Bhosale 2009108 Data
Title Midterm to Long-Term Longitudinal Outcome of Autologous Chondrocyte
Implantation in the Knee Joint
Type of study Cohort study
Quality of study NIH Good
No. of patients 80
Population Mean 34.6 (SD 9.1) years
78.8% male
Reason for injury not reported
Intervention ACI-P
Duration of injury? NR
Previous attempts at repair? Previous repair (not defined) 70/80 (87.5%) had median of 1 (IQR 1–2)
repairs
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Bhosale 2009108 Data
(Do not count debridement and lavage – only
previous MF, abrasion, drilling, ACI)
Size of defect in cm2
Depth or severity if given
Median defect area 4.1 cm2 (IQR 3.0–6.0 cm2)
Maximum size 20 cm2
Duration of FU Mean 5 years (range 2.7–9.3 years)
Survival curve provided? No
Results
Modified Lysholm score, median IQR Preop.: 54 (IQR 35.5–68.5)
1 year: 78 (IQR 52–87)
Median increase of 24 points
Subgroup data given? l Age
l Gender
l Defect size
l Defect location (lateral femoral condyle; medial femoral condyle;
multiple defects; trochlea; other)
l Previous procedures
l Baseline Lysholm score
Regression analysis as potential predictors for change in Lysholm score.
Results not extracted
Losses to FU: percentage and reasons if given NA
Any costs given? None
Survival curve? No
FU, follow-up; IQR, interquartile range; NA, not applicable; NR, not reported; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
Long-term data measured but not reported.
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Biant 2014
Biant 201479 Data
Title Long-term Results of Autologous Chondrocyte Implantation in the Knee for
Chronic Chrondral and Osteochondral Defects
Type of study Case series
Quality of study Good
No. of patients 104
Population Mean age: 30.2 years (range 15–49 years)
52.9% male
Reason for injury?
l Trauma: 55 (53%)
l OCD: 17 (16%)
l Chondromalacia patellae: 23 (22%)
l Childhood osteomyelitis: 2 (2%)
l Other/unknown: 7 (7%)
Intervention ACI-P
Duration of injury? Mean 7.8 years
Previous attempts at repair? Previous repair (MF, drilling, mosaicplasty, carbon fibre matrix support
prosthesis): 73 (70%) had ≥ 1 previous operation
31 (29.8%) had previous arthroscopic surgery and arthroscopic debridement
No. of previous repairs: mean 1.3 (range 0–5)
Size of defect in cm2
Depth or severity if given
4.78 cm2 (range 1.2–25 cm2)
Duration of FU Minimum of 10 years (range 10–12 years)
Mean 5.7 years’ graft failure
Survival curve provided? Yes
Results
Graft failure 27 (26%): all occurred within 8 years
Definition: patients who underwent revision surgery of any kind (thereby
altering or removing the original graft) or arthroplasty
Pain, VAS, 10-point scale Preop.: 6
Change to last FU: –8.3 (95% CI –10.8 to –5.8)
Modified Cincinnati knee score:
l excellent (> 80 points)
l good (55–79)
l fair (30–54)
l poor (< 30)
Preop.: NR
Last FU (intact graft, n= 73): 78 (range 10–100)
Change: 53 (95% CI 34 to 71)
Excellent: 46 (63%)
Good: 18 (24.7%)
Fair: 6 (8.2%)
Poor: 3 (4.1%)
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Biant 201479 Data
Stanmore/Bentley functional rating
system
Preop.: not reported. Assume change score is for patients with an intact graft
(n= 73)
Change to last FU: –2.6 (95% CI –3.7 to –1.5)
Score (n= 73?), n (%)
l 0: 14 (19.2%)
l 1: 38 (52.1%)
l 2: 8 (11%)
l 3: 8 (11%)
l 4: 5 (6.8%)
Satisfaction
Patients asked by an independent
interviewer if they were satisfied with
their ACI surgery and whether or not
they would consider undergoing it again
if the same symptoms arose in the other
knee
98/100 (98%)
Complications 3 (2.9%)
2 (1.9%) manipulation under anaesthesia within 8 weeks of surgery because
of early postoperative stiffness
1 (0.96%) DVT
Subgroup data given? l No prior cartilage surgery, n = 32
l Preop. modified Cincinnati knee score: mean 49 (range 18–94); last FU
mean 71 (range 10–100)
l Preop. Stanmore/Bentley score mean 3 (range 1–4); last FU mean 1.5
(range 0–4)
l Preop. mean VAS score 7 (range 1–10); last FU: mean 3.5 (range 0–10)
l Graft failures 6/32 (18.7%)
Four were lost to FU, but ITT n used here
for proportion
l Prior cartilage repair surgery, n = 72; states 73 earlier in report
l Preop. modified Cincinnati knee score mean 42 (range 12–82); last FU:
mean 65 (range 10–100)
l Preop. Stanmore/Bentley score mean 3 (range 0–4); last FU: 2 (range 0–4)
l Preop. mean VAS score was 5.5 (range 0.5–10); last FU: mean 3.5
(range 0–10)
l Graft failures: 21/72 (29.2%)
Patellar lesions, n = 36 l n= 36
l Preop. mean modified Cincinnati knee score: 40 (range 14–73); last FU
(n = 27): 79 (range 48–100)
l Excellent: 17 (63%)
l Good: 8 (30%)
l Fair: 2 (7%)
l Preop. mean Stanmore/Bentley score 3 (range 2–4); last FU (n= 27): 1.3
(range 0–4)
l Preop. mean VAS score: 6.4 (range 2.5–10); last FU (n = 27): 2 (range 0–8)
l Graft failure: 9 (25%)
l The mean time to failure 5.8 years (range 1–8 years)
Losses to FU: percentage and reasons if
given
4 (3.8%)
Any costs given? No
Survival curve? No
FU, follow-up; NR, not reported; postop., postoperative; preop., preoperative.
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Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Browne 2005
Browne 2005109 Data
Title Clinical Outcome of Autologous Chrondrocyte Implantation at 5 Years in US
Subjects
Type of study Case series prospective registry from 40 centres
Quality of study NIH Poor
No. of patients 100
Population Mean 37.0 (SD 9.1) years, range 14–55 years
65% male
Reason for injury?
l Acute injury: 58/100 (58%)
Intervention ACI-P
Duration of injury? NR
Previous attempts at repair? l At least one surgical procedure: 78/100 (78%)
l At least one cartilage repair procedure: 70/100 (70%)
l Abrasion/drilling/MF: 36/100 (36%)
l Fragment reattachment/removal: 1/100 (1%)
l Osteochondral allograft/autograft: 1/100 (1%)
l ACI: 1/100 (1%)
l Meniscus repair/meniscectomy: 32/100 (32%)
l Ligament repair/reconstruction: 14/100 (14%)
l Patella alignment: 1/100 (1%)
l Other: 4/100 (4%)
Size of defect in cm2
Depth or severity if given
l Mean 4.9 cm2 (SD 3.8, range 0.84–23.54 cm2)
l < 2.0 cm2: 15/100 (15%)
l 2.0 to < 4.0 cm2: 38/100 (38%)
l 4.0 to < 6.0 cm2: 17/100 (17%)
l ≥ 6.0 cm2: 30/100 (30%)
l Multiple defects: 15/100 (15%)
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Browne 2005109 Data
Duration of FU 5 years
Survival curve provided? No
Results
Overall condition score, mean (SD), n = 87,
modified Cincinnati knee rating system
Preop.: 3.2 (1.5)
5-year FU: 5.8 (2.8)
Change: 2.6 (3.2); p< 0.0001 (95% CI 1.9 to 3.2)
Pain mean (SD), n= 86
Patient rated measure (6 point scale 0–10),
unlikely validated
Preop.: 3.1 (2.2)
5-year FU: 5.5 (3.2)
Change: 2.3 (3.7); p< 0.0001 (95% CI 1.5 to 3.1)
Preop.: 4.1 (2.7)
5-year FU: 6.1 (3.1)
Change: 2.0 (3.8); p< 0.0001 (95% CI 1.2 to 2.8)
Swelling mean (SD), n= 85
Proportion in response sets Improved: 62/100 (62%)
No change: 6/100 (6%)
Worsened: 19/100 (19%)
Definitions not provided; states ‘additional examination’
Failure: Cases in which a patient needed an
operation after ACI that necessitated the
removal of the graft, confirmed a loss of
defect fill or violated the subchondral bone
(e.g. abrasion chondroplasty, MF, drilling,
unicompartmental knee replacement, TKR)
13/100 (13%)
Complications Joint infections, n= 0
Arterial injuries, n= 0
Nerve injuries, n = 0
DVT, n= 1
Reflex sympathetic dystrophy, n= 1
Closed manipulation under anaesthesia, n= 2
Subgroup data given?
Modified Cincinnati knee rating system
Overall condition, change from baseline
Men (n= 65) vs. women (n= 35): 2.4 vs. 2.8
Concurrent procedures (n = 21) vs. no concurrent procedures (n= 79):
2.5 vs. 2.6
Overall condition Patients rated as improved, n= 62
Preop.: 3.0 (1.4)
5-year FU: 7.1 (2.2)
Change: 4.1 (2.2); p< 0.0001 (95% CI 3.6 to 4.7)
Losses to FU: percentage and reasons if
given
Unable to collect 5-year FU data on 13 participants
Numbers reporting outcomes varied from 62 to 87
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Browne 2005109 Data
Any costs given? No
Survival curve? No
FU, follow-up; NR, not reported; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: POOR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments (if POOR, please state why)
Proportion ‘improved’ and ‘worsened’ not defined.
Gomoll 2014
Gomoll 2014110 Data
Title Autologous Chondrocyte Implantation in the Patella: A Multicentre Experience
Type of study Case series. Retrospective analysis, but based on a prospective patient
registry from four centres specialising in cartilage repair
All four surgeons had extensive experience
Quality of study Poor
No. of patients 110
Additional 23 were lost to FU (FU rate 83%)
Population Age – mean 33 (SD 10.1) years (range 15–55 years)
41.8% male
No bilateral ACI included
All patients with ACI for patellar defects (including trochlear graft) with at
least 4 years’ FU were included. Defects outside the patellofemoral
compartment were excluded
Text discusses differences in population by centres (not data extracted)
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Gomoll 2014110 Data
Intervention ACI-P (procedure described by Minas et al., 1999)
Duration of injury? Reported symptoms for mean of 3 years (SD 35 months), range 2–144 months
Previous attempts at repair? Mean of 1.2 previous surgery (range 0–12, SD 1.7)
Most common prior procedures were chondroplasty and lateral release
Size of defect in cm2
Depth or severity if given
Mean 5.4 (SD 2.7) cm2; range 1–13.2 cm2
30 (27%) had bipolar disease with an additional trochlear defect; mean size
of 4.5 (SD 2.8) cm2, range 1–13 cm2
12 distal (11%; type I), 3 lateral (3%; type II), 16 medial (15%; type III) and
79 central/panpatellar defects (72%; type IV) by Pidoriano/Fulkerson
classification
82 (75%) of patellar defects and 26 (87%) of trochlear defects were
circumferentially shouldered by healthy cartilage (contained)
Duration of FU Mean of 90 (SD 31.7) months, range 48–192 months
States data collected yearly intervals; patient-reported outcomes analysed at
latest FU
Survival curve provided? No
Results, measured at latest FU
SF-12 (QoL) Physical subscale, n= 89 (81%); baseline: 38.6; last FU 44.1 (p= 0.001)
Mental subscale, n = 89 (81%; baseline: 49.7; last FU: 53.5 (p = 0.1)
KSS Knee, n= 44 (40%); baseline: 61.8; last FU: 85.2 (p< 0.001)
Function n= 44 (40%); baseline: 58.5; last FU: 72.7 (p< 0.0001)
IKDC n= 65 (60%)
Baseline: 40.2
Last FU: 69.4 (p< 0.0001)
86% and 74% of patients demonstrated more than 10 and 20 points of
improvement, respectively (considered to exceed the minimal clinically
important difference)
Modified Cincinnati rating scale, range
2–10
n= 85 (78%); baseline: 3.2; last FU: 6.2 (p< 0.0001)
WOMAC n= 44 (40%); baseline: 50.4; last FU: 28.6 (p < 0.0001)
l 75% of patients exceeded a commonly accepted threshold for MCIDs,
with more than a 26% improvement in WOMAC from baseline
Satisfaction with procedure
Measure used not reported
n= 93 (84.5%)
84% felt improvement at the time of final FU
86% rated their knee function as good or excellent
92% would choose to undergo ACI again
Treatment failure 9/110 (8.2%). If diagnosed by MRI and/or arthroscopy, with structural
failure of the ACI graft in conjunction with pain requiring revision surgery
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Gomoll 2014110 Data
Subgroup data given? p-values only given, data not extracted
States that none of the differences among subgroups reached statistical
significance:
l polarity (bipolar vs. unipolar)
l containment (contained vs. uncontained; patellar defects only)
l concomitant tibial tuberosity transfer (yes vs. no)
l patellar defect location (lateral, medial, panpatellar)
l defect size (< 4 cm2 vs. > 4 cm2)
l sex (male vs. female)
Losses to FU: percentage and reasons if
given
NA (only those not lost to FU were included)
Note that questionnaires were added as they became available and
validated, and the start date varied between institutions. Therefore, not all
patients answered the same battery of questionnaires
Any costs given? None
Survival curve? No
FU, follow-up; MCID, minimum clinically important difference; NA, not applicable; KSS, Knee Society Score; SF-12, Short
Form questionnaire-12 items; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional Comments (if POOR, please state why)
Measures of variance not reported.
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Jungmann 2012
Jungmann 2012111 Data
Title Autologous Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee
Type of study Case series. Retrospective analysis of prospective database. Described in paper as a cohort
study, level 3 evidence
Quality of study Good
No. of patients 413
Population Age 34.9 (SD 9.0) years
57.4% male
Origins of the cartilage defect:
l Traumatic, 7.0%
l Degenerative, 52.0%
l Protracted traumatic-degenerative, 28.3%
l Previous OCD or flake fracture, 12.6%
Intervention l ACI-P, n= 109
l ACI-C, n= 235
l MACI, n= 69
CellGenix (Freiburg, Germany) for cell suspensions [periosteum patch-covered ACI and
Chondro-Gide™ (Geistlich, Wolhusen, Switzerland)-covered ACI] or BioTissue Technologies
(Freiburg, Germany) for BioSeed-C (matrix associated) procedure
Duration of injury? NR
Previous attempts at repair? No previous knee surgery: 29.8%
MF: 18.6%
Pridie drilling: 7.3%
ACI: 4.2%
Abrasion arthroplasty/debridement: 3.1%
Mosaicplasty (OATS): 1.9%
Autologous spongiosa graft: 1.7%
Retrograde drilling: 0.72%
Size of defect
Depth or severity if given
5.6 (SD 3.0) cm2
Duration of FU 2–11.8 years
FU cut-off was at 5 years
62.5% had a FU at 5 years
Survival curve provided? Yes
Results
Revision surgery (treatment
failure), n (%)
Treatment failure, represented by need for revision surgery, indicated by:
l persistent pain at the operated knee joint;
l significant loss of function of the operated knee joint; and
l clinical findings and/or MRI revealed compatibly pathological changes to confirm
symptoms, such as MRI evidence of graft delamination, hypertrophy, severely abnormal
signal, insufficient fusion with adjacent cartilage, or secondary transplant defects
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Jungmann 2012111 Data
88/413 (21.3%)
ACI-P: 34/109 (31.2)
ACI-C: 43/235 (18.3)
MACI: 11/69 (15.9)
Periosteum patch-covered technique [p= 0.031: odds ratio, 2.4 (BioSeed-C) vs. 2.0
(Chondro-Gide)] increased the risk for the need of re-intervention
Time to revision surgery,
mean (SD) years
l ACI-P: 1.7 (1.2)
l ACI-C: 1.7 (1.1)
l MACI: 2.4 (1.2)
p = NS
Subgroup data:
Treatment failure (revision),
prognostic factors n%
Defects related to a trauma
within the past 6 months
before surgical treatment
were considered ‘traumatic,’
while those associated with
a traumatic incident more
than 6 months before
surgical treatment were
considered ‘posttraumatic.’
Degenerative’ defects were
considered those cases in
which no trauma could be
evaluated.
Age (years)
l < 30: 24/123 (19.5)
l 30–39: 39/179 (21.8)
l ≥ 40: 25/111 (22.5)
BMI
l < 25: 55/232 (23.7)
l 25–29: 25/149 (16.8)
l ≥ 30: 8/32 (25.0)
No. of defects
l 1: 74/340 (21.8)
l > 1: 14/73 (19.2)
Defect size (cm3)
l < 3: 12/44 (27.3)
l ≥ 3: 76/369 (20.6)
Cause
l Degenerative: 43/215 (20.0)
l Protracted traumatic-degenerative:26/117 (22.2)
l OCD, flake fracture: 11/52 (21.2)
l Trauma: 8/29 (27.6)
Gender
l Male: 41/237 (17.3)
l Female: 47/176 (26.7)
Location
l Multiple: 13/68 (19.1)
l Patella: 26/111 (23.4)
l Medial femoral condyle: 36/168 (21.4)
l Lateral femoral condyle: 3/37 (24.3)
l Trochlea: 4/29 (13.8)
Nicotine
l No: 59/298 (19.8)
l Yes: 29/115 (25.2)
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Jungmann 2012111 Data
Parallel treatment
l Without, 67/306 (21.9)
l With, 21/107 (19.6)
Previous surgery
l No, 17/123 (13.8)
l 1, 41/223 (20.2)
l > 1, 26/67 (38.8)
Previous treatment
l No, 54/289 (18.7)
l Bone marrow stimulation, 28/94 (29.8)
l Previous transplantation, 5/23 (21.7)
l Other, 1/7 (14.3)
Female gender (p = 0.015; odds ratio 1.7), more than one previous surgery (p< 0.001;
odds ratio 4.0), and previous BMS (p= 0.017; odds ratio 1.9), increased the risk for the
need of re-intervention
Losses to FU: percentage
and reasons if given
NA
Any costs given? No
Survival curve? No
BMS, bone marrow stimulation; FU, follow-up; NA, not applicable; NR, not reported; NS, not significant.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
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Knutsen 2007
Knutsen 200767 Data
Title A Randomised Trial Comparing Autologous Chondrocyte Implantation with MF
Type of study RCT
Quality of study Uncertain risk of bias
No. of patients Total 80
l ACI, 40
l MF, 40
Population Reason for injury:
l Trauma, 65%
l OCD, 28%
l Unknown, 7%
Baseline characteristics available in online supplement – unable to access
Intervention ACI-P
MF
Duration of injury? 36 months
Previous attempts at repair? 74 (93%) had previous knee surgery, including anterior cruciate ligament
reconstruction (15), meniscal surgery (14), arthroscopic lavage and
debridement (29), Pridie drilling (3), operations for OCD, such as drilling or
fixation of a fragment (13)
Size of defect
Depth or severity if given
No included defects were deeper than 10mm
Duration of FU 5 years
Survival curve provided? Yes
Results
Failures:
Operation considered to have failed if patient
needed reoperation because of symptoms
due to a lack of healing of the treated
defect. The need for shaving or trimming of
a lesion was not defined as a failure
l ACI: 9/40 (23%)
l MF: 9/40 (23%)
Failures occurred at a mean of 26.2 months after ACI and 37.8 months
after MF (p= 0.101)
Median Lysholm score (assume range) ACI estimated from figure:
l Baseline: 62 (25–90)
l 5 years: 78 (21–100)
MF:
l Baseline: 58 (12–95)
l 5 years: 80 (37–100)
Difference between groups p= 0.227 after adjustment for pretreatment
values
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Knutsen 200767 Data
VAS pain scale, median (assume range) Estimated from figure:
ACI
l Baseline: 52 (2–100)
l 5 years: 26 (0–100)
MF
l Baseline: 52 (18–83)
l 5 years: 26 (0–86)
Difference between groups p= 0.278 after adjustment for pretreatment values
SF-36 PCS, median (assume range) Estimated from figure:
ACI
l Baseline: 42 (26–58)
l 5 years: 48 (20–65)
MF
l Baseline: 38 (20–56)
l 5 years: 48 (12–68)
Difference between groups p= 0.054 after adjustment for pretreatment values
Proportion compared with baseline Less pain: 72%
Improvement in Lysholm score: 80%
Improvement in SF-36 PCS: 72%
Mean Tegner score ACI
l Baseline: 3.28
l 5 years: 4.05; p= 0.007
MF
l Baseline: 3.16
l 5 years: 4.36; p= 0.002
Difference between groups p= 0.323 after adjustment for pretreatment values
Subgroup data
No. of failures by 5 years
l Grade 1= predominantly hyaline tissue
l Grade 2= fibrocartilage hyaline
l mixture
l Grade 3= fibrocartilage
l Grade 4= inadequate biopsy or no repair
tissue (predominantly bone)
None of the patients with a failure had the
best-quality cartilage (p= 0.001)
Histological grade (no. of knees): no. of failures
l 1: (n = 10) 0
l 2: (n = 16) 3
l 3: (n = 29) 6
l 4: (n = 12) 3
Younger patients (less than 30 years old) had a better clinical outcome than
did older patients (p= 0.013) regardless of their treatment group
Data not presented, unclear if subgroup defined a priori
Losses to FU: percentage and reasons if given No losses to FU
The patients with a failure remained in the study, with their last recorded
clinical FU scores before the failure considered to be their final clinical score
Any costs given? No
Survival curve? No
FU, follow-up; PCS, physical component score.
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Cochrane risk of bias score
Bias Author judgement Support for judgement
Random sequence generation (selection bias) Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel (performance bias) Unclear risk NR
Blinding of outcome assessment (detection bias) Unclear risk NR
Incomplete outcome data (attrition bias) Low risk No losses to FU
Selective reporting (reporting bias) Unclear risk
Other bias Low risk
FU, follow-up; NR, not reported.
Krych 2012
Krych 2012112 Data
Title Activity Levels Are Higher after Osteochondral Autograft Transfer
Mosaicplasty than after Microfracture for Articular Cartilage Defects of the
Knee
Type of study Case series (retrospective)
Only MF data extracted
Quality of study Good
No. of patients 48 with full-depth lesions
Analysed at 1, 2, 3 and 5 years’ FU; mean FU 4.4 years (range 2–10 years)
Population Age at MF, mean 32.5 years (range 15–46 years)
Male/female: 32:16
Lesion mean size 2.55 cm2 (range 1.00–6.25) cm2
BMI 25.5 kg/m2 (range 21–31 kg/m2)
Defect locations
l Medial femoral condyle, n = 27
l Lateral femoral condyle, n = 16
l Trochlea, n= 5
Intervention MF
Duration of injury? NR
Previous attempts at repair? None
Size of defect in cm2
Depth or severity if given
Mean 2.55 cm2 (range 1.00 to 6.25 cm2)
Full-depth lesions
Duration of FU Mean FU 4.4 years (range 2–10 years)
Survival curve provided? No
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Krych 2012112 Data
Results
Definitions of success and failure NR
SF-36 physical component mean (SD)SD
10 read from graph
Preop., 40.5 (10)
Year 1, 47.9 (10)
Year 2, 50.8 (10)
Year 3, 52.6 (10)
Year 5, 52.0 (10)
The Knee Outcome Survey ADL score
mean (SD)SD read from graph
Preop., 64.1 (16)
Year 1, 78.7 (19)
Year 2, 79.1 (16)
Year 3, 86.6 (13.4)
Year 5, 84.4 (15.6)
SD read from graph Preop., 49.7 (16)
Year 1, 65.4 (16)
Year 2, 69.2 (24)
Year 3, 69.2 (25)
Year 5, 84.4 (26)
Marx Activity Rating Scale score, mean
(SD)
Preop., 7.3 (5.4)
Year 1, 4.11 (1.05)
Year 2, 3.71 (1.64)
Year 3, 2.91 (2.12)
Year 5, 2.89 (2.5)
Subgroup data: none reported
Losses to FU: percentage and reasons if
given
NR
Any costs given? No
Survival curve? No
FU, follow-up; NR, not reported; preop., preoperative.
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Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? CD
4. Were the subjects comparable? NA
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Moseley 2010
Moseley 2010115 Data
Title Long-Term Durability of Autologous Chondrocyte Implantation:
A Multicenter, Observational Study in US Patients
Type of study Case series
Quality of study Fair to good
No. of patients 72
Population N = 72
Mean FU (years), 10.9, SD 1.1
Mean age (years) 37.0 ± 9.27, range 14–53
Male (%) 61
% with single defect, 60/72
% with multiple defects, 12/72
BMI mean ± SD, 27.2 kg/m2 range 13.2–42.4 kg/m2
Defect size:
l Total surface area, cm2: mean 5.2, range 0.4–23.5
Defect sites (total defects = 84):
l Medial femoral %, 72
l Lateral femoral %, 18
l Trochlea %, 10
Intervention Carticel (Genzyme) ACP
ACP received on or before 1996; 2044/2194 excluded because
ACI treatment occurred after 31 December 1996
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Moseley 2010115 Data
Duration of injury? NR; 47/62 had acute onset of injury
Previous attempts at repair?
(Do not count debridement and lavage – only previous
MF, abrasion, drilling, ACI)
Previous intervention (in previous 5 years), %:
l At least 1 surgical procedure, 74%
l At least 1 cartilage repair procedure, 68%
l Abrasion/drilling/MF (MST), 36%
l Meniscus repair/meniscectomy, 28%
Size of defect, cm2
Depth or severity if given
5.2, range 0.4–23.5
Full-thickness defects
Duration of FU 6–10 years
Survival curve provided? Yes
Results
Failure Failure defined as: ‘patient needed an operation after ACI that
necessitated removal of the graft, confirmed a loss of defect fill,
or violated the subchondral bone (e.g. abrasion chondroplasty,
MF, drilling, unicompartmental knee replacement, total knee’
Failures = 12/72
18 patients who did not meet the definition of failure had
operations for: presence of fibrotic tissue (4), periosteal flap
complications (4), graft hypertrophy (3), adhesions (3), loose
body (2), synovitis (2) and maltracking (2)
OCS: A 1–10 VAS, with status allocated to scores of 2,
4, 6, 8, 10 defined, respectively as follows:
l Poor: I have significant limitations that affect ADL
l Good: I have moderate limitations that affect ADL,
no sports possible
l Very good: I have only a few limitations with sports
l Excellent: I am able to do whatever I wish (any
sport) with no problems
l Improved at 1–5 years and at 6–10 years, n= 47
l Improved at 1–5 years and not at 6–10 years, n= 7
l Not improved at 1–5 years improved at 6–10 years, n= 3
l Not improved at 1–5 years or at 6–10 years, n= 15
No improvement from baseline was defined as a negative
change or no change in OCS from baseline to latest FU.
Improvement was defined as a positive score change of at least
1 point from baseline to latest FU
Pain (mean SD) 1–10 VAS l Preop., 3.3 (3), n = 72
l Year 1–5, 6.1 (3), n = 72
l Year 6–10, 5.3 (3), n= 72
Improved patients only:
l Year 1–5, 7.5 (2), n = 50
l Year 6–10, 7.4 (2.5), n = 39
Swelling (mean SD) 1–10 VAS l Preop., 4.3 (3), n = 72
l Year 1–5, 6.8 (4.4), n= 72
l Year 6–10, 6.0 (4.5), n = 72
Improved patients only:
l Year 1–5, 7.5 (2), n = 50
l Year 6–10, 7.4 (2.5), n = 39
Subgroup data given? Satisfaction according to defect site subgroups
Losses to FU: percentage and reasons if given These covariate analyses were likely to be underpowered
Any costs given? No
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Moseley 2010115 Data
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes
Risk table attached? No
Total events reported? Yes
HRs, p-value and/or 95% CI, and whether adjusted or
not
NA, no subgroups analysed, so no HRs
FU, follow-up; NA, not applicable; NR, not reported; OCS, overall condition score; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? NA
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
CD
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR TO GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
The large number of losses to FU is worrying.
Nawaz 2014
Nawaz 201480 Data
Title Autologous Chondrocyte Implantation in the Knee: Mid-Term to Long-Term Results
Type of study Case series
Quality of study Good
No. of patients 869 met inclusion criteria
41 lost to FU (one died before study)
827 analysed
Population N = 827
Mean FU (years) 6.2 [2–12]
Mean age (years) 34 [14–56]
Male (%) 59.6
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Nawaz 201480 Data
Defect size (cm2) 4.09 [0.64–20.7]
Previous intervention 34%
Defect site:
l Medial femoral, 51%
l Lateral femoral, 13%
l Patellar, 24.%
l Trochlear, 6%
l Multisite, 6%
Intervention ACI-P/ACI-C/MACI
Duration of injury? NR
Previous attempts at repair? 34% not including debridement and lavage – only previous MF, abrasion, drilling, ACI
Size of defect in cm2
Depth or severity if given
Size, see above. Patients with defect with estimated depth of > 8mm were not
included. Lesions in the target population described as ‘regardless of depth or size’
Duration of FU See above
Survival curve provided? Yes
Results
Failure Presented in KM plots
Data extracted elsewhere
Stanmore functional rating (mean)
The p-value from ANOVA
adjusted for time of postoperative
estimate
Preop. 2.7
Postop. 1.7
Mean difference –1.09
95% CI –1.18 to –1.00
p < 0.001
VAS (0–10)
The p-value from ANOVA
adjusted for time of postoperative
estimate
Preop. 5.95
Postop. 3.561
Mean difference –2.39
95% CI –2.61 to –2.19
p < 0.001
Modified Cincinnati (0–100)
p-value from ANOVA adjusted for
time of postoperative estimate
Preop. 46.91
Postop. 66.74
Mean difference 19.83
95% CI 18.1 to 21.56
p < 0.001
Complications NR
Subgroup data given? Yes for KM plots of failure
Losses to FU: percentage and
reasons if given
41 lost to FU, 1 died; 869 – 42= 827 analysed
Any costs given? No
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Nawaz 201480 Data
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes. Several by subgroup
Risk table attached? To some
Total events reported? For some
HRs, p-value and/or 95% CI, and
whether adjusted or not
Yes for subgroup analyses; multivariate Cox regression
ANOVA, analysis of variance; FU, follow-up; NR, not reported; postop., postoperative; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Niemeyer 2014117
Niemeyer 2014117 Data
Title Long-term Outcomes After First-Generation Autologous Chondrocyte Implantation for
Cartilage Defects of the Knee
Type of study Case series
Quality of study Good
No. of patients 70
Population N = 70
16 were lost to FU
Mean FU (years) 10.9 (SD 1.1)
Mean age (years) 33.3 (SD 10.2)
Male (%) 35.7
Defect size (cm2) 6.5 (SD 4.0)
Previous intervention (%) 62.8
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Niemeyer 2014117 Data
Defect site:
l Medial femoral, 41.1%
l Lateral femoral, 18.6%
l Patellar, 20%
l Trochlear, 2.9%
l Multisite, 17.1%
Intervention First-generation ACP
Duration of injury? ‘the mean duration of symptoms was several years’
Previous attempts at repair? (44/70) 62.8% had previous intervention
20/44 were not defect associated
Size of defect in cm2
Depth or severity if given
Size, see above
Full-thickness defects
Defects of the subchondral bone plate exceeding a depth of 3–4mm were excluded
Duration of FU See above
Survival curve provided? Yes
Results
Failure KM plot
VAS pain (mean SD) At FU, pain at exposure on the VAS decreased from 7.2± 1.9 preop. to 2.1 ± 2.1
postop. (p< 0.01)
Lysholm (mean SD) 42.0 ± 22.5 preop. to 71. ± 17.4 postop.
IKDC (mean SD) FU 74.0± 17.3
Tegner score (mean SD) Decreased from 5.67± 2.39 to 4.36 ± 1.63 (p< 0.01)
This represents slight worsening
FU scores: mean (SD)
KOOS version 4 68.4 ± 19.9
KOOS-pain 81.4 ± 18.2
KOOS-symptoms 75.6 ± 17.3
KOOS-ADL 86.0 ± 16.7
KOOS-sports 62.3 ± 29.0
KOOS-QoL 54.3 ± 23.9
Satisfaction (at FU), n Very satisfied, 28
Satisfied, 26
Neutral, 14
Not satisfied, 2
Total, 70
Complications No complications related to the surgical procedure itself
Subgroup data given? Satisfaction according to defect site subgroups
Little difference, but numbers too small for conclusions
Losses to FU: percentage and
reasons if given
16 were lost to FU; no details
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Niemeyer 2014117 Data
Any costs given? No
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes
Risk table attached? No
Total events reported? Yes
HRs, p-value and/or 95% CI, and
whether adjusted or not
NA, no subgroups analysed
FU, follow-up; NA, not applicable; postop., postoperative; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: GOOD
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
The large number of losses to FU is worrying.
Niemeyer 2014102
Niemeyer 2014102 Data
Title First-generation vs. Second-generation Autologous Chondrocyte Implantation
for Treatment of Cartilage Defects of the Knee: A Matched-pair Analysis on
Long-term Clinical Outcome
Type of study Cohort with matched historical controls
Criteria for matching were defect location and patient age. If there were
multiple options in the database, defect size was used an additional
parameter for selection
Quality of study Good
Five stars
Newcastle/Ottawa
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Niemeyer 2014102 Data
No. of patients N= 46
l ACI-P= 23 – ACI-P were the historical controls
l ACI-C= 23
Population Age (years) mean (SD):
l ACI-P, 31.7 (6.9)
l ACI-C, 31.4 (7.8)
% male not reported
Reason for injury not reported
Intervention ACI-P (chondrocytes provided by Genzyme, Cambridge, MA, USA and
Metreon Bioproducts GmbH, Freiburg, Germany)
ACI-C (Chondro-GideTM, Geistlich, Wolhusen, Switzerland)
Duration of injury? NR
Previous attempts at repair? NR
Size of defect in cm2 mean, (SD)
Depth or severity if given
ACI-P: 5.1 (2.3)
ACI-C: 4.9 (1.5)
All graded 3 or 4 according to the ICRS classification
Duration of FU, mean (SD) ACI-P: 10.7 (1.0) years
ACI-C: 10.5 (0.6) years
Survival curve provided? Yes
Results
Re-intervention rate. Definition for
re-intervention not given
ACI-P: 4/23 (17.4%), including one total knee joint replacement
ACI-C: 4/23 (17.4%) including one total knee joint replacement
Lysholm score, mean SD ACI-P:
l Preop., 38.4 (18.3)
l FU, 75.6 (11.8)
ACI-C:
l Preop., 44.1 (21.3)
l FU, 82.7 (9.9)
ACI-P vs. ACI-C preop.: p = 0.371
ACI-P vs. ACI-C at FU: p= 0.031
No baseline data ACI-P: 68.0 (12.0)ACI-C: 76.4 (12.8) p= 0.023
Subgroup data given? No subgroup data
Losses to FU: percentage and reasons if
given
NA
Any costs given? No
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Niemeyer 2014102 Data
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes
Risk table attached? No
Total events reported? No
HRs, p-value and/or 95% CI, and whether
adjusted or not
No
FU, follow-up; NR, not reported; preop., preoperative.
Peterson 2010
Peterson 2010118 Data
Title Autologous Chondrocyte Implantation: A Long-term Follow-up
Type of study Case series. Retrospective data collection and analysis
Quality of study Poor
No. of patients 590 had ACI-P
341 eligible
224 responded to questionnaires
Isolated cartilage lesions n= 159
Multiple lesions n= 56
Population Age 33.3 years (SD 9.5 years, range 14–61.5 years)
% male not reported
Reason for injury not reported
Intervention ACI-P
Duration of injury? NR
Previous attempts at repair? 30/82 (37%) had a previous operation that included drilling or shaving of the chondral
lesion
Not clear what the n of 82 relates to
Size of defect in cm2
Depth or severity if given
5.3 cm2 (range 0.6–15.8 cm2) per lesion
7 cm2 (range 0.6–27 cm2) per patient
Duration of FU 12.8 years (range 9.3–20.7 years)
Survival curve provided? No
Results
At FU:
l Better or same: 165/224 (74%)
l Worse: 59/224 (26%)
Satisfied with ACI and would do again: 202/219 (92%)
Success/failure not reported
Current status during the past 10 years rated as better, worse, or unchanged
(no further details)
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Peterson 2010118 Data
Lysholm score Preop.: 60.3
FU: 69.5
(p= 0.009 from two-sample t-test; p = 0.0016 from paired t-test pertaining to
58 patients)
Tegner–Walgren score Preop.: 7.22
FU: 8.2
(p= 0.002 from two-sample t-test; p = 0.0008 from paired t-test pertaining to
109 patients)
Brittberg–Peterson score
10 cm VAS with 13 parameters,
where 0 relates to normal
function and 130 severe
disability
Preop.: 59.4
FU: 40.9 (p< 0.001 from two-sample t-test; p= 0.004 from paired t-test pertaining to
53 patients)
KOOS No baseline data
FU:
Pain, 74.76
Symptoms, 63
ADL, 81
Sports, 41.5
QoL, 49.3
Noyes score FU: 5.4
Subgroup data
Improved compared with
previous years, n (%)
Isolated femoral condyle defects (n= 52): 14 (27)
Multiple lesions (n = 55): 12 (22)
OCD lesions (n= 26): 7 (27)
Patellar lesions with realignment (n= 34): 6 (18)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46): 11 (24)
Same compared with previous
years, n (%)
Isolated femoral condyle defects (n= 52): 22 (42)
Multiple lesions (n = 55): 20 (40)
OCD lesions (n= 26): 14 (54)
Patellar lesions with realignment (n= 34): 18 (53)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46): 24 (52)
Would do ACI again, n (%) Isolated femoral condyle defects (n= 52): 47 (90)
Multiple lesions (n = 55): 51 (94)
OCD lesions (n= 26): 25 (96.2)
Patellar lesions with realignment (n= 34): 31 (91.2)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46): 41 (91.1)
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Peterson 2010118 Data
Lysholm score, mean (range)
[available no. of values]
Isolated femoral condyle defects (n= 52):
l Preop.: 60.1 (46–81) [13]
l FU: 72.6 (25–96)
l p = 0.02 (two-sample t-test)
l p = 0.03 (paired t-test)
Multiple lesions (n = 55):
l Preop.: 50.9 [8]
l FU: 67.7 (17–100)
l p = 0.05 (two-sample t-test)
l p = 0.15 (paired t-test)
OCD lesions (n= 26):
l Preop.: 56.2 (SD 22, range 13–85) [12]
l FU: 67.4 (SD 16.4), (31–95)
l p = 0.1 (two-sample t-test)
l p = 0.3 (paired t-test)
Patellar lesions with realignment (n= 34):
l Preop.: 69 (47–85)6
l FU: 66 (17–100)
l p = 0.8 (two-sample t-test)
l p = 0.3 (paired t-test)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46):
l Preop.: 59.1 [16]
l FU: 69.2 (34–100)
l p = 0.05 (two-sample t-test)
l p = 0.1 (paired t-test)
Tegner–Wallgren score, mean
(range) [available no. of values]
Isolated femoral condyle defects (n= 52):
l Preop.: 7.8 [2.6]
l FU: 8 (2–14)
l p = 0.7 (two-sample t-test)
l p = 0.7 (paired t-test)
Multiple lesions (n = 55):
l Preop.: 7.2 [22]
l FU: 8 (3–11)
l p = 0.1 (two-sample t-test)
l p = 0.2 (paired t-test)
OCD lesions (n= 26):;
l Preop.: 6.4 (SD 2.2, range 1–9) [16]
l FU: 8.6 (SD 1.6, range 5–13)
l p = 0.01 (two-sample t-test)
l p = 0.03 (paired t-test)
Patellar lesions with realignment (n= 34):
l Preop.: 7.4 (3–14) [17]
l FU: 8.1 (3–14)
l p = 0.3 (two-sample t-test)
l p = 0.2 (paired t-test)
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Peterson 2010118 Data
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46):
l Preop.: 7.2 [33]
l FU: 8.1 (3–15)
l p = 0.1 (two-sample t-test)
l p = 0.07 (paired t-test)
Brittberg–Peterson score, mean
(range) [available no. of values]
Isolated femoral condyle defects (n= 52):
l Preop.: 65.9 (31–107) [12]
l FU: 38.4 (3–102.8)
l p = 0.02 (two-sample t-test)
l p = 0.08 (paired t-test)
Multiple lesions (n = 55):
l Preop.: 64.1 [8]
l FU: 46.3 (1.7–115.8)
l p = 0.12 (two-sample t-test)
l p = 0.9 (paired t-test)
OCD lesions (n= 26):
l Preop.: 51.8 (SD 32, range 9.4–104) [11]
l FU: 38.6 (SD 29, range 2.7–99)
l p = 0.3 (two-sample t-test)
l p = 0.8 (paired t-test)
Patellar lesions with realignment (n= 34):
l Preop.: 50.1 (31–65) [6]
l FU: 49.2 (31–65)
l p = 0.9 (two-sample t-test)
l p = 0.5 (paired t-test)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46):
l Preop.: 56.3 [14]
l FU: 41.1 (2–103.4)
l p = 0.08 (two-sample t-test)
l p = 0.2 (paired t-test)
KOOS Isolated femoral condyle defects (n= 52):
l Pain, 77.3
l Symptoms, 65
l ADL, 83.1
l Sports, 45.1
l QoL, 51
Multiple lesions (n = 55):
l Pain, 71.3
l Symptoms, 61.5
l ADL, 77.8
l Sports, 37.4
l QoL, 51
OCD lesions (n= 26):
l Pain, 78
l Symptoms, 65.2
l ADL, 85.6
l Sports, 46.9
l QoL, 54.3
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Peterson 2010118 Data
Patellar lesions with realignment (n= 34):
l Pain, 69.7
l Symptoms, 57.9
l ADL, 75
l Sports, 34.4
l QoL, 44.1
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46):
l Pain, 72.8
l Symptoms, 67.5
l ADL, 81.3
l Sports, 41.1
l QoL, 48.2
Noyes score, mean range Isolated femoral condyle defects (n= 52): 5.4 (1–9); states 5.4 in text, 5.3 in table
Multiple lesions (n = 55): 5.2 (1–10)
OCD lesions (n= 26): 5.7 (3–9)
Patellar lesions with realignment (n= 34): 5.1 (1–10)
Femoral condyle lesions with anterior cruciate ligament reconstruction (n= 46): 5.2
(1–9)
Losses to FU: percentage and
reasons if given
224/341 (65%) responded to questionnaires
Only responders included in analysis
Any costs given? No
Survival curve No
FU, follow-up; NR, not reported; preop., preoperative.
Quality Assessment Tool for Case Series Studies
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? CD
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
Preoperative values not available for some outcomes. Baseline measures collected retrospectively from medical files.
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Salzman 2013
Salzman 2013137 Data
Title Reoperative characteristics after MF of knee cartilage lesions in 454 patients
Type of study Case series
Quality of study Fair
No. of patients 560 consecutive patients of which 454 were evaluated and 123 found to
have been reoperated on the index lesion
Mean FU for the 123 receiving reoperation was 5 years (SD 2.1)
Population n= 123
Age at surgery: 44.2 ± 13.9 years
Male/female: 67/56
BMI: 25.8± 3.6 kg/m2
Smoking/non-smoking: 30/93
Intervention MF
Duration of injury? Symptom duration: 61.3 ± 68.6 months
Previous attempts at repair? No. of previous surgeries: 1.9 ± 2.1
Size of defect
Depth or severity if given
All 123 had one defect or more; 22 had two
defects; 2 had three defects
So:
l 99 had only one defect
l 22 had two defects
l 2 had three defects
Commonest depth for defect: ICRS °3C and
ICRS °3B
Very few ICRS °2 or ICRS °4
# of defects, cm2: 1.2 ± 0.5
Defect size/knee, cm2: 2.1 ± 1.7
Defect #1 (n = 123), #2 (n = 22), #3 (n = 2)
99 with 1 defect, depth according to ICRS:
l ICRS °2# 1
l ICRS °3B #26
l ICRS °3C #36
l ICRS °4 #36
22 with second defect (depth of largest):
l ICRS °2 #1
l ICRS °3B #5
l ICRS °3C #12
l ICRS °4 #4
2 with third defect (depth of largest):
l ICRS °2 #0
l ICRS °3B #0
l ICRS °3C #1
l ICRS °4 #1
Duration of FU Mean FU for the 123 receiving reoperation was 5 years (SD 2.1)
On average, reoperation commenced 18 months after initial MF
Survival curve provided? No
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Salzman 2013137 Data
Results
Definitions of success and failure Failure defined as above
Lysholm score mean (SD) Preop. not reported
Postop. Lysholm: 62.8 ± 24.5
VAS knee pain, mean (SD)
Numeric analogue scale (NAS) for pain
(NAS-P), with 10 representing ‘no pain’ and
0 representing ‘maximal imaginable pain.’
Preop. NAS-P 3.1 ± 2.1, n= 123
Postop. NAS-P 5.2 ± 2.4, n = 123
VAS knee function, mean (SD) NAS-F definition unclear
l Preop. NAS-F 2.8 ± 1.8
l Postop. NAS-F 4.8 ± 2.2
Subgroup data
Failure Findings based on regression analysis
Failure was associated with the following factors: smaller lesions; more
previous surgery; preoperative subjective sensation of less pain and less
function; smoking; patellofemoral defects
VAS knee pain, mean (SD) NR
VAS knee function, mean (SD) NR
Losses to FU: percentage and reasons if given Telephone interviews of some of the 560 patients were incomplete,
leaving 454 for analysis
Any costs given? No
Survival curve? No
FU, follow-up; NAS, numeric analogue scale; NAS-F, numeric analogue scale for function; NAS-P, numeric analogue scale
for pain; NR, not reported; postop., postoperative; preop., preoperative.
Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? CD
4. Were the subjects comparable? NA
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
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Shive 2015
Shive 2015122 Data
Title BST-CarGel® (Piramal Life Sciences, Mumbai, India)Treatment Maintains
Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter
Randomised Controlled Trial
Type of study RCT
Quality of study Fair
No. of patients 80 originally randomised; this report n= 60
Population:
The trial randomised 41 and 39 to BST-
CarGel and MF, respectively; these data
are only for those followed to 5 (?) years
Inclusion if single, focal cartilage lesion on
the femoral condyles and moderate knee
pain (> 4 on a 10-cm VAS)
BST-CarGel MF
N 34 26
Mean FU NR NR
Age mean (SD), years 34.3 (9.7) 40.1 (10.1)
Male, % 64.7 53.8
Defect size, cm2
mean (SD) 2.41 (1.5) 2.08 (1.22)
maximum 6.77 4.46
BMI (kg/m2) mean (SD) 27.6 (2.7) 25.7 (2.9)
Symptom duration years
Median [range] 1.4 [0.1–19.6] 3 [0.3–27.8]
Activity level n (%)
High 16 (47.1) 15 (57.5)
Medium 16 (47.1) 11 (42.3)
Low 2 (5.8) 0 (0)
Previous intervention NR NR
Intervention MF or enhanced MF with BST-CarGel
Multiple surgeons
Duration of injury? See above
Previous attempts at repair? NR
Size of defect in cm2
Depth or severity if given
See above
Full thickness
Duration of FU Appears to be 5 years
Survival curve provided? No
Results
Failure NR
Lesion% fill
Least squares means± SE
BST-CarGel MF
n 34 26
% fill 93.79± 1.16 86.96± 2.85
p= 0.017.
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Shive 2015122 Data
WOMAC:
Change from baseline (least squares
means± SE adjusted for baseline)
BST-CarGel MF
Pain
n 33 26
Score –15.37 ± 1.47 –16.56± 1.19
Stiffness
n 33 26
Score −5.63± 0.72 −6.68± 0.58
Physical function
n 33 26
Score −56.52± 4.57 −62.10± 3.43
No significant differences between groups.
SF-36:
Change from baseline (least squares
means± SE adjusted for baseline)
Physical component:
BST-CarGel MF
n 34 27
Score 13.12± 1.63 14.48± 1.42
Mental component:
BST-CarGel MF
n 34 27
Score 2.72± 1.30 −0.17 ± 1.76
No significant differences between groups.
Mean T2 MRI relaxation time (ms) (least
squares means ± SE)
BST-CarGel MF
n 29 22
Score 75.68± 5.25 90.41 ± 6.56
Aberrant data points for some patients were discarded.
p= 0.026.
Complications NR
Subgroup data given? No
Losses to FU: percentage and reasons if
given
25% of patients lost to FU
Any costs given? No
Survival curve? No
FU, follow-up; NR, not reported.
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Shive 2015 Quality Assessment Tool for RCT
Bias
Author
judgement Support for judgement
Random sequence generation (selection bias) Low risk Via telephone interactive voice response system
with use of a central, computer-generated
randomisation schedule
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
Low risk MRI assessments were blinded
Blinding of outcome assessment (detection bias) Unclear risk Patients not blinded because of incision size,
bias in responses to questionnaires possible
Incomplete outcome data (attrition bias) High risk 25% of patients missing at 5-year FU
Selective reporting (reporting bias) Unclear risk Some non-primary outcomes appear to have
been selected
Other bias Low risk None identified
FU, follow-up; NR, not reported.
Solheim 2014
Solheim 2014124 Data
Title Results at 10–14 years after microfracture treatment of articular cartilage defects in
the knee
Follow-up to 2010 paper
Type of study Case series
Quality of study Fair
12 years’ median FU (range 10–14 years) was reported for 110 (?) patients.
Because baseline values differ between 2010 and 2014 papers, it is possible fewer
than 110 were analysed in 2014
No. of patients 2010 paper: 116 eligible, 110 included in analysis; median age 38 years
(range 15–60)
2014 paper: Included patients aged 60 years or younger
Patients having had a knee replacement (in the ipsilateral knee during the
observation period) were denoted as failure, and their outcome score was not
included in the calculations (of Lysholm score and VAS outcomes)
Population Age 38 years (range 15–60 years)
58% male
Reason for injury not reported
Based on 110 analysed
Intervention MF
Duration of injury? Median 40 months (range 1 month to 20 years)
Previous attempts at repair? NR
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Solheim 2014124 Data
Size of defect in cm2
Depth or severity if given
One (n= 76), two (n= 27) or three (n= 7)
(n = 7) lesions with a median total treated area of 4 cm2 (range 1–15 cm2)
Subgroups:
l Single cartilage defect: mean 3.8 cm2 (SD 1.5)
l Multiple defects mean 7.5 cm2 (SD 3.0)
Duration of FU Median 5 years (range 2–9 years)
Median 12 (range 10–14) in 2014 paper
Survival curve provided? No (lacking both publications)
Results
Definitions of success and failure:
Failure defined as a new surgical
procedure with the intention to treat
the cartilage lesion Lysholm score
(e.g. another cartilage repair
procedure, an osteotomy or a knee
replacement)
Failures: 24/110 (22%)
Improved Lysholm score in non-failures: 67/86 (78%). Definition of ‘improved’ not
reported
The 2014 paper: Patients having had a knee replacement (in the ipsilateral knee
during the observation period) were denoted as failure, and their outcome score
was not included in the calculations (of Lysholm score and VAS outcomes)
The percentage patients with Failure/poor result was 47% (at medium term) and
45.5% (at 10–14 years). Failure (n = 7) was defined asabove, and ‘poor result’ was
defined as a Lysholm score of 64 or less or having a knee replacement
Lysholm score mean (SD) Preop.: 51 (18)
FU: 71 (23); p< 0.001
In 2014 paper:
l Preop.: 49 (18)
l ‘Medium FU’ in 2014, 67 (23)
l FU (10–14 years) 65 (24) The number of failures = 7 (omitted from calculation)
l ‘Medium FU’ in 2014, 67 (23) [not 71 (23) as in 2010]
l Presumably: 65 –7 = 58 ‘poor’ but without knee replacement at 10–14 years’ FU
VAS knee pain, mean (SD)
Grading of knee pain and function
of the knee
By patient-administered VASs (VAS):
0= no pain to 100 =worst possible
pain
Preop.: 52 (22)
FU: 30 (24); p< 0.001
In 2014 paper:
l Preop.: 55(21)
l Medium FU 34 (24)
l FU (10–14 years) 31 (24) The number of failures = 7 (omitted from calculation)
l 2014 medium FU 34 (24) not same as 2010 [30 (24)]
VAS knee function, mean (SD)
VAS function:
0= useless to 100 = full function
Preop.: 41 (23)
FU: 69 (22); p< 0.001
In 2014 paper:
l Preop.: 40 (22)
l Medium FU 63 (23)
l FU (10–14 years) 65 (28) The number of failures = 7 (omitted from calculation)
Subgroup data Failures:
l Single chondral lesion 14/76 (18%)
l Multiple lesions 10/34 (29%)
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Solheim 2014124 Data
Improved Lysholm score in non-failures:
l Single chondral lesion, 50/62 (18%)
l Multiple lesions, 17/24 (29%)
Lysholm score mean (SD) Single defect:
l Preop.: 53 (17)
l FU: 74 (21); p< 0.001
Multiple defects:
l Preop.: 46 (21)
l FU: 63 (24); p= 0.005
In 2014 paper:
l A subgroup (n = 30) with ≤ 40 preoperative score had a poorer 10–14 years
score than > 40 preoperative group: 56 (24) vs. 68 (22); p = 0.02
l No relationship found between preoperative age or size of defect and
10–14 years FU score
l Poor outcome (score of ≤ 64) at 10–14 years (in 50 of 110, 45.5%) was
associated with following subgroups: (a) signs of degenerative change around
lesion at time of surgery (signs 54% poor vs. no signs 34% poor, p = 0.04);
(b) previous or concurrent partial medial meniscectomy in ipsilateral knee (59%
poor vs. 40% poor; p = 0.048; (c) a ≤ 40 preoperative Lysholm score (60%
poor vs. 39%; p = 0.047; (d) ≥ 36 months’ preoperative duration of symptoms
(52% poor vs. 30%; p = 0.047)
l Percentages only reported (no n/N data)
l If 110 were analysed the N in each subgroup would appear to be:
l (a) Signs = 63, no signs = 47
l (b) Meniscectomy = 32%, no meniscectomy = 78%
l (c) ≤ 40 = 34*, > 40 = 76
l (d) ≥ 36 months = 32, < 36 months = 78
l *This number should be 30, the discrepancy may be due to rounding of
percentages and that fewer than 110 were in fact analysed
VAS knee pain, mean (SD) Single defect:
l Preop.: 52 (22)
l FU: 26 (21); p< 0.001
Multiple defects:
l Preop.: 53 (22)
l FU: 41 (27); p= 0.018
VAS knee function, mean (SD) Single defect:
l Preop.: 41 (24)
l FU: 74 (19); p< 0.001
Multiple defects:
l Preop.: 40 (19)
l FU: 54 (24); p= 0.009
Losses to FU: percentage and
reasons if given
6/116 (5.2%) excluded from analysis (two died, four lost to FU or refused)
Any costs given? No
Survival curve? No
FU, follow-up; NR, not reported; preop., preoperative.
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Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? CD
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
‘Improvement’ on Lysholm scale not defined.
Steadman 2003
Steadman 2003126 Data
Title Outcomes of Microfracture for Traumatic Chondral Defects of the Knee: Average
11-Year Follow-up
Type of study Case series
Quality of study Fair
No. of patients 72 (75 knees) met inclusion criteria
68 (71 knees) included in results analysis
Population Mean age (range): 30.4 years (13–35 years)
66.2% male
Reason for injury? Either traumatic or degenerative
Acute 15 knees, chronic 56 knees
Intervention MF
Duration of injury? Mean 3.2 years (range 0.02–16.1 years)
Previous attempts at repair? Unclear
Size of defect in cm2
Depth or severity if given
2.77 cm2 (range 0.2–10 cm2)
Full thickness
Duration of FU Mean 11.3 years (range 7–17 years)
Survival curve provided? No
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Steadman 2003126 Data
Results
MF failure Extremely low rate; definition of failure not clear
Questionnaire scales vary: final vs.
preop.
l Satisfaction 1–10
l Pain 1–4
l Swelling 1–4
l ADL 1–10
l Strenuous work 1–10
l Sport 1–10
All scores represent clinical improvement
Mean SD Range
8.3 1.6 4 to 10
–1.5 0.9 –3 to 1
–1.5 1 –3 to 1
2.8 2.6 –3 to 8
2.7 3 –4 to 9
2.9 3.4 –4 to 8
Tegner final vs. preop. 1–10 best Mean SD Range
2.7 1.7 –1 to 6
Assume this is mean of the individual score changes
Lysholm final vs. preop.
1–100 best
Mean SD Range
30.1 12.3 4 to 61
Assume this is mean of the individual score changes
Satisfaction See above
Complications ‘No perioperative complications were related to the surgical procedure’
Others not reported
Subgroup data given?
Lysholm
Age
Chronicity
Location
Size of lesions
Multivariate linear regression
Coefficient p-value
–0.299 0.011
–0.084 0.466
–0.226 0.066
–0.146 0.225
Age is only influential factor and has negative effect on Lysholm score
Losses to FU: percentage and
reasons if given
Two reasons given; also two patients who were considered failures were not
included in analyses
Any costs given? No
Survival curve? No
FU, follow-up; preop., preoperative.
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Quality Assessment Tool for Case Series Studies: NIH
Criteria Yes No Other (CD, NR, NA)
1. Was the study question or objective clearly stated? ✓
2. Was the study population clearly and fully described,
including a case definition?
✓
3. Were the cases consecutive? ✓
4. Were the subjects comparable? ✓
5. Was the intervention clearly described? ✓
6. Were the outcome measures clearly defined, valid, reliable
and implemented consistently across all study participants?
✓
7. Was the length of FU adequate? ✓
8. Were the statistical methods well described? ✓
9. Were the results well described? ✓
QUALITY RATING: FAIR
CD, cannot determine; FU, follow-up; NA, not applicable; NR, not reported.
Additional comments
The selection of participants was clearly retrospective and not consecutive (i.e. 25% of 302 consecutive patients were
included). There was no mention of any re-intervention after MF. Only two MFs were judged to be failures, but no clear
criteria for failure were offered. Outcome measures were subjective and some designed for this study only (not validated).
Some patients with poor outcome were omitted from analyses.
Vanlauwe 2011
Vanlauwe 201143 Data
Title Five-Year Outcome of Characterised Chondrocyte Implantation versus Microfracture for
Symptomatic Cartilage Defects of the Knee
Type of study RCT
Quality of study Uncertain risk of bias [based on risk of selection bias (Cochrane risk of bias tool); see below]
No. of patients Total 112: ACI 57 (51 treated); MF 61
Population
Duration of injury?
Previous attempts at repair?
Note: CCI – six did not get treated
CCI MFR
n 57 61
Age, years 33.9± 8.6 33.9 ± 8.5
Height, cm 177.0± 8.5 176.5± 10.8
Weight, kg 80.6± 13.3 78.3 ± 13.9
Male, n (%) 41 (67) 35 (61)
Female, n (%) 20 (33) 22 (39)
Duration since onset, years: median (range) 1.57 (0–18) 1.97 (0–18)
Proportion with previous surgery 77% 88%
No. (%) with previous surgeries = 0 14 (23) 7 (12)
No. (%) with previous surgeries = 1 34 (56) 29 (51)
No. (%) with previous surgeries ≥ 2 13 (21) 21 (37)
Defect size, cm2 2.4± 1.2 2.6 ± 1.0
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Vanlauwe 201143 Data
Intervention ACI-P: ChondroCelect
MF: as Steadman
Size of defect
Depth or severity if given
See above, ICRS grade 3 or 4
Deep lesions
Duration of FU 5 years
Survival curve provided? Yes
Results
Failures ACI: 7/51 (13.7%)
MF 10/61 (16.4%) log-rank p= 0.561
Failure defined as re-intervention
KOOS Change from baseline at 5 years
ACI MF Difference (95% CI) p-value
Overall KOOS 21.17± 2.88 14.07± 2.54 7.1 (–0.52 to 14.73) 0.068
ADL 16.42± 2.97 11.35± 2.62 5.07 (–2.79 to 12.94) 0.203
Pain 19.04± 3.17 13.27± 2.74 5.77 (–2.55 to 14.09) 0.172
Symptoms/
stiffness
17.70± 2.82 10.90± 2.52 6.81 (–0.70 to 14.32) 0.075
QoL 32.12± 4.30 21.23± 3.87 10.89(–0.59 to 22.38) 0.062
Function, sports
and recreational
32.50± 5.88 22.98± 5.69 9.52 (–6.87 to 25.90) 0.25
KOOS subgroup Change from baseline at 5 years, patients with < 3 years of symptoms
Pre-planned subgroup
ACI MF Difference (95% CI) p-value
Overall KOOS 25.96± 3.45 15.28± 3.17 10.69 (1.30 to 20.07) 0.026
ADL 18.95± 3.46 12.53± 3.18 6.41 (–3.01 to 15.83) 0.178
Pain 22.86± 3.66 13.75± 3.30 9.12 (–0.76 to 18.99) 0.07
Symptoms/
stiffness
21.43± 3.47 13.34± 3.19 8.09 (–1.35 to 17.54) 0.092
QoL 40.51± 5.47 21.48± 5.03 19.02 (4.14 to 33.91) 0.013
Function, sports
and recreational
activities
40.15± 7.66 24.85± 7.66 15.29 (–6.65 to 37.23) 0.166
AEs Over 5 years 42 (82%) and 38 (62%) ACI and MF patients experienced at least one
TEAEs
Mean Tegner score NR
Subgroup data See above for KOOS
No. of failures by 5 years See above
Losses to FU 6/57 in the ACI arm did not receive treatment
Any costs given? No
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Vanlauwe 201143 Data
Only for papers with survival curves
Is curve KM?
If not, what is it?
Yes
Risk table attached? Yes (but for the MF arm does not appear sensible)
Total events reported? Yes
HRs, p-value and/or 95% CI, and
whether adjusted
No
Log-rank test p-value
No adjustment
FU, follow-up; NR, not reported; TEAE, treatment-emergent adverse event.
Cochrane risk of bias score
Bias
Author
judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Minimisation not fully described
Allocation concealment (selection bias) Low risk Allocation through an interactive voice response
system
Blinding of participants and personnel
(performance bias)
High risk Patients not blinded bias likely but unclear
Blinding of outcome assessment (detection bias) Unclear risk MRI independent centre carrying out the analyses of
primary end points was unaware of patient treatment
Incomplete outcome data (attrition bias) Low risk FU complete for treated patients
Selective reporting (reporting bias) Low risk KOOS and AEs prespecified and reported
Other bias Unclear risk Errors in risk table for KM plot
FU, follow-up.
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Appendix 9 Models of time to failure included
published autologous chondrocyte implantation and
microfracture studies
This appendix lists information criteria for models used in analyses of reconstructed KM plots andreconstructed IPD. Graphs-of-model fits for included studies that are most relevant to the decision
problem are presented, arranged by study in alphabetical order. Other appendices provide model
information for the MF study of Bae et al.,134 Gudas et al.128 and the unpublished ACTIVE trial.35
Data from some studies were sparse and immature (a small proportion of participants experienced an
event) and, using the specified methods, some models and/or model 95% CIs could not be computed.
Cumulative hazard model tests are available from authors on request.
TABLE 56 The AIC and BIC information criteria for parametric models
Bentley 201278
Model Obs. ll(model) df AIC BIC
Gamma 58 –44.3728 3 94.74568 100.927
Exponential 58 –46.9174 1 95.83471 97.89515
Weibull 58 –46.7082 2 97.4164 101.5373
Gompertz 58 –46.8558 2 97.71164 101.8325
Log-normal 58 –45.6348 2 95.26963 99.39052
Log-logistic 58 –46.3567 2 96.7133 100.8342
Linearly increasing hazard (one parameter) 58 –49.498 1 100.996 103.0565
Biant 201479
Model Obs. ll(model) df AIC BIC
Gamma 104 –77.5841 3 161.1683 169.1014
Exponential 104 –81.5033 1 165.0067 167.6511
Weibull 104 –80.2895 2 164.579 169.8678
Gompertz 104 –81.488 2 166.976 172.2648
Log-normal 104 –78.3939 2 160.7879 166.0766
Log-logistic 104 –79.5402 2 163.0805 168.3693
Linearly increasing hazard (one parameter) 104 –82.9069 1 167.8137 170.4581
Bathtub 104 –81.443 3 168.886 176.8191
Linearly increasing hazard (two parameters) 104 –81.443 2 166.886 172.1748
continued
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Knutsen 2007,67 ACI
Model Obs. ll(model) df AIC BIC
Gamma 40 –28.8468 3 63.69364 68.76028
Exponential 40 –29.6877 1 61.37538 63.06426
Weibull 40 –29.5975 2 63.1949 66.57266
Gompertz 40 –29.6668 2 63.33367 66.71143
Log-normal 40 –29.1317 2 62.26343 65.64118
Log-logistic 40 –29.4573 2 62.91451 66.29226
Linearly increasing hazard (one parameter) 40 –31.4127 1 64.82539 66.51427
Knutsen 2007,67 MF
Model Obs. ll(model) df AIC BIC
Gamma 40 –25.7202 3 57.44034 62.50698
Exponential 40 –27.0267 1 56.05329 57.74217
Weibull 40 –25.7411 2 55.48211 58.85987
Gompertz 40 –25.8565 2 55.71308 59.09084
Log-normal 40 –25.7855 2 55.57099 58.94875
Log-logistic 40 –25.7727 2 55.54536 58.92312
Linearly increasing hazard (two parameters) 40 –25.801 2 55.60197 58.97973
Linearly increasing hazard (one parameter) 40 –25.8169 1 53.63372 55.3226
Layton 2015113
Model Obs. ll(model) df AIC BIC
Flexible parametric 3498 –1988.591 2 3981.182 3993.502
Gamma 3498 –1972.989 3 3951.978 3970.458
Exponential 3498 –2080.367 1 4162.734 4168.894
Weibull 3498 –1981.392 2 3966.784 3979.104
Gompertz 3498 –1972.5 2 3948.999 3961.319
Log-normal 3498 –1981.837 2 3967.675 3979.995
Log-logistic 3498 –1988.591 2 3981.182 3993.502
Linearly increasing hazard (one parameter) 3498 –1985.295 1 3972.59 3978.75
Linearly increasing hazard (two parameters) 3498 –1985.276 2 3974.553 3986.873
Minas 2014,164 all
Model Obs. ll(model) df AIC BIC
Exponential 210 –196.368 1 394.7365 398.0836
Weibull 210 –191.79 2 387.5798 394.274
Gompertz 210 –185.425 2 374.8509 381.5451
Log-normal 210 –187.581 2 379.162 385.8562
Log-logistic 210 –190.557 2 385.1139 391.8081
Linearly increasing hazard (one parameter) 210 –243.436 1 488.8725 492.2196
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Minas 2014,164 previous intervention
Model Obs. ll(model) df AIC BIC
Gamma 89 –92.1654 3 190.3308 197.7967
Exponential 89 –100.147 1 202.2938 204.7824
Weibull 89 –99.7299 2 203.4597 208.437
Gompertz 89 –97.3564 2 198.7128 203.69
Log-normal 89 –96.9522 2 197.9044 202.8817
Log-logistic 89 –98.646 2 201.2921 206.2693
Linearly increasing hazard (one parameter) 89 –118.007 1 238.0132 240.5019
Minas 2014,164 no-previous intervention
Model Obs. ll(model) df AIC BIC
Gamma 121 –87.4531 3 180.9063 189.2936
Exponential 121 –94.5668 1 191.1335 193.9293
Weibull 121 –93.769 2 191.5379 197.1295
Gompertz 121 –91.2933 2 186.5866 192.1782
Log-normal 121 –91.9782 2 187.9563 193.5479
Log-logistic 121 –93.3413 2 190.6826 196.2742
Linearly increasing hazard (one parameter) 121 –110.052 1 222.1033 224.8991
Moseley 2010115
Model Obs. ll(model) df AIC BIC
Gamma 72 –45.9957 3 97.99145 104.8214
Exponential 72 –47.6374 1 97.27483 99.5515
Weibull 72 –47.359 2 98.71793 103.2713
Gompertz 72 –46.8926 2 97.78513 102.3385
Log-normal 72 –46.8112 2 97.62248 102.1758
Log-logistic 72 –47.2613 2 98.52252 103.0759
Linearly increasing hazard (one parameter) 72 –54.408 1 110.8159 113.0926
Nawaz 201480
Model Obs. ll(model) df AIC BIC
Gamma 827 –568.507 3 1143.014 1157.167
Exponential 827 –625.545 1 1253.089 1257.807
Weibull 827 –570.836 2 1145.672 1155.108
Gompertz 827 –586.411 2 1176.822 1186.258
Log-normal 827 –569.915 2 1143.831 1153.266
Log-logistic 827 –568.834 2 1141.668 1151.103
Linearly increasing hazard (two parameters) 827 –571.708 2 1147.416 1156.851
Linearly increasing hazard (one parameter) 827 –571.82 1 1145.64 1150.358
continued
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Nawaz 2014,80 previous intervention
Model Obs. ll(model) df AIC BIC
Gamma 280 –323.345 3 652.69 663.5944
Exponential 280 –360.259 1 722.5175 726.1522
Weibull 280 –335.845 2 675.6899 682.9595
Gompertz 280 –351.191 2 706.3822 713.6518
Log-normal 280 –323.529 2 651.058 658.3276
Log-logistic 280 –323.9 2 651.7998 659.0694
Linearly increasing hazard (one parameter) 280 –348.764 1 699.5281 703.1629
Bathtub 280 –344.046 3 694.091 704.9954
Linearly increasing hazard (two parameters) 280 –344.046 2 692.091 699.3606
Nawaz 2014,80 no previous intervention
Model Obs. ll(model) df AIC BIC
Gamma 547 –404.093 3 814.186 827.0994
Exponential 547 –422.594 1 847.1882 851.4926
Weibull 547 –413.556 2 831.1128 839.7217
Gompertz 547 –421.083 2 846.1666 854.7755
Log-normal 547 –405.991 2 815.9812 824.5901
Log-logistic 547 –410.462 2 824.9231 833.532
Bathtub 547 –418.881 3 843.7628 856.6761
Linearly increasing hazard (two parameters) 547 –418.881 2 841.7628 850.3717
Linearly increasing hazard (one parameter) 547 –423.034 1 848.0674 852.3718
Nawaz 2014,80 lateral femoral site
Model Obs. ll(model) df AIC BIC
Gamma 109 –80.7189 3 167.4378 175.5118
Exponential 109 –84.7776 1 171.5553 174.2466
Weibull 109 –83.4963 2 170.9926 176.3753
Gompertz 109 –84.7494 2 173.4988 178.8815
Log-normal 109 –81.5869 2 167.1738 172.5565
Log-logistic 109 –82.759 2 169.5179 174.9006
Linearly increasing hazard (one parameter) 109 –86.1576 1 174.3151 177.0065
Linearly increasing hazard (two parameters) 109 –84.6778 2 173.3557 178.7384
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Nawaz 2014,80 medial femoral site
Model Obs. ll(model) df AIC BIC
Gamma 421 –466.36 3 938.719 950.8469
Exponential 421 –489.691 1 981.3818 985.4245
Weibull 421 –478.693 2 961.3867 969.4719
Gompertz 421 –487.87 2 979.7396 987.8249
Log-normal 421 –467.487 2 938.973 947.0583
Log-logistic 421 –470.581 2 945.1612 953.2465
Bathtub 421 –486.252 3 978.5033 990.6312
Linearly increasing hazard (one parameter) 421 –501.922 1 1005.844 1009.887
Linearly increasing hazard (two parameters) 421 –486.252 2 976.5033 984.5886
Nawaz 2014,80 multisite
Model Obs. ll(model) df AIC BIC
Gamma 47 –43.0205 3 92.04091 97.59135
Exponential 47 –49.4276 1 100.8552 102.7053
Weibull 47 –44.5392 2 93.07841 96.77871
Gompertz 47 –46.4715 2 96.94301 100.6433
Log-normal 47 –43.2675 2 90.5349 94.2352
Log-logistic 47 –43.7604 2 91.52073 95.22102
Linearly increasing hazard (one parameter) 47 –44.5599 1 91.11976 92.96991
Linearly increasing hazard (two parameters) 47 –44.0869 2 92.17384 95.87413
Nawaz 2014,80 patella site
Model Obs. ll(model) df AIC BIC
Gamma 200 –213.659 3 433.3189 443.2138
Exponential 200 –227.676 1 457.3519 460.6502
Weibull 200 –216.182 2 436.3644 442.961
Gompertz 200 –221.612 2 447.2244 453.821
Log-normal 200 –213.703 2 431.4064 438.003
Log-logistic 200 –213.828 2 431.6568 438.2534
Linearly increasing hazard (two parameters) 200 –218.561 2 441.1217 447.7183
Linearly increasing hazard (one parameter) 200 –220.296 1 442.5924 445.8907
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Nawaz 2014,80 trochlea site
Model Obs. ll(model) df AIC BIC
Gamma 50 –46.1589 3 98.31787 104.0539
Exponential 50 –48.5806 1 99.16116 101.0732
Weibull 50 –46.3142 2 96.62834 100.4524
Gompertz 50 –47.1127 2 98.22545 102.0495
Log-normal 50 –46.2374 2 96.47485 100.2989
Log-logistic 50 –46.1139 2 96.2278 100.0518
Linearly increasing hazard (one parameter) 50 –46.8221 1 95.64415 97.55618
Linearly increasing hazard (two parameters) 50 –46.5753 2 97.15064 100.9747
Niemeyer 2014117
Model Obs. ll(model) df AIC BIC
Gamma 70 –61.0638 3 128.1277 134.8732
Exponential 70 –60.8876 1 123.7751 126.0236
Weibull 70 –60.8874 2 125.7747 130.2717
Gompertz 70 –60.8557 2 125.7113 130.2083
Log-normal 70 –60.0888 2 124.1775 128.6745
Log-logistic 70 –60.7415 2 125.4829 129.9799
Linearly increasing hazard (one parameter) 70 –68.8165 1 139.6329 141.8814
Linearly increasing hazard (two parameters) 70 –60.8622 2 125.7245 130.2215
Vanlauwe 2011,43 ACI
Model Obs. ll(model) df AIC BIC
Gamma 51 –21.6794 3 49.35883 55.1543
Exponential 51 –23.3598 1 48.71968 50.65151
Weibull 51 –21.681 2 47.3619 51.22555
Gompertz 51 –21.8389 2 47.67779 51.54144
Log-normal 51 –21.8216 2 47.6432 51.50685
Log-logistic 51 –21.6851 2 47.3701 51.23375
Linearly increasing hazard (one parameter) 51 –21.6856 1 45.37118 47.30301
Linearly increasing hazard (two parameters) 51 –21.6531 2 47.30627 51.16992
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TABLE 56 The AIC and BIC information criteria for parametric models (continued )
Vanlauwe 2011,43 MF
Model Obs. ll(model) df AIC BIC
Gamma 61 –32.4298 3 70.85961 77.19223
Exponential 61 –35.7444 1 73.48888 75.59975
Weibull 61 –35.628 2 75.25597 79.47772
Gompertz 61 –35.6081 2 75.21612 79.43787
Log-normal 61 –34.7726 2 73.54515 77.76689
Log-logistic 61 –35.4313 2 74.86256 79.08431
Linearly increasing hazard (one parameter) 61 –37.6677 1 77.3354 79.44627
Linearly increasing hazard (two parameters) 61 –35.3329 2 74.66589 78.88763
Saris 2009,70 MF
Model Obs. ll(model) df AIC BIC
Gamma 61 –22.6833 3 51.36665 57.69927
Exponential 61 –25.351 1 52.70196 54.81284
Weibull 61 –23.947 2 51.89407 56.11582
Gompertz 61 –24.5998 2 53.19964 57.42138
Log-normal 61 –23.5357 2 51.07138 55.29313
Log-logistic 61 –23.8799 2 51.75988 55.98163
Linearly increasing hazard (one parameter) 61 –23.9471 1 49.89419 52.00507
AIC, Akaike information criterion; BIC, Bayesian information criterion; df, degrees of freedom; Obs., observations.
For Figures 49–74, unless stated otherwise, the following abbreviations apply: bt, bathtub; ex, exponential;
ga, Gamma; go, Gompertz; ll, log-logistic; ln, log-normal; ord, ordinate; ra, two-parameter linearly
increasing hazard model (Rayleigh); sq, single parameter linearly increasing hazard model; we, Weibull.
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Appendix 10 Economic search strategies
MEDLINE search strategy (1946 to July 2014)
1. exp Economics/
2. exp “Costs and Cost Analysis”/
3. exp Cost-Benefit Analysis/
4. Health Status/
5. exp “Quality of Life”/
6. exp Quality-Adjusted Life Years/
7. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
8. (health state* or health status).tw.
9. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form 36 or short form 36
or SF-36 or SF36 or SF-6D or SF6D or SF-12 or SF12 or health utilities index or HUI).tw.
10. (markov or time trade off or TTO or standard gamble or SG or hrql or hrqol or disabilit* or disutilit* or
net benefit or net-benefit or contingent valuation).tw.
11. (quality adj2 life).tw.
12. (decision adj2 model).tw.
13. (quality of wellbeing or qwb visual analog* scale* or discrete choice experiment* or health* year*
equivalen* or hyes or hye or 15-D or 15D or (willing* adj2 pay)).tw.
14. (“resource use” or resource utili?ation or resource$).tw.
15. (utility* adj2 (value* or index* or health or measure* or estimate*)).tw.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Chondrocytes/tr [Transplantation]
18. exp Cartilage, Articular/tr [Transplantation]
19. exp Transplantation, Autologous/
20. (MACI or MACT or chondrocelect or ACI).tw.
21. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
22. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
23. (cartilage* adj2 (transplant* or implant*)).tw.
24. 17 or 18 or 19 or 20 or 21 or 22 or 23
25. Knee/ or knee*.mp.
26. 24 and 25
27. Animals/
28. Humans/
29. 27 not 28
30. 26 not 29
31. 16 and 30
32. limit 31 to yr=“2004 -Current”
EMBASE search strategy (1947 to July 2014)
1. exp health economics/
2. exp health status/
3. exp “quality of life”/
4. exp quality adjusted life year/
5. (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw.
6. (health state* or health status).tw.
7. (qaly* or ICER* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or short-form 36 or SF-36 or SF36
or SF-12 or SF12 or SF36 or SF-6D or SF6D or health utilities index or HUI).tw.
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8. (markov or time trade off or TTO or standard gamble or SG or hrql or hrqol or disabilit* or disutilit* or
net benefit* or contingent valuation).tw.
9. (quality adj2 life).tw.
10. (decision adj2 model).tw.
11. (“quality of wellbeing” or “quality of well-being” or qwb or visual analog* scale* or discrete choice
experiment* or health* year* equivalen* or hye* or (willing* adj2 pay)).tw.
12. resource*.tw.
13. (utility* adj2 (value* or index* or health or measure* or estimate*)).tw.
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp *chondrocyte implantation/
16. (MACI or MACT or chondrocelect or ACI).tw.
17. (chondrocyte* adj4 (implant* or transplant* or matrix or characteri*)).tw.
18. (autologous adj3 (implant* or transplant* or chondrocyte* or cartilage)).tw.
19. (cartilage* adj2 (transplant* or implant*)).tw.
20. 15 or 16 or 17 or 18 or 19
21. exp knee/
22. knee*.tw.
23. 21 or 22
24. 20 and 23
25. (rat or rats or pig or pigs or porcine or mice or murine or mouse or sheep or rabbit* or canine
or dog*).ti.
26. 24 not 25
27. 14 and 26
28. limit 27 to yr=“2004 -Current”
Search strategy for Web of Science Core Collection (2004 to
July 2014)
TOPIC: (cost* or economic* or qaly* or “quality of life” or E .More TOPIC: (cost* or economic* or qaly* or
“quality of life” or EQ-5D or ICER* or utlit* or health stat* or resource* or SF-36 or short form* or markov
or standard gamble or time trade) AND TITLE: (autologous chondrocyte or autologous cartilage or MACI or
MACT or chondrocelect) AND TOPIC: (knee*)
Search strategy for NHS Economic Evaluation Database: Issue 2 of 4,
April 2014
Search on ‘(autologous chondrocyte or autologous cartilage or MACI or MACT or chondrocelect) and
knee* in Title, Abstract, Keywords in Economic Evaluations’
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Appendix 11 Annual transition probabilities
This section reports on the sources of the progression rates used in the Markov model. These transitionprobabilities were derived from the literature and in consultation with clinical experts.
Most studies presented information in the form of success (progression) rates over a specified time period.
These rates were converted to transition probabilities using the formula below, where ‘r’ is the progression
rate and ‘t’ is time:
ptransition = 1− exp f− rtg (8)
Where progression rates were not available from the literature, we converted the probability of the event
over a period of time to a constant rate using the formula below:
r = −½ln (1−P)/t (9)
Patients receiving an autologous chondrocyte implantation
procedure: ACI(ACI), 20–54 years (see Table 57)
Primary repair
Progression rates for people who progressed from ‘primary repair’ to ‘successful primary’ and to a ‘second
repair’ were obtained from Saris et al.70 These authors provided information on a 3-year failure rate of
3.9% for people who required reoperation of the same lesion. The 3-year probability was obtained and
then converted to a 1-year transition probability of 0.01317, which was used in the model. They also
reported a success rate of 83.0% over a 3-year period. We assumed a 3-year failure rate of 13.1% for
people who had no further repair following the primary repair. Three-year probabilities were obtained for
these latter two rates and then converted to 1-year transition probabilities.
Successful primary
Progression rates for people who progressed from a successful primary repair to a second repair, and for
those who remain in that health state, were based on information from Saris et al.100 These authors
reported a response rate of 87.5% over a 2-year time period for people who had undergone a MACI
implant. We assumed that 12.5% of the non-responders would move to the ‘no further repair’ health
state and, of these 12.5% patients, we assumed that 10% would move from the ‘successful primary
repair’ to the ‘second repair’ health state. Based on this information, the following annual transition
probabilities were derived: 0.93580, 0.05793 and 0.00627, respectively.
Second repair
The transitions required here include people who have undergone a second repair that was successful, and
people in whom it was unsuccessful who have not had a further repair. Saris et al.70 reported a 3-year
success rate for an initial procedure as 83.0%. Here, we assumed that the success rate in the second repair
is the same as the success rate in the primary repair, if the second repair is the same as the first. For the
people who have no further repair following the second repair, we derived a 1-year transition probability
of 0.06022. Here, we assumed that 17.0% of people will have no further repair over a 3-year time period.
Successful second
Progression rates for people who progressed from a ‘successful second repair’ to ‘no further repair’, and
for those who remain in that health state, were based on information from Saris et al.100 These authors
reported a response rate of 87.5% over a 2-year time period for people who had undergone a MACI
implant. We assumed that 12.5% of people would move from the ‘successful second repair’ to the ‘no
further repair health’ state. Based on this information, the following annual transition probabilities were
derived: 0.93541 and 0.06459, respectively.
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Patients receiving a microfracture procedure: MF(MF),
20–54 years (see Table 57)
Primary repair
People who received a primary repair can remain in the ‘successful primary repair’ health state, have a
second repair, or have no further repair, and these values were obtained from Saris et al.70 These authors
reported that 11.5% of people who had undergone a primary repair required reoperation of the same
lesions within 36 months. From this, we derived an annual transition probability of 0.03990 for those who
require a second repair. The authors also reported that 62.0% of people will have a successful primary
repair within 36 months. Taking account of the 62% who have initial success, and the 11.5% who have a
second repair within 3 years, leaves 26.5% of the initial MF group who have no further repair in the first
3 years. We derived an annual transition probability of 0.09754 for people who receive no further repair.
Successful primary
Saris et al.100 reported on the percentage (68.1%) of people who responded to treatment at 2 years.
We assumed that 31.9% of the non-responders will move to the ‘no further repair’ health state and, of
these 31.9% patients, we assumed that 10% will move from the ‘successful primary repair’ to the ‘second
repair’ health state. Based on this information, the following annual transition probabilities were derived:
0.82825, 0.15567 and 0.01608, respectively.
Second repair
Saris et al.70 reported a 62.0% success rate for people who had an initial primary repair over 36 months.
Owing to the paucity of information on the success rate for people receiving a second repair, we assumed
the same percentage success for a second repair as for people who had a primary repair. For the people
who have no further repair following the second repair, we derived a 1-year transition probability of
0.14730. Here, we assumed that 38.0% of people will have no further repair over a 3-year time period.
Successful second
Saris et al.100 reported on the percentage (68.1%) of people who responded to treatment at 2 years.
Here, we assumed that the percentage success for the second repair is the same for people who had a
successful primary repair. We assumed 31.9% of people would receive no further repair. From this, we
derived an annual transition probability of 0.17477 to represent those people who would receive no
further repair. The annual transition probability of 0.82523 was derived to represent people who remained
in a ‘successful second repair’ health state.
Patients receiving microfracture after failed autologous
chondrocyte implantation: ACI(MF), 20–54 years (see Table 57)
We report here the values for MF as a second procedure after ACI, as these transition probabilities are
different from ACI(ACI).
Second repair
People who had a second repair can have a successful second repair or do not receive a further repair. For
those people who do not receive a further repair, we obtained information from Vanlauwe et al.43 These
authors reported that for 16.4% of people who had the MF procedure following an ACI procedure, this
procedure failed at 5 years. From this, we derived an annual transition probability of 0.03519 for people
who do not receive a further repair. We assumed the remainder of the people would have a successful MF
procedure following an ACI. From this, we derived an annual transition probability from ‘second repair’ to
‘successful second repair’ as 0.96481.
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Successful second
Saris et al.100 reported that 68.1% of people responded to treatment at 2 years. We assumed that the
percentage success for the second MF is as the first MF. We assumed that 31.9% of people would receive
no further repair. From this, we derived an annual transition probability of 0.17477 to represent those
people who would not receive a further repair. The annual transition probability of 0.82523 was derived to
represent people who remained in a ‘successful second repair’ health state.
Patients receiving autologous chondrocyte implantation after
failed microfracture: MF(ACI), 20–54 years (see Table 57)
We report here the values for ACI as a second procedure after MF as these transition probabilities are
different from MF(MF).
Second repair
People who had a second repair can have a successful second repair. If the second repair is unsuccessful,
we assumed that they do not receive a further repair. For those people who do not receive a further
repair, we obtained information from Biant et al.79 These authors reported that for 30.9% of people who
had the ACI procedure following a MF procedure, this procedure failed at 10-year follow-up. From this,
we derived an annual transition probability of 0.03629 for people who do not receive a further repair. We
assumed the remainder of the people would have a successful ACI procedure following a MF. From this,
we derived an annual transition probability from second repair to successful second repair as 0.96371.
Successful second
Saris et al.100 reported that 68.1% of people responded to treatment at 2 years. We assumed that the
percentage success for the second repair is the same for people who had a successful primary repair
(assuming that this repair was MF). We assumed 31.9% of people would receive no further repair. From
this, we derived an annual transition probability of 0.17477 to represent those people who would not
receive a further repair. The annual transition probability of 0.82523 was derived to represent people who
remained in a ‘successful second repair’ health state.
Patients 55+ years: all comparisons (see Table 58)
We report here only the transition probability values for the comparisons for patients aged 55+ years,
which are different from those for patients aged between 20 and 54 years.
Successful primary, successful second and no further repair
Information required for people who required a TKR was obtained from Knutsen et al.67 These authors
reported that at the 5-year follow-up, of the 40 patients who received an ACI and of the 40 patients who
received a MF, nine patients in both groups failed the primary procedure and of these nine patients only
one went on to have TKR (the same failure rate for both ACI and MF). For people who require a PKR
following a failed primary repair, we assumed that this number would be the same as those receiving a
TKR. From this information reported, we derived a 1-year transition probability of 0.00505 to be used in
the model for patients moving to the ‘first TKR’ and ‘first PKR’ health states from the ‘successful primary’,
‘successful second repair’ and ‘no further repair’ health states.
To estimate values for people who remain in the other health states (‘second repair’, ‘successful second
repair’ and ‘no further repair’), the percentages for TKR and PKR were removed from the totals (i.e. from
the success and failure rates) and the annual transition probabilities were re-estimated.
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Patients 55+ years: all comparisons (see Table 59)
First total knee replacement
Gerlier et al.141 reported information on the percentage success (99%) for people who had a TKR. We
assumed this success to be at 5 years following the initial TKR. We derived a transition probability of
0.99223 for patients moving from a first TKR to a successful first TKR. For the progression rates to further
knee replacement, Dong and Buxton158 reported that approximately 2% of people who had undergone
their first TKR required a total revision within 2–5 years. Here, we assumed that 2% of people would
require a revision procedure in 3.5 years. From this, we derived a 1-year transition probability of 0.00576.
We assumed that 1% of people would not receive a further knee replacement 5 years following their first
knee replacement.
First partial knee replacement
Owing to the paucity of progression rates available from the literature for people who received a PKR,
we used the percentage success and progression for people who received their first TKR. We assumed a
transition probability of 0.99223 for a successful first PKR, 0.00576 for people requiring a revision, and
0.00201 for people who receive no further knee replacement.
Successful first total knee replacement
For people who received their primary knee replacement that was successful, we obtained this transition
probability from Dong and Buxton.158 These authors provided information on the 1-month probability
of a successful knee replacement and remaining in normal health after the primary TKR. This 1-month
probability was converted into a 1-year transition probability of 0.9737. Information on the progression to
further knee replacement from a first knee replacement was obtained from Gerlier et al.141 These authors
reported a 15% revision for people requiring further knee replacement, 15 years after the first TKR. From
this, we estimated an annual transition probability of 0.01078 for people requiring further revision. For
people who receive no further knee replacement after the initial knee replacement, we derived an annual
transition probability based on information on the percentage of successful and revision procedures
reported in the studies by Dong and Buxton158 and Gerlier et al.141
Successful partial knee replacement
We assumed the transition probabilities for people who had a PKR to be the same for people who had a
TKR. We assumed a 1-year transition probability of 0.97307 for a successful PKR, a probability of 0.01078
for people requiring further revision, and 0.01615 for people who receive no further knee replacement.
Further knee replacement
Gerlier et al.141 reported a 90% success rate for people who have received a further knee replacement.
We assumed this success to be at 5 years following the further knee replacement. We also assumed that
10% of people would receive no further knee replacement following the further knee replacement.
We derived a transition probability of 0.02085 for people requiring no further knee replacements.
Successful further knee replacement
Gerlier et al.141 reported a 15% revision rate 15 years after successful TKR. From this we derived a
transition probability of 0.01078 for people requiring a further knee replacement. For people who remain
in the ‘successful further knee replacement’ health state following further knee replacement, Gerlier et al.141
reported a 90% success rate and we assumed this to be at 5 years. We derived an annual transition
probability of 0.97307 for people who remain in this health state. For people who had a successful further
knee replacement and require no further knee replacement, we assumed this to be the same as a 1-year
transition probability of 0.01615 for successful first TKR and requiring no further knee replacements.
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TABLE 60 Sensitivity analysis: mean utility values used in the economic model
Repairs
First repair
SourceACI MF
Before primary repair 0.519 Oswestry submission35
Successful primary
First year 0.645 0.627 Oswestry submission35
Second year 0.669 0.667
Third year 0.674 0.673
Fourth year 0.647 0.674
Five years plus 0.698 0.658
Before second repair 0.519
Choose not to have a second repair 0.600
Second repair ACI MF ACI MF
Successful second
First year 0.645 0.627 0.645 0.627 Oswestry submission35
Second year 0.669 0.667 0.669 0.667
Third year 0.674 0.673 0.674 0.673
Fourth year 0.647 0.674 0.647 0.674
Five years plus 0.698 0.658 0.698 0.658
No further repair 0.600
Replacements
Before first knee replacement (TKR) 0.615 Dong and Buxton,158 Jansson and Granath159
Before first knee replacement (PKR) 0.615
Successful first knee replacement: TKR 0.780 Dong and Buxton158
Successful first knee replacement: PKR 0.780
Before further TKR 0.557 Gerlier et al.141
Successful further TKR 0.780 Dong and Buxton158
No further TKR 0.691 Gerlier et al.141
Some patients decide not to have another repair attempt after unsuccessful first repair. We have assumed that they had the
same benefit and do not go back to their baseline utility.
TABLE 59 Annual transition probabilities: 55+ years (for all scenarios)
From\to
Successful
first TKR
Successful
first PKR
Further knee
replacement
Successful further
knee replacement
No further knee
replacement
All comparisons
First TKR 0.99223 – 0.00576 – 0.00201
First PKR – 0.99223 0.00576 – 0.00201
Successful first TKR 0.97307 – 0.01078 – 0.01615
Successful first PKR – 0.97307 0.01078 – 0.01615
Further knee replacement – – – 0.97915 0.02085
Successful further knee
replacement
– – 0.01078 0.97307 0.01615
No further knee replacement – – – – 1.00000
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